*COVID-19 Notice*

The Ministry of Health has made some changes to the Ontario Drug Benefit Program and may continue to make changes related to COVID-19. The changes related to COVID-19 are not reflected in this Manual. Please refer to the Executive Officer Notices and Qs & As posted on the Ministry’s website for the following:

- Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies
- Publicly Funded COVID-19 Testing Services in Ontario Pharmacies
- Supplying of Publicly Funded Evusheld™ for Pre-Exposure Prophylaxis of COVID-19 in Ontario Pharmacies
- Prescribing & Dispensing Publicly Funded Paxlovid™ in Ontario Pharmacies
- Executive Officer Notice: Dispensing Publicly Funded Remdesivir (Veklury™) in Ontario Pharmacies

The Executive Officer Notices may be found at the following link: [http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx)

Pharmacies are reminded to check their Microsoft Office 365 (O365) email account (replacement of the ONE® Mail email account) for regular updates to these policies and others that apply during this period.

**Reminder to pharmacies**

Due to the COVID-19 pandemic, most Ontarians with expiring and expired Ontario Health cards will continue to have access to insured health services. Pharmacy staff are reminded to encourage patients to update their Ontario Health card if applicable.

For more information, please access the ministry announcements on extended coverage: [OHIP – Bulletins – Health Care Professionals – MOH (gov.on.ca)](http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx)
Revision #8 Updates

The following updates are reflected in this Revision (Revision #8), effective July 6, 2023:

<table>
<thead>
<tr>
<th>Section</th>
<th>Description of update</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 2</td>
<td>NEW - Executive Officer Notice: Dispensing Publicly Funded Remdesivir (Veklury™) in Ontario Pharmacies</td>
</tr>
<tr>
<td>Section 5</td>
<td>Standard Online Claims: Conditions for Payment of Dispensing Fees – updated exemptions</td>
</tr>
<tr>
<td>Section 6.12</td>
<td>Updated Diabetes Testing Agents – program details added</td>
</tr>
<tr>
<td>Section 6.15</td>
<td>Updated Reimbursement of Epinephrine Auto-Injector for Emergency Treatment to include COVID-19 vaccine</td>
</tr>
<tr>
<td>Section 6.16</td>
<td>Updated LTC home capitation funding model</td>
</tr>
<tr>
<td>Section 6.20</td>
<td>NEW - Biosimilar Policy</td>
</tr>
<tr>
<td>Section 7.1</td>
<td>MedsCheck Program – removed reference to Pharmacy Council</td>
</tr>
<tr>
<td>Section 7.2</td>
<td>Pharmaceutical Opinion Program (POP) – program details added for further clarity</td>
</tr>
<tr>
<td>Section 7.3</td>
<td>Pharmacy Smoking Cessation Program – program details and template / forms added as Appendix F</td>
</tr>
<tr>
<td>Section 7.7</td>
<td>UPDATE - Reimbursement of Minor Ailment Services</td>
</tr>
<tr>
<td>Appendix F</td>
<td>Pharmacy Smoking Cessation Templates</td>
</tr>
</tbody>
</table>
# Table of Contents

* COVID-19 Notice .............................................................................................................................. 2

  Reminder to pharmacies .......................................................................................................................... 2

Revision #8 Updates .................................................................................................................................. 3

Introduction ........................................................................................................................................... 13

Purpose ............................................................................................................................................... 13

Background .......................................................................................................................................... 14

  Health Network System (HNS) ............................................................................................................... 14

  Narcotics Monitoring System ................................................................................................................. 15

  Drug Profile Viewer ............................................................................................................................... 15

  Digital Health Drug Repository ............................................................................................................ 16

  Ontario Public Drug Programs Forms .................................................................................................. 17

Section 1: Updates .................................................................................................................................. 18

  Overview ............................................................................................................................................. 18

Section 2: Registration and Notice of Changes ....................................................................................... 19

  Overview ............................................................................................................................................. 19

2.1 Program Registration ....................................................................................................................... 19
2.2 Notification of Change(s) .................................................................................................................... 23

2.3 Closure or Sale of Pharmacy ........................................................................................................... 24

Section 3: Confidentiality and Security .............................................................................................. 25

Overview.................................................................................................................................................... 25

3.1 Privacy of Patient Information ...................................................................................................... 25

3.2 Security............................................................................................................................................. 26

Section 4: Eligibility .............................................................................................................................. 27

Overview.................................................................................................................................................... 27

4.1 Program Eligibility ......................................................................................................................... 27

4.2 Policy for Establishing Payment Eligibility .................................................................................. 50

Section 5: Standard Online Claims ...................................................................................................... 56

Overview.................................................................................................................................................... 56

5.1 To Submit a Standard Online Claim ............................................................................................ 61

5.2 To Reverse a Standard (or Non-Standard) Online Claim .............................................................. 66

5.3 Reconciliation of Online Claims and Reversals .......................................................................... 68

5.4 To Request Daily Totals .................................................................................................................. 69

5.5 To Request Claim Details ............................................................................................................... 72
5.6 To Request Same Day Reversal Details ..............................................................74
5.7 To Request Prior Day Reversal Details ..............................................................76

**Section 6: Submit Non-Standard Online Claims** ..............................................79

Overview ....................................................................................................................79

6.1 Extemporaneous Preparations ........................................................................80
6.2 Medically Necessary “No Substitution” Claims .............................................86
6.3 Limited Use Products ........................................................................................89
6.4 Claim Submission for Prescription with Drug Costs $10,000 or Over ..........99
6.5 Approved Non-Prescription Drugs .................................................................100
6.6 Allergen Program ..............................................................................................103
6.7 Cost-to-Operator Claims ................................................................................106
6.8 Duplicate Claim Submission Including Vacation Supply and Methadone
    Claims .....................................................................................................................108
6.9 Exceptional Access Program ...........................................................................121
6.10 Compassionate Review Policy .......................................................................130
6.11 Nutrition Products ..........................................................................................131
6.12 Diabetic Testing Agents ..................................................................................134
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.13</td>
<td>30-Day Prescription Program</td>
<td>144</td>
</tr>
<tr>
<td>6.14</td>
<td>Special Drugs Program</td>
<td>146</td>
</tr>
<tr>
<td>6.15</td>
<td>Universal Influenza Immunization Program</td>
<td>150</td>
</tr>
<tr>
<td>6.16</td>
<td>Policy for Pharmacy Payments under the Long-Term Care Home</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td>Capitation Funding Model, 2020</td>
<td></td>
</tr>
<tr>
<td>6.17</td>
<td>Valved Holding Chambers</td>
<td>167</td>
</tr>
<tr>
<td>6.18</td>
<td>Flash Glucose Monitoring Systems</td>
<td>171</td>
</tr>
<tr>
<td>6.19</td>
<td>Temporary Benefit Listing</td>
<td>175</td>
</tr>
<tr>
<td>6.20</td>
<td>Biosimilar Policy</td>
<td>176</td>
</tr>
<tr>
<td></td>
<td><strong>Section 7: Professional Pharmacy Services</strong></td>
<td>181</td>
</tr>
<tr>
<td>7.1</td>
<td>MedsCheck Program</td>
<td>181</td>
</tr>
<tr>
<td>7.2</td>
<td>Pharmaceutical Opinion Program</td>
<td>182</td>
</tr>
<tr>
<td>7.3</td>
<td>Pharmacy Smoking Cessation Program</td>
<td>191</td>
</tr>
<tr>
<td>7.4</td>
<td>Ontario Naloxone Program for Pharmacies</td>
<td>201</td>
</tr>
<tr>
<td>7.5</td>
<td>Reimbursement and Claims Submission using the Health Network System</td>
<td>216</td>
</tr>
<tr>
<td></td>
<td>relating to Drugs for Medical Assistance in Dying</td>
<td>223</td>
</tr>
</tbody>
</table>
7.6 Reimbursement and Claim Submissions for Mifepristone / Misoprostol (Mifegymiso) ................................................................................................................................. 230

7.7 Funding for Minor Ailment Services in Ontario Pharmacies .............................................. 234

Section 8: Paper Drug Benefit Claim Submissions and Drug Benefit Claim Reversals

Overview .................................................................................................................................................. 246

8.1 When to Submit Manual Benefit Claim Submission and Drug Benefit Claim Reversal Forms ................................................................................................................................. 247

8.2 Paper Drug Benefit Claim Submission and Drug Benefit Claim Reversal Forms .............................................................................................................................................................. 248

8.3 Instructions for Completion of Manual Drug Benefit Claim Submission and Drug Benefit Claim Reversal Forms ........................................................................................................................................ 254

8.4 Supporting Documentation for Manual Drug Benefit Claim and Drug Benefit Claim Reversal Forms ........................................................................................................................................ 256

Section 9: Prospective Drug Utilization Review ........................................................................ 258

Overview .................................................................................................................................................. 258

9.1 Overall System Description ........................................................................................................ 259

9.2 Drug Utilization Review Response Codes .............................................................................. 262
9.3 Drug Utilization Review Intervention Codes .......................................................... 267
9.4 Claim Submissions ...................................................................................................... 271
9.5 Claim Resubmissions ................................................................................................. 272
9.6 Claim Rejections ....................................................................................................... 272
9.7 Claim Reversals ........................................................................................................ 272
9.8 Help Desk Assistance .............................................................................................. 272
9.9 Confidentiality ........................................................................................................... 273

Section 10: Response and Intervention Codes ............................................................... 274
Overview .......................................................................................................................... 274
10.1 Response Codes Table ............................................................................................ 274
10.2 Intervention/Exception Codes Table ....................................................................... 296

Section 11: Reconciliation/Payment ............................................................................... 299
Overview .......................................................................................................................... 299
11.1 Payment Information for Online Claims/Reversals ................................................ 299
11.2 Payment & Drug Utilization Review Information for Manual Drug Benefit

Claim Submissions and Drug Benefit Claim Reversals ................................................. 300
11.3 Reconciliation of Remittance Statements .............................................................. 308
11.4 Payment Schedule ................................................................. 309

11.5 Direct Deposit ............................................................................. 310

**Section 12: Inspection** ................................................................. 311

Overview ......................................................................................... 311

Use of Intervention/Exception Codes ............................................. 311

Policy for Establishing Eligibility ................................................ 311

Acceptable Supporting Documentation ........................................ 311

Other Rules Regarding Retention of Records .............................. 319

Control of Network Access ........................................................... 320

Recoveries ....................................................................................... 320

Penalties .......................................................................................... 321

**Section 13: Prescription Forgery** ............................................. 322

**Section 14: Electronic Mail** ..................................................... 323

Overview ......................................................................................... 323

**Section 15: Narcotic Monitoring System** ................................. 326

Overview ......................................................................................... 326

15.1 NMS Requirements............................................................... 328
Appendix E: Attestation / Notice of Change in LTC Home Primary Pharmacy Service Provider Form .......................................................... 377

Appendix F: Templates for the Pharmacy Smoking Cessation Program ....... 380

Readiness Assessment ................................................................................................................................. 380

Pharmacy Smoking Cessation Program

Patient Agreement to Enrol & Patient Consent Form .......................................................... 381

FIRST QUIT CONSULTATION MEETING ........................................................................................... 382
Introduction

The Health Programs and Delivery Division (HPDD) of the Ministry of Health (MOH or Ministry) administers several publicly funded drug programs, the largest of which is the Ontario Drug Benefit (ODB) Program. The Ontario Drug Benefit Act (“ODBA”) and the Drug Interchangeability and Dispensing Fee Act (“DIDFA”) provide the legislative framework under which the ODB program is administered.

Purpose

The purpose of the Ontario Drug Programs Reference Manual (“Reference Manual”) is to direct pharmacies how to:

- complete the required application to register for the Health Network System (HNS)
- submit online and manual claims for payment (claims), and reversals of claims
- submit claims for professional pharmacy services
- submit narcotics monitoring transactions
- understand claim response codes and intervention codes
- understand the Drug Utilization Review (DUR) module.

A pharmacy is required to comply with the Reference Manual, pursuant to its HNS Subscription Agreement with the Ministry, and, in the case of the ODB Program, pursuant to Ontario Regulation 201/96 under the ODBA.

Background

Health Network System (HNS)

The HNS is a province-wide communication network that links Ontario pharmacies to the Ministry’s online claims processing and adjudication system and the Narcotics Monitoring System (NMS) in real-time.

The HNS provides pharmacies with the following benefits:

- timely reconciliation and payment of claims
- real-time adjudication of claims, 24 hours per day, seven days per week
- DUR, including narcotic monitoring review
- real-time notification of a recipient’s deductible and ODB eligibility status.

The HNS also provides increased quality of care and potential cost savings to the health care system by identifying:

- potential drug interactions
- duplicate prescriptions
- potential multiple prescribers and multiple pharmacy use
- inappropriate or fraudulent use of the system
- verification of some reimbursement conditions/criteria.

Pursuant to the HNS Subscription Agreement, a dispenser must ensure that all claims for payment submitted to the Ministry comply with the requirements outlined in the Reference Manual. Claims for payment that do not comply with these requirements may be recovered by the Ministry.

Further information on the HNS registration process can be found in Section 2.

As part of the HNS registration process, pharmacies must also register for access to the Microsoft Office 365 (O365) email to receive information on changes to drug
benefits, programs, policies, and payment information, as well as advisories and reminders.

Pharmacies are reminded that under the terms of the HNS Subscription Agreement, they are required to log on to the O365 email at least once per week. Further information on the O365 email registration process can be found in Section 14.

**Narcotics Monitoring System**

The misuse, abuse and diversion of monitored drugs (prescription narcotics and other controlled substances) are a public health and safety concern for Ontarians. The *Narcotics Monitoring System (NMS)* was introduced to help reduce misuse, addiction, unlawful activities and deaths related to these medications.

The NMS was established under the authority of the *Narcotics Safety and Awareness Act, 2010* ("NSAA") and collects community pharmacy dispensing data about all monitored drugs i.e., pharmacy dispensed narcotics and other controlled substances, regardless of whether the prescription is paid for under a publicly funded drug program, through private insurance, or by cash. The collected data may be reviewed and analyzed by the Ministry for a variety of purposes, including: educational and public health purposes, reporting possible professional misconduct to regulatory health profession colleges and reporting possible criminal conduct to law enforcement agencies.

The *Monitored Drugs List (MDL)* provides a list of products that the Ministry has selected for monitoring. This list can be used as a reference to determine if a submission to the NMS is required for the product being dispensed. Pursuant to Section 8 of the NSAA, all pharmacy dispensers are required to submit dispensing information to the NMS about all monitored drugs dispensed to people, and must also do so in accordance with the requirements outlined in Section 15. Note that the former Narcotics Monitoring System (NMS) Pharmacy Reference Manual is now incorporated into Section 15 of this Manual.

**Drug Profile Viewer**

In 2005, the Ministry implemented the *Drug Profile Viewer (DPV)*, a secure, web-enabled application that provides authorized health care providers across the
province with real-time electronic access to the prescription drug and pharmacy service history of ODB recipients to help facilitate the provision of timely and appropriate treatment.

The DPV contributes to improved quality and efficiency of health care delivery by:

- Reducing the need for individuals to repeat drug information to multiple health care providers and assisting individuals who have difficulty remembering or recounting what medications they are taking upon a visit to a health care provider.
- Increasing the speed and accuracy of diagnoses and improving the ability of clinicians to identify and prevent adverse drug reactions.
- Assuring better continuity of pre-existing drug therapy, if required, while a patient receives treatment in hospital.

**Digital Health Drug Repository**

The Digital Health Drug Repository (DHDR), which has replaced the Drug Profile Viewer (DPV), contains information about publicly funded dispensed drugs and pharmacy services, as well as information about all pharmacy dispensed monitored drugs (narcotics and controlled substances), regardless of payor. Authorized health care providers (e.g., physicians, pharmacists, nurse practitioners) in various community care settings (e.g., pharmacies, community health or mental health centres, long-term care facilities, public health units) have access to DHDR information through the provincial clinical viewers (ClinicalConnect and Connecting Ontario).

With DHDR, authorized health care providers are able to securely view their patient’s comprehensive drug and pharmacy service profile, at point of care, informing appropriate prescribing and supporting the clinician’s ability to prepare the Best Possible Medication History (BPMH) to assist the clinical drug assessment for their patient.

Developing an accurate BPMH can help prevent specific adverse drug events (ADEs) that can result from prescribers’ incomplete knowledge of their patients’ medication and pharmacy service history. ADEs harm patients and result in the need for costly interventions. Effective implementation of medication reconciliation is considered
essential to reduce preventable ADEs occurring at transitions between community and hospital care and between prescribers (e.g., family physician and specialists, and when a patient changes prescribers).

The DHDR provides the ability to drive and support quality-based care. Access to a comprehensive drug and pharmacy service history can support patient safety through medication reconciliation processes and digitally-enabled decision aids. Similarly, making up-to-date dispensed medication information from the NMS readily available can help physicians and pharmacists when making decisions concerning opioid prescribing and dispensing.

The DHDR currently leverages existing HNS/NMS data sets and assets. In the future, it is hoped that the DHDR will expand to include more data sources (e.g., privately paid dispensing data, prescribed events information) and additional clinically relevant data, and to include additional clinical viewers, consumer portals, and other point-of-service systems.

The DHDR is currently part of the province’s Electronic Health Record (EHR) and is shareable within the patient’s health care team across multiple health care settings (e.g., hospitals, community pharmacies, hospital in-patient pharmacies, family health teams, community health centres), significantly extending the reach of the Drug Profile Viewer.

Health care providers and health care organizations (including community pharmacies) can obtain access to the EHR through the clinical viewer organizations if they meet the privacy and security requirements to access the provincial assets.

**Ontario Public Drug Programs Forms**

All forms discussed in this Reference Manual may be revised by the Ministry from time to time. Up-to-date versions of the forms can be obtained from the Ministry’s [website](#) or the [Ontario central forms repository](#). Where appropriate, links to specific forms will be made available under the corresponding section of the Reference Manual.
Section 1: Updates

Overview

Pharmacies are reminded that under the terms of the HNS Subscription Agreement, claims are to be submitted in accordance with “Ministry Policies”, which is defined to include the Reference Manual and any other policies, directives, protocols, rules or guidelines applicable to the pharmacy operator that may be published by the Executive Officer or otherwise communicated to the operator from time to time.

The Ministry will provide information and/or updates to the Reference Manual as changes occur. Communications may be in the form of O365 email notices or other mailings/postings.
Section 2: Registration and Notice of Changes

Overview

Ontario Drug Programs (ODP) registration allows pharmacies to submit online claims and claim reversals through HNS.

Pharmacies must also register for a O365 email account to receive information on changes to drug benefits programs, policies and payment information, as well as advisories and reminders. Pharmacies are reminded that under the terms of the HNS Subscription Agreement, they are required to log on to the O365 email at least once per week (see Section 14).

This section outlines specific instructions for:

- ODP registration (see Section 2.1)
- Notification of ODP registration changes (see Section 2.2)
- Closure or sale of a pharmacy (see Section 2.3)

2.1 Program Registration

Pharmacy Registration

A pharmacy registration package will need to be completed and submitted to the Ministry if you are applying for a new HNS account to obtain billing privileges under the ODBA. Such situations can occur when:

- opening a new Ontario pharmacy
- purchasing or acquiring an existing Ontario pharmacy
- a new accreditation number is assigned to a pharmacy with an existing ODP account by the Ontario College of Pharmacists (OCP) (e.g., relocation)
- there is an ownership change in an Ontario pharmacy.
The pharmacy registration package can be obtained via email at: HNS-Registration.MOH@ontario.ca or by contacting the Ministry via fax to number 613-545-4470. The pharmacy registration package includes the following:

- Pharmacy Registration Checklist
- Ontario Drug Programs Application
- HNS Subscription Agreement for Pharmacy Operators
- O365 email account registration form.

To register for an ODP account, please submit a fully completed registration package either by email at: HNS-Registration.MOH@ontario.ca, or via fax to: 613-545-4470.

Note: Pharmacies that do not register for an HNS account are still required to obtain access to NMS in order to be compliant with the monitored drug submission requirements under Section 8 of the NSAA. A copy of the NMS pharmacy registration form can be requested by email at: HNS-Registration.MOH@ontario.ca, or via fax: 613-545-4470.

The activation of an HNS account involves the granting of billing privileges under section 4.1 of the ODBA. The granting of billing privileges under the ODBA is a discretionary power exercised in the public interest. In order for the Executive Officer of Ontario Public Drug Programs to consider granting billing privileges to a pharmacy operator, the Executive Officer must be satisfied that, among other things, the operator will submit claims for reimbursement that are valid and in accordance with the law.

Corporations/Officers/Directors/Shareholders/Designated Managers of pharmacy operators that have had their ODP account(s) terminated may have restrictions on their ability to receive a new ODP account and be required to comply with certain conditions. Such conditions must be met in order for billing privileges to be granted.
Remote Dispensing Location(s)

For pharmacies wishing to register for one or more remote dispensing location(s), a complete registration package including the ODP application, HNS Subscription Agreement and O365 email account registration form, must be submitted to the Ministry for consideration.

All publicly funded prescriptions dispensed from a remote dispensing location must be submitted using the remote dispensing location's pharmacy identification (ID) number.

**Note:** Remote dispensing locations are not eligible to make MedsCheck and/or Pharmaceutical Opinion Program (POP) claims or publicly funded influenza vaccine administration claims.

Health Network System

HNS must only be used for the following purposes:

- Submitting claims or claim reversals for adjudication for prescriptions or pharmacy services which were dispensed or conducted at the location of the account for which the HNS Subscription Agreement was signed.
- Receiving responses to submitted claims or claim reversals.
- Receiving remittance (payment) information and Ministry communications through the O365 email.

HNS **cannot** be used for:

- Unauthorized access to other networks or email systems.
- Any transaction that contravenes the HNS Subscription Agreement, the ODBA or its regulation, or any other applicable law (e.g., submitting claims or transactions for products or services which were dispensed or had occurred at another location).
- Transactions not authorized by the Ministry.

In the event that misuse is detected, the Ministry will notify the pharmacy. The pharmacy will be required to take immediate corrective action. Failure to take
corrective action may result in revocation of the pharmacy’s access to HNS and its billing privileges under the ODBA.

The Executive Officer may allow for expanded uses of HNS by providing notice to pharmacy operators through the O365 email.

**Pharmacy ID Number**

Upon registration, the pharmacy/remote dispensing location will be assigned a unique identification (ID) number known as the pharmacy ID number.

For accredited pharmacies, the pharmacy ID number begins with the characters “ON” followed by a two-character (numeric) prefix, followed by the OCP pharmacy accreditation number. The process for assignment of the pharmacy ID number for accredited pharmacies is in alignment with the Canadian Pharmacists Association (CPhA) Claim Standard Version 3.

The pharmacy ID number is required for online transaction processing and O365 email access, which is required in order to receive correspondence from the Ministry.

The pharmacy ID number will become effective on the activation date (i.e., when the pharmacy connects online to HNS).

*It is important to be online as soon as possible since claims with a date of service prior to the pharmacy’s activation date will not be processed.*

*Activation of the pharmacy ID number and initiation of access to HNS is available during the hours of 8:30 a.m. to 5 p.m., Monday through Friday (excluding Statutory Holidays).*

New accreditation numbers are issued by the OCP each time there is a change in pharmacy ownership, location, etc. For each change in pharmacy accreditation number assigned by the OCP, the Ministry will assign a new pharmacy ID number and a new HNS agency ID. This process involves completion of an ODP application, the signing of a new HNS Subscription Agreement (to reflect the updated pharmacy details), and completion of a new O365 email account registration form.

The Ministry’s process of issuing a new pharmacy ID number includes a review of the application to ensure the pharmacy operator is compliant with the HNS
Subscription Agreement. This process generally takes several business days after receipt of all required paperwork from the applicant and the OCP. Occasionally, additional information is required from the applicant before the registration process can proceed.

In order to ensure that this process is as seamless and efficient as possible, it is suggested that new applicants, as well as current HNS account operators who will be receiving new accreditation numbers, should inform the Ministry as soon as possible to allow sufficient time to process applications. The Ministry’s review process may be commenced prior to final issuance of new accreditation numbers by OCP.

**Pharmacist ID Number**

All pharmacists submitting claims to the ODB program must be registered within HNS. To register a pharmacist ID number, (i.e., the pharmacist license number) please call the ODB Help Desk at 1-800-668-6641 or via fax at 613-545-4470 during business hours.

### 2.2 Notification of Change(s)

Pharmacies are required to notify the Ministry in writing of any change(s) affecting their ODP registration no later than seven days after the change, including any changes in:

- pharmacy information (e.g., trade name, address, phone number)
- ownership type
- type of pharmacy (e.g., retail pharmacy, rural pharmacy, hospital outpatient dispensary)
- software vendor information
- network connection
- banking information
- Owner/Partner/Director/Shareholder/Designated Manager information
- authorized personnel signing authority
• transmission of remittance totals.

To notify the Ministry of any change(s) affecting ODP registration, pharmacies must forward a complete and signed Notification of Change form either by email to: HNS-Registration.MOH@ontario.ca, or via fax to: 613-545-4470.

The notification of change form for ODP registration can be obtained by contacting the ODB Help Desk at 1-800-668-6641 or via fax at 613-545-4470.

Note: For pharmacies with an active HNS account that are assigned new OCP accreditation numbers, the existing HNS account must be closed and new ODP application, new HNS Subscription Agreement and new O365 email registration form must be submitted.

### 2.3 Closure or Sale of Pharmacy

In the event that a pharmacy is being closed or sold, the Ministry must be notified in writing no later than 30 days prior to the date of closure or sale either by email at: HNS-Registration.MOH@ontario.ca, or via fax to: 613-545-4470.

- **Note:** Claims will only be accepted for prescriptions dispensed up to the date of closure.

- A pharmacy owner is not permitted to assign its ODP registration or HNS Subscription Agreement to a new owner.

- The new owner cannot submit claims with a date of service prior to the activation date of its new pharmacy ID number.

- At the time of sale or closure, all Electronic Funds Transfer (EFT) payments are automatically reverted to cheque payments and are mailed to the pharmacy address on file, unless the Ministry receives a written notice signed by an authorized signing officer for whom the Ministry has confirmation of signing authority on file, directing otherwise.
Section 3: Confidentiality and Security

Overview

In accordance with applicable privacy legislation and the HNS Subscription Agreement, pharmacies are responsible for maintaining the confidentiality and security of data transmitted and received over HNS.

The Ministry’s online claims adjudication system requires that specific information pertaining to the dispensing of drugs be collected and transmitted over the HNS. The Ministry’s collection, use and disclosure of personal information through the HNS are governed by Section 13 of the ODBA and the Personal Health Information Protection Act, 2004 (“PHIPA”). This information is necessary to adjudicate the claim and to administer payment. In addition, the prospective DUR systems will use this information to identify potential drug related problems.

The Ministry may also securely disclose information of Ontarians about their publicly-funded drugs and pharmacy services, as well as all dispensed narcotics and other controlled substances regardless of payor, to authorized health care providers in multiple health care settings for the purpose of informing clinical decision making and supporting the provision of health care.

This section explains the policies and procedures to ensure:

- Confidentiality of patient information (see Section 3.1)
- On-site physical security and password (network access) security (see Section 3.2)

3.1 Privacy of Patient Information

A pharmacy’s collection, use, disclosure and retention of patients’ personal health information are governed by PHIPA. Pharmacists should consult the OCP regarding the application of PHIPA to their practice and to obtain any guidelines or best practices pertaining to the collection, use and disclosure of patients’ personal health information.

Learn more about privacy protection in Ontario.
3.2 Security

HNS access must be:

- Restricted to those whose access is required to perform their professional duties.

- Authorized by the pharmacy owner or designated manager of the registered OCP pharmacy.

Transactions submitted via an Acquirer Host network (i.e., third party network service provider) are subject to the security measures implemented by the Acquirer Host.
Section 4: Eligibility

Overview

This section explains:

- Recipient eligibility under the ODB program and procedures for identifying recipients (see Section 4.1)
- The policy with respect to Health Card Version Code when processing claims (see Section 4.2)
- The policy for establishing eligibility for payment that may apply under certain eligibility streams and a summary of the availability and limitations applicable to the policy (see Section 4.2)

4.1 Program Eligibility

The ODB program provides community-based drug benefits to:

1. Individuals entitled to receive drug benefits under the Ontario Disability Support Program Act, 1997 (“ODSPA”) including Assistance for Children with Severe Disabilities (ACSD), and the Ontario Works Act, 1997 (“OWA”) including Temporary Care Assistance (TCA); and

2. Individuals who are insured persons under the Health Insurance Act (“HIA”) and who are:
   a. 65 years of age or older (seniors)
   b. 24 years of age and under (children and youth) who do not have a private plan
   c. residents of Long-Term Care (LTC) homes
   d. residents of Homes for Special Care (HSC) or Community Homes for Opportunity (CHO)
   e. enrolled in the Trillium Drug Program (TDP)
3. Individuals who are receiving:

- a professional service (other than training) under O. Reg 187/22 (Home and Community Care Services) made under the Connecting Care Act, 2019 that is provided by a health service provider or Ontario Health Team; or

- a substantially equivalent service that is provided by an Indigenous organization that has entered into an agreement with the Ministry of Health.

Details of recipient eligibility criteria are outlined on the following pages.

**Seniors**

All residents of Ontario (including permanent residents) who are eligible for coverage under OHIP will qualify for drug benefits under the ODB program on the first day of the month following their 65th birthday. For example, if a resident’s 65th birthday is April 15th, he/she will become eligible for coverage under the ODB program on May 1st.

*Policy for establishing eligibility for payment does not apply (see Section 4.2).*

**How recipients are identified:**

- Seniors (65 years of age or older) who present with a valid Ontario Health number.

**Health card samples:**

![Health Card Sample]
Required claim information:

- Enter the Health number in the Client ID # field
- Include the version code if embossed on the Health Card

Deductible/co-payments:

There are two categories of co-payments for seniors based on net income level:

1. A higher-income co-payment category and
2. A lower-income co-payment category.

Higher-income co-payment:

A single senior who has an annual net income greater than the Senior Co-payment Program (SCP) individual threshold or a senior with a spouse who (along with their spouse) has a combined annual net income greater than the SCP couple threshold is included in the higher-income co-payment category. Seniors in this category are each responsible for paying the first $100 (i.e., deductible) in prescription costs each year. After that, each senior may pay up to $6.11 (i.e., co-payment) toward the ODB dispensing fee on each prescription for an eligible benefit.

The ODB deductible for newly eligible seniors in the higher-income co-payment category is prorated based on the number of months they are eligible for ODB coverage in their first year of eligibility. The ODB benefit year begins August 1st of each year and ends on July 31st of the subsequent year. The HNS will automatically track and notify pharmacists of an individual’s deductible based on the month when they become eligible in their first year of ODB coverage. A response message is returned to the pharmacy indicating how much of the deductible has been paid.
Once the deductible has been reached, HNS adjudicates claims with a $6.11 co-payment.

Only allowable drug expenses will count towards the $100 deductible, namely, amounts spent on co-payments in respect of prescriptions for drug products listed as benefits in the Ontario Drug Benefit Formulary (ODB)/Comparative Drug Index (CDI), amounts spent in respect of prescriptions for nutrition products and diabetic testing agents approved as benefits under the ODB program, extemporaneous products that are designated pharmaceutical products under the ODBA and products that are approved under the Exceptional Access Program (EAP).

The deductible is ‘paid’ only through accumulated allowable drug expenses. The pharmacy may not collect $100 as a one-time payment, or any portion of that amount from the senior in excess of any allowable drug expenses accumulated on individual prescription claims.

### Seniors Co-payment Thresholds:

<table>
<thead>
<tr>
<th>SCP individual threshold</th>
<th>Prior to August 1, 2021: $19,300</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>As of August 1, 2021: $22,200</td>
</tr>
<tr>
<td>SCP couple threshold</td>
<td>Prior to August 1, 2021: $32,300</td>
</tr>
<tr>
<td></td>
<td>As of August 1, 2021: $37,100</td>
</tr>
</tbody>
</table>

### Lower-income co-payment:

A single senior who has an annual net income equal to or less than the SCP individual threshold or a senior with a spouse who (with their spouse) has a combined annual net income equal to or less than the SCP couple threshold can apply to be included in the lower-income co-payment category, and may pay up to $2 (co-payment) for each prescription for an eligible benefit. There is no annual deductible for these seniors.

To become eligible for the lower income co-payment category, these seniors must complete a Seniors Co-payment Program Application form and submit it to the SCP.

Once the application has been processed, seniors are notified by mail and HNS will process claims based on the lower-income co-payment category, if applicable.
The foregoing co-payment rules only apply to a senior if he/she is not part of any other class of eligible persons (e.g., ODSP, OW, LTC home resident, HSC or CHO resident, home care recipient). If a senior belongs to one of these other eligibility categories, then only a $2 co-payment may be charged.

Questions regarding the SCP application/guide should be directed to:

In Toronto, call: 416-503-4586
Toll-free: 1-888-405-0405
Email: seniors@ontariodrugbenefit.ca

Children and Youth 24 Years and Under Who Do Not Have a Private Plan (OHIP+)

Ontario children and youth, aged 24 years and under, who have OHIP coverage, and do not have a private plan, also qualify for drug benefits under the ODB program. This coverage ends on the person's 25th birthday unless the person has other ODB coverage through another eligibility stream.

How recipients are identified:

- Children and youth, aged 24 years and under, who present with a valid Health number and who do not have a private plan.

- Pharmacies are required to confirm whether the child or youth (aged 24 and under) has a private plan before submitting the claim to the HNS for adjudication with the Special Service Code (SSC) “U” - No-Private-Insurance Attestation

Private plan definition:

“Private plan” is defined to mean an employer, group or individual plan, program or account, however described, that could provide coverage for drug products, including the provision of funding that could be used to pay for drug products, regardless of whether:

- The private plan covers the particular drug for which coverage is sought,
• The child or youth or another person captured under the private plan is required to pay a co-payment, deductible, or premium, or,

• The child or youth has reached their annual maximum under the private plan and no further coverage is available

Health card samples:

Required claim information:

• Enter the Health number in the Client ID # field

• Include the Version Code if there is one on the Health Card

• If the claim is rejected at the time of dispensing due to recipient ineligibility, the pharmacy may establish eligibility by entering an appropriate intervention code if appropriate documentation is first obtained (see Section 12, Inspection)

• If the child/youth or the parent/guardian/agent confirms the child/youth does not have a private plan, enter "U" in the Special Service Code (SSC) field

• The SSC “U” must be included as part of every claim submission for eligible children/youth who do not have a private plan. Failure to do so could result in a rejection by the HNS with one of the following response codes:
<table>
<thead>
<tr>
<th>“PM”</th>
<th>No-Private-Insurance-Attestation Missing (i.e., claim was submitted for a child/youth 24 years of age and under and confirmation of no private plan was missing)</th>
</tr>
</thead>
<tbody>
<tr>
<td>“ZR”</td>
<td>Submit receipt to TDP or Attest to No PI (i.e., claim was submitted for child/youth 24 years of age and under who is enrolled in TDP)</td>
</tr>
</tbody>
</table>

**Note:** For response codes “PM” and “ZR”, there is no override code. Reconfirm the patient’s private plan status:

- If the child/youth does not have a private plan, resubmit the claim with SSC “U”

- If the child/youth has a private plan, submit the claim to the private plan. If the recipient is also enrolled in TDP, advise the recipient to submit private plan information and receipts for out-of-pocket expenses to TDP.

**Deductible/co-payments:**

There are no deductibles or co-payments for OHIP+ recipients.

**Ontario Disability Support Program and Ontario Works**

Most social assistance clients do not receive a paper Drug Benefit Eligibility card each month and will be required to present their Ontario Health number when filling prescriptions under the ODB program, consistent with requirements for other ODB program recipients.

**Verifying social assistance eligibility where coverage cannot be validated by the HNS:**

When the HNS returns a response message that indicates the client is not eligible for ODB, there are two channels available for social assistance verification **before utilizing the “ML” or “MK” intervention codes to establish eligibility for clients**. It is important to confirm eligibility before establishing eligibility for a client.
Pharmacies are able to verify social assistance eligibility by using the monthly statement of assistance to look up the client’s eligibility for ODB in the Social Assistance Verification (SAV) Portal. This should be used as the primary mechanism for the social assistance eligibility verification. The SAV portal can be accessed from the following web address: https://www.verify.sa.mcss.gov.on.ca. Pharmacies who do not have access must register online to gain access to the portal. For registration and login related issues, help is available by contacting support by e-mail at SAVPortalSupport@accerta.ca.

The SAV Portal should only be used for verifying social assistance eligibility and should not be used for other purposes, such as to obtain the Health number for clients who are eligible for OHIP coverage.

Pharmacies should use the SAV Helpline only in the event that the SAV Portal is unavailable to verify social assistance eligibility. The SAV Helpline is a provincially managed call centre and available toll-free at 1-888-284-3928 during regular business days.

Both the SAV Portal and the SAV Helpline will also provide the client’s assigned temporary health reference number to the pharmacy to support the claims submission process.

The majority of clients can be verified using the Ontario health card number. If eligibility cannot be verified through the SAV Portal using the health card number, Pharmacies should remove the Ontario health card number and use the person's name and date of birth combination to verify eligibility.

For inspection and claim validation purposes, the MOH requires pharmacies to provide a record log for claims where social assistance recipients’ eligibility for coverage was confirmed through the SAV Portal or SAV Helpline.

The SAV Portal allows a pharmacy to print the results of the search, which would contain the necessary information for claim validation purposes. Documentation must be maintained on file and be readily available for two years following the last claim date. If a printed copy of the search results is not maintained, documentation must be maintained that contains:

- Reference number
- Date of search (‘Eligibility Result as of’)

Ontario Drug Programs Reference Manual
- Type of Coverage (‘Plan Code C’ or ‘Plan Code D’)
- Results of the search (e.g., eligible or ineligible)

Clients who are not eligible for an Ontario Health number or do not have other government identification or statement of assistance, and clients with specific circumstances, will continue to receive a paper drug card to access the ODB program, including First Nations clients receiving assistance from Ontario Works administrators except for M'Chigeeng First Nations.

For these social assistance clients who continue to receive paper drug cards as proof of eligibility, pharmacies must continue to retain copies of the paper drug cards on file. For claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable, copies of the paper drug cards must be maintained for the Retention Period. Discarding copies of paper drug cards prior to the end of the Retention Period may result in claim recoveries.

Further details can be accessed through the Executive Officer Communications webpage at: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx.

For additional program related questions about the paperless drug card, please contact the MCCSS e-mail account at SASM-Q&A@ontario.ca.

For all ODB related questions, please call the ODB Help Desk at: 1-800-668-6641.

Policy for establishing eligibility for payment applies (see Section 4.2).

See Acceptable Supporting Documentation requirements.

How recipients are identified:

- Recipients who present with a valid Ontario Health number or present with a Drug Benefit Eligibility Card valid for the date of service.
Health Card Samples:

Paper Drug Benefit Eligibility sample:
Required claim information:

If the social assistance recipient presents his/her Health number:

- Enter the Health number in the Client ID # field
- Include the version code if embossed on the Health Card
- If the claim is rejected at the time of dispensing due to recipient ineligibility, the pharmacy may establish eligibility by entering an appropriate intervention code if appropriate documentation is first obtained (see Section 4.2 for further details) once eligibility has been confirmed by SAV Portal or SAV Helpline in the event the SAV Portal is unavailable. For claim validation, and in accordance with O Reg 264/16 under the DPRA if applicable, documentation of the eligibility verification results must be recorded and maintained in a readily-accessible format for the Retention Period.

If the social assistance client presents other government identification or monthly statement of assistance:

- Access the SAV Portal to verify social assistance eligibility and obtain the temporary health reference number, if one has been assigned. For claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable, ensure documentation required prior to submitting a claim for payment is maintained in a readily-accessible format for the Retention Period [see Section 12, Inspection].

If the social assistance client presents a paper Drug Benefit Eligibility Card:

- Enter the eligibility number from the Drug Benefit Eligibility Card in the Client ID # field (omit any letter preceding the Eligibility Number)
- If the recipient also presents a Health number and it differs from the eligibility number on the Drug Benefit Eligibility Card, in addition to the above, also:
  - Enter the Health number in the Provincial Health Care ID Code field
  - Include the version code if embossed on the Health Card
- Ensure the Drug Eligibility Card or a copy of the card is maintained in a readily-accessible format. For claim validation purposes, and in accordance
with O Reg 264/16 under the DPRA if applicable, this record must be maintained for the Retention Period.

**Co-payment:**

- Recipients 25 years of age or older may pay up to $2 (co-payment) for each prescription for an eligible benefit

- Recipients 24 years of age and under have no co-payment

**Home Care**

Individuals receiving a professional service (other than training) under O. Reg 187/22 (Home and Community Care Services Regulation) made under the Connecting Care Act, 2019 are eligible to receive benefits under the ODB program. Individuals receiving a substantially equivalent service that is provided by an Indigenous organization that has entered into an agreement with the Ministry of Health are also eligible to receive benefits under the ODB Program. The health service provided (HSP) or Ontario Health Teams (OHT) determine eligibility for coverage.

*Policy for establishing eligibility for payment applies (see Section 4.2).*

*See Acceptable Supporting Documentation requirements.*

**How recipients are identified:**

- Recipients may present a Drug Benefit Eligibility Card valid for the date of service or the HSP/OHT may fax a copy of the Drug Benefit Eligibility Card or other notification indicating eligible recipients directly to the pharmacy.
Samples of Drug Benefit Eligibility Card and Notification of Eligibility for home care recipients:

North West LHIN

ODB Notification

North West LHIN

ODB Pharmacy Notification
20-Sep-2018 8:41 AM EDT

Shoppers Drug Mart - Thunder Bay (300 Memorial Ave)
Memorial Ave, Thunder Bay, Ontario Canada P7B 3Y2
Phone: 8073433010
Fax: 8073433015

Care Coordinator:

Client name: Demo, Kyla
Health Card Number:
Notification Type: New
Start date: 20-Sep-2018
Renewal date: 20-Sep-2018
Estimated end date: 18-Dec-2018
Actual end date: --
Required claim information:

- Enter the eligibility number from the Drug Benefit Eligibility Card or fax notification in the Client ID # field (omit any preceding letters).

- If the HSP/OHT has provided other written/fax notification to establish eligibility:
  - enter the Health / eligibility number in the Client ID # field
  - include the version code if embossed on the Health Card.

- If the recipient recently moved from another province/territory, does not have OHIP coverage and is receiving end-of-life professional home care services:
  - Enter the temporary eligibility number (begins with ‘08’) from the Drug Benefit Eligibility Card or notification in the Client ID # field

- If the recipient is receiving professional home care services from an Indigenous organization:
  - For recipients who do not have a Health Card, enter the eligibility number (begins with ‘08’) from the Drug Benefit Eligibility Card or notification in the Client ID # field; OR
  - For recipients with a Health Card, enter the Health Card number in the Client ID # field and include the version code if embossed on the Health Card

Co-payment:

- Recipients 25 years of age or older may pay up to $2 (co-payment) for each prescription for an eligible benefit.

- Recipients 24 years of age and under have no co-payment

Note: If a person is discharged from home care professional services prior to the expiry date of the Drug Benefit Eligibility Card or other notification, the individual is no longer eligible to receive benefits under the ODB program unless otherwise eligible (e.g., resident of an LTC home, senior, eligible through the TDP, etc.). The Drug Benefit Eligibility Card or other notification is valid only during the time the recipient is receiving certain professional. The eligibility of an individual discharged
from such professional services may only be re-established if the individual begins receiving such professional services again and a new Drug Benefit Eligibility Card is presented or a new notification is faxed.

- If the pharmacy receives a notification fax from the HSP/OHT with an updated (actual) end date, then the individual will no longer be eligible to receive benefits under the ODB program after that date, even if an earlier notification fax from the HSP/OHT included a later end date for coverage.

**Long-Term Care Home Residents**

Residents of an LTC home licensed under the Long-Term Care Homes Act, 2007 (“LTCHA”) are eligible for benefits under the ODB program.

*Policy for establishing eligibility for payment applies (see Section 4.2).*

*See Acceptable Supporting Documentation requirements.*

**How recipients are identified:**

- Names and Health numbers of eligible recipients will be provided by the LTC home.

- Prescriptions for LTC home residents are provided on prescriber order/reorder sheets which designate the LTC home.

**Required claim information:**

- Enter Health number in Client ID # field

- Include version code if embossed on Health Card

- Enter the LTC home identification number (ODP number) in the Group Number field

- A valid LTC agency ID number (ODP number) must be included as part of the claim submission for LTC residents. Failure to do so could result in a rejection by HNS with response code “31”- Group Number Error
The first claim of every calendar month for most LTC recipients who are not a senior with coverage under another ODB eligibility stream will initially be rejected. LTC eligibility must be established for the current month by entering an appropriate intervention code (ML or MK) (see Section 4.2).

If a recipient is discharged from an LTC home, the pharmacy should call the ODB Help Desk with the date of discharge and request that LTC eligibility coverage be terminated as program eligibility may need to be adjusted.

If response code “31”- Group Number Error is received when submitting a claim for a person who is not an LTC home resident, please contact the ODB Help Desk to adjust program eligibility. Submission of claims and/or establishing ODB eligibility under an unauthorized program can be considered an invalid claim and may result in recovery of payments by the Ministry.

Co-payment:

- There is no co-payment for all LTC home residents for eligible ODB claims.

Changes to Reimbursement for Pharmacy Services for Long-Term Care Home Residents

The reimbursement model for pharmacies that provide pharmacy services, including prescription dispensing and MedsCheck / Pharmaceutical Opinion programs, to residents of Long-Term Care Homes has changed effective January 1, 2020 from a fee-for-service model to a per-bed-fee capitation model. Please refer to Section 6.16 for the full Policy.

Homes for Special Care / Community Homes for Opportunity

Residents of HSC licensed under the Homes for Special Care Act (“HSCA”) are eligible for benefits under the ODB program. Residents of homes that are a part of the Ministry’s Community Homes for Opportunity program are also eligible for benefits under the ODB program.
Policy for establishing eligibility for payment applies (see Section 4.2).

Patient eligibility (i.e., residents of Homes for Special Care/Community Homes for Opportunity) can be confirmed by contacting the MOH’s Financial Management Branch (FMB) at: 416-326-9842.

See Acceptable Supporting Documentation requirements.

How recipients are identified:

- Names and Health numbers of eligible recipients are provided by the home

Required claim information:

- Enter Health number in Client ID # field
- Include version code if embossed on Health Card
- Enter the HSC/CHO identification number (ODP number) in the Group Number field
- If the claim is rejected at the time of dispensing due to recipient ineligibility, the pharmacy may establish eligibility by entering an appropriate intervention code (see Section 4.2 for further details) once eligibility has been confirmed by FMB. Documentation of the call (including ODB Help Desk ticket # if it was contacted) must be recorded and maintained for the Retention Period for claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable.

Co-payment:

- Recipients 25 years of age and older may pay up to $2 (co-payment) for each prescription for an eligible benefit
- Recipients 24 years of age and under have no co-payment

Trillium Drug Program

The Trillium Drug Program (TDP) helps people who have high drug costs in relation to their incomes. The TDP benefit year begins August 1st and an annual deductible is
Ontario Drug Programs Reference Manual 44

determined for each household. The deductible is payable quarterly, and ODB eligible drug costs must be paid by the individual up to the deductible level before eligibility for coverage begins for that quarter. All claims are also subject to ODB payment rules (e.g., drug benefit price, dispensing fees, mark-up). The TDP deductible is based on income and household size.

Individuals may qualify for TDP if they:

- Have a valid Ontario Health number
- Are not currently eligible to receive drug benefits under the ODB program
- Do not have prescription drug costs fully covered by a private insurance plan
- Have high drug costs relative to their income (usually three to four per cent).

Policy for establishing eligibility for payment does not apply (see Section 4.2).

How applicants/recipients are identified:

- TDP recipients who have enrolled in the program will present a valid Health number.

Health Card Samples:
Required claim information:

- Enter the Health number in the Client ID # field
- Include the version code if embossed on the Health Card

Deductible/co-payment:

For TDP recipients who have not met the deductible requirements, HNS will process the prescription claim showing progress toward the quarterly deductible. Applicants with a private insurance plan that includes drug benefits who have not met their TDP deductible should submit their original prescription receipts to the TDP that show the amount that they spent out-of-pocket towards their ODB eligible prescriptions. Once the receipts are received by the TDP, they will be processed manually and the amount that was spent on ODB eligible benefits will be applied to the quarterly deductible. Once the deductible has been met, HNS can process ODB eligible prescription claims with a $2 co-payment amount.

For TDP recipients who have met deductible requirements, HNS will process ODB prescription claims with a $2 co-payment amount.

To enroll in TDP, applicants must complete and submit an Application for Trillium Drug Program form along with all necessary documents to TDP (e.g., prescription drug receipts, private insurance documentation, and financial documentation). A Guide to Understanding the Trillium Drug Program can be found on the Government of Ontario’s website.

In addition, program details and deadlines may be obtained from:

Trillium Drug Program
P.O. Box 337, Station D
Etobicoke, ON
M9A 4X3

Tel: 416-642-3038
Fax: 416-642-3034
Toll-Free: 1-800-575-5386
TTY: 1-800-387-5559
Further Information on the Trillium Drug Program:

The TDP benefit year runs from August 1st of one year to July 31st of the following year. The annual deductible is paid in four installments over the TDP benefit year. For example, a family with an annual deductible of $500 will pay $125 for prescriptions purchased at the start of each quarter on August 1st, November 1st, February 1st, and May 1st.

After the deductible is paid in each quarter, the household will receive benefits for that quarter and may be charged up to $2 per prescription for an eligible drug product. Any unpaid deductible in a quarter will be added to the next quarter’s deductible. Any unpaid deductible amount at benefit year-end does not transfer to the following benefit year. The household is re-assessed, and a new annual deductible is calculated at the start of each new benefit year.

By regulation, drugs costs covered by any third party (i.e., private insurers, employers or manufacturers / patient support programs) do not count towards the TDP deductible. **TDP deductibles must be paid out-of-pocket by the household.**

Any claim for a TDP recipient that causes a quarterly deductible for the TDP household to be reached will receive the following response code:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>“EM”</td>
<td>ODB pricing-TDP deductible reached</td>
</tr>
</tbody>
</table>

New applicants to TDP can choose the date within the program year on which they wish eligibility to begin (i.e., start date). Applicants are not required to select a start date at the time they submit the application. They may apply and be enrolled, with a start date to be selected later. When a household is ready to select a start date, the pharmacy may contact the TDP during business hours with the selected start date, which will be applied immediately.

The deductible is prorated based on the number of days left in the benefit year. The prorated deductible applies only for the first year of enrollment into the program.
Prescriptions filled and paid for by the individual or household prior to the chosen start date will not count towards the prorated deductible. Claims submitted for a date of service prior to the chosen enrolment start date will be rejected with one of the following response codes:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;EL&quot;</td>
<td>Prior to prorated start date</td>
</tr>
<tr>
<td>&quot;C8&quot;</td>
<td>No record of beneficiary</td>
</tr>
</tbody>
</table>

Each benefit year, Trillium recipients enrolled in the previous benefit year will automatically be renewed unless one of the following conditions applies:

- Consent for the Ministry to access any household member income information from Canada Revenue Agency (CRA) is missing.
- Any household member is turning 16 years of age prior to August 1st.
- The household has not utilized the TDP for the two consecutive previous benefit years.
- All members of the household are over 65 years of age.

A confirmation letter is mailed to households starting June of each year confirming TDP renewal details for the upcoming benefit year. Households are required to inform the program of any changes or incorrect enrolment information.

**Eligible expenses that can be counted towards TDP deductible:**

Allowable, out-of-pocket drug expenses that will count towards the Trillium deductible include the cost (i.e., product price and dispensing) of the following products, if used by a member of the TDP household:

- Drug products listed as ODB benefits in the ODBF/CDI (e.g., General Benefits, General Benefits with Therapeutic Notes, Limited Use (LU) Benefits (if clinical criteria are met), products on the Facilitated Access list).

- Therapeutic substances listed as benefits in the ODBF/CDI (e.g., nutrition products, diabetic testing agents, and valved holding chambers if applicable eligibility criteria are met, see section 6).
• Extemporaneous preparations designated as pharmaceutical products under the ODBA.

• Products approved under the EAP.

• Products listed in Schedule 2 to O. Reg. 201/96 (i.e., insulin, adrenocorticotropic hormones, or nitrate vasodilators).

**Note:** As there are no co-payments or deductibles for children and youth 24 years of age and under who are ODB eligible outside of the TDP (e.g., OHIP+, social assistance), there will be no out-of-pocket expenditures for these household members to count towards the TDP annual deductible.

**Drug quantity:**

For Trillium eligible recipients, the Ministry will pay for the lesser of a 100 days’ supply or a quantity sufficient to extend up to 30 days after the end of the TDP eligibility period (e.g., in July, a quantity sufficient to last until August 30 will be covered). In addition, to ensure proper application of the TDP for households that have not met their annual deductibles as of the third quarter, the days’ supply for claims submitted during this period cannot exceed more than 30 days beyond the end of the quarter (i.e., beyond May 30th of each benefit year). HNS automatically calculates the days’ supply in these circumstances and will not reimburse any excess amounts. The TDP 100 days’ supply limit applied to TDP recipients will be reduced for each day after February 20th (i.e., the days’ supply limit for a February 21st dispense date will be 99 reducing by 1 with each passing day). The last two months of the benefit year are left open to collect outstanding deductible contributions prior to the end of the benefit year.

**Health Card Version Codes**

Version codes were introduced to uniquely identify a Health Card and allow the Ministry to verify the status of a Health Card to reduce fraud. While all photo Health Cards have a version code, some red and white Health Cards do not.

Enter the one- or two-character version code in the Client ID # field, appearing immediately after the Health number, if shown (or embossed) on the Health Card:
Processing of claims with missing or incorrect version codes will result in the following response code:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>“CK”</td>
<td>Health Card Version Code error (Information Message only*)</td>
</tr>
</tbody>
</table>

*Information Messages may be cautionary in nature or may simply provide additional information. Do not respond to an Information Message. The claim has been approved for payment.

An attempt to override the “CK” response code with an intervention/exception code will cause the claim to reject.

Contact the recipient to obtain his/her accurate (current) Health Card version code information and update your records.

If discrepancies in Health Card version codes are not resolved, recipients can contact ServiceOntario. Find the closest ServiceOntario location online or contact the ServiceOntario INFOline at 1-866-532-3161 for more information.
4.2 Policy for Establishing Payment Eligibility

The Ministry has implemented a policy for establishing eligibility for recipients who are not deemed eligible on HNS.

Claim Validation

Supporting documentation may be requested by the Ministry at any time.

For claim validation purposes and in accordance with O Reg 264/16 under the DPRA if applicable, pharmacies and dispensing physicians are required to maintain supporting documentation that verifies a patient’s eligibility on file for the Retention Period. The supporting documentation that must be obtained and maintained is specific to the type of eligible person. Please see Acceptable Supporting Documentation requirements or Section 4.1 for further details.

Response Codes

HNS will reject claims for recipients deemed ineligible at the time of dispensing with one of the following response codes:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>“32”</td>
<td>Client ID # error (i.e., Health number incorrectly entered in the Client ID # field or incorrect in the HNS database)</td>
</tr>
<tr>
<td>“C2”</td>
<td>Service provided before effective date</td>
</tr>
<tr>
<td>“C3”</td>
<td>Coverage expired before service</td>
</tr>
<tr>
<td>“C8”</td>
<td>No record of this beneficiary (i.e., Ministry not advised of eligibility of recipient)</td>
</tr>
<tr>
<td>“CJ”</td>
<td>Patient not covered by this plan (i.e., may be covered under another plan)</td>
</tr>
</tbody>
</table>
Note: The policy for establishing eligibility for payment does not apply to:

- Seniors
- TDP households

If HNS rejects a claim for seniors or TDP households who have proof of eligibility under one of these programs, you may refer:

- TDP households to the Ministry 416-642-3038, or 1-800-575-5386 (outside Toronto)
- Seniors to ServiceOntario INFOline at 1-866-532-3161

Eligibility Override Codes

If proof of eligibility has been established, Eligibility Override Codes can be used by pharmacies to override the Response Code and complete the dispensing transaction for the following ODB eligibility classes only:

- ODSP
- OW
- Home Care
- LTC
- HSC/CHO
- Children and youth who do not have a private plan (OHIP+)

The pharmacy has access to two levels of Eligibility Override Codes:

- Level 1: Standard Override
- Level 2: Emergency Override

Level 1: Standard override (applies to response code “C2”, “C3”, “C8” or “CJ”)

If the recipient:

- presents with a valid Drug Benefit Eligibility Card or other written notification
• in the case of a child or youth, presents with an Ontario Health number or the detachable portion of the Ontario Health Coverage Infant Registration Form and confirms that they do not have a private plan
• has been confirmed as eligible through the SAV helpline
• is a confirmed resident of an LTC home or HSC/CHO

and the eligibility number is rejected, the pharmacy may establish eligibility by entering:

• Carrier ID (or Plan Code, as shown on the Drug Benefit Eligibility Card / fax notification or as indicated in the table below)
• Date of Birth
• Gender
• “ML” in the Intervention/Exception Code field
• Pharmacist ID

**Note:** If intervention code “ML” does not change the response code, advise the recipient to contact the agency responsible for the recipient’s ODB eligibility or Ontario Health number in the case of children and youth (e.g., MCCSS, ServiceOntario, etc.).

For Home Care recipients with an eligibility number that begins with ‘08’ that is rejected, the pharmacy may establish eligibility by entering the following:

• Carrier ID / Plan Code “P”
• Date of Birth
• Gender
• “ML” in the Intervention/Exception code field
• Pharmacist ID

‘Note: Do not use the “MK” intervention code for recipients with an eligibility number that begins with ‘08’. Using “MK” will result in the claim being rejected with the response codes “C8” (no record of beneficiary) and “65” (intervention/exception code error).
The eligibility established by a standard override is effective from the date established until the end of the eligibility establishment period.

For children and youth who do not have a private plan, the eligibility established by the standard override ("ML") is effective for one day only (i.e., the date of service). Eligibility can be re-established on subsequent days if required.

**Level 2: Emergency override (applies to response code “32”)**

When a Client ID # error is detected, the pharmacy must verify the Client ID # with the referring agency. If the pharmacy deems that the recipient’s health may be at risk, eligibility can be established by entering:

- Carrier ID (or Plan Code, as shown on the Drug Benefit Eligibility Card)
- Date of Birth
- Gender
- “MK” in the Intervention/Exception Code field
- Pharmacist ID

The eligibility established by an emergency override (“MK”) is effective for one day only (i.e., the date of service).

Processing of claims exceeding the limitation will result in the following response code:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>“CL”</td>
<td>Exceeds good faith limit</td>
</tr>
</tbody>
</table>

The eligibility establishment limitation can be overridden, with valid reason, by entering:

- “MW” in the Intervention/Exception Code field
- Pharmacist ID
Eligibility Establishment Summary

The policy for establishing eligibility for payment has different eligibility establishment (availability) periods and limitations depending upon the program, and is only applicable when recipients present proof of eligibility.

Availability periods and limitations are shown below for the different programs:

<table>
<thead>
<tr>
<th>Carrier ID (Plan Code)</th>
<th>Program</th>
<th>Eligibility Establishment Availability Periods (Level 1: Standard Override)</th>
<th>Eligibility Establishment Availability Periods (Level 2: Emergency Override)</th>
</tr>
</thead>
<tbody>
<tr>
<td>“A”</td>
<td>Higher Income Seniors</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td>“E”</td>
<td>LTC</td>
<td>To end of current month</td>
<td>Date of service only (one day)</td>
</tr>
<tr>
<td>“P”</td>
<td>Home Care</td>
<td>30 days</td>
<td>Date of service only (one day)</td>
</tr>
<tr>
<td>“C”***</td>
<td>MCCSS-ODSP</td>
<td>To end of current month</td>
<td>Date of service only (one day)</td>
</tr>
<tr>
<td>“D”***</td>
<td>MCCSS-OW</td>
<td>To end of current month</td>
<td>Date of service only (one day)</td>
</tr>
<tr>
<td>“H”</td>
<td>HSC/CHO</td>
<td>Current month + one month**</td>
<td>Not available</td>
</tr>
<tr>
<td>“T”</td>
<td>TDP</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td>“R”</td>
<td>Lower Income Seniors</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td>“J”</td>
<td>Children and Youth</td>
<td>Date of service only</td>
<td>Not available</td>
</tr>
</tbody>
</table>
*Limitation: 15 claims per recipient per program year. For more details on ODSP and OW eligibility, please refer to section 4.1

**Contact FMB at 416-326-9842 to request confirmation of patient eligibility.

***Only plan code C or D should be used for patients eligible for social assistance. Historically, individual OW offices used specific plan codes, such as L, M, N and Y. Some OW offices continue to issue paper drug cards using these other plan codes. The system has been centralized and all OW clients are under Plan D. If pharmacists receive an error response code, even after entering the claim using Plan D, they would confirm the client’s social assistance eligibility for the period in question through the SAV helpline.
Section 5: Standard Online Claims

Overview

This section explains the procedures on how to:

- Submit a standard online claim (see Section 5.1)
- Submit a standard (or non-standard) online claim reversal (see Section 5.2)
- Reconcile online claim and reversal transactions (see Section 5.3)
- Request payment information for any of the most current seven days
  - Daily Totals (see Section 5.4)
  - Claim Details (see Section 5.5)
  - Same Day Reversal Details (see Section 5.6)
  - Prior Day Reversal Details (see Section 5.7)

This section also outlines the different HNS generated system responses that confirm payment approval or transaction rejection, and how pharmacies may intervene by reversing and resubmitting a claim and/or by including applicable intervention/exception codes with each transaction.

Conditions for Payment of Dispensing Fees

In order to receive payment of a dispensing fee under the ODB program, the dispenser must supply at one time the lesser of:

1. The maximum quantity of the listed drug product that the dispenser is authorized to supply at one time; or

2. The maximum quantity of a listed drug product for which the Executive Officer is required to pay under section 18 of O. Reg. 201/96.

The amount referred to above (in either item 1 or 2) is the “Maximum Quantity.”
This condition for receiving a dispensing fee does not apply in the following scenarios:

1. The ODB recipient is a resident of a residential facility, other than a long-term care home, funded by the Government of Ontario that is designated by the Executive Officer (e.g., Home for Special Care) and published on the Ministry website at: “Other Homes List”.*

2. The listed drug product is a product or belongs to a class of drug product that is specified by the Executive Officer and published on the Ministry website at: “Exempted Medication List No. 1” and the dispenser has determined that the quantity supplied should be less than the Maximum Quantity because, in the dispenser’s professional opinion,
   a. The safety of the ODB recipient is a concern, or
   b. There is a risk of abuse or diversion if the drug product is supplied to the ODB recipient.* and **

3. The dispenser has determined that the quantity supplied should be less than the Maximum Quantity, because,
   a. in the dispenser’s professional opinion, the eligible person is incapable of managing his or her medication as a result of physical, cognitive or sensory impairment, and
   b. the eligible person or the person presenting the prescription agrees that the quantity supplied should be less than the Maximum Quantity

*Note: In the case of Exceptions 1 and 2, ODB recipients who are deemed to require more frequent dispensing should be assessed regularly to verify an ongoing need for more frequent dispensing.

**Note: In the case of Exception 2, the dispenser must perform all of the following:

- The dispenser must make a written record of the reasons for his or her opinion;
- The dispenser must notify the prescriber in writing about the assessment and retain a copy of the notification; and
Upon request, the dispenser must provide the Ministry with copies of the written record and the written notification to the prescriber.

**Note:** In the case of Exception 3, the dispenser must perform all of the following:

- The dispenser must make a written record of the reasons for his or her opinion. The nature of the physical, cognitive or sensory impairment must be clearly documented;
- The dispenser must notify the prescriber in writing about the assessment and retain a copy of the notification;
- The pharmacy shall obtain in writing the agreement of the ODB recipient or the person presenting the prescription for the reduced quantity (i.e., patient / agent’s signature on the record of authorization);
- Upon request, the dispenser must provide the Ministry with copies of the written record, agreement and notification to the prescriber; and
- Assessment and documentation records are only valid for 365 days and must be re-evaluated annually. The following must be re-assessed and updated annually, and maintained as part of the ODB recipient’s permanent pharmacy health record:
  - A dispenser’s assessment that a patient requires more frequent dispensing;
  - Notification to the prescriber, and:
  - Record of the authorization received from the ODB recipient (or person presenting the prescription) for dispensing in reduced quantities (i.e., patient or agent’s signature for the reduced quantity).

**All dispensing fees are subject to recovery if found to be ineligible for payment under the ODB program.**

**Two Fees/28 Days**

In most cases, the Executive Officer will only pay a pharmacy a maximum of two dispensing fees per 28 days for the supply of a listed drug product, even if the prescription directs more frequent dispensing. This rule is subject to the rule respecting [Chronic-Use Medications](#) (see section below).
Subject to any additional requirements in the ODBA Regulation, the two-dispensing-fees-per-month rule does not apply if:

1. The ODB recipient is a resident of a residential facility, other than a long-term care home, funded by the Government of Ontario that is designated by the Executive Officer (e.g., Homes for Special Care) and included in the “Other Homes List”.

2. The listed drug product is a product or belongs to a class of drug product that is specified by the Executive Officer and included in the “Exempted Medication List No. 1” and the dispenser has determined that the quantity supplied should be less than the Maximum Quantity because, in the dispenser’s professional opinion,
   a. The safety of the ODB recipient is a concern, or
   b. There is a risk of abuse or diversion if the drug product is supplied to the ODB recipient.

3. The listed drug product is supplied in the Maximum Quantity (see definition above) and is a product or belongs to a class of drug product that is specified by the Executive Officer and included in the “Exempted Medications List No. 2”.

Dispensing Fees for Chronic-Use Medications

There is a limit on the number of dispensing fees that can be billed to the Executive Officer for certain chronic-use medications included in the “Chronic Medications List”. Dispensers are entitled to receive a maximum of five dispensing fees per 365-day period, commencing on the day the first claim for an identified chronic-use medication is submitted to the Ministry. Dispensers are encouraged to provide most ODB recipients with a 100 days’ supply of most chronic-use medications to ensure that they receive a dispensing fee for each dispensing event. Subject to any requirements in O. Reg. 201/96, this limit on the number of dispensing fees for chronic-use medications does not apply in the circumstances listed below. In these circumstances, the general rule of a maximum of two-dispensing-fees-per-28-days applies, unless the dispensing event is also exempt from that rule (see section above).
1. The ODB recipient is a resident of a residential facility, other than a long-term care home, funded by the Government of Ontario that is designated by the Executive Officer (e.g., Home for Special Care) and included in the list below (see “Other Homes List”).

2. The listed drug product dispensed is an extemporaneous preparation.

3. The ODB recipient is on a complex medication regime where patient safety is at risk and requires more frequent dispensing of the listed drug product to assist with the proper administration of the medication regime. **

4. The dispenser dispenses less than the Maximum Quantity because in the dispenser’s professional opinion, the ODB recipient is incapable of managing his or her medication as a result of physical, cognitive or sensory impairment, and the ODB recipient or the person presenting the prescription has consented to obtaining the lesser quantity. **

The chronic-use medications subject to this rule are listed on the Ministry website: Chronic-use Medications List by Generic Name.

**Note:** In the case of Exception 3 and 4, the dispenser must perform all of the following:

- The dispenser must make a written record of the reasons for his or her opinion. The nature of the physical, cognitive or sensory impairment or complex medication regimen must be clearly documented, including clinical or safety risks to the patient if larger quantities were dispensed;

- The dispenser must notify the prescriber in writing about the assessment and retain a copy of the notification;

- The dispenser must obtain in writing the agreement of the ODB recipient or the person presenting the prescription for the reduced quantity (i.e., patient / agent’s signature on the record of authorization);

- Upon request, the dispenser must provide the Ministry with copies of the written record, agreement and notification to the prescriber; and

- Exceptions 3 and 4 are only valid for a period of 365 days. A dispenser’s assessment that a patient requires more frequent dispensing, notification to the prescriber and record of the authorization received from the ODB recipient
(or person presenting the prescription) for dispensing in reduced quantities, (i.e., patient or agent’s signature for the reduced quantity) must be reassessed, and updated annually, and maintained as part of the ODB recipient’s permanent pharmacy health record.

All dispensing fees are subject to recovery if found to be ineligible for payment under the ODB program.

**Note:** Any reference in this section to the term “written”, “in writing” or “written record” includes electronic scanned images of original paper documents or electronic records of written records.

Please refer to Section 12: Inspection for more information about recordkeeping requirements for the records relating to dispensing fees described above.

### 5.1 To Submit a Standard Online Claim

A standard online claim must conform to the CPhA Pharmacy Claim Standard Version 3 and includes the following information:

<table>
<thead>
<tr>
<th>Required Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank ID Number</td>
<td>610054</td>
</tr>
<tr>
<td>Version Number</td>
<td>CPhA Pharmacy Claim Standard Version currently used (i.e., Version 3)</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>‘01’</td>
</tr>
<tr>
<td>Provider Software ID</td>
<td>CPhA-assigned code, identifying pharmacy software currently used</td>
</tr>
<tr>
<td>Provider Software Version</td>
<td>Pharmacy Software Vendor (PSV)-assigned code, identifying the version of the pharmacy software currently used</td>
</tr>
<tr>
<td>Pharmacy ID Code</td>
<td>CPhA number or Ministry-assigned number of the pharmacy, (see Section 2.1)</td>
</tr>
<tr>
<td>Provider Transaction Date</td>
<td>Date (YYMMDD) of service</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Group Number or Code</td>
<td>LTC home number for recipients from LTC, or HSC number for recipients of HSC, (see list of LTC homes and/or HSC)</td>
</tr>
<tr>
<td>Client ID # or Code</td>
<td>Recipient identification number (see Section 4)</td>
</tr>
<tr>
<td>Patient First Name</td>
<td>First name of patient</td>
</tr>
<tr>
<td>Patient Last Name</td>
<td>Last name of patient</td>
</tr>
<tr>
<td>Provincial Health Care ID Code</td>
<td>To be provided, if different from the Client ID # or Code; otherwise, may be blank</td>
</tr>
<tr>
<td>Current Prescription Number</td>
<td>Unique prescription number (from the prescription label or record of service)</td>
</tr>
<tr>
<td>DIN/GP#/?PIN</td>
<td>DIN/PIN of product, (see Appendix A for Extemporaneous Mixture DIN/PINs, Appendix C for Emergency Authorization Products and Appendix D for Allergen Products)</td>
</tr>
<tr>
<td>SSC</td>
<td>Required for claims for children and youth 24 years of age and under who have no private plan.</td>
</tr>
<tr>
<td>Quantity</td>
<td>Quantity dispensed</td>
</tr>
<tr>
<td>Days Supply</td>
<td>Estimated number of days (as accurate as possible) supplied by the prescription</td>
</tr>
<tr>
<td>Prescriber ID Reference</td>
<td>Reference number for prescriber, (see prescriber ID reference chart noted below)</td>
</tr>
<tr>
<td>Prescriber ID</td>
<td>Prescriber license number</td>
</tr>
<tr>
<td>Drug Cost/Product Value</td>
<td>Total drug cost or product value</td>
</tr>
</tbody>
</table>
Cost Mark-up
- Enter the mark-up amount, 8% when the total drug cost is less than $1,000.00 or 6% when the total drug cost is greater than or equal to $1,000.00

Professional Fee
- Professional fee (i.e., the lesser of the pharmacist’s usual/customary dispensing fee or the applicable ODB fee prescribed by regulation), can be equal to 0, (see conditions for payment of dispensing fees)

Please refer to your PSV manual for specific instructions on how to use your pharmacy software for this type of transaction.

Note: Additional fields may be required for non-standard online claims (see Section 6) and claim transactions where eligibility is established (see Section 4.2).

Prescriber ID Reference Chart

<table>
<thead>
<tr>
<th>Prescriber Regulatory College</th>
<th>Prescriber ID Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>College of Physicians &amp; Surgeons of Ontario</td>
<td>01</td>
</tr>
<tr>
<td>Royal College of Dental Surgeons of Ontario*</td>
<td>02</td>
</tr>
<tr>
<td>College of Chiropodists of Ontario</td>
<td>03</td>
</tr>
<tr>
<td>Carrier Designated Out of Province ID</td>
<td>05</td>
</tr>
<tr>
<td>College of Midwives of Ontario</td>
<td>08</td>
</tr>
<tr>
<td>Ontario College of Pharmacists</td>
<td>09</td>
</tr>
<tr>
<td>College of Optometrists of Ontario</td>
<td>43</td>
</tr>
<tr>
<td>College of Nurses of Ontario</td>
<td>44</td>
</tr>
<tr>
<td>College of Naturopaths of Ontario</td>
<td>NO</td>
</tr>
</tbody>
</table>
For most dentists, the licensing number has a prefix, “D”, which should be entered for adjudications. However, for some dentists, no prefix is used (i.e., just submit the number), or the prefix may be an “S”, “A”, “M”, or “E”.

Note: For unknown prescribers, pharmacists must enter prescriber ID = 99999 and prescriber ID reference = 99. This mechanism is to be used only as a last resort for the adjudication of ODB claims, and is not permitted on submissions to the NMS.

In circumstances where pharmacists are extending, adapting or initiating a prescription, the pharmacist becomes the prescriber of that medication and this must be recorded appropriately for the HNS claim that is submitted to the Ministry. For details on how to register a pharmacist's licence # in the HNS, please see registration, Section 2.1.

Pharmacists must include their pharmacist ID number (i.e., pharmacist license #) in the prescriber field for all expanded scope of practice activities. This includes but is not limited to:

- Prescribing under the expanded scope of practice (e.g., smoking cessation drugs).
- Authorizing renewals of chronic medications (without consulting the original prescriber).
- Administering publicly funded influenza vaccine.
- Providing professional pharmacy services (e.g., MedsCheck).
System Response: Standard (and Non-Standard) Online Claims

The system response will provide the following details:

<table>
<thead>
<tr>
<th>Response Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication Date*</td>
<td>Date (YYMMDD) assigned to the transaction by HNS</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>&quot;51&quot;</td>
</tr>
<tr>
<td>Reference Number</td>
<td>Internal reference number assigned by HNS</td>
</tr>
</tbody>
</table>
| Response Status | A = Accepted as transmitted, no adjustments  
B = Accepted with prescription price adjustment  
R = Rejected claim |
| Response Code | (See Section 10.1 for valid response codes) |
| Drug Cost/Product Value | Allowed drug cost or product value |
| Cost Mark-up | Allowed mark-up amount on cost of dispensed product |
| Professional Fee | Allowed professional fee |
| Compounding Charge | Allowed compounding charge |
| Deductible to Collect | Deductible or co-payment amount which provider collects from recipient |
| Plan Pays | Total amount payable for the claim |
| Message Data Line Number 1 | Detailed response information |
| Message Data Line Number 2 | Detailed response information |
The adjudication date allows for a uniform method of identifying timeframe for accounting and reconciliation purposes. It begins at 3:30 a.m. (Eastern Time) and concludes 24 hours later.

**Note:** During early morning hours, the adjudication date will not be the same as the provider transaction date.

### 5.2 To Reverse a Standard (or Non-Standard) Online Claim

Online claims submitted on any one of the most recent 90 days, including the current date, can be reversed online for any reason, including any of the following situations:

- The Ministry was overcharged
- Payment has been allocated for a prescription not picked up
- Erroneous claim (i.e., incorrect information) was submitted
- Subsequent to a DUR intervention

An online claim reversal conforms to the CPhA Pharmacy Claim Standard Version 3 and must include the following information:

<table>
<thead>
<tr>
<th>Required Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank ID Number</td>
<td>610054</td>
</tr>
<tr>
<td>Version Number</td>
<td>CPhA Pharmacy Claim Standard Version currently used (i.e., Version 3)</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>“11”</td>
</tr>
<tr>
<td>Provider Software ID</td>
<td>CPhA-assigned code, identifying pharmacy software currently used</td>
</tr>
<tr>
<td><strong>Provider Software Version</strong></td>
<td>PSV-assigned code, identifying the version of the pharmacy software currently used</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Intervention/Exception Code</strong></td>
<td>Code used to reverse transactions as a result of DUR intervention, (see Section 9.3) (if applicable)</td>
</tr>
<tr>
<td><strong>Pharmacy ID Code</strong></td>
<td>CPhA number or Ministry-assigned number of the pharmacy, (see Section 2.1)</td>
</tr>
<tr>
<td><strong>Provider Transaction Date</strong></td>
<td>Date (YYMMDD) of service of claim to be reversed</td>
</tr>
<tr>
<td><strong>Trace Number</strong></td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td><strong>Client ID # or Code</strong></td>
<td>Recipient identification number entered on the claim to be reversed</td>
</tr>
<tr>
<td><strong>Current Prescription Number</strong></td>
<td>Unique prescription number entered on the claim to be reversed</td>
</tr>
<tr>
<td><strong>Adjudication Date</strong></td>
<td>Date (YYMMDD) on which claim to be reversed was originally adjudicated</td>
</tr>
</tbody>
</table>

*Please refer to your PSV manual for specific instructions on how to use your pharmacy software for this type of transaction.*

**Note:** If more than 90 days have elapsed since the claim was initially processed and accepted by HNS, the claim must be reversed manually using the Drug Benefit Claim Reversal form (see Section 8).
**System Response: Online Claim Reversal**

The system response will provide the following details:

<table>
<thead>
<tr>
<th>Response Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication Date</td>
<td>Date (YYMMDD) assigned to the transaction by HNS</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>&quot;61&quot;</td>
</tr>
<tr>
<td>Reference Number</td>
<td>Internal reference number assigned by HNS</td>
</tr>
<tr>
<td>Response Status</td>
<td>R = Rejected Reversal</td>
</tr>
<tr>
<td></td>
<td>V = Reversal Accepted</td>
</tr>
<tr>
<td>Response Code</td>
<td>(See Section 10.1 for valid response codes)</td>
</tr>
</tbody>
</table>

5.3 **Reconciliation of Online Claims and Reversals**

At the end of each business day (after all transactions have been processed), submit a request for Daily Totals to use for reconciliation (see Section 5.4).

You can submit and review online the Daily Totals (or details) for any one of the most recent seven days, including the current day. Outside of that range, your online request will be rejected.

Compare the claim totals provided by HNS against the claim totals generated by your pharmacy software. Identify and resolve any discrepancies.

For discrepancies that cannot be resolved, submit a request for claim details and reversal details for a specified adjudication date. Do a claim by claim comparison against the details generated by your pharmacy software (see Section 5.5, Section...
5.6 and Section 5.7). The table below will help identify which claims details request to submit:

<table>
<thead>
<tr>
<th>Discrepancies for</th>
<th>Details Request</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Number or Value of Claims Approved</td>
<td>Claim Details (see Section 5.5)</td>
</tr>
<tr>
<td>Total Number or Value of Same Day Reversals</td>
<td>Same Day Reversal Details (see Section 5.6)</td>
</tr>
<tr>
<td>Total Number or Value of Prior Day Reversals</td>
<td>Prior Day Reversal Details (see Section 5.7)</td>
</tr>
</tbody>
</table>

Before submitting a detailed request, identify an adjudication date during which the discrepancy may have occurred. This will enable you to narrow down the range/volume of details by specifying:

- Beginning of Record, i.e., the prescription number which precedes the prescription for which the request is to begin.
- End of Record, i.e., the prescription number of the last prescription to be included in the request.

The maximum number of details provided per system response is 14, sequenced in time of day order.

If you are unable to resolve discrepancies based on the first 14 details provided by the initial system response, submit another request for the next fourteen 14 details.

*Please refer to your PSV manual for specific instructions on how to generate the claim totals using your pharmacy software.*

### 5.4 To Request Daily Totals

Daily totals should be requested from HNS at the end of each business day and compared against the claim totals generated by your actual reimbursement as calculated through your accounting processes.
Daily totals can only be requested for claim transactions processed for any one of the most recent seven days, including the current day.

A daily totals transaction conforms to the CPhA Pharmacy Claim Standard Version 3 and must include the following information:

<table>
<thead>
<tr>
<th>Required Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank ID Number</td>
<td>610054</td>
</tr>
<tr>
<td>Version Number</td>
<td>CPhA Pharmacy Claim Standard Version currently used (Version 03)</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>“30”</td>
</tr>
<tr>
<td>Provider Software ID</td>
<td>CPhA-assigned code, identifying pharmacy software currently used</td>
</tr>
<tr>
<td>Provider Software Version</td>
<td>PSV-assigned code, identifying the version of the pharmacy software currently used</td>
</tr>
<tr>
<td>Pharmacy ID Code</td>
<td>CPhA number or Ministry-assigned number of the pharmacy, (see Section 2.1)</td>
</tr>
<tr>
<td>Provider Transaction Date</td>
<td>Date (YYMMDD) on which the pharmacy sends the request</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Adjudication Date</td>
<td>Adjudication date (YYMMDD) for which daily totals are being requested</td>
</tr>
</tbody>
</table>

Please refer to your PSV manual for specific instructions on how to use your pharmacy software for this type of transaction.
**System Response: Daily Totals**

The system response will provide the following details:

<table>
<thead>
<tr>
<th><strong>Response Fields</strong></th>
<th><strong>Explanation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication Date</td>
<td>Date (YYMMDD) assigned to the transaction by HNS</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>“80”</td>
</tr>
<tr>
<td>Reference Number</td>
<td>Internal reference number assigned by HNS</td>
</tr>
<tr>
<td>Response Status</td>
<td>Y = Accumulated Daily Totals&lt;br&gt;R = Request Rejected</td>
</tr>
<tr>
<td>Response Code</td>
<td>(See Section 10.1 for valid response codes)</td>
</tr>
<tr>
<td>Total Number of Claims Approved</td>
<td>Number of approved claims for requested date</td>
</tr>
<tr>
<td>Total Value of Claims Approved*</td>
<td>Value of claims approved for requested date</td>
</tr>
<tr>
<td>Total Number of Reversals</td>
<td>Number of reversals processed against claims approved for requested date</td>
</tr>
<tr>
<td>Total Value of Reversals*</td>
<td>Value of reversals processed against claims approved for requested date</td>
</tr>
<tr>
<td>Total Number of Prior Reversals</td>
<td>Number of reversals processed on requested date against claims processed previously</td>
</tr>
<tr>
<td>Total Value of Prior Reversals*</td>
<td>Value of reversals processed on requested date against claims processed previously</td>
</tr>
<tr>
<td>Date of Payment</td>
<td>Date of payment (by cheque or EFT deposit)&lt;br&gt;(See Section 11.4, Payment Schedule)</td>
</tr>
</tbody>
</table>
To calculate the net amount approved for payment for the requested adjudication date:

\[
\text{Net Amount Payable for the Adjudication Date} = (\text{Total Value of Claims Approved}) - (\text{Total Value of Reversals}) - (\text{Total Value of Prior Reversals})
\]

5.5 To Request Claim Details

Pharmacies can request claim details for claim transactions processed for any one of the most recent seven days, including the current day.

**Note:** Submit a request for claim details only if a discrepancy is noted for total number or value of claims approved.

A claim details transaction conforms to the CPhA Pharmacy Claim Standard Version 3 and must include the following information:

<table>
<thead>
<tr>
<th>Required Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank ID Number</td>
<td>610054</td>
</tr>
<tr>
<td>Version Number</td>
<td>CPhA Pharmacy Claim Standard Version currently used (i.e., Version 03)</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>“31”</td>
</tr>
<tr>
<td>Provider Software ID</td>
<td>CPhA-assigned code, identifying pharmacy software currently used</td>
</tr>
<tr>
<td>Provider Software Version</td>
<td>PSV-assigned code, identifying the version of the pharmacy software currently used</td>
</tr>
<tr>
<td>Pharmacy ID Code</td>
<td>CPhA number or Ministry-assigned number of the pharmacy, (see Section 2.1)</td>
</tr>
<tr>
<td>Provider Transaction Date</td>
<td>Date (YYMMDD) on which the pharmacy sends the request</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
</tbody>
</table>
Adjudication Date | Adjudication date (YYMMDD) for which claim details are being requested.
---|---
Beginning of Record* | Rx number of the last prescription that precedes the prescription for which the request is to begin
End of Record* | Rx number of the last prescription to be included in the request

*This will enable you to narrow down the range/volume of claim details by specifying these fields. If the value is zero, Beginning of Record defaults to the first prescription submitted on the requested date. End of Record defaults to the last prescription submitted on the requested date.

Please refer to your PSV manual for specific instructions on how to use your pharmacy software for this type of transaction.

**System Response: Claim Details**

The system response will provide the following details:

<table>
<thead>
<tr>
<th>Response Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication Date</td>
<td>Date (YYMMDD) assigned to the transaction by HNS</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>&quot;81&quot;</td>
</tr>
<tr>
<td>Reference Number</td>
<td>Internal reference number assigned by HNS</td>
</tr>
<tr>
<td>Response Status</td>
<td>Z = Detailed Record as Requested</td>
</tr>
<tr>
<td></td>
<td>R = Request Rejected</td>
</tr>
<tr>
<td>Response Code</td>
<td>(See <a href="#">Section 10.1</a> for valid response codes)</td>
</tr>
<tr>
<td>Number of Detail Records</td>
<td>Number of claim details included</td>
</tr>
</tbody>
</table>
Current Rx Number* | Prescription number of claim
---|---
Amount Payable* | Value of claim

*Current Rx Number and Amount Payable will be repeated for each claim detail.

The maximum number of claim details per system response is 14, sequenced in time of day order.

For additional claim details beyond the first 14 provided by the initial system response, submit another request for the next 14 claim details.

### 5.6 To Request Same Day Reversal Details

A same day reversal is a claim reversal processed on the same adjudication date as the original claim submission.

Note: Submit a request for same day reversal details only if a discrepancy is noted for total number or value of same day reversals.

A same day reversal details transaction conforms to the CPhA Pharmacy Claim Standard Version 3 and must include the following information:

<table>
<thead>
<tr>
<th><strong>Required Fields</strong></th>
<th><strong>Explanation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank ID Number</td>
<td>610054</td>
</tr>
<tr>
<td>Version Number</td>
<td>CPhA Pharmacy Claim Standard Version currently used (e.g., Version 03)</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>“32”</td>
</tr>
<tr>
<td>Provider Software ID</td>
<td>CPhA-assigned code, identifying pharmacy software currently used</td>
</tr>
<tr>
<td>Provider Software Version</td>
<td>PSV-assigned code, identifying the version of the pharmacy software currently used</td>
</tr>
<tr>
<td>Pharmacy ID Code</td>
<td>CPhA number or Ministry-assigned number of the pharmacy, (see Section 2.1)</td>
</tr>
</tbody>
</table>
Provider Transaction Date | Date (YYMMDD) on which the pharmacy sends the request
---|---
Trace Number | Pharmacy system-generated number assigned to the transaction
Adjudication Date | Adjudication date (YYMMDD) for which same day reversal details are being requested.
Beginning of Record* | Rx number of the last prescription that precedes the prescription for which the request is to begin
End of Record* | Rx number of the last prescription to be included in the request

*This will enable you to narrow down the range/volume of reversal details by specifying these fields. If the value is zero, Beginning of Record defaults to the first reversal transaction submitted on the requested date. End of Record defaults to the last reversal transaction submitted on the requested date.

Please refer to your PSV manual for specific instructions on how to use your pharmacy software for this type of transaction.

**System Response: Same Day Reversal Details**

The system response will provide the following details:

<table>
<thead>
<tr>
<th>Response Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication Date</td>
<td>Date (YYMMDD) assigned to the transaction by HNS</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>“82”</td>
</tr>
<tr>
<td>Reference Number</td>
<td>Internal reference number assigned by HNS</td>
</tr>
<tr>
<td>Response Status</td>
<td>Z = Detailed Record as Requested</td>
</tr>
<tr>
<td></td>
<td>R = Request Rejected</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Response Code</th>
<th>(See Section 10.1 for valid response codes.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Detail Records</td>
<td>Number of reversal details included</td>
</tr>
<tr>
<td>Current Rx Number*</td>
<td>Prescription number of reversal</td>
</tr>
<tr>
<td>Amount Reversed*</td>
<td>Value of reversal</td>
</tr>
</tbody>
</table>

*Current Rx Number and Amount Reversed will be repeated for each reversal detail.

The maximum number of reversal details per system response is 14, sequenced in time of day order. For additional reversal details beyond the first 14 provided by the initial system response, submit another request for the next 14 reversal details.

### 5.7 To Request Prior Day Reversal Details

A prior day reversal is a claim reversal processed on a later adjudication date than the original claim submission.

Pharmacies can request prior day reversal details for prior day reversals processed within the most recent seven days, including the current day.

**Note:** Submit a request for prior day reversal details only if a discrepancy is noted for the total number or value of prior reversals.

A prior day reversal details transaction must include the following information:

<table>
<thead>
<tr>
<th>Required Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank ID Number</td>
<td>610054</td>
</tr>
<tr>
<td>Version Number</td>
<td>CPhA Pharmacy Claim Standard Version currently used (i.e., Version 03)</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>&quot;33&quot;</td>
</tr>
<tr>
<td>Provider Software ID</td>
<td>CPhA-assigned code, identifying pharmacy software currently used</td>
</tr>
<tr>
<td>Provider Software Version</td>
<td>PSV-assigned code, identifying the version of the pharmacy software currently used</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pharmacy ID Code</td>
<td>CPhA number or Ministry-assigned number of the pharmacy. (see Section 2.1)</td>
</tr>
<tr>
<td>Provider Transaction Date</td>
<td>Date (YYMMDD) on which the pharmacy sends the request</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Adjudication Date</td>
<td>Adjudication date (YYMMDD) for which prior day reversal details are being requested.</td>
</tr>
<tr>
<td>Beginning of Record*</td>
<td>Rx number of the last prescription that precedes the prescription for which the request is to begin</td>
</tr>
<tr>
<td>End of Record*</td>
<td>Rx number of the last prescription to be included in the request</td>
</tr>
</tbody>
</table>

*This will enable you to narrow down the range/volume of reversal details by specifying these fields. If the value is zero (0). Beginning of Record defaults to the first reversal transaction submitted on the requested date. End of Record defaults to the last reversal transaction submitted on the requested date.

Please refer to your PSV manual for specific instructions on how to use your pharmacy software for this type of transaction.

**System Response: Prior Day Reversal Details**

The system response will provide the following details:

<table>
<thead>
<tr>
<th>Response Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication Date</td>
<td>Date (YYMMDD) assigned to the transaction by HNS at the time the request was processed</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
</tbody>
</table>
### Transaction Code
- **“83”**

<table>
<thead>
<tr>
<th>Reference Number</th>
<th>Internal reference number assigned by HNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response Status</td>
<td>Z = detailed record as requested</td>
</tr>
<tr>
<td></td>
<td>R = request rejected</td>
</tr>
<tr>
<td>Response Code</td>
<td>(See Section 10.1 for valid response codes.)</td>
</tr>
<tr>
<td>Number of Detail Records</td>
<td>Number of reversal details included</td>
</tr>
<tr>
<td>Current Rx Number*</td>
<td>Prescription number of reversal</td>
</tr>
<tr>
<td>Amount Reversed*</td>
<td>Value of reversal</td>
</tr>
</tbody>
</table>

*Current Rx Number and Amount Reversed will be repeated for each reversal detail.

The maximum number of reversal details per system response is 14, sequenced in time of day order.

For additional reversal details beyond the first 14 provided by the initial system response, submit another request for the next 14 reversal details.
Section 6: Submit Non-Standard Online Claims

Overview

This section outlines specific instructions for online submission of each of the following non-standard claims, and highlights the significant differences from the procedure for submitting standard online claims (as discussed in Section 5.1):

- Extemporaneous Preparations (see Section 6.1)
- Medically Necessary “No Substitution” Claim (see Section 6.2)
- Limited Use Products (see Section 6.3)
- Claim Submission for Prescription with Drug Costs over $10,000 (see Section 6.4)
- Approved Non-Prescription Drug Products and Emergency Authorization Drugs to Long-Term Care Homes (see Section 6.5)
- Allergen Claims (see Section 6.6)
- Cost-to-Operator Claims (see Section 6.7)
- Duplicate Claim Submission including Vacation Supply and Methadone Claims (see Section 6.8)
- Exceptional Access Program (see Section 6.9)
- Compassionate Review Policy (see Section 6.10)
- Nutrition Products (see Section 6.11)
- Diabetic Testing Agents (see Section 6.12)
- Thirty-Day Prescription Program (see Section 6.13)
- Special Drugs Programs (see Section 6.14)
- Universal Influenza Immunization Program (see Section 6.15)
6.1 Extemporaneous Preparations

This policy effective on January 1, 2020 replaces the previous extemporaneous preparation policy. Please also refer to the updated EO Notice of Interim Change to Extemporaneous Preparation Policy for Anti-Infectives dated April 16, 2021 and May 31, 2022 found at the following URL - Executive Officer Communiqués - Executive Officer Communications - Drugs and Devices - Health Care Professionals - MOH (gov.on.ca)

Section 17 of the Ontario Drug Benefit Act (ODBA) gives the Executive Officer of the Ontario public drug programs (the “Executive Officer”) the authority to:

- determine the conditions which must be met before a pharmaceutical product, including an extemporaneous preparation, is designated as a designated pharmaceutical product (DPP) and therefore eligible for reimbursement under the Ontario Drug Benefit (ODB) Program; and
- determine the drug benefit price of a DPP including a formula by which the drug benefit price may be calculated.

Extemporaneous Preparations

An extemporaneous preparation is defined in section 1(1) of O. Reg 201/96 made under the ODBA as a “drug or combination of drugs prepared or compounded in a pharmacy according to a prescription”.

In this policy “ODB benefit” refers to any of the following:

- A General Benefit on the Formulary;
• A General Benefit with Therapeutic Notes on the Formulary, where the Therapeutic Note requirements are satisfied by the patient or prescriber, as applicable;

• A Limited Use Benefit on the Formulary, where the Limited Use criteria are satisfied by the patient and the required Reason for Use code appears on the prescription for the patient;

• A drug product approved for the patient under the Exceptional Access Program¹

¹It is the responsibility of the dispenser to refer to the list of drugs requiring authorization of funding through the Exceptional Access Program. A searchable list is provided on the Ministry website at the following URL: https://www.ontario.ca/page/check-medication-coverage/

The ODB benefit utilized in an extemporaneous mixture must meet all other reimbursement conditions for that product under the ODB program (e.g., Limited Use Criteria, generic substitution regulations and policies, Medically Necessary “No Substitution” claims, Cost-to-Operator claims).

Only the cost of the quantity of each ingredient used in the preparation of a DPP is eligible for reimbursement. Drug costs for unused or wasted portions of any ingredient are not eligible for reimbursement.

An extemporaneous preparation that meets the general guidelines of compounding activities as described in the Regulatory Framework section of the Guidance Document for Pharmacy Compounding of Non-Sterile Preparations published by the National Association of Pharmacy Regulatory Authorities will be deemed by the Executive Officer to be a DPP and therefore eligible for reimbursement under the ODB Program, in the circumstances set out in paragraphs 1 to 4 below, provided that the preparation does not meet any of the exclusion criteria in paragraph 5:

1. The preparation is compounded into a liquid or capsule for internal oral consumption and contains a single ODB benefit that is a solid oral dosage form and no other medicinally active substance. For example, compounded lozenges, lollipops, or other solid or semi-solid formulations are not eligible for funding.
2. The preparation is for dermatological/topical use and:

   a. Contains a single ODB benefit approved by Health Canada for dermatological/topical use and no other medicinally active substances other than one or more of the following: camphor, compound benzoin tincture, hydrocortisone powder, liquor carbonis detergens, menthol, salicylic acid, sulfur or tar distillate; or

   b. is a dermatological/topical nitrogen mustard preparation; or

   c. is a dermatological/topical preparation consisting of liquor carbonis detergens, salicylic acid, sulfur and/or tar distillate, but no other medicinally active substances, and is compounded in petrolatum jelly or lanolin.

   **Note:** In this section the term "dermatological/topical" refers to a formulation intended for use on the surface of the skin and does not include suppositories or formulations intended for other routes of administration (e.g., intrathecal, intranasal, rectal, intravaginal).

   The combining of two or more ODB benefits (e.g., combining two or more topical ODB benefits approved by Health Canada for dermatological/topical use) is not eligible for reimbursement as a DPP.

3. The preparation is for ophthalmic administration and contains either:

   a. Amikacin, cefazolin or vancomycin; or

   b. Gentamicin or tobramycin in a concentration greater than three milligrams per milliliter.

4. The preparation is for injectable administration and contains:

   a. An ODB benefit that is approved by Health Canada for injectable administration; or

   b. Ingredients used in the preparation of a DPP which is an extemporaneous Total Parenteral Nutrition (TPN) solution; or

   c. An injectable drug product which received a Notice of Compliance from Health Canada on or prior to September 3, 2003 or which is listed
by Health Canada with an original market date on or prior to September 3, 2003, except:

i. Injectable vitamins, minerals, amino acids, lipids, botanicals and other natural health products (NHPs)

ii. Vaccines

iii. Alprostadil injection

iv. Ketorolac injection

v. Injectable products funded under the Ministry’s Special Drugs Program, Visudyne Program, Inherited Metabolic Disease Program, Respiratory Syncytial Virus (RSV) Program, or the New Drugs Funding Program

5. Restrictions Regarding the Reimbursement of Extemporaneous Preparations:

Note that the following are ineligible for reimbursement:

a. An extemporaneous preparation that is equivalent to a commercially manufactured product.

b. Transferring a manufacturer prepared drug solution to another vessel.

c. Transferring an ODB benefit into a new dosage delivery format (e.g., pre-filling insulin syringes).

d. Insertion of an infusion set into a manufacturer prepared preparation.

e. Products prepared from medicinally active bulk drug substances that are not an ODB benefit. These may include medicinally active substances in dry powder or solution that are used to prepare a sterile or non-sterile medicinally active drug product used to treat patients by any route of administration.

f. Reconstitution of an ODB benefit provided by a manufacturer in a dry powder format that is to be used for any route of administration (for example, oral, injectable, rectal, intrathecal, intravaginal)
g. Cutting or crushing of tablets, opening capsules, or otherwise altering any solid oral dosage form, including transferring the altered dosage form into an empty capsule or other vessel without added excipients.

h. Filling a capsule or other vessel with non-medicinal ingredients.

Pharmacists are reminded that claims reimbursed under the Ontario Drug Benefit Act are subject to post-payment verification.

Questions can be directed to the Ministry’s ODB Health Network System (HNS) Help Desk at 1-800-668-6641.

**Extemporaneous Preparations Claim Requirements**

Aside from the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting claims for extemporaneous preparations (DPPs), namely:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the DIN or Ministry-assigned PIN of the listed drug product with the highest cost for a Formulary benefit, OR Enter the specific compounding PIN (see Appendix A, Extemporaneous Preparation Table) if applicable.</td>
</tr>
<tr>
<td>Quantity</td>
<td>Y</td>
<td>Enter total volume or weight of compound dispensed unless otherwise indicated. (e.g., if using seven tablets to compound 100mL, enter 100; if compounding injection into one 50mL cassette/bag/vial, enter 1)</td>
</tr>
<tr>
<td>Unlisted Compound*</td>
<td>Y</td>
<td>If a DIN (not a Ministry-assigned extemporaneous PIN) is entered for a Formulary benefit product (or EAP approved product), enter the appropriate Compound Type Code (see below) in the Unlisted Compound field</td>
</tr>
</tbody>
</table>
Ministry-assigned extemporaneous PIN’s require the Unlisted Compound field to be blank.

0 = compounded topical cream (category 4)
1 = compounded topical ointment (category 4)
2 = compounded external lotion (category 4)
3 = compounded internal use liquid (category 2)
5 = compounded internal powder (category 2)
6 = compounded injection or infusion (category 3)
7 = compounded ear/eye drop (category 7 & 8)

(See Appendix A, Extemporaneous Preparation Table)

<table>
<thead>
<tr>
<th>Drug Cost/Product Value</th>
<th>Y</th>
</tr>
</thead>
</table>
|                        | Enter the total cost of all ingredients used, based on the following:
| For Formulary products, use the Drug Benefit Price (DBP).
| For non-Formulary products, such as products granted approval of reimbursement by the Exceptional Access Program, refer to the Ministry website for Drug Benefit Price at http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx
| If the DBP of a product used in the preparation of a DPP is not listed on the Ministry website or on the e-Formulary, use the actual or net Acquisition Cost (equal to manufacturer’s or wholesaler’s invoice amount minus discounts). Do not include mark-ups and/or HST in this field.
| (Refer to Acquisition Cost in Section 6.7) |
### Cost Mark-up

| Y | Enter the mark-up amount, 8% when the total drug cost is less than $1,000.00 or 6% when the total drug cost is greater than or equal to $1,000.00. |

### Compounding Charge*

| Y | Enter the total amount billed for compounding the prescription (equal to Compounding Rate x Compounding Time) |

### Compounding Time*

| Y | Enter the actual time required to mix the ingredients. This does not include weighing, measuring, and other dispensing activities. |

*The asterisk (*) indicates additional fields.*

### 6.2 Medically Necessary “No Substitution” Claims

The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must:

- Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Forms); and

- Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription.

The prescriber should keep a copy of the completed form in the patient’s record for future use and reference.

In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission.

Upon receipt, the pharmacist must:

- Fax, [submit online](#) or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and

- Retain his or her copy of the completed and signed Side Effect Reporting Form.

The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered.

### Claim Validation

**Supporting documentation may be requested.**

For claim validation purposes, and in accordance with O Reg 264/16 under the DPRA, the pharmacy or dispensing physician must maintain a copy of the prescription that contains a direction that there be no substitution and the Health Canada Side Effect Reporting Form for each of the lower cost interchangeable drug products (completed and signed by the prescriber) for the Retention Period.

If two (2) completed and signed Side Effect Reporting Forms are not available at the pharmacy during an inspection, the claim will be subject to recovery, in the case
where two or more products have been designated as interchangeable with the
drug product supplied and are generally available for sale in Ontario. In the case
where only one product has been designated as interchangeable with the drug
product supplied and is generally available for sale in Ontario, if one (1) completed
and signed Side Effect Reporting Form is not available at the pharmacy during an
inspection, the claim will be subject to recovery.

The pharmacist must fax, submit online or mail the completed Side Effect Reporting
Form(s) to:

Canada Vigilance Program
Marketed Health Products Directorate
Health Canada
Address Locator 1908C
Ottawa, Ontario
K1A 0K9

Fax: 1-866-678-6789 (toll-free)

Additional information on the Canada Vigilance Program can be accessed online or
by calling 1-866-234-2345.

Claim Requirements

Aside from including the fields indicated in Section 5.1, there are additional fields
required (or certain exceptions applicable to specific fields) when submitting
medically necessary “no substitution” claims, namely:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Selection*</td>
<td>Y</td>
<td>Enter reason code “1” to indicate prescriber-directed medically necessary “No Substitution”</td>
</tr>
<tr>
<td>Medical Reason Reference*</td>
<td>Y</td>
<td>Enter “B” (i.e., ODB reason for use codes)</td>
</tr>
</tbody>
</table>
Ontario

| Medical Condition/Reason for Use* | Y | Enter “901” to indicate that a Side Effect Reporting Form has been completed and signed by the prescriber |
| Drug Cost/Product Value | Y | Enter the Drug Benefit Price or Unit Cost |
| Cost Mark-up | Y | Enter the mark-up amount, 8% when the total drug cost is less than $1,000.00 or 6% when the total drug cost is greater than or equal to $1,000.00 |

*Note: If the product claimed is a Limited Use (LU) product, enter the appropriate Reason for Use code instead of “901”

The asterisk (*) indicates additional fields.

6.3 Limited Use Products

LU drug products are listed in the ODBF/CDI with specific clinical criteria/conditions for use. The LU criteria identify the clinical conditions for which these drugs will be reimbursed under the ODB program. Each LU criterion has a corresponding Reason for Use (RFU) code.

LU products will be reimbursed under the ODB program only when prescribed for an ODB program eligible recipient in accordance with the applicable LU criteria and the prescriber has provided the RFU code with the prescription.

To search for a list of LU products, their LU criteria, and the RFU codes, refer to the ODB e-Formulary.

Monitoring and Accountability Framework

Reimbursement for LU claims is made under the authority of Section 23 of ODBA and can only be made if the LU criteria set out in the ODBF/CDI have been met. By writing the RFU code on a prescription for the LU drug product, the authorized prescriber affirms that the patient meets the LU criteria.
For the purposes of claims review under ODBA, it may be necessary on occasion for prescribers to provide supporting documents on request. Pursuant to section 14(2) of the ODBA, inspectors may require prescribers to provide supporting documentation if the inspector believes on reasonable grounds that the documentation will assist the inspector in determining the accuracy and completeness of LU claims submitted to the Ministry for payment. LU prescriptions may therefore be monitored by the Ministry to ensure that the RFU code indicated is in accordance with the LU criteria listed in the ODBF/CDI.

Pharmacists must ensure that the appropriate RFU code has been provided by the prescriber for the LU prescription. Where the pharmacist has concerns about whether the clinical criteria have been met, the pharmacist should discuss it with the prescriber and record the outcome of the discussion on the LU prescription according to standard pharmacy practice.

In instances where an ODB program eligible patient does not meet the listed LU criteria, prescribers may make a written request for special consideration for coverage under the EAP.

**Ontario Drug Benefit Inspection of Limited Use Claims**

The Pharmaceutical Strategy Unit of OPDD routinely conducts inspections of all pharmacies for claim validation and reimbursement under the ODB program. The Ministry will recover monies paid for LU product claims if any of the following apply:

- The RFU code is not provided with the prescription.
- The prescription is incomplete (e.g., the date, drug, patient name or the correct regulatory college registration number is missing, or the authorized prescriber has not signed the prescription).
- The LU authorization period is expired.
- A prescription with valid LU documentation was not obtained/maintained in the pharmacy.
- The dispensed prescription does not comply with the applicable LU criteria (e.g., days’ supply exceeds authorization period, or patient does not satisfy criteria).
Pharmacists are reminded that prescriptions with LU documentation must be maintained by the pharmacy for claim validation purposes, and in accordance with O. Reg. 264/16 made under the DPRA if applicable, for the Retention Period.

**Limited Use Reimbursement Process**

**Completing a Limited Use Prescription**

Claims for LU drugs will be reimbursed under the ODB program only when prescribed for an ODB program eligible recipient in accordance with the LU criteria outlined for each product and accompanied by a valid, fully completed prescription with the appropriate LU (RFU code). The pharmacist should review the prescription and process the claim only if all the required information is provided.

**Limited Use Authorization Period**

The LU authorization is valid for the duration indicated by the listed LU criteria. Some LU drugs used in chronic conditions have been granted extended authorization periods beyond one year. For drugs with an “indefinite” authorization period, it is only necessary for the prescriber to confirm that the patient meets the LU clinical criteria by completing an LU prescription once.

For drugs with a defined LU authorization period, a new LU prescription must be completed according to the authorization period provided in the LU criteria (usually annually). An exception to this policy may occur in situations where LU criteria have changed. In situations where LU criteria have changed, prescribers must consider whether recipients meet the new criteria. If so, a new LU prescription must be completed within three months of the change in LU criteria.

**Reason for Use Code**

All LU prescriptions require an RFU code to be completed by the prescriber. The RFU code verifies that the patient meets the LU criteria. The RFU code may be communicated by one of the following methods:

- writing on an LU prescription
- electronically on an electronically generated LU prescription
- verbally during a verbal order of an LU prescription by a prescriber
• verbally during a LU prescription transfer between pharmacies*.

*Verbal communications of RFU codes must be documented by the receiving pharmacy in writing.

**RFU code “279” (the “grand-parenting” code) may be used in the following two situations associated with LU claims:**

**If the RFU code has changed due to a change in LU criteria:**

RFU Code “279” may be used for up to three months until a new LU prescription is received. The dispensing pharmacist cannot use the “LU” intervention code with RFU Code “279”. This RFU Code is only valid for claims submissions and is not to be used by prescribers on LU prescriptions.

**If the RFU code has been discontinued:**

“RFU Code 279” may be used for claim submission for the remaining duration of the original LU authorization period, or up to 12 months, whichever comes first.

**Note:** Continued or incorrect use of the RFU code 279 will be subject to recoveries during the claim validation process.

**RFU Code “979” (New residents of LTC Homes):**

This three-month transition RFU code may be used to submit claims for ODB program recipients first entering LTC homes to allow prescribers time to ensure the patient’s eligibility for the LU drug.

**Note:** This RFU code cannot be used for non-LTC patients and is subject to claim validation as per standard procedure.

**Documentation**

Pharmacies are required to maintain LU documentation on file for the purposes of claim validation, and in accordance with O. Reg. 264/16 made under the DPRA if applicable, for the Retention Period. Documentation must be complete at the time of claim submission.

The pharmacist should review the prescription and process the claim only if all the required information is provided. Pharmacists must ensure that the following
information has been provided by the prescriber, in addition to the usual information required for a prescription in accordance with the regulations of the OCP:

- The appropriate RFU code
- The date and prescriber’s signature
- The prescriber’s college registration number

Only the prescriber may fill in this information or communicate it to the pharmacy. If the prescriber’s college registration number is missing, pharmacists may enter it only if they are certain it is the correct number. **Claims for LU products must contain a valid CPSO or college registration number (i.e., 99999 is not acceptable).**

Incomplete LU documentation (e.g., prescriptions that do not include the appropriate RFU code, date, prescriber’s signature and college registration number) will be subject to recoveries.

The LU authorization must be documented and will be valid for the duration indicated by the listed LU criteria. During this period, any repeat prescription may be given verbally by a prescriber to a pharmacist. For drugs with extended or indefinite authorization periods, a new prescription may be required after a certain period of time to allow the drug to be dispensed in accordance with the requirements of the OCP.

If a patient has met the LU criteria before being eligible for ODB, and supporting documentation is available (e.g., the diagnostic test was done prior to the person turning 65 years of age), that information can still be used to verify the LU claim. For instance, a patient who had step-up therapy in the past will not have to have step-up therapy again to prove eligibility to receive an LU drug as long as supporting documentation is available. In these cases, a prescription that contains an RFU code is still required.

If the pharmacist is prescribing the drug therapy according to his/her scope of practice, the pharmacist can complete the LU documentation to confirm that the patient meets the LU criteria. As the prescriber of the medication, documentation of the assessment must be recorded appropriately before the claim is submitted, including a prescription that contains an RFU code. Documentation may be requested for claim validation.
Limited Use Claim Requirements

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting LU product claims, namely:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Reason Reference*</td>
<td>Y</td>
<td>Enter “B” (i.e., ODB Reason for Use codes)</td>
</tr>
<tr>
<td>Medical Condition/Reason for Use*</td>
<td>Y</td>
<td>Enter the appropriate Reason for Use code to indicate that a LU prescription has been completed and signed by the prescriber. Refer to the Formulary/CDI for Reason for Use codes</td>
</tr>
<tr>
<td>Intervention/Exception Code</td>
<td>Y (for initial LU claim only)</td>
<td>Enter “LU” (i.e., start new LU authorization)</td>
</tr>
<tr>
<td>Drug Cost/Product Value</td>
<td>Y</td>
<td>Enter the Drug Benefit Price</td>
</tr>
<tr>
<td>Cost Mark-up</td>
<td>Y</td>
<td>Enter the mark-up amount. 8% when the total drug cost is less than $1,000.00 or 6% when the total drug cost is greater than or equal to $1,000.00</td>
</tr>
</tbody>
</table>

The asterisk (*) indicates additional fields.

All initial claims for LU products (i.e., when the pharmacist receives a LU prescription) must be submitted with the intervention code “LU” in order to start a new LU authorization period on HNS.
Promoting Compliance with Limited Use Criteria for the Fentanyl Transdermal Patch

OPDD is committed to supporting the appropriate prescribing and dispensing of opioids and addressing the issue of prescription opioid misuse and abuse. A network rule has been implemented in the HNS to promote the safe and effective use of fentanyl transdermal patches by promoting compliance with the LU criteria.

Fentanyl transdermal patches are listed under the ODB program as an LU benefit with RFU code 511: For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long acting opioid will be subject to verification at the time of dispensing. LU Authorization Period: One year.

For ODB eligible recipients, the HNS assists pharmacists to ensure that patients meet the applicable clinical criteria for fentanyl transdermal patches at the time of dispensing, promoting the appropriate prescribing and dispensing of these products. This network rule utilizes the dispensing histories contained in both the HNS and the NMS to determine if a patient received a long-acting opioid or a fentanyl transdermal patch in the previous 180-day period.

- If a dispensing record is found for a long-acting opioid or a fentanyl transdermal patch in the previous 180 days, the current claim for fentanyl transdermal patch will be accepted.

- If no prior dispensing records are found in the HNS or the NMS, then the current claim for fentanyl transdermal patch will be rejected with response code QM (No Record of Required Prior Therapy).

- An override code MZ (Required Prior Therapy Documented) can be used to allow pharmacists to use their professional judgement to submit the claim as appropriate by confirming the patient meets the RFU code criteria. Documentation may be requested for claim validation verification.

This HNS feature is only applicable to the listed Formulary fentanyl transdermal patches, 25 mcg/hour and 50 mcg/hour strengths. Fentanyl transdermal patches funded under the Exceptional Access Program or through Palliative Care Facilitated Access are not subject to the rule.
Promoting Compliance with the Existing Limited Use Criteria for Specified Drug Products

Effective April 1, 2021, new network rules were implemented in the HNS to promote the safe and effective use of specified drug products with age-related and gender-related/sex-related restrictions by promoting compliance with the LU criteria for these medications. The LU criteria for all related products were already in place (i.e., there were no criteria changes) and are aligned with Health Canada-authorized product labelling indications and/or drug expert advisory committee recommendations.

These changes reflect a Ministry policy that must be complied with, in accordance with the HNS Subscription Agreement for Pharmacy Operators.

Reimbursement Criteria and Restrictions

The drug products affected by the new HNS network rules, as well as related LU codes, a summary of current LU criteria, and associated age-related and gender-related/sex-related restrictions being implemented, are summarized in the table below.

<table>
<thead>
<tr>
<th>Drug product(s) (LU code)</th>
<th>Reimbursement criteria summary</th>
<th>Restriction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age-based restrictions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abobotulinum toxin A, Botulinum toxin type A, Clostridium botulinum neurotoxin type A (130)</td>
<td>To reduce the symptoms and signs of cervical dystonia (spasmodic torticollis) in adults</td>
<td>Age ≥18 years</td>
</tr>
<tr>
<td>Abobotulinum toxin A, Botulinum toxin type A, Clostridium botulinum neurotoxin type A (412)</td>
<td>For the management of focal spasticity, due to stroke or spinal cord injury, in adults</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Uses</td>
<td>Notes</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Adalimumab (417)</td>
<td>Treatment of severe plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies</td>
<td></td>
</tr>
<tr>
<td>Ustekinumab (419)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clostridium botulinum neurotoxin type A (421)</td>
<td>Treatment of blepharospasm associated with dystonia in adults</td>
<td></td>
</tr>
<tr>
<td>Botulinum toxin type A (440)</td>
<td>For adult patients with urinary incontinence due to neurogenic detrusor overactivity who have failed other therapies</td>
<td></td>
</tr>
<tr>
<td>Botulinum toxin type A (460)</td>
<td>For adult patients with urinary frequency, urgency or urge incontinence due to overactive bladder who have failed other therapies</td>
<td></td>
</tr>
<tr>
<td>Filgrastim (specific vial format only) (500)</td>
<td>For pediatric patients (less than 18 years age) who are unable to achieve the appropriate dose of granulocyte colony-stimulating factor with the formulary listed formats of pre-filled syringes</td>
<td>Age ≤17 years</td>
</tr>
</tbody>
</table>

**Gender-based/sex-based restrictions**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Uses</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfuzosin, Silodosin (351)</td>
<td>Management of benign prostatic hyperplasia where other formulary alpha</td>
<td>Male gender/sex</td>
</tr>
<tr>
<td>Drug(s)</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>Alfuzosin, Silodosin (352)</td>
<td>Management of benign prostatic hyperplasia where other formulary alpha blockers produced intolerable side effects</td>
<td></td>
</tr>
<tr>
<td>Dutasteride, Finasteride (384)</td>
<td>For use in combination with an alpha blocker for the treatment of men with symptomatic benign prostatic hyperplasia</td>
<td></td>
</tr>
<tr>
<td>Dutasteride, Finasteride (385)</td>
<td>For use as second-line monotherapy (after failure/intolerance to an alpha blocker) for the treatment of men with symptomatic benign prostatic hyperplasia</td>
<td></td>
</tr>
<tr>
<td>Testosterone (397)</td>
<td>For male patients with confirmed low morning serum testosterone levels</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the Ministry’s online e-Formulary (Formulary Search) to find a listing of all affected DINs/PINs.

In some cases, requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

**Pharmacy Procedures**

There are no changes to the claim submission process. The current process for submitting claims for LU products still applies.
HNS Response Codes

The new network rules utilize the HNS database as the source for ODB recipients’ date of birth and gender/sex.

Automated adjudication will ensure current LU criteria for the identified drug products are met and there will be a rejection response to submitted claims where the age or gender/sex criteria are not met.

- If a claim is submitted for an identified drug product restricted to use in patients of a certain age group (i.e., adults or pediatrics as per the LU criteria) and the patient does not meet the age requirement specified in the LU criteria, the claim will be rejected with the response code “CD – Patient Not Entitled to Drug Claimed”.

- If a claim is submitted for an identified drug product restricted to use in patients of a certain gender/sex (i.e., male patients as per the LU criteria) and the patient does not meet the gender/sex requirement specified in the LU criteria, the claim will be rejected with the response code “CD – Patient Not Entitled to Drug Claimed”.

6.4 Claim Submission for Prescription with Drug Costs $10,000 or Over

Since the current pharmacy claim standard does not support drug costs exceeding $9,999.99, the Ministry allows pharmacists to submit online claims for prescriptions with a drug cost of $10,000 or more by splitting the claim into multiple submissions, with the exception of claims for extemporaneous compounds. Extemporaneous compounds with drug costs of $10,000 or more must be submitted using the standard manual claims process.

Claims can only be split for the purpose of online claim submission. There are no changes to the manual claim submission process.

In order for HNS to adjudicate the “split” claims appropriately, pharmacists are required to submit the claims according to the following rules:
• The quantity supplied must be split into approximately equal portions without any changes to the submitted price per unit (each split claim with drug costs less than $10,000);

• The day’s supply must be split accordingly (please note DUR responses such as refill too soon, and duration of therapy messages would be based on this reduced day’s supply);

• Mark-up remains at 6% on all split claims; and,

• A dispensing fee must be submitted for the first split claim only.

Additional details can be found in the frequently asked questions (FAQ) document.

6.5 Approved Non-Prescription Drugs

The Ontario Government Pharmaceutical and Medical Supply Service (OGPMSS) centrally purchases and distributes Approved Non-Prescription Drugs (ANPDs) to LTC homes. OPDD is responsible for the reimbursement of drugs provided to residents of LTC homes through the ODB program, including the cost of drugs provided as ANPDs.

Dispensing Solid Oral Dosage Forms of Approved Non-Prescription Drugs to LTC Home Patients

Pharmacists can order and receive solid oral dosage form ANPD stock directly from OGPMSS to be included with pre-packaged prescription medications which are provided to residents of LTC homes. This stock can only be dispensed to residents of LTC homes licensed under the Long-Term Care Homes Act, 2007.

This initiative is voluntary. Participation requires that interested pharmacists obtain an account with OGPMSS to order and receive ANPD stock. Stock will be provided to pharmacies at no charge. No reimbursement will be provided for dispensing ANPD products and no additional charges can be passed on to the LTC homes or their residents. New client application forms can be obtained by contacting OGPMSS by telephone at 416-327-0837.
Pharmacies are required to submit claims for each ANPD prescription that is dispensed. **PINs are provided that must be used for claim submission** (see Appendix B).

### Approved Non-Prescription Drug Claim Requirements

Aside from including the fields indicated in [Section 5.1](#), there are additional fields required (or certain exceptions applicable to specific fields) when submitting ANPD claims, namely:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention/ Exception Code</td>
<td>N</td>
<td>Leave blank</td>
</tr>
<tr>
<td>Group Number or Code</td>
<td>N</td>
<td>LTC home number (see for a <a href="#">list of LTC homes</a>)</td>
</tr>
<tr>
<td>Client ID # or Code</td>
<td>Y</td>
<td>Enter ODB eligibility number</td>
</tr>
<tr>
<td>Patient First Name</td>
<td>Y</td>
<td>ODB recipient’s first name</td>
</tr>
<tr>
<td>Patient Last Name</td>
<td>Y</td>
<td>ODB recipient’s last name</td>
</tr>
<tr>
<td>Drug Cost/Product Value</td>
<td>Y</td>
<td>Enter “0”</td>
</tr>
<tr>
<td>Cost Mark-up</td>
<td>Y</td>
<td>Enter “0”</td>
</tr>
<tr>
<td>Professional Fee</td>
<td>Y</td>
<td>Enter “0” for allowed professional fee.</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the ANPD PIN (Refer to Appendix B)</td>
</tr>
</tbody>
</table>

Please be reminded that claims submitted to HNS are subject to claim validation.
Emergency Authorization to Dispense Approved Non-Prescription Drug Products to Long-Term Care Homes

In certain situations (e.g., a product is on backorder), the Ministry will provide authorization for a pharmacy to dispense ANPD items usually provided directly to LTC homes by OGPMSS.

In order to receive emergency authorization, contact the OGPMSS at 416-327-0837.

The authorization must be maintained on file by the pharmacy for the Retention Period for the purposes of claim validation and in accordance with O Reg 264/16 under the DPRA if applicable.

Emergency Authorization to Dispense Approved Non-Prescription Drug Claim Requirements

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting emergency authorization claims, namely:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention/Exception Code*</td>
<td>Y</td>
<td>Enter &quot;MJ&quot; (i.e., OGPMSS authorized claim)</td>
</tr>
<tr>
<td>Group Number or Code</td>
<td>Y</td>
<td>Enter the number for the LTC home receiving services. (See a list of LTC homes and/or HSC)</td>
</tr>
<tr>
<td>Client ID # or Code</td>
<td>N</td>
<td>Leave blank</td>
</tr>
<tr>
<td>Patient First Name</td>
<td>N</td>
<td>Leave blank</td>
</tr>
<tr>
<td>Patient Last Name</td>
<td>N</td>
<td>Leave blank</td>
</tr>
<tr>
<td>Pharmacist ID*</td>
<td>Y</td>
<td>Enter the Pharmacist ID</td>
</tr>
</tbody>
</table>
### Drug Cost/Product Value

Enter the actual Acquisition Cost (equal to manufacturer’s or wholesaler’s invoice amount minus discounts). Do not include mark-ups here. HST is not applicable, (refer to Acquisition Cost Calculations in Section 6.7)

### Cost Mark-up

Enter the mark-up amount

**Note:** Up to 1/3 of the drug cost mark-up is payable

### Professional Fee

Enter 0 for allowed professional fee

### DIN/GP#/PIN

Enter the PIN of the product authorized

(Refer to Appendix C)

---

The asterisk (*) indicates additional fields.

### Claim Validation

**Supporting documentation may be requested.**

*A copy of the authorization to dispense items usually provided to LTC homes by the OGPMSS must be kept on file for the Retention Period.*

### 6.6 Allergen Program

The Allergen Program provides coverage for ODB program eligible recipients to receive certain products used to treat allergies and allergic reactions. Products reimbursed through the Allergen Program may be provided by an allergen vendor that has an agreement with the OPDP and has received an HNS account from the Ministry or may also be provided through an accredited retail pharmacy that has an HNS agreement and has received an HNS account from the Ministry.

For a complete list of products funded through the Allergen Program, please see Appendix D.
Special Authorization Allergen Form

Except for epinephrine products listed in Appendix D, a valid Special Authorization Allergen (SAA) form is required before an allergen claim can be processed. The SAA form is valid for two years commencing on the date it is signed by the prescriber and applies to the allergen extract described in the form that has been prescribed by the prescriber and any renewals of that prescription.

In order for an SAA form to be valid, the following conditions must be met:

Section A of the form must be completed (in writing) by the prescriber before forwarding to the pharmacy.

The allergen product that is claimed and dispensed must match the allergen product that is written on the SAA form by the prescriber.

If the allergen product is being provided by an authorized allergen vendor that has an account with the Ministry, the allergen vendor must complete section B of the SAA form and submit it to the Ministry for reimbursement within six months of the date of service.

If the allergen product is being supplied by an accredited retail pharmacy, the recipient provides the prescription and the SAA form (with Section A completed by the prescriber) to the pharmacy. The pharmacist completes section B of the SAA form, submits an online claim to the ODB program through HNS using the DIN/PIN of the product, and maintains the completed SAA form on file, as supporting documentation for the allergen product claim.

The drug cost submitted can only include the drug cost, mark up and professional fee, and cannot include costs for training, other professional fees, equipment used in preparation, packaging of the product, or delivery of the product.

The SAA form must be maintained on file for claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable, for the Retention Period.

Effective December 1, 2017, a completed SAA form is not required for claims for epinephrine products reimbursed through the Allergen Program. A valid prescription is required, and billing procedures remain the same.
Special Authorization Allergen Claim Requirements

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting Allergen claims, namely:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the DIN/PIN of the product authorized, (refer to Appendix D)</td>
</tr>
<tr>
<td>Drug Cost</td>
<td>Y</td>
<td>Enter the actual Acquisition Cost (equal to manufacturer’s or wholesaler’s invoice amount minus discounts)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Do not include mark-ups and/or HST in this field (refer to Acquisition Cost in Section 6.7)</td>
</tr>
<tr>
<td>Mark-up</td>
<td>Y</td>
<td>Enter the mark-up amount. 8% when the total drug cost is less than $1,000.00 or 6% when the total drug cost is greater than or equal to $1,000.00</td>
</tr>
</tbody>
</table>

For SAA forms submitted for children and youth 24 years of age and under who do not have a private plan, the SSC (Special Service Code) box must be populated with a “U” code to confirm that the recipient does not have a private plan.

Claim Validation

Supporting documentation may be requested for claim validation.

1) The SAA form (completed and signed by the prescriber) and 2) A valid prescription for the allergen product(s) dispensed must be maintained on file for claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable, for the Retention Period.

3) For claim validation purposes and in accordance with Regulation 936 under the DIDFA, a copy of the manufacturer/wholesaler’s invoice or purchase record must
be maintained on file for at least two years from the day the invoice or record was received.

Deductible and co-payment rules in O. Reg. 201/96 made under the ODBA do not apply to products supplied under the Allergen Program. As a result, accredited retail pharmacies are not entitled to charge patients any deductible or co-payment when dispensing a product covered under the Allergen Program to an ODB recipient.

6.7 Cost-to-Operator Claims

In accordance with clause 14(3)(b) of O. Reg. 201/96 made under the ODBA, the allowable use of the ‘MI’ (Cost-to-Operator or ‘CTO’) intervention code is restricted to cases where a pharmacy is unable to acquire the lowest DBP product in an interchangeable category and must dispense the original product or a higher-priced interchangeable drug product. For claim validation purposes and in accordance with Regulation 936 under the DIDFA if applicable, supporting documentation (manufacturer’s or wholesaler’s invoice), which clearly indicates that the generic product had been ordered and was unavailable during the appropriate time period, and a detailed calculation in accordance with s. 14 of O Reg 201/96 must be maintained on file for at least two years from the day the invoice was received. Overpayments due to inappropriate submission of MI intervention codes are subject to recovery through claim validation.

Acquisition Cost

If the pharmacy is unable to acquire an interchangeable drug product and must dispense either the original product or an interchangeable product with a higher DBP, the pharmacy will be reimbursed the Acquisition Cost of the drug product (also known as cost-to-operator or CTO).

Cost-to-Operator Claim Requirements

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting CTO claims, namely:
### Fields

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention/Exception Code*</td>
<td>Y</td>
<td>Enter &quot;MI&quot; (e.g., pharmacy unable to acquire the lowest DBP product)</td>
</tr>
<tr>
<td>Pharmacist ID*</td>
<td>Y</td>
<td>Enter the Pharmacist ID</td>
</tr>
<tr>
<td>Drug Cost/Product Value</td>
<td>Y</td>
<td>Enter the actual or net Acquisition Cost (equal to manufacturer's or wholesaler’s invoice amount minus discounts). Mark-ups and HST are not applicable</td>
</tr>
<tr>
<td>Cost Mark-up</td>
<td>Y</td>
<td>Must be equal to 0</td>
</tr>
</tbody>
</table>

*The asterisk (*) indicates additional fields.*

### Claim Validation

*Supporting documentation may be requested. The dispenser must obtain and retain a copy of:*

(a) *The manufacturer’s or wholesaler’s invoice which clearly indicates that the generic product had been ordered and was unavailable during the appropriate time period*

(b) *The supplier’s invoice, and*

(c) *A detailed calculation of the cost of purchasing the drug product (in accordance with section 14 of [O. Reg. 201/96](#) under the Ontario Drug Benefit Act).*

*These records must be maintained on file for at least two years from the day the invoice was received. The supplier’s invoice must clearly indicate that the lower priced interchangeable product had been ordered and was unavailable during the appropriate time.*
6.8 Duplicate Claim Submission Including Vacation Supply and Methadone Claims

A duplicate claim occurs when two or more claims are submitted with the:

- same date of service; and
- same recipient; and
- same DIN, PIN, or interchangeable product

OR, when two or more claims are submitted with the:

- same date of service; and
- same prescription number; and
- same pharmacy

Vacation Supply - Ontario Drug Benefit Program Recipients

Most ODB program recipients traveling outside the province for at least 100 days within six months of their last filled prescription may obtain an early refill (up to a 100-day supply) of medication before leaving the province. The normal co-payments and deductibles apply to the 100-day supply.

In order to obtain an early refill for a vacation supply, ODB program recipients must provide documentation confirming that they are leaving the province for more than 100 days including either:

- A letter signed and dated by the ODB program recipient indicating travel dates; or
- A copy of the ODB program recipient’s travel documentation (e.g., travel insurance).

Documentation associated with verifying the validity of vacation supply claims are subject to claim validation. For claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable, the letter, or copy of travel documentation, must be maintained on file for a period of the Retention Period. It is suggested that these documents be maintained in a separate file, instead of
attaching to the prescription hardcopy. Pharmacists must have the letter or copy of their travel insurance confirming travel outside of Ontario before submitting claims for a vacation supply and overriding any rejections generated by the HNS (use intervention code “MV” to override the “duplicate claim” rejection if two claims for 100-day supply of medication are submitted for the recipient on the same day).

ODB program recipients under the OW program may no longer be eligible for benefits if they leave the province for more than seven days without prior approval from MCCSS. ODB program recipients under the ODSP program may no longer be eligible for benefits if they leave the province for more than 30 days without prior approval from MCCSS. Patients should contact their caseworker to discuss potential plans for extended absences from Ontario.

If written confirmation of approval has been provided to the pharmacy by the local OW or ODSP office for an absence out of the province beyond seven days for OW and beyond 30 days for ODSP, a sufficient supply of medication for the required period, up to a 100-day supply, may be dispensed with appropriate documentation.

**Vacation supply - Trillium Drug Program Recipients**

Additional rules apply to people who access the ODB program through the Trillium Drug Program (TDP). Based on the specific quarter in the TDP benefit year, some TDP recipients traveling outside the province for at least 100 days may be eligible to obtain an early refill (up to a 100-day supply) of medication before leaving the province.

During the first and second quarters of the Trillium benefit year (August 1-January 31 of the following calendar year), a vacation supply claim of up to 100 days may be allowed (in addition to the regular 100 maximum days’ supply) for TDP recipients travelling outside the province for between 100 and 200 days, before they leave Ontario.

In order to obtain a refill for a vacation supply of up to 100 days of ODB medication, provided that the prescription allows for the additional supply, recipients must provide the pharmacist with documentation confirming that they are leaving the province for more than 100 days including:

- A letter signed and dated by the patient indicating dates of travel; or
- A copy of the patient's travel documentation.
Vacation supply claims must not be submitted through HNS for TDP recipients during the third and fourth quarters of the TDP benefit year (February 1-July 31). TDP recipients must pay for their vacation supply for the third and fourth quarters of the benefit year. Pharmacists should advise TDP recipients that the Ministry will not reimburse vacation supplies paid out-of-pocket during the third and fourth quarters of the benefit year except in rare circumstances.

**Claim Validation**

Supporting documentation may be requested for claim validation. The letter, or copy of travel documentation, must be maintained on file in a readily retrievable location for the Retention Period for claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable.

**Duplicate Claim Submission Claim Requirements**

Listed below are the only acceptable intervention/exception codes for submission of a duplicate claim:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacist ID*</td>
<td>Y</td>
<td>Enter the Pharmacist ID.</td>
</tr>
<tr>
<td>Intervention/Exception Code*</td>
<td>Y</td>
<td>Enter any one of the following:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“MM” = replacement claim, drug cost only¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“MN” = replacement claim due to dosage change</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“MR” = replacement claim, item lost or broken</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“UA” = consulted prescriber and filled Rx as written</td>
</tr>
</tbody>
</table>

¹ Depending on the code entered in the Drug Cost Replacement Code field.
<table>
<thead>
<tr>
<th>“UB”</th>
<th>consulted prescriber and changed dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>“UC”</td>
<td>consulted prescriber and changed instructions for use</td>
</tr>
<tr>
<td>“UE”</td>
<td>consulted prescriber and change quantity</td>
</tr>
<tr>
<td>“UF”</td>
<td>patient gave adequate explanation (Rx filled as written)</td>
</tr>
<tr>
<td>“MV”</td>
<td>vacation supply</td>
</tr>
</tbody>
</table>

The asterisk (*) indicates additional fields.

1Duplicate claims resulting from multiple directions on medications. (For example, “Drug X: Take 1 am and 2 hs” dispensed as two prescriptions, one labeled “Take one in the morning” and the other labeled “Take two at bedtime.”) Additional fees will not be paid.
Methadone Maintenance Treatment

The Methadone Maintenance Treatment Reimbursement Policy, 2022 replaced the Methadone Maintenance Treatment Reimbursement Policy, 2020 to reflect additional methadone 10mg/mL oral concentrate product options that are listed on the Ontario Drug Benefit Formulary (Formulary).

The Methadone Maintenance Treatment Reimbursement Policy, 2022 was effective on August 31, 2022 and replaced the 2020 policy as of that date.

Methadone Maintenance Treatment Reimbursement Policy, 2022

As a precondition to obtaining billing privileges under the Ontario Drug Benefit Act (ODBA), all pharmacy operators are required to enter into a Health Network System (HNS) Subscription Agreement with the Executive Officer. Under section 3.2 of this Agreement, pharmacy operators are required to comply with all Applicable Law, Ontario College of Pharmacists Rules, and Ministry Policies.¹

The Executive Officer of the Ontario Public Drug Programs of the Ministry of Health (the “Ministry”) hereby establishes a policy for the reimbursement of methadone for all pharmacy operators in Ontario that supply methadone to Ontario Drug Benefit (ODB) eligible persons requiring methadone maintenance treatment (MMT) for opioid use disorder (hereinafter, referred to as the “Policy”). The Policy is comprised of this notice and the accompanying Questions & Answers document available on the ministry’s website.

The Policy is made in accordance with section 5(2) of the ODBA and subsection 20(1) of O. Reg. 201/96 under the ODBA and applies to claims submitted through the HNS for ODB eligible recipients.

Under this Policy the Ministry will reimburse all pharmacy claims for the Formulary listed methadone 10mg/mL oral concentrate products that are dispensed to ODB eligible persons receiving MMT in the manner outlined in the next page.

¹ The terms ‘pharmacy’ and ‘pharmacy operators’ are used in this Policy for consistency and ease of reading, however, all pharmacy requirements refer equally to ‘dispensing physicians’ as well. The term ‘dispensing physician’ refers to a physician who has a valid HNS Subscription Agreement with the ministry and is connected to the HNS.
Table 1: Publicly funded methadone hydrochloride 10mg/mL oral concentrate

<table>
<thead>
<tr>
<th>Product Name</th>
<th>DIN</th>
<th>Manufacturer</th>
<th>Colour/flavour/sweetener</th>
<th>Interchangeable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamp Methadone*</td>
<td>02495783</td>
<td>Jamp Pharma Corporation</td>
<td>Blue/unflavoured/sugar-free, sweetened with sorbitol</td>
<td>Y</td>
</tr>
<tr>
<td>Methadose</td>
<td>02394618</td>
<td>Mallinckrodt Canada ULC</td>
<td>Clear/unflavoured/unsweetened</td>
<td>Y</td>
</tr>
<tr>
<td>Odan-Methadone*</td>
<td>02495880</td>
<td>Odan Laboratories Ltd.</td>
<td>Clear/unflavoured/unsweetened</td>
<td>Y</td>
</tr>
<tr>
<td>Methadose**</td>
<td>02394596</td>
<td>Mallinckrodt Canada ULC</td>
<td>Red/cherry flavour/sucrose</td>
<td>N</td>
</tr>
<tr>
<td>Metadol-D**</td>
<td>02244290</td>
<td>Paladin Labs Inc.</td>
<td>Clear/unflavoured/unsweetened</td>
<td>N</td>
</tr>
</tbody>
</table>

*The generic methadone hydrochloride 10mg/mL oral concentrate formulations, Jamp Methadone DIN 02495783 and Odan-methadone DIN 02495880 are interchangeable with Methadose (unflavoured) DIN 02394618.

**The Formulary listings of Methadose (cherry flavour) DIN 02394596 and Metadol-D DIN 02244290 are not designated as interchangeable with any drug products.

Payment of Drug Cost

A transition period was provided (from August 31, 2022 to September 28, 2022), during which the Ministry continued to reimburse Methadose (unflavoured) DIN 02394618 at its Formulary Drug Benefit Price (DBP). The lowest cost interchangeable product payment rule was not applied during this transition period.

Effective September 29, 2022, the usual lowest cost interchangeable payment rule was implemented. Where a methadone 10mg/mL oral concentrate product in an interchangeable category is dispensed, the Ministry only pays the lowest Drug Benefit Price of the interchangeable products in the category. A patient wishing to receive a higher-priced interchangeable product at their request or pursuant to a “no sub” prescription must pay the difference in price, unless the patient has a “no sub” prescription and has experienced an adverse reaction to at least two of the lower
priced interchangeable products, if available, as documented by their prescriber in a Health Canada Side Effect Reporting Form. Please refer to the Ontario Drug Programs Reference Manual s. 6.2 for requirements and details on how to submit a “no substitution” claim.

For a methadone 10mg/mL oral concentrate product that is not in an interchangeable category (e.g., Methadose (cherry flavour) DIN 02394596 and Metadol-D DIN 02244290), the drug cost paid is the Drug Benefit Price of the product on the Formulary.

Health Canada Safety Information

- Pharmacists are reminded of the two Health Canada “Dear Healthcare Professional” letters posted in March 2020 and July 2020 regarding switching of methadone hydrochloride oral concentrate products.

- Pharmacists are encouraged to discuss switching products with patients and prescribers. The following excerpt is taken from the product monograph of methadone hydrochloride oral concentrate solutions:

  General Disorders and Administration Site Conditions: drug ineffective

  Isolated reports have been received for drug ineffectiveness following a switch between different methadone products. The current data are insufficient to support an estimate of the incidence or to establish causation. Patients presenting with symptoms of withdrawal following formulation change should be clinically monitored and dose titrated as needed.

- When switching from Methadose to a generic formulation, patients should be monitored as per the precautions noted above.

Ministry requirements for reimbursement of methadone claims under the Policy for Pharmacy Operators:

The Ministry will pay pharmacies, via the HNS, one ODB dispensing fee per daily supply (i.e., the pharmacy’s applicable ODB dispensing fee) for dispensing methadone 10mg/mL oral concentrate, as listed on the Formulary, to an ODB eligible person for MMT.
For example, for a prescription written to witness one dose on Monday and dispense 6 carry doses for Tuesday to Sunday, the ministry pays one dispensing fee for one witnessed dose on Monday and one dispensing fee for each daily supply carry dose labelled for Tuesday through Sunday; all 7 prescription claims would be submitted on the Monday, the day of the witnessed dose, and all 7 claims are eligible for a dispensing fee.

Please note:

- persons whose household has not yet reached its quarterly Trillium Drug Program deductible are not eligible for ODB benefits, and as such, their MMT claims do not fall under this Policy.

- the Policy does not apply to the Primary Pharmacy Service Providers (PSP) that dispense MMT to residents of Long-Term Care (LTC) homes as dispensing fees submitted for LTC home residents are included as part of the capitation payment to Primary PSPs effective January 1, 2020. However, the Policy does apply to the dispensing of methadone to a LTC home resident for MMT by a Secondary PSP. Secondary PSPs that dispense to residents of LTC homes on an emergency basis, will follow the protocol outlined under the Policy for Pharmacy Payments under the LTC Home Capitation Funding Model, 2020 that was posted on the ministry’s website on December 16, 2019 and can be accessed at this link:

Payment of mark up

The Ministry will reimburse the pharmacy for the applicable drug cost in respect of each claim for methadone 10mg/mL oral concentrate plus the applicable % mark-up on that amount. See above section on “Payment of Drug Cost” for more information.

No co payment

No co payment may be charged to the ODB eligible person or a private third party with respect to the supply of methadone for maintenance treatment. However, the amount of the co-payment that would apply to the ODB recipient for other drug
claims (i.e., $0, $2.00 or $6.11 depending on their class of eligibility) will still be deducted from the dispensing fee paid for the methadone claim.

**Additional Requirements**

- A separate claim must be submitted on-line for each day’s supply of methadone for ODB eligible persons receiving MMT (i.e., one claim for each day’s supply) using the appropriate Drug Identification Number (DIN) and the quantity of methadone 10mg/mL oral concentrate dispensed.

- The quantity must reflect only the amount of methadone 10mg/mL oral concentrate dispensed, and must not include any amount of drink mix (e.g., Tang®) also included in the bottle dispensed.
  
  o one claim is submitted for each witness dose and one claim is submitted for **each** daily supply carry dose that is provided to the ODB recipient
  
  o claims for witness doses and individual carry doses must be submitted on the date that the witness dose and/or carry doses are dispensed
  
  o a maximum of one dispensing fee may be claimed per ODB recipient per daily dose

- For example, if you have a prescription for one witnessed dose on Monday and 6 carry doses for Tuesday through Sunday, on Monday the claims appear as follows:
  
  o one claim is submitted for the Monday witnessed dose
  
  o one claim is submitted for the Tuesday carry dose
  
  o one claim is submitted for the Wednesday carry dose; and so on for Thursday, Friday, Saturday and Sunday
  
  o each claim for the carry doses is submitted on the day that the carry doses were dispensed (i.e., Monday in this example)

- In other words, on Monday when all of the doses were dispensed, a total of 7 claims with 7 dispensing fees would have been submitted to the Ministry for payment through the HNS.
When more than one claim is submitted for the same DIN on the same day for the same patient, the HNS will reject the second (and subsequent) claim(s) with response code “A3” – identical claim processed which can be overridden with an appropriate intervention code. Please refer to the Ontario Drug Programs Reference Manual for intervention codes.

If replacement claims are required because of dose changes after carry doses have already been dispensed, the replacement claims are not eligible for additional dispensing fees as this would exceed the maximum number of dispensing fees allowed. Similarly, additional doses to supplement the carry doses already dispensed are not eligible for additional dispensing fees.

- All labels must adhere to all Ontario College of Pharmacists policies and guidelines including the dose and date of ingestion on each labelled bottle.

- No co-payment amount may be collected from ODB eligible persons or a private third party for ODB eligible persons receiving methadone for MMT. However, additional charges such as ODB deductible amounts and out-of-pocket charges for patients who request a higher priced interchangeable product but do not meet the medically necessary “no substitution” requirements are eligible to be collected.

- No compounding time or charge is permitted for the dispensing of methadone 10mg/mL oral liquid. For example, when methadone 10mg/mL oral concentrate is diluted prior to dispensing, this practice is not considered compounding.

- No other ingredient costs may be added to the amount billed to the ministry (i.e., cost of distilled water or drink mix (e.g., Tang®) may not be billed to the ministry in addition to the cost of methadone amount already being reimbursed).

- If an ODB recipient’s dose is changed by their prescriber after the ODB recipient’s carry doses have already been dispensed (i.e., the dispensing fee from that day’s dose has already been billed with the original carries), the replacement claim must not include a dispensing fee.
The quantity of methadone 10mg/mL oral concentrate used in dispensing the final prescribed methadone dose must be entered as milliliters (mLs) of drug dispensed. The milligrams of methadone prescribed must be converted to mLs of methadone 10mg/mL oral concentrate dispensed and entered as a single dose for the submission to the HNS and the Narcotics Monitoring System (NMS). For example, if the physician prescribed methadone 100 mg each day, the claim submission to the HNS and the NMS record must indicate a quantity of 10 mLs of methadone 10mg/mL oral concentrate.

The pharmacy-generated prescription label must comply with the appropriate Ontario College of Pharmacists policies and guidelines.

The drug cost, plus the applicable % mark-up and the applicable dispensing fee are to be submitted on-line via the HNS. The prescription receipt must indicate a zero co-payment amount.

Methadone used for the treatment of chronic pain is not eligible for reimbursement under this Policy. An application for funding consideration must be submitted by an authorized prescriber to the Exceptional Access Program for any ODB eligible patient who is prescribed methadone for chronic pain.

Use of extemporaneous compounded methadone liquid:

- Effective September 1, 2014, the extemporaneously compounded methadone solution prepared using methadone powder is no longer funded under the ODB program for MMT.

- However, compounded methadone (using methadone powder) under the Policy may only be dispensed to patients who have had an allergic reaction to all manufactured methadone products listed on the Formulary. Exceptional Access Program approval is required.

Amendments and Updates

The Ministry may make changes to this Policy at any time upon giving at least 30 days’ notice to Ontario pharmacy operators.
Buprenorphine/ Naloxone (Suboxone® and generics)

Reimbursement

Reminder under the Ontario Drug Benefit Program

Buprenorphine/Naloxone is used for the treatment of opioid use disorder and is listed on the Ontario Drug Benefit (ODB) Formulary as a general benefit. As a narcotic drug, Buprenorphine/Naloxone requires a written or faxed prescription from a prescriber who is expected to have undergone appropriate training / education on Buprenorphine/Naloxone treatment and addiction medicine.

Best practice guidelines direct that Buprenorphine/Naloxone be prescribed similar to methadone maintenance treatment including:

- Start and stop dates
- Days for supervised administration (witness doses)
- Days for take home doses

Please note: Buprenorphine/Naloxone is not included in the Methadone Maintenance Treatment (MMT) Reimbursement Policy for all pharmacies that dispense methadone maintenance treatment for opioid use disorder under the ODB Program. Therefore, pharmacies are not entitled to submit separate claims for each take-home dose of Buprenorphine/Naloxone as is the practice for methadone maintenance treatment claims dispensed under the MMT Reimbursement Policy.

Buprenorphine/Naloxone Claims Submission for ODB eligible recipients:

Prescriptions for Buprenorphine/Naloxone will vary depending on the clinical assessment of the patient. Pharmacists may receive prescriptions that indicate:

- daily dosing for a period of time
- take home supplies and/or
- supplemental dosing.

As a narcotic, Buprenorphine/Naloxone is one of the drugs that is exempted by the Executive Officer from the two-dispensing-fees-per-28-days rule set out in subsection 18(10) of Ontario Regulation 201/96 under the Ontario Drug Benefit Act.
For more information on the exempted medication lists please visit the ministry website.

Pharmacists must bear in mind the requirements regarding narcotic prescription dispensing in general, as well as recordkeeping and data disclosure procedures for opioids and monitored drugs under the Narcotics Safety and Awareness Act, 2010. Pharmacists should ensure accurate prescriptions in all cases. For possible prescription scenarios refer to the table below.

- Pharmacies may claim one dispensing fee per day per patient for each supervised / witnessed Buprenorphine/Naloxone dose on the day the dose is witnessed by the pharmacist.

- If a prescription directs a take home supply in addition to one witnessed dose, one extra fee may be submitted on the same day for the take home “carry” doses.

- If a prescription directs a supplemental supply of Buprenorphine/Naloxone in addition to the take home supply of doses, only one dispensing fee for the total supplemental and take-home supply may be claimed on the same day.

- When two fees are charged in one day, pursuant to the conditions above, the “UA” intervention code will be required.

- A pharmacy may only bill one fee per day for patients if the patient attends the pharmacy daily for witnessed doses.

- Buprenorphine/Naloxone prescriptions that are dispensed by pharmacies for transferred patient care via batch shipping to physician offices or to off-site care facilities (i.e., addiction treatment centers) are eligible for one dispensing fee per patient prescription that could encompass both witness and carry doses, since they are dispensed from the pharmacy at one time.

**Table 1: Possible Buprenorphine/Naloxone prescription scenarios:**

<table>
<thead>
<tr>
<th>Prescription direction</th>
<th>Dispensing fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 witness doses</td>
<td>1 fee allowed each day</td>
</tr>
<tr>
<td>1 witness dose &amp; 6 carry doses</td>
<td>2 fees allowed; 2 claims submitted on the day the dose was witnessed in the</td>
</tr>
</tbody>
</table>
pharmacy and the take home doses were provided

<table>
<thead>
<tr>
<th>1 witness dose each day Mon – Fri; 2 carry doses</th>
<th>1 fee allowed per day from Mon-Thurs with each witnessed dose; 2 fees allowed on Friday – one for the witnessed dose, one for the weekend carry doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 carry doses</td>
<td>1 fee for all carry doses combined</td>
</tr>
<tr>
<td>Any combination of witness and carry doses where care has been transferred to a physician, clinic or other care facility.</td>
<td>1 fee for all doses combined</td>
</tr>
</tbody>
</table>

In summary, the Ministry pays the sum of:

- Drug cost as per the ODB Formulary listing;
- Current mark-up on the ODB drug cost, and
- ODB dispensing fee up to a maximum of one fee per witness dose and one fee for all take-home doses that are dispensed at one time.
- Co-payments may be charged to the eligible recipient; however, pharmacies may choose to waive the co-payment amount.

For more information refer to the Notice from the Executive Officer from March 13, 2019 on the ministry website: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx

### 6.9 Exceptional Access Program

The Exceptional Access Program (EAP) facilitates patient access to drugs not listed on the ODBF/CDI, or where no listed alternative is available. In order to receive coverage, the patient must be eligible to receive benefits under the ODB program.
Submitting Exceptional Access Program Requests

Requests for authorization of EAP listed drugs can be submitted to the Ministry through one of the following channels:


   The SADIE (Special Authorization Digital Information Exchange) portal is available 24x7 to authorized prescribers (Ontario physicians and nurse practitioners) and their delegates and designates (e.g., nurses, pharmacists, reimbursement coordinators) enabling the creation and submission of web-based electronic requests directly to the Exceptional Access Program.

   To help prescribers make decisions about submitting requests, the clinical criteria associated with most EAP products can be found within the SADIE portal.

   Authorized prescribers who are Manitoba and Quebec physicians and nurses with the authority to prescribe drugs cannot submit EAP requests through SADIE. EAP requests should be faxed to 1-833-905-4260. This number is for the use of Manitoba and Quebec physicians and nurses only.

   More information about SADIE can be found at www.ontario.ca/SADIE.

2. Submitting the completed request form/information by fax to the EAP Toll-free to 1-866-811-9908 or 416-327-7526 (Toronto area).

   Authorized prescribers in Manitoba and Quebec may fax EAP requests to 1-833-905-4260.

3. For selected drugs, the Telephone Request Service is available to authorized prescribers or their designates. In most cases, the funding decision is provided by the end of the call and processed within one business day. The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) and select the TRS option. (See broader description in the section below.)

4. EAP requests for hospitalized patients who are imminently awaiting hospital discharge may be submitted electronically through SADIE or on the hospital discharge form and faxed toll-free to 1-844-829-6807 or 416-314-3857 (Toronto area).
5. For authorized prescribers unable to use any of the above options, requests may be mailed to:

**Exceptional Access Program**
3rd Floor, 5700 Yonge St.
North York, ON M2M 4K5

Submission by mail may delay the receipt of the request by the Exceptional Access Program.

Only authorized prescribers within the meaning of the ODBA may submit an EAP request. Under the ODBA, authorized prescribers include Ontario physicians and nurse practitioners, and physicians and nurses in the provinces of Manitoba and Quebec who have the authority to prescribe drugs.

**Note:** Effective June 14, 2021, a new regulation was made under the to the ODBA to expand the definition of “authorized prescribers” who can submit EAP requests on behalf of an ODB recipient to include Manitoba and Quebec physicians and nurses who have authority to prescribe (see Ontario Regulation 470/21). This regulation replaces the former Provincial Borders Drug Program, a policy-based pilot program which enabled consideration of EAP requests from physician prescribers in the provinces of Manitoba and Quebec.

The patient’s authorized prescriber must submit a request documenting complete and relevant medical information in accordance with the approved clinical criteria associated with the drug and indication being requested. This may include providing the clinical rationale for requesting the drug and reasons why drug products listed on the ODBF/CDI are not suitable.

All requests are reviewed according to the guidelines and criteria recommended through an established national and/or provincial process and as approved by the Executive Officer (EO) of the OPDP. This review includes a thorough assessment of the patient’s specific case and clinical circumstances, as provided by the authorized prescriber, as well as the scientific evidence available. If EAP approval is granted, the coverage period begins as of the effective date and extends only to the specified date which are provided on the Ministry response letter to the prescriber.

The criteria for the funding of frequently requested drugs considered through the EAP can be found on the SADIE (Special Authorization Digital Information Exchange) portal or on the Ministry’s website at: Exceptional Access Program.
Authorized prescribers are encouraged to utilize these resources to ensure that they provide the clinical information necessary for the EAP to assess the requested drug(s).

**Exceptional Access Program Application Process**

To apply through the EAP, the patient’s authorized prescriber must submit a request documenting complete and relevant medical information to the Ministry, providing the clinical rationale for requesting the drug and reasons why covered benefits are not suitable. Authorized prescribers who are Ontario physicians and nurse practitioners, and physicians and nurses in the provinces of Manitoba and Quebec who have the authority to prescribe drugs may submit an EAP request.

For more information on how to submit a request to the Exceptional Access Program, see section above: Submitting Exceptional Access Program Requests

All requests are reviewed according to the guidelines and criteria recommended through a national or provincial established process of review and approved by the Executive Officer (EO) of the OPDP. This review includes a thorough assessment of the patient’s specific case and clinical circumstances, as provided by the authorized prescriber, as well as the scientific evidence available. If EAP approval is granted, the coverage period begins as of the effective date and extends only to the specified date.

The criteria for the funding of frequently requested drugs considered through the EAP can be found on the SADIE (Special Authorization Digital Information Exchange) portal or on the Ministry’s website at: Exceptional Access Program.

Authorized prescribers are encouraged to utilize the Reimbursement criteria for EAP Frequently Request Drugs resource on the Ministry’s website to ensure that they provide the adequate clinical information necessary for the EAP to assess the requested drug(s). Note: authorized prescribers who have access to SADIE can also find such information on the SADIE portal.

**Exceptional Access Program Approvals**

Following assessment, the Ministry will fax a decision to the prescriber who submitted the request. For requests that meet EAP criteria and are approved, the
effective date of coverage and the expiry date of coverage will be communicated to the authorized prescriber in the Ministry’s response letter.

Although it is not mandatory, authorized prescribers should provide a copy of the response letter to the patient and/or the patient’s pharmacy as this letter identifies the name of the drug(s) approved, the drug identification number or product identification number for the funded product, and the coverage period. This information may help with oversight of the duration of coverage of products and avoid gaps in treatment if an extension/renewal of the funding is required. It should be noted that the EAP may not cover all manufactured brands of a specific drug and that the response letter does not list all funded off-formulary interchangeable (OFI) products that may be covered since interchangeable products may change, be added or be withdrawn from the ODBF/CDI over time. It is the pharmacy’s responsibility to ensure that they are dispensing an ODB funded brand by referring to the status of OFI drugs listed on the ODBF/CDI. Any prescription which fails to be adjudicated at the time of dispensing should be further investigated to validate the individual coverage status.

Pharmacists are not required to keep a copy of the Ministry’s response letter on file.

**Exceptional Access Program Coverage Duration**

For requests that meet EAP criteria and are approved, the effective date of coverage and the expiry date of coverage will be communicated to the authorized prescriber in the Ministry’s response letter.

Authorized prescribers should provide a copy of the response letter to the patient and/or the pharmacy as this may help to avoid a gap in treatment if an extension/renewal of funding is required.

The coverage period for approved requests generally will begin on the day that the request is received by the program. However, the EAP applies a standard approval procedure to qualified requests that may backdate the coverage period by up to 30 business days from the date the request is received by the program to recognize that authorized prescribers may not submit an EAP request at the same time as the clinical decision to prescribe an unlisted drug is made.

Only eligible approved requests that meet EAP clinical criteria at the time they are received by the program will be aligned. For example, alignment will not be provided for requests with a short duration of approval (e.g., an antibiotic, a drug
required before surgery); for renewal requests that are approved before the expiry date of an existing approvals; for requests that do not meet EAP criteria at the time of receipt; for requests made through the Telephone Request Service (TRS); or for requests made through the Compassionate Review Policy (CRP). Additionally, coverage periods will not be provided to a date prior to the effective date of provincial coverage of the EAP drug product and indication. Other exceptions may apply.

EAP approvals are not guaranteed as requests must meet EAP clinical criteria. Patients who choose to purchase unlisted drugs in advance of an EAP decision are responsible for out-of-pocket costs.

To receive funding for a drug approved by the EAP, the patient must be ODB-eligible. Additionally, only ODB-eligible costs are considered for reimbursement. For example, drug costs over ODB-eligible costs, credit card and banking charges will not be reimbursed.

**Off-Formulary Interchangeability and Generic substitution of Exceptional Access Program Drugs**

Off-Formulary Interchangeability (OFI) is the application of interchangeable designations to generic drug products that are not listed benefits under the ODBA. OFI became effective April 1, 2007 when changes to Regulation 935 under the DIDFA came into force.

If a drug has been approved by the EAP, authorization will automatically be granted for the generic interchangeable product(s) of the same strength if they are listed as an OFI. It should be noted that the EAP response letter does not identify all OFI drug products and not all generic products of the same strength are deemed interchangeable. As such, pharmacists should refer to the ODBF/CDI for interchangeable OFI funded EAP products. Pharmacists should forward any questions regarding authorization of a specific EAP claim, including requests to change the DIN, dosage form or strength of a drug product, to the ODB Help Desk or directly to the EAP. If contacting the EAP, queries should be e-mailed to EAPFeedback@ontario.ca.

Generic substitution applies to the EAP.
Under this policy, if an EAP drug has an interchangeable generic product designated through the OFI mechanism, the Ministry will only approve the funding of the generic product. Where ODB recipients have had a documented adverse reaction to at least two (2) generic versions, the Ministry will reimburse the higher-cost brand product. Similar to products listed on the ODB Formulary, the “No Substitution” policy applies.

Pharmacists must dispense an OFI generic product in the pharmacy’s inventory to ODB recipients with an EAP approval from the Ministry. Pharmacists will be reimbursed the cost of the generic product that is dispensed. Given that inventory selection differs from pharmacy to pharmacy, the Health Network System (HNS) will have system rules in place, to reduce the value of the “Amount MOH Pays” for a brand name OFI drug product to that of the highest-cost generic in the interchangeable category. This information can be found in the e-formulary.

In order for ODB to reimburse the brand name product, prescribers are required to complete, sign and forward to the pharmacist, a copy of the Health Canada Side Effect Reporting Form for each interchangeable drug product trialed, and are required to write “no substitution” on a written prescription or indicate “no substitution” to the pharmacist in the case of a verbal prescription. The form(s) must be completely filled out noting the details of the adverse reaction(s) and signed by the prescriber. This process aligns with the rules for formulary listed benefit products.

If ODB recipients choose to exercise their personal preference for the brand therapy without complying with the ODB policy on generic substitution, it will be the responsibility of the recipient to pay for the cost difference as determined by the pharmacy.

**Exceptional Access Program Renewal of Coverage**

If it is anticipated that a patient will continue to require the product beyond the approval period, the authorized prescriber is required to request an extension of coverage. Coverage will not be continued automatically between expiration and re-issuance of approval. It is recommended that the request for continued reimbursement and all supporting documentation be submitted to the Ministry to enable re-evaluation of the request within the timeframe appropriate to the approval duration granted. For instance, drugs that are granted coverage for one or more years duration should submit extension of coverage requests six to eight weeks prior
to the expiration of the current approval. For EAP drugs approved for shorter coverage durations, evaluation of the response to the drug should occur within a time period that provides clinically relevant information to meet renewal criteria requirements.

Authorized Prescribers are encouraged to review the EAP criteria for renewal consideration of individual drugs to ensure that sufficient and appropriate information is provided to facilitate a timely response. The request should address the renewal criteria required for the specific drug (as applicable) and include a summary of the patient’s response to therapy typically as progress on the drug product compared to “baseline” before starting the treatment or as compared to a prior renewal, any changes in drug therapy, or dose/dose regimen, the rationale for the continued need for the product, and a list of all concomitant drug therapies.

**Telephone Request Service**

The Telephone Request Service (TRS) offers prescribers another way to submit EAP requests for a group of selected drugs. In most cases, these requests will be assessed in real-time. Authorized prescribers or their delegates may call the TRS to submit their requests and obtain a faster decision for selected drugs and indications. Additional information, including evaluation questionnaires and the reimbursement criteria for drugs that can be considered through the TRS, is posted on the [Exceptional Access Program – Telephone Request Service](#) web page.

Authorized prescribers and their delegates are encouraged to review the TRS reimbursement criteria before calling to ensure that the drug they are requesting is one that can be considered through this service and to ensure that they have the necessary information readily available to receive a decision during the call. Requests for drug products or indications not currently available through TRS must be submitted via Special Authorization Digital Information Exchange (SADIE) or fax.

Authorized prescribers and their delegates may call 1-866-811-9893 or 416-327-8109 and select the TRS option. The hours of operation of EAP’s TRS are from 8:30 a.m. to 5 p.m. Monday to Friday. Service is not available on weekends, provincial statutory holidays, Easter Monday or Remembrance Day.
## Exceptional Access Program Claim Requirements

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting a claim for an EAP authorized drug product, namely:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the DIN/PIN of the product authorized</td>
</tr>
<tr>
<td>Quantity</td>
<td>Y</td>
<td>Enter the quantity to be billed (in units)</td>
</tr>
<tr>
<td>Drug Cost/Product Value</td>
<td>Y</td>
<td>Enter the DBP (if available in the Formulary/CDI or posted on the M) or the actual Acquisition Cost (equal to manufacturer’s or wholesaler’s invoice amount minus discounts). Do not enter mark-ups here. HST is not applicable. (refer to Acquisition Cost Calculations in Section 6.7)</td>
</tr>
<tr>
<td>Cost Mark-up</td>
<td>Y</td>
<td>Enter the mark-up amount, 8% when the total drug cost is less than $1,000.00 or 6% when the total drug cost is greater than or equal to $1,000.00</td>
</tr>
</tbody>
</table>

**Note:** The Ministry is aware of its obligations under PHIPA to ensure the confidentiality of all personal patient information which it holds on file as provided by requesting prescribers. Prescribers are requested to ensure continuation of this vigilance as it relates to patient privacy issues, particularly when transmitting EAP approval information to other parties.
Claim Validation

Supporting documentation may be requested.

Where Acquisition Cost is being claimed, the pharmacy must retain on file for two years from the day the invoice was received a copy of: (a) the supplier’s invoice which demonstrate the Acquisition Cost claimed, (b) invoices which show that the lowest price interchangeable product was ordered and not available at the time of the cost-to-operator claim, and (c) a detailed calculation of the cost of purchasing the drug product (in accordance with section 14 of the O. Reg. 201/96 under the Ontario Drug Benefit Act).

6.10 Compassionate Review Policy

The Compassionate Review Policy (CRP) enables consideration of coverage of requests for drugs and indications which have not been reviewed through the established national and or provincial processes for a final provincial funding decision by the Executive Officer of the OPDP. The CRP is used to review requests for funding for rare clinical circumstances in immediately life-, limb-, or organ-threatening conditions. The CRP is not to be used to bypass the established processes for decisions related to provincial drug funding, and it will not be used to consider coverage of a reviewed drug and indication where the Executive Officer has made a decision not to fund. Requests must meet the criteria for the Compassionate Review Policy (CRP).

The CRP may be used in situations where a drug has undergone a clinical review through the established national/provincial processes and is awaiting completion of the negotiations with the manufacturer towards a final provincial funding decision by the Executive Officer. The CRP may be used to consider coverage of requests on a case by case basis for individuals who have been urgently hospitalized due to an immediate life-, limb-, or organ threatening complication which aligns to the drug and indication under negotiations. The hospitalization must be directly related to the clinical indication for which the negotiations of the drug are ongoing. Interim EAP approval of a request will be limited to a maximum of six months and will begin once the patient is discharged from hospital. Further coverage may not be approved once final criteria have been established.
Under CRP, the Executive Officer will also consider requests for drugs without a Notice of Compliance (NOC) and DIN issued by Health Canada if the prescriber indicates in the request that approval has been obtained through the Health Canada Special Access Program (SAP).

For requests for drugs (oral or injectable) that are used to treat cancer that have not been reviewed through the established national or provincial processes, Cancer Care Ontario (CCO) administers the Case-by-Case Review Program (CBCRP) on behalf of the Ministry. The CBCRP extends and adapts the Compassionate Review Policy to unreviewed therapies that are administered for the treatment of cancer in life-, limb-, and organ-threatening situations. Consideration through CBCRP must be for the treatment of cancer. A cancer drug used to treat a non-cancer condition would not be considered under CBCRP.

Further information on the CBCRP including eligibility criteria and how to apply is available on the CCO website.

While CCO administers the CBCRP, the Executive Officer of OPDP makes all final funding decisions.

### 6.11 Nutrition Products

Nutrition Products are listed substances reimbursed as additional benefits for ODB eligible persons in defined circumstances.

**Patient Eligibility Criteria for Coverage of Nutrition Products**

Enteral nutrition products will be reimbursed for ODB eligible persons when prescribed by a physician or nurse practitioner as the patient’s sole source of nutrition and when any of the following criteria is met:

- Oropharyngeal or gastrointestinal disorders resulting in esophageal dysfunction or dysphagia (e.g., head and neck surgery, neuromuscular disorder, or cerebral vascular disease where dysphagia prevents eating).

- Malabsorption disorder and/or significant gut failure where food is not tolerated (e.g., pancreatic insufficiency, biliary obstruction, short bowel syndrome).
• For patients requiring the use of a chemically defined diet as a primary
  treatment of a disease where the therapeutic benefit has been demonstrated
  (i.e., Crohn’s disease).

**Exclusion Criteria**

A nutrition product will not be reimbursed under the ODB program if it is intended
for one of the following uses:

• prescribed weight loss in the treatment of obesity
• food allergies
• body building
• voluntary meal replacement
• nutritional supplement
• convenience
• replacement for breast-feeding for infants with normal gastrointestinal
  absorptive function.

**Nutrition products are eligible for coverage under the ODP program only when**
**prescribed by a physician or nurse practitioner as the patient’s sole source of**
**nutrition. Patients tolerating some solid foods and requiring only**
**supplementation in addition to food are not eligible for coverage.**

**Nutrition Products Form**

Each claim for reimbursement must be supported by a valid and fully completed
**Nutrition Products form.** A valid Nutrition Products form is required before any claim
for reimbursement can be processed.

In order for a Nutrition Products form to be valid, the following conditions must
apply:

• The recipient must meet the patient eligibility criteria for coverage of nutrition
  products.
The Nutrition Products form must be fully completed and signed by eligible prescriber.

The nutrition product that is claimed and dispensed must match the nutrition product that is written by the eligible prescriber on the Nutrition Products form.

The Nutrition Products form will be valid only for one year from the initial date it was completed and signed by the eligible prescriber.

Nutrition products are designated as listed substances under ODBA and require a valid Nutrition Products form signed by an eligible prescriber in order to be eligible for reimbursement under the ODB program.

A valid and complete Nutrition Products form supporting an ODB eligible nutrition product claim must be maintained on file for claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable, for the Retention Period.

Prescribers can obtain an Nutrition Products form from the Ministry website.

Pharmacists should note the maximum amount the Ministry will reimburse pharmacies for each approved nutrition product. **CTO claims will not be accepted. Nutrition Products are not eligible for a mark-up.**

For more information regarding the reimbursement of nutrition products, including the specific nutrition products approved for coverage and the maximum price up to which they will be reimbursed, please refer to the Maximum Allowable Reimbursement (MAR) Schedule of the ODBF/CDI.

**Note:** Nutritional requirements for residents of LTC homes and HSC are met by the home responsible for their care. Nutrition product claims for these residents are not reimbursed under the ODB program.

**Nutrition Product Claim Requirements**

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting a nutrition product claim, namely:
## Fields

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the PIN of the product, as listed in the ODBF/CDI</td>
</tr>
<tr>
<td>Quantity</td>
<td>Y</td>
<td>Enter the quantity to be billed, in terms of package size (not as mL or g) based from the Cost per Pack column in Part IX of the ODBF/CDI. For example, a 500 mL product (Pkg Size = 250 mL) must be billed as two.</td>
</tr>
<tr>
<td>Drug Cost/Product Value</td>
<td>Y</td>
<td>Enter the actual or net Acquisition Cost (equal to manufacturer’s or wholesaler’s invoice amount minus discounts). Mark-ups and HST are not applicable, refer to pricing information in ODBF/CDI.</td>
</tr>
<tr>
<td>Cost Mark-up</td>
<td>Y</td>
<td>Must be equal to zero</td>
</tr>
</tbody>
</table>

### Claim Validation

**Supporting documentation may be requested for claim validation.**

*A valid prescription, and valid and complete Nutrition Products form (completed and signed by the prescriber) must be maintained on file for the Retention Period for the purposes of claim validation, and in accordance with O. Reg. 264/16 made under DPRA if applicable.*

### 6.12 Diabetic Testing Agents

Blood Glucose Test Strips (BGTS) that are listed substances in the ODB Formulary are covered as additional benefits for ODB program eligible persons.
General Information

BGTS are designated as listed substances under the ODBA and require a valid prescription signed by an eligible prescriber (an Ontario physician or nurse practitioner) in order to be eligible for reimbursement under the ODB program. Prescriptions and prescription extensions by pharmacists for BGTS are not eligible for reimbursement under the ODB program.

Pharmacists should note the maximum amount the Ministry will reimburse pharmacies for each approved test strip. **CTO claims will not be accepted. Test strips are not eligible for a mark-up.**

**Note:** Only one PIN for each brand of test strips can be used for billing. The PIN must match the brand of test strips that is prescribed and dispensed. Dispensing a brand of test strips that has not been prescribed or dispensing one brand of test strips and billing another brand, will result in invalid claims for payment that are subject to recovery. When billing test strips, the package size (e.g., one box) cannot be used since reimbursement is based on the number of units (i.e., strips) of each product dispensed. Test strip allotments for ODB recipients take into account diabetic test strip products that contain for example, 51 and 102 test strips per package.

Blood Glucose Test Strips Reimbursement Maximums

The limits noted below are aligned with the [Canadian Diabetes Association (CDA) recommendations](https://www.diabetes.ca) to encourage proper testing practices for optimal patient outcomes and to test according to the current medication profile. HNS will track and determine appropriate levels of reimbursement of BGTS based on the current diabetes therapy used by eligible ODB program recipients. The HNS determines the treatment category for an ODB recipient based upon claims for insulin products or other anti-diabetes medications available on the ODB Formulary.

When a claim is submitted for BGTS for eligible ODB program recipients, the HNS will automatically review the insulin and anti-diabetes medications claims or prescription receipts within the **previous 180 days** to identify claims or receipts for insulin products and other anti-diabetes medications. The HNS will then apply a maximum number of self-monitoring BGTS that may be reimbursed for the recipient, based on both online and manual claims submitted by pharmacies and prescription...
receipts submitted by ODB-eligible recipients to the ministry for reimbursement or to satisfy a TDP deductible as follows:

<table>
<thead>
<tr>
<th>Diabetes Treatment Category</th>
<th>Number of BGTS allowed over the course of 365 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients managing diabetes with insulin</td>
<td>3,000</td>
</tr>
<tr>
<td>Patients managing diabetes with anti-diabetes medication with high risk of causing hypoglycemia*</td>
<td>400</td>
</tr>
<tr>
<td>Patients managing diabetes using anti-diabetes medication with low risk of causing hypoglycemia**</td>
<td>200</td>
</tr>
<tr>
<td>Patients managing diabetes through diet/lifestyle therapy only (no insulin or anti-diabetes medications)</td>
<td>200</td>
</tr>
</tbody>
</table>

*Including but not limited to glyburide, gliclazide, chlorpropamide, tolbutamide, repaglinide, nateglinide, or glimepiride

**Including but not limited to metformin, sitagliptin phosphate monohydrate, saxagliptin, acarbose, rosiglitazone, pioglitazone, linagliptin, liraglutide, canagliflozin or empagliflozin

Recipients will be allotted the indicated number of test strips for use over the course of a 365-day period. The test strip allotment will apply to both online and manual claims submitted by pharmacies as well as prescription receipts submitted by ODB-eligible recipients to the ministry for reimbursement or to satisfy a TDP deductible.

When a claim is submitted, HNS calculates whether the recipient has met their allotted maximum for the year by reviewing BGTS claims and receipts history in the last 365-day period. The allotment is recalculated each time the HNS reviews the 365-day period prior to every BGTS claim. If the recipient has not reached their maximum number of allotted test strips, they will be eligible to receive test strips up to that maximum number.
The test strip allotment is based on a patient's current treatment method, as based on their claims and prescription receipts history in the HNS in the previous 180 days and may change during this period based on changes to anti-diabetic medications (e.g., if a patient originally uses a medication with a high risk of hypoglycemia, but then only uses medications with a low risk of hypoglycemia or vice versa).

For example, a physician discontinues glyburide, a medication with a high risk of hypoglycemia, and the patient remains on medications with a low risk of hypoglycemia. The patient’s allotment was originally 400 annual test strips, but will change to 200 annual test strips 180 days after the last fill of glyburide. The total number of strips reimbursed within a 365-day period is still calculated in the same manner. Education of the patient’s monitoring frequency is important when there are changes with the patient’s medications.
Pharmacies may override the current test strip allotment for patients who receive medications not billed through the HNS that put them at higher risk of hypoglycemia, up to the maximum as outlined in the table above. See override codes below for more information, including supporting documentation requirements.

However, in exceptional clinical circumstances where some people may require more frequent testing, in order to obtain a greater number of BGTS, a physician or nurse practitioner must indicate the reason for the higher than recommended monitoring schedule and the specific testing frequency on the BGTS prescription.
See override codes below for more information, including supporting documentation requirements.

**Note:** When submitting a claim for insulin or anti-diabetes medication along with a claim for BGTS, pharmacists must **submit the claims for insulin or anti-diabetes medications prior to submitting the BGTS claim**. This ensures that the most current drug profile is included in the historical treatment review, and patients are allocated the proper number of test strips. Similarly, all related manual claims must be submitted by the pharmacy for processing as soon as possible. Finally, where an ODB-eligible person pays for the BGTS, insulin or anti-diabetes medication out-of-pocket and intends to submit their prescription receipt to the ministry for reimbursement or to satisfy their TDP deductible, then the pharmacy should advise the person to submit their prescription receipt to the ministry as soon as possible to ensure the prompt updating of their claims history.

### Diabetic Testing Agents Claim Requirements

Pharmacies may not charge eligible ODB recipients any amount other than the co-payment for supplying BGTS under the ODB program. The Ministry will reimburse pharmacies the amount identified in the column “Amount MOH Pays” in the Formulary. **No mark-up will be permitted for BGTS. CTO claims will not be accepted.**

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting a diabetic testing agent claim, namely:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the PIN of the specific brand of test strips that is dispensed, as listed in the ODBF/CDI</td>
</tr>
</tbody>
</table>
| Quantity   | Y              | Enter the quantity to be billed, in terms of number of units (not as package size) dispensed  
For example, one box of 50 test strips must be billed as units = 50 |
Drug Cost/Product Value | Y | Enter the actual Acquisition Cost (equal to manufacturer’s or wholesaler’s invoice amount minus discounts). Mark-ups and HST are not applicable, refer to pricing information in the ODBF/CDI
Cost Mark-up | Y | Must be equal to zero

The reconciliation adjustment process described in the most recent version of EO Notice: Reconciliation Adjustment Percentages to Improve the Value of Pharmacy Payments applies to BGTS claims and is posted on the ministry’s website at this link:
https://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.a spx

Blood Glucose Test Strips Claim Submission Responses

If the maximum number of test strips is exceeded in a 365-day period for a given patient, a response code is provided to the pharmacist indicating that the recipient has reached their limit and the claim is rejected. Two different response codes may be provided by HNS in this scenario:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
<th>Explanation of condition generating response code</th>
</tr>
</thead>
<tbody>
<tr>
<td>“OC”</td>
<td>Quantity Reduction Required</td>
<td>This response code will be displayed if the claim can be accepted by reducing the quantity. A message data line* will be included to advise of the remaining allowable number of test strips for the recipient before they reach their limit.</td>
</tr>
<tr>
<td>“LO”</td>
<td>Maximum Benefit Exceeded</td>
<td>This response code indicates that the recipient has exceeded their maximum benefit and cannot receive any additional test strips without an override. A message data line* will be included to advise of the remaining allowable number of test strips for the recipient.</td>
</tr>
</tbody>
</table>
HNS tracks and determines the BGTS reimbursement level based on each patient’s diabetes treatment to help monitor the number of strips an ODB program recipient has received during a 365-day period. To assist ODB program recipients and pharmacists in tracking a patient’s BGTS utilization and identifying the next period start date for their patients, a response message data line is delivered to pharmacies after adjudicating claims for BGTS.

**HNS Response Message Data Line for BGTS Claims**

“Remaining Qty: #### until MMM DD, YYYY”.

For example: “Remaining Qty: 100 until FEB 15, 2019”.

This response message data line is sent in addition to the reject response codes sent to pharmacy systems after processing a BGTS claim.

In addition, patients should be encouraged to have their prescriptions filled at one pharmacy to ensure that they have a complete history of all the medications and test strips that they have received in the past especially if they want to track the remaining number of strips available for reimbursement.

**Override Codes**

There may be exceptional clinical circumstances where patients may require additional test strips. When a patient has reached their limit of available test strips in a 365-day period, two intervention codes are available for pharmacists. Documentation to support the application of each intervention code is required. Dispensers must maintain this information on file for claim validation purposes, and in accordance with O Reg 264/16 under the DPRA if applicable, for the Retention Period.

<table>
<thead>
<tr>
<th>Intervention Code</th>
<th>Message Description</th>
<th>Explanation of condition generating response code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>“NF”</strong></td>
<td>Override-Quantity Appropriate</td>
<td>This intervention code may be used for patients who require more than 200 or 400 test strips in a 365-day period, because they had claims for insulin and/or anti-diabetes medications with high risk of causing hypoglycemia in the previous 180 days, that were not reimbursed under the ODB program</td>
</tr>
</tbody>
</table>
or not recorded in the HNS. The identified anti-diabetes medications that were reimbursed by private drug insurance plans or paid by the patient and not recorded in the HNS must be documented and readily available for inspection purposes.

<table>
<thead>
<tr>
<th>&quot;MG&quot;</th>
<th>Override-Clinical Reasons</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>This override code will allow for 100 additional test strips at a time to be reimbursed for non-insulin dependent patients who have been directed by a healthcare professional to monitor blood glucose levels more frequently for a specific clinical reason. If additional 100 strips are required beyond the prescribed annual limit for a given 365-day period, a new script with the proper documentation would have to be submitted by the prescriber for each individual request. Documentation must include the reason for exceeding the recommended frequency of monitoring, specific testing frequency (if not indicated on the prescription) and the name of the referring healthcare professional and the dispensing pharmacist’s OCP license number. The additional test strips distributed to patients for exceptional clinical circumstances will not have an impact on the allotment of test strips for the patient within the next 365-day period.</td>
</tr>
</tbody>
</table>

*Clinical reasons for which an individual may require more frequent testing may include the following:

- Patient has experienced acute illness or infection that affected blood glucose control over a sustained period of time
- Issues related to drug interactions which have impacted blood glucose control
- Patient has gestational diabetes
• Patient has an occupation that requires strict avoidance of hypoglycemia (e.g., pilots, air-traffic controllers, critical positions in railways)

• Patient is not meeting glycemic targets for 3 months or greater

If a patient provides information that differs from what is being indicated in the HNS, the patient medication profile may be out of date or incomplete.

If there is a discrepancy, the pharmacist should:

• Reconfirm the patient’s allotment based on the patient history to ensure that the limit indicated in the HNS is correct. All prescription information should be confirmed as up-to-date.

• Review what order prescriptions were entered - if a prescription was entered into the system after the claim for the test strips, the limit indicated for the patient may not be accurate.

• Inquire to see if the patient has received any medications outside of the ODB program within the past 180 days that would entitle them to a higher allotment.

If it is determined that the patient is wrong about their allotment (change in medication profile, etc.), an override is not allowed.

**Note:** Changing to a new device does not qualify as a clinical reason for additional test strips. If the patient has not reached their allotment, they can receive test strips for their new device, but the total allocation includes the test strips from their previous device. It is recommended that the patient use a device that will be compatible with their current test strips to ensure the patient does not exceed their allocated maximum number of test strips for the year. If there are malfunctions with their current device, it is recommended that the patient use a new device that remains compatible with their test strips.
6.13 30-Day Prescription Program

New prescriptions for ODB program recipients are generally limited to a maximum of 30 days’ supply if the medication has not been received by the recipient in the preceding 12 months. If the newly prescribed medication is well tolerated after 30 days, the remainder of the prescription can be dispensed up to a maximum 100 days’ supply. All claims that do not meet the requirements of the 30-day Prescription Program will be rejected by HNS with the following response code:

“OF” = initial supply for the claim exceeds 30 days.

Claims for insulin, diabetic testing agents, methadone maintenance, nutritional products, and allergen products are exempt from this program.

If necessary, the response code “OF” (rejection) can be overridden by entering the intervention code “NH”. This will allow the claim to adjudicate normally. The “NH” intervention code can only be submitted if:

- The patient had the product in the preceding 12 months but it was not recorded on HNS.
- The patient will be out of province for more than 100 days.
- The patient is unable to return to the pharmacy within the 30-day period.

Reasons for override must be clearly documented on the prescription.
Response code | Message description | Explanation of condition generating response code | Intervention/Override Code
---|---|---|---
"OF" | Initial Rx Days' Supply Exceeded | An initial prescription for a drug product must not exceed 30 days' supply | "NH" = Initial Rx Program Declined

If a rejected claim is resubmitted but the quantity has not been reduced (e.g., only the days' supply is changed on the claim), the claim will be rejected with the response code "OC." If the quantity does not need to be reduced for the initial 30 days, the intervention code "NF" can be used.

Response code | Message description | Explanation of condition generating response code | Intervention/Override Code
---|---|---|---
"OC" | Quantity Reduction Required | An initial prescription that previously rejected with response code "OF" (= Initial Rx Days' Supply Exceeded) was resubmitted with a reduced Days' Supply, but the corresponding quantity was not reduced accordingly | "NF" = Override - Quantity Appropriate

30-Day Prescription Program Claim Requirements

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacist ID*</td>
<td>Y</td>
<td>Enter the Pharmacist ID.</td>
</tr>
<tr>
<td>Intervention/ Exception Code*</td>
<td>Y</td>
<td>To override response code “OF” - enter “NH” (= Initial Rx Program Declined) To override response code “OC” - enter “NF” (= Override-Quantity Appropriate)</td>
</tr>
</tbody>
</table>

The asterisk (*) indicates additional fields.
Claim Validation

Supporting documentation may be requested for claim validation.

Reasons for override must be clearly documented on the prescription. If intervention codes are entered to override the 30-day limitation, documentation must be available on the prescription hard copies and maintained for the Retention Period for the purposes of claim validation and in accordance with O. Reg. 264/16 made under the DPRA if applicable.

6.14 Special Drugs Program

The Special Drugs Program (SDP) covers the full cost of specified hospital outpatient drugs for all Ontario residents with a valid Ontario Health number and who meet the criteria for coverage. Drugs covered under SDP include:

- erythropoietins for anemia in patients with end-stage renal disease,
- cyclosporine for patients with solid-organ or bone-marrow transplants,
- human growth hormone for patients with endogenous growth hormone deficiency,
- clozapine for treatment-resistant schizophrenia,
- imiglucerase for Gaucher disease,
- zidovudine and pentamidine for HIV/AIDS, and
- specified drug products for the treatment of cystic fibrosis and thalassemia.

The SDP is distinct from the ODB program, with different legislative authority, method of drug distribution and payment structure. The SDP is governed by the Health Insurance Act, and Regulation 552 made under that Act. The drugs must be prescribed by a prescriber affiliated with an authorized hospital and dispensed from an authorized hospital pharmacy. Hospitals dispensing drugs for certain SDP diseases (e.g., cystic fibrosis), must be listed as part of a specific hospital group class under the Public Hospitals Act.
Patients do not pay deductibles or co-payments. In addition, hospital pharmacies are reimbursed for actual drug costs only. No cost mark-up or fees apply to prescriptions dispensed under the SDP.

Hospital pharmacies submit claims either manually or online (in real-time) through the HNS for actual drug acquisition cost reimbursement. Manual claims are submitted with wholesaler or manufacturer issued invoices to support claims for reimbursement. The SDP is strictly a hospital service and both the manual and online claims processes are ONLY applicable to specific authorized hospital pharmacies and not to community pharmacies, unless permitted by the Ministry.

**Special Drugs Program Claim Requirements**

SDP online claims are processed by the HNS in the same manner as other standard online claim transactions.

SDP hospitals are identified in HNS as agencies with authority to dispense the identified drug products through HNS.

Deductibles and co-payments are not applicable.

No cost mark-up or dispensing fee will be paid.

Eligibility will not be set up on the HNS prior to a patient’s first prescription under SDP. HNS will reject the initial claim for recipients without established eligibility at the time of dispensing with a response code of "KT-Assess Recipient SDP Eligibility".

SDP patients will be enrolled on HNS by submitting a standard online transaction as noted below. When a claim is submitted and paid with the "NC" intervention code, the system will automatically enroll the recipient under the SDP for a one-year period based on the dispensing date of the claim. Patients will need to be re-enrolled annually for SDP coverage.

Although the maximum days' supply is 180 days, SDP hospitals are encouraged to dispense minimum quantities to reduce wastage.

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting a claim for an SDP authorized drug product, namely:
To enroll SDP recipient:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIN/GP#/?PIN</td>
<td>Y</td>
<td>Enter the PIN of the SDP product authorized</td>
</tr>
<tr>
<td>Pharmacist ID</td>
<td>Y</td>
<td>Enter the Pharmacist ID of the pharmacist involved in the intervention</td>
</tr>
<tr>
<td>Intervention/Exception Code</td>
<td>Y (annually for each recipient)</td>
<td>&quot;NC&quot; = Patient SDP Eligibility Confirmed</td>
</tr>
<tr>
<td>Carrier-ID</td>
<td></td>
<td>&quot;V = Special Drugs Program&quot;</td>
</tr>
<tr>
<td>Client ID # or Code, Patient First Name, Patient Last Name, Patient Gender and Patient Date of Birth</td>
<td>Y</td>
<td>Enter recipient’s Health number, name, sex and DOB.</td>
</tr>
</tbody>
</table>
Other fields:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days' Supply</td>
<td>Y</td>
<td>Maximum of 180 days.</td>
</tr>
<tr>
<td>Intervention/Exception Code for high cost claims</td>
<td>Y</td>
<td>Claims up to $9,999.99 may be billed online without an intervention code. Claims of $10,000 or more, can be submitted by splitting the claim (see Section 6.4) into multiple submissions: The quantity supplied must be split in approximately equal portions without any changes to the submitted price per unit (each split drug claim with drug costs less than $10,000) The days' supply must be split accordingly (please note Drug Utilization Review (DUR) responses such as refill too soon, and duration of therapy messages would be based on this reduced days' supply) “MP” = valid claim value $1,000 to $9,999.99 Submit to override response code D6 (maximum cost exceeded) “MM” = replacement claim, drug costs only Submit to override response code “A3” (identical claim has been processed)</td>
</tr>
<tr>
<td>Intervention/Exception Code for initial 30 days' supply</td>
<td>N</td>
<td>30-Day Prescription Program does not apply</td>
</tr>
</tbody>
</table>
Claim Validation

*Invoices may be required to validate claims and must be maintained on file for at least two years from the day the invoice was received for purposes of claim validation, and in accordance with Regulation 936 under the DIDFA if applicable. Utilization may be periodically reviewed.*

### 6.15 Universal Influenza Immunization Program

Ontario’s [Universal Influenza Immunization Program (UIIP)](https://www.health.gov.on.ca/en/pro/programs/immunize/univ_influenza_program.html) helps with the administrative costs associated with the delivery of the publicly funded influenza vaccines administered by pharmacies.

For more information, pharmacies must access the [Executive Officer Notice](https://www.health.gov.on.ca/en/pro/programs/immunize/univ_influenza_program.html) for detailed information including submitting claims for pharmacy-administration of the influenza vaccine using HNS for the current influenza season.

Under the UIIP, trained pharmacy staff are authorized to administer publicly funded influenza vaccines by injection to people aged two years and older who live, work or go to school in Ontario.

Only Part A pharmacists and trained pharmacy staff (defined as pharmacy technicians, pharmacy students and pharmacy interns) who are registered with the OCP as having successfully completed an OCP approved injection training program and hold current CPR and First Aid certification may administer the publicly funded influenza vaccine. In addition, trained pharmacy staff must administer the vaccine under the direct supervision of an injection-trained pharmacist (Part A pharmacist or pharmacist [emergency assignment]).

Only pharmacies that are approved by the Ministry via a User Agreement can provide the publicly funded influenza vaccine to the public. In order for a pharmacy to be approved to administer the publicly funded influenza vaccine, pharmacy managers must complete the Ministry’s User Agreement for Pharmacies with a Licensed Injection-Trained Pharmacist Requesting Publicly Funded Influenza Vaccines for the UIIP each year.

Further information on the UIIP, including requirements under the annual User Agreement is available by emailing [UIIP.MOH@ontario.ca](mailto:UIIP.MOH@ontario.ca).
Restrictions

Please refer to the Executive Officer Notice, accompanying Questions & Answers, and the UIIP User Agreement for the applicable terms and conditions governing the UIIP.

Claim Requirements for Pharmacists Administering Influenza Vaccine

The claim for payment for administration of the publicly funded influenza vaccine must be submitted through HNS after administering the influenza vaccine to the patient on the same day of administration. Manual claims are not eligible for payment unless there is a need to use 3 intervention codes.

Pharmacies will be reimbursed $8.50 per injectable vaccine and $5.00 per nasal spray vaccine per eligible claim (if the nasal spray is available for the flu season) for the administrative costs associated with the delivery of one of the publicly funded influenza vaccines. This includes providing patients with a written record of influenza immunization.

Influenza products that are publicly funded under the UIIP may differ from year to year and changes occur throughout the seasons. Please refer to the Ministry’s website for more specific and the most recent information on the publicly funded influenza vaccines available for the current Influenza Immunization Season.

The pharmacist who administers or directly supervises the administration of the publicly funded influenza vaccine must use their Pharmacist ID as the Prescriber ID when submitting a claim for the influenza vaccine. The claim must be submitted on the day of the vaccine administration, subject to the exception below.

Exception: if the influenza vaccine was administered off-site in accordance with applicable terms and conditions, then pharmacists may submit the claim on the next business day provided the correct date and time of administration is noted on the record.

Claims must be submitted for publicly funded influenza vaccine only using the appropriate DIN/PIN of the vaccine that was administered to the patient. Pharmacists must not enter a drug cost or a dispensing fee or a mark-up on publicly funded influenza vaccines.
Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting a claim for an influenza vaccine administered by the pharmacist or trained pharmacy staff, namely:

**Fields required for all claims for pharmacist administered influenza vaccines (ODB program recipients and non-ODB program recipients):**

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the appropriate DIN or PIN if applicable as per the publicly funded influenza vaccine administered</td>
</tr>
<tr>
<td>Professional Fee</td>
<td>Y</td>
<td>$8.50 (injectable influenza vaccine)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$5.00 (nasal spray influenza vaccine), if available</td>
</tr>
</tbody>
</table>

**Note:** Influenza products that are publicly funded under the UIIP may differ from year to year. Please see the EO Notice on the Ministry’s website for more specific information on the publicly funded influenza vaccines available for the current Influenza Immunization Season and the associated DINs.

<table>
<thead>
<tr>
<th>Pharmacist’s ID code</th>
<th>Y</th>
<th>Pharmacist Licence #</th>
</tr>
</thead>
</table>

**Additional fields required for non-ODB recipients:**

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“ML” = Eligibility established-Standard coverage</td>
</tr>
<tr>
<td>Fields</td>
<td>Required (Y/N)</td>
<td>Explanation</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“PB” = Name entered is consistent with card</td>
</tr>
<tr>
<td>Patient Gender</td>
<td>Y</td>
<td>“F” = female, “M” = male, “U” = unknown</td>
</tr>
<tr>
<td>Patient Date of Birth</td>
<td>Y</td>
<td>YYYYMMDD</td>
</tr>
<tr>
<td>Proxy ID # or Code</td>
<td>Y</td>
<td>6999 999 995</td>
</tr>
</tbody>
</table>
Claim Validation for Influenza Vaccine

Pharmacies are required to keep a record of every dose of publicly funded influenza vaccine administered. Required documentation includes record of:

- Name of patient, date of birth and patient’s address
- Name of vaccine administered, strength/dose (if applicable), Lot # and expiry date of the publicly funded influenza vaccine that was administered as well as route and site of administration
- Time and date the vaccine was administered; Location of the immunization
- Name and signature of the trained pharmacist (or trained pharmacy staff) who administered the vaccine; name and address of the pharmacy
- Signed and dated patient consent form completed by the patient or patient’s substitute decision-maker as applicable
- A record of influenza immunization record provided to the patient
- A record of any adverse events following immunization (AEFIs) that may or may not result in the administration of epinephrine, and the circumstances relating to the administration of the substance.
- Pharmacists are required by law to report AEFIs. Reports should be made using the Ontario Adverse Events Following Immunization Reporting Form and sent to the local public health unit (PHU). A copy of the Reporting Form sent to the PHU must be retained by the pharmacy.

Pharmacists, trained pharmacy staff and pharmacies shall keep records consistent with their obligations under the Pharmacy Act, 1991, the Drug and Pharmacies Regulation Act, as applicable, and any instructions or guidelines provided by the OCP or the ministry.

For purposes of post-payment verification, pharmacy records related to claims for administering a publicly funded influenza vaccine must be maintained in a readily available format for the Retention Period.
Reimbursement of Epinephrine Auto-Injector for Emergency Treatment

In a situation of an adverse event resulting immediately after the administration of:

i. the publicly funded influenza vaccine to an eligible person aged two or older;
   or

ii. publicly funded COVID-19 vaccine,

the Ministry will reimburse pharmacies the Acquisition Cost of the epinephrine auto-injector when used for emergency treatment in the pharmacy or at the immunization location.

**Note:** The reimbursement procedure set out in this Section 6.15 applies to submitting claims for the Acquisition Cost of epinephrine auto-injectors used for emergency treatment of adverse events resulting from administering publicly funded influenza vaccines to eligible persons and public funded COVID-19 vaccines to eligible persons.

Under the Regulated Health Professions Act, 1991, pharmacy staff may render emergency first aid or temporary assistance in an emergency situation. However, pharmacists are advised to speak with the Ontario College of Pharmacists if they have any additional questions.

**Restrictions:**

Epinephrine auto-injection by pharmacy staff will **not** be reimbursed in the following situations (other examples may apply):

- Providing the epinephrine auto-injector to the patient to self-administer or take home (e.g., in the event the patient may experience an adverse event after leaving the pharmacy)

- Emergency injection of epinephrine auto-injector that is not due to an adverse drug reaction resulting from the administration of the publicly funded influenza or COVID-19 vaccine

- Emergency injection of epinephrine auto-injector at a nurse-led pharmacy clinic
• Emergency injection after providing any injection or inhalation for the purpose of demonstration or education.

The Ministry does not accept manual claims for epinephrine auto-injection claims submitted for this purpose unless there is a need to use 3 intervention codes.

**Claim Requirements for Epinephrine Auto-Injector for Emergency Treatment**

The Acquisition Cost of epinephrine auto-injector will be reimbursed by the Ministry if the above requirements are met.

If administering for emergency use, the epinephrine auto-injector PIN must be billed as a second claim following the publicly funded vaccine claim on the same day of service. Please note the cost of the epinephrine auto-injector for this transaction will appear in the Dispensing Fee field of the claim.

Pharmacists must use their Pharmacist ID as the Prescriber ID when submitting a claim for epinephrine injection.

Claims must be submitted using the PIN associated with the epinephrine product. Only the Acquisition Cost of the drug is eligible for reimbursement. **Do not enter the DIN or a mark-up or a dispensing fee.**

**Epinephrine products and reimbursement for emergency treatment after administering a publicly funded vaccine**

<table>
<thead>
<tr>
<th>PIN</th>
<th>Epinephrine Product</th>
<th>Total Amount Reimbursed</th>
</tr>
</thead>
<tbody>
<tr>
<td>09857423</td>
<td>Epipen 1/1000 (1mg/1mL) DIN 00509558</td>
<td>$94.44</td>
</tr>
<tr>
<td>09857424</td>
<td>Epipen Jr. 0.5mg/mL DIN 00578657</td>
<td>$94.44</td>
</tr>
<tr>
<td>09857439</td>
<td>Allerject 0.15mg/0.15mL DIN 02382059</td>
<td>$94.44</td>
</tr>
<tr>
<td>09857440</td>
<td>Allerject 0.3mg/0.3mL DIN 02382067</td>
<td>$94.44</td>
</tr>
</tbody>
</table>
Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting a claim for reimbursement of epinephrine auto-injector for emergency treatment, namely:

**Fields required for reimbursement of all claims for epinephrine auto-injector for emergency treatment (ODB program recipients and non-ODB program recipients):**

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the appropriate PIN as per the epinephrine auto-injector administered.</td>
</tr>
<tr>
<td>Pharmacist's ID code</td>
<td>Y</td>
<td>Pharmacist Licence #</td>
</tr>
<tr>
<td>Professional Fee</td>
<td>Y</td>
<td>Please note that the cost of the epinephrine auto-injector will appear in the Dispensing Fee field of the claim.</td>
</tr>
</tbody>
</table>
### Additional fields required for non-ODB recipients:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“ML” = Eligibility established – Standard coverage</td>
</tr>
<tr>
<td>Patient Gender</td>
<td>Y</td>
<td>“F” = female, “M” = male</td>
</tr>
<tr>
<td>Patient Date of Birth</td>
<td>Y</td>
<td>YYYYMMDD</td>
</tr>
<tr>
<td>Client ID # or Code</td>
<td>Y</td>
<td>Ontario Health number</td>
</tr>
<tr>
<td>Carrier ID</td>
<td>Y</td>
<td>“S”</td>
</tr>
</tbody>
</table>

### Additional fields required for patients without an Ontario health number:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“PB” = Name entered is consistent with card</td>
</tr>
<tr>
<td>Patient Gender</td>
<td>Y</td>
<td>“F” = female, “M” = male, “U” = unknown</td>
</tr>
<tr>
<td>Patient Date of Birth</td>
<td>Y</td>
<td>YYYYMMDD</td>
</tr>
<tr>
<td>Proxy ID # or Code</td>
<td>Y</td>
<td>6999 999 995</td>
</tr>
</tbody>
</table>
Claim Validation for Epinephrine Auto-injector Administration

Pharmacies are required to keep a record of when an epinephrine auto-injector was administered for emergency use following an influenza or COVID-19 injection administered by a pharmacist or trained pharmacy staff. Required documentation includes:

- Name and signature of the pharmacist (or trained pharmacy staff) who administered the epinephrine auto-injector;
- The name and address of the pharmacy;
- Name, strength/dose (if applicable) of the epinephrine auto-injector that was administered;
- Name of Patient, date of birth and patient’s address;
- Time and date the epinephrine auto-injector was administered; place of administration if not at the pharmacy;
- Cross-reference to the Vaccine Administration claim for the patient receiving epinephrine auto-injector

Pharmacists, trained pharmacy staff and pharmacies shall keep records consistent with their obligations under the Pharmacy Act, 1991, as applicable, the Drug and Pharmacies Regulation Act, and any instructions or guidelines provided by the OCP or the ministry.

For purposes of post-payment verification, pharmacy records related to claims for administering a publicly funded epinephrine auto-injector must be maintained in a readily available format for the purpose of ministry inspection for the Retention Period.

- Time and date the epinephrine auto-injector was administered; place of administration if not at the pharmacy;
- Cross-reference to the Vaccine Administration claim for the patient receiving epinephrine auto-injector

Pharmacists, trained pharmacy staff and pharmacies shall keep records consistent with their obligations under the Pharmacy Act, 1991, as applicable,
6.16 Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020

Overview

Effective January 1, 2020, the Executive Officer of the Ontario Public Drug Programs of the Ministry of Health (the “Ministry”) established this Policy regarding payments made to pharmacies for supplying listed drug products or listed substances and providing professional services to residents of long-term care (LTC) homes.

As a precondition to obtaining billing privileges under the Ontario Drug Benefit Act (ODBA), all pharmacy operators are required to enter into a Health Network System (HNS) Subscription Agreement with the Executive Officer. Under section 3.2 of the HNS Subscription Agreement, pharmacy operators are required to comply with all Applicable Law, Ontario College of Pharmacists Rules, and Ministry Policies.

This Policy governs payments made to LTC home primary pharmacy service providers under a capitation funding model, as well as payments made to secondary pharmacy service providers under a fee-for-service funding model.

- A primary pharmacy service provider is defined as the pharmacy that is under contract with a LTC home to provide pharmacy services to residents of the LTC home.

- A secondary pharmacy service provider is defined as a community pharmacy that may dispense a prescription for a LTC home resident through an arrangement with the primary pharmacy service provider (as defined above) for emergency prescriptions. On rare occasions, it could be a pharmacy that

For purposes of post-payment verification, pharmacy records related to claims for administering a publicly funded epinephrine auto-injector must be maintained in a readily available format for the purpose of ministry inspection for the Retention Period.
the resident attends for emergency purposes, for example, while on a visit with family outside the LTC home.

This Policy also clarifies that no co-payment may be charged to a resident of a LTC home for dispensing a listed drug product or listed substance.

How the LTC capitation funding model works

Effective January 1, 2020, the ministry replaced the fee-for service model for paying primary pharmacy service providers that provide medication dispensing and professional pharmacy services for residents of LTC homes with a fee-per-bed capitation model.

The primary pharmacy service provider is paid an annual fee-per-bed (on a monthly schedule) for all medication dispensing and professional pharmacy services based on the number of licensed LTC home beds serviced. The annual fees were initially set as follows:

- $1,500 in 2019/20 ($125/month)
- $1,500 in 2020/21 ($125/month)
- $1,400 in 2021/22 ($116.67/month)
- $1,300 in 2022/23 ($108.33/month)
- $1,200 in 2023/24 ($100/month)

The schedule reductions to the annual fee-per-bed in the Policy were delayed twice due to the COVID-19 pandemic on:

- April 1, 2021 (see EO Notice and accompanying materials posted on January 15, 2021 here); and
- April 1, 2022 (see EO Notice and accompanying materials posted on February 18, 2022 here).

The scheduled fee reduction is being put ON HOLD for one more year until 2024 and the $1,500 payment per bed per year will be maintained for Fiscal Year (FY) 2023/24.
The Ministry amended the Policy to provide for revised annual fees-per-bed for FY 2024/24 to FY 2026/27. Primary pharmacy service providers will be paid an annual fee-per-bed (in monthly allotments), in accordance with the amended Policy, over the next four FYs as follows:

- $1,500 in FY2023-2024 ($125/month)
- $1,400 in FY2024-2025 ($116.67/month)
- $1,300 in FY2025-2026 ($108.33/month)
- $1,200 in FY2026-2027 ($100/month)

There continues to be no co-payment for all LTC home residents for eligible Ontario Drug Benefit (ODB) claims submitted through the Health Network System (HNS).

The fee-per-bed reimburses pharmacies for all pharmacy services provided for LTC home residents including medication dispensing services for eligible ODB products and all professional pharmacy services.

To receive the fee-per-bed, primary pharmacy service providers are expected to continue to provide medication management services, including medication reviews (such as MedsCheck LTC annual and quarterly medication reviews), medication assessments (e.g., as with the Pharmaceutical Opinion Program [POP]), and smoking cessation counselling (e.g., as with the Smoking Cessation Program), as appropriate.

- Claims for providing POP and Smoking Cessation services to LTC home residents should not be submitted through the HNS for reimbursement; overpayments due to inappropriate claim submissions are subject to recovery.
- MedsCheck LTC annual and quarterly medication review PINs were discontinued in the HNS.

**How pharmacies receive the capitation payment**

Primary pharmacy service providers must notify the ministry of the name(s) of the long-term care home(s) (including the LTC Agency IDs) with whom they have entered pharmacy services contracts in order to receive the monthly capitation payment. (Note: This was initially confirmed via an attestation process in December 2019.)
If the contract between a LTC home and the pharmacy service provider ends, the previous and new pharmacy service provider that ends or enters into a contract with the LTC home must notify the ministry in writing by the 15th of the previous month before the effective date of the change to ensure payments are processed in a timely manner (i.e., only attestation / notice of change forms that are received by the 15th will be processed for the following month’s capitation payment). The capitation payment will be pro-rated based on the effective date of the change in pharmacy service provider once the ministry has been notified. Note that this may not be reflected in the monthly capitation payment until the following month.

Pharmacies that have entered into new pharmacy service contracts with LTC homes (not listed on their original Attestation Form in December 2019) must complete an “Attestation / Notice of Change in LTC Home Primary Pharmacy Service Provider Form”; see Appendix E.

Attestation / Notice of Change in LTC Home Primary Pharmacy Service Provider Form must be emailed to ODBLTCcap@ontario.ca. The ministry requires the following information:

- Pharmacy name
- Pharmacy address
- Pharmacy ID #
- Pharmacy fax
- Pharmacy O365 email address
- Effective date of the contract change
- Name of the LTC home
- Address of the LTC home
- LTC Agency ID #
- Attestation that the above information is accurate

The monthly capitation payment is based on the number of licensed LTC home beds on the last day of the previous month. For example, for the January 2020 payment,
the number of licensed beds at the LTC home as of December 31, 2019 was used to determine payment.

The primary pharmacy service provider on file at the ministry on the last day of the previous month will receive the capitation payment for that LTC home at the end of the current month.

The monthly capitation payment is based on the following formula:

\[
\text{(# of licensed LTC home beds on the last day of the previous month) X (annual bed fee / 12 months)} = \$ \text{ amount paid to the pharmacy service provider for the LTC home for the current month; paid on the date of the second bi-weekly HNS payment for the current month.}
\]

For example, in January 2020 for a LTC home with 100 beds:

\[
100 \times (\$1500 / 12) = \$12,500 \text{ for Jan 2020; payment on January 31, 2020.}
\]

The monthly LTC capitation payment is included on the regular HNS payment date at the end of the month and will appear as a single line adjustment under the heading “Agency Level Adjustments” on the pharmacy’s ODB Summary Remittance Advice (RA) report:

- Adjustment Type: “14 – Long Term Care Capitation Payment”
- Transaction Code: “A2 – Ministry Initiated Batch Adjustment”

Capitation payment dates follow the HNS payment schedule. The monthly capitation payment is reflected on the second HNS payment date of the month (i.e., the end of the month).

**Recovery of capitation payments**

The ministry’s payment of capitation fees to primary pharmacy service providers is based on ODB claims data, an attestation from the primary pharmacy service provider, and notices of change to the attestation submitted by a primary pharmacy service provider. These data sources identify a pharmacy as a primary pharmacy service provider and the LTC home(s) for whom a pharmacy is the primary pharmacy service provider.

Errors in any of the above data sources may result in a pharmacy operator receiving a capitation payment for which they are not entitled – i.e., a capitation payment in
respect of a LTC home for which the pharmacy is not contracted as the primary pharmacy service provider. The ministry will recover such capitation payments so that they can be paid to the actual contracted primary pharmacy service provider for the LTC home.

In accordance with section 8.1 of the Health Network System Subscription Agreement for Pharmacy Operators, the following additional conditions are imposed on all pharmacy operators that submit claims in respect of long-term care home residents, effective January 1, 2020.

**A9.0 RECOVERY OF OVERPAYMENTS**

A9.1 Where the Executive Officer has reasonable grounds to believe that the Executive Officer has paid an amount to the Operator that is based on the number of beds in a Long-Term Care Home for which the Operator is not the Primary Pharmacy Service Provider for the relevant time period used to calculate the payment, that amount will be deemed to be a debt due and owing by the Operator to Her Majesty the Queen in right of Ontario.

A9.2 The Executive Officer may obtain or recover a debt that arises under section A9.1 by way of set off against any amount payable to the Operator under the ODBA.

A9.3 Prior to initiating any recovery under section A9.2, the Executive Officer will provide the Operator with not less than twenty (20) Days written notice together with reasons for the recovery.

A9.4. In section A9.1, the following terms have the following meanings:

“Long-Term Care Home” means a long-term care home within the meaning of the Long-Term Care Homes Act, 2007; and

“Primary Pharmacy Service Provider” means the operator of a pharmacy that has been retained by the licensee of a Long-Term Care Home in accordance with section 119 of Ontario Regulation 79/10 (General) made under the Long-Term Care Homes Act, 2007.
Claims submission

A valid LTC agency ID number (ODP number) must be included as part of the claim submission for LTC home residents. Failure to do so could result in a rejection by HNS with response code “31” - Group Number Error.

All pharmacies submitting claims for LTC home residents are reimbursed for the ODB allowable drug cost, applicable mark-up and compounding fee (if applicable). The dispensing fee is zero.

Secondary pharmacy service providers that provide additional and/or emergency prescription claims to residents of LTC homes that they do not have a contract with receive a dispensing fee ($5.57 for most retail locations and a range from $6.67 to $9.99 for rural pharmacies) by submitting the claim with the intervention code “LT – LTCH Disp. Fee Payment for Emergency Rx” in order to be paid their corresponding ODB dispensing fee. The PINs previously used by secondary pharmacy service providers to submit the second claim for a dispensing fee will be discontinued. Any claim using these PINs will be rejected with the response code “D2 – DIN/PIN/GP # is discontinued”. The patient copay is zero.

Primary pharmacy service providers must submit ODB-eligible claims through the HNS as per the normal process for claim submissions. No dispensing fee is paid.

The claim submission for secondary pharmacy service providers who provide emergency prescriptions for residents of LTC homes follows the normal process for submitting LTC claims on the Health Network System with the following additional information:

- Intervention code ‘LT’: (LTCH Disp. Fee Payment for Emergency Rx)
- Valid Pharmacist ID

No copay is to be collected from the LTC home resident. The co-pay portion of the dispensing fee has been removed.

Restrictions and Exemptions

Pharmacies can no longer submit claims through the HNS for MedsCheck LTC (both annual and quarterly medication reviews). The PINs have been discontinued. Primary pharmacy service providers are expected to continue to provide professional
pharmacy services including medication reviews/reconciliation and assessments to residents of the LTC homes as part of their capitation payment and in accordance with their contracts with LTC homes.

Claims for LTC home residents submitted by the primary pharmacy service provider cannot be submitted with the intervention code “LT”.

Claims for the Pharmaceutical Opinion Program by secondary pharmacy service provider if required, are eligible for reimbursement and can be submitted with the intervention code “LT”. For clarity, payment eligibility rules for the Pharmaceutical Opinion Program apply to these claims.

Claims for LTC home residents submitted by secondary pharmacy service providers are exempt from the dispensing fee rules 2 fees/28 days and 5 fees/365 days. In other words, a dispensing fee for each ODB-eligible prescription dispensed will be paid if the applicable dispensing fee PIN is submitted by the secondary pharmacy service provider in accordance with this Policy.

Claims for LTC home residents, including those submitted by secondary pharmacy service providers, are also exempt from the Reconciliation Adjustment process implemented on January 1, 2020 that impacts all other ODB claims submitted for reimbursement.

All other HNS rules and Ministry Policies remain the same.

### 6.17 Valved Holding Chambers

Effective January 1, 2018, Ontario publicly funds select Valved Holding Chambers (VHC) through the ODB program for eligible recipients (see Restrictions below)

**Overview**

VHCs are used in conjunction with metered-dose inhalers to deliver inhaled asthma medications. A VHC includes a one-way valve at the mouthpiece. This device traps and holds the aerosolized medication, which improves drug delivery by allowing the patient to take slow, deep breaths to inhale all of the medicine. The one-way valve prevents patients from accidentally exhaling into the tube.

**Pharmacy Billing Procedure**
This is the list of the funded VHCs and the amount reimbursed by the Ministry (subject to change and communicated to pharmacies via email to the pharmacy’s O365 email account). You can select “Valved Holding Chambers” from the Coverage Status drop down menu at: [https://www.formulary.health.gov.on.ca/formulary/](https://www.formulary.health.gov.on.ca/formulary/)

<table>
<thead>
<tr>
<th>PIN</th>
<th>PIN Description</th>
<th>Manufacturer</th>
<th>Amount MOH Pays</th>
</tr>
</thead>
<tbody>
<tr>
<td>09858012</td>
<td>AeroChamber Plus Flow-Vu Anti-Static Valved Holding Chamber Infant Small Mask</td>
<td>Trudell Medical International</td>
<td>$37.6700</td>
</tr>
<tr>
<td>09858013</td>
<td>AeroChamber Plus Flow-Vu Anti-Static Valved Holding Chamber Child Medium Mask</td>
<td>Trudell Medical International</td>
<td>$37.6700</td>
</tr>
<tr>
<td>09858014</td>
<td>AeroChamber Plus Flow-Vu Anti-Static Valved Holding Chamber Youth Mouthpiece</td>
<td>Trudell Medical International</td>
<td>$23.5500</td>
</tr>
<tr>
<td>09858015</td>
<td>AeroChamber Plus Flow-Vu Anti-Static Valved Holding Chamber Girls Mouthpiece</td>
<td>Trudell Medical International</td>
<td>$23.5500</td>
</tr>
<tr>
<td>09858016</td>
<td>AeroChamber Plus Flow-Vu Anti-Static Valved Holding Chamber Adult Mouthpiece</td>
<td>Trudell Medical International</td>
<td>$23.5500</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Manufacturer</td>
<td>Price</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------</td>
<td>--------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>09858017</td>
<td>AeroChamber Plus Flow-Vu Anti-Static Valved Holding Chamber Adult Small Mask</td>
<td>Trudell Medical International</td>
<td>$39.8600</td>
</tr>
<tr>
<td>09858018</td>
<td>AeroChamber Plus Flow-Vu Anti-Static Valved Holding Chamber Adult Large Mask</td>
<td>Trudell Medical International</td>
<td>$39.8600</td>
</tr>
<tr>
<td>09858005</td>
<td>A2A Aerosol to Airways Spacer</td>
<td>Clement Clarke International Limited</td>
<td>$9.0000</td>
</tr>
<tr>
<td>09858006</td>
<td>A2A Spacer with Small Mask</td>
<td>Clement Clarke International Limited</td>
<td>$12.0000</td>
</tr>
<tr>
<td>09858007</td>
<td>A2A Spacer with Medium Mask</td>
<td>Clement Clarke International Limited</td>
<td>$12.0000</td>
</tr>
<tr>
<td>09858001</td>
<td>InspiraChamber</td>
<td>INSPIRX INC.</td>
<td>$23.5500</td>
</tr>
<tr>
<td>09858002</td>
<td>InspiraChamber + Mask Small</td>
<td>INSPIRX INC.</td>
<td>$37.6700</td>
</tr>
<tr>
<td>09858003</td>
<td>InspiraChamber + Mask Medium</td>
<td>INSPIRX INC.</td>
<td>$37.6700</td>
</tr>
<tr>
<td>09858004</td>
<td>InspiraChamber + Mask Large</td>
<td>INSPIRX INC.</td>
<td>$39.8600</td>
</tr>
<tr>
<td>09858008</td>
<td>Optichamber Diamond Valved Holding Chamber</td>
<td>Respironics Respiratory Drug Delivery (UK) LTD.</td>
<td>$16.3400</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Supplier</td>
<td>Price</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------</td>
<td>-----------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>09858009</td>
<td>Optichamber Diamond Valved Holding Chamber + Small Mask</td>
<td>Respironics Respiratory Drug Delivery (UK) LTD.</td>
<td>$27.9300</td>
</tr>
<tr>
<td>09858010</td>
<td>Optichamber Diamond Valved Holding Chamber + Medium Mask</td>
<td>Respironics Respiratory Drug Delivery (UK) LTD.</td>
<td>$27.9300</td>
</tr>
<tr>
<td>09858011</td>
<td>Optichamber Diamond Chamber + Large Mask</td>
<td>Respironics Respiratory Drug Delivery (UK) LTD.</td>
<td>$30.7800</td>
</tr>
</tbody>
</table>

The Ministry will reimburse pharmacies the amount identified in the column “Amount MOH Pays” in the Formulary plus a mark-up of 8% and the applicable ODB dispensing fee. There is no cost to the recipient.

For the purpose of claim validation and in accordance with O. Reg. 264/16 made under the DPRA if applicable, documentation must be maintained for the Retention Period. Overpayments due to inappropriate claim submissions are subject to recovery.

**ODB-eligible Recipients**

Claims must be submitted online through the HNS. The claim submission follows the normal process for submitting claims through the HNS with the following additional information:

- Product Identification Number (PIN): Select the appropriate PIN from the table above or Formulary
- Quantity: Submit the value as “1”
- Days’ Supply: Submit the value as “1” (or any other value up to 100)

**Restrictions**

Only ODB-funded VHCs supplied to an eligible ODB recipient with a valid prescription from a physician or nurse practitioner will be reimbursed. ODB eligible
recipients aged 12 years and younger are entitled to receive one (1) VHC (with or without mask/mouthpiece) per 365-day period. ODB recipients aged 13 years and older are not eligible for ODB-funded VHCs.

If a VHC claim is submitted for an ODB recipient aged 13 years and above, the claim will be rejected with the following response code:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
<th>Explanation of condition generating response code</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;CD&quot;</td>
<td>Patient Not Entitled to Drug Claimed</td>
<td>VHC is not a benefit based on the information provided on the claim (i.e., recipient is 13 years of age or over).</td>
</tr>
</tbody>
</table>

If a VHC claim is submitted that exceeds the claim count limit of one per 365-day period, the claim will be rejected with the following response code:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
<th>Explanation of condition generating response code</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;LO&quot;</td>
<td>Maximum Benefit Exceeded</td>
<td>This response code indicates that the recipient has exceeded his/her maximum benefit and cannot receive another VHC. A message data line* will be included to indicate the date of when the next VHC can be claimed.</td>
</tr>
</tbody>
</table>

HNS Response Message Data Line for VHC Claims

Example: “Remaining Qty: 0 until OCT 15, 2019"

6.18 Flash Glucose Monitoring Systems

Overview – FreeStyle Libre 14-day sensors and reader

Effective September 16, 2019, Ontario began funding FreeStyle Libre 14-day sensors and readers through the Ontario Drug Benefit (ODB) program. The FreeStyle Libre
system belongs to a class of glucose monitoring systems called Flash Glucose Monitoring (FGM) Systems. Each FreeStyle Libre sensor measures glucose for 14 days and does not require the use of test strips for calibration purposes.

It has two components:

- Disposable sensor worn on the back of the upper arm, and;
- Reader (or via phone app) used to scan the sensor and review glucose data.

**Reimbursement Criteria**

All ODB eligible recipients receiving insulin therapy who also have a valid prescription from a physician or nurse practitioner for FreeStyle Libre sensors and readers are eligible to receive ODB-funded FreeStyle Libre sensors and readers.

**Restrictions**

Patients managing their diabetes with insulin are eligible for a maximum quantity of sensors over the course of a 365-day period as outlined in the table below:

<table>
<thead>
<tr>
<th>Diabetes treatment</th>
<th>Maximum number of sensors per 365 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients managing diabetes with insulin</td>
<td>33 (one sensor lasts up to 14 days)</td>
</tr>
</tbody>
</table>

Pharmacists must adhere to the quantity restriction as noted above. Effective March 21, 2021, the HNS includes quantity restrictions in place for the submission of FGM claims according to this policy announced in September 2019. For each claim submitted on or after March 21, 2021, the HNS will review the previous 365 days of claims and ensure that the permitted maximum of 33 sensors per 365-day period is not exceeded.

In addition, the conditions and restrictions respecting the payment of a dispensing fee in O. Reg. 201/96 under the Ontario Drug Benefit Act apply to the dispensing of FGM systems as if they are listed drug products. More information is available in Section 5 and here:
Pharmacy Billing Procedure

Claims must be submitted online through the HNS. The claim submission follows the normal process for submitting claims through the HNS:

- Product Identification Number (PIN)
- Valid Pharmacist ID

The Product Identification Number (PIN) is to be used for billing purposes. Pharmacies will be reimbursed for supplying FGM sensors and readers in accordance with the table below.

<table>
<thead>
<tr>
<th>PIN</th>
<th>PIN Description</th>
<th>Manufacturer</th>
<th>Reimbursable Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>09857632</td>
<td>FreeStyle Libre 14-day Sensor</td>
<td>Abbott Laboratories Limited</td>
<td>$89.0000</td>
</tr>
<tr>
<td>09857633</td>
<td>FreeStyle Libre Reader</td>
<td>Abbott Laboratories Limited</td>
<td>$49.0000</td>
</tr>
</tbody>
</table>

Pharmacies are eligible to be reimbursed in accordance with the following formula:

\[
\text{Reimbursable amount} \times \text{mark-up} \times \text{applicable ODB dispensing fee}^\ast
\]

\(^\ast\text{The payment of dispensing fee is subject to the restrictions and conditions in section 18 of O. Reg. 201/96 under the ODBA. See note above.}\)

HNS Response Codes and Messages

- If an FGM claim is submitted for an ODB recipient whose past 180 day claim history recorded in the Health Network System (HNS) does not include a claim for insulin, the claim will be rejected with a response code “QM- No Record of Required Prior Therapy”. FGMs are only eligible for ODB recipients who are also receiving insulin therapy.
• If the pharmacist has confirmed that the patient is currently receiving insulin therapy which has not been recorded in the HNS (for example, insulin that is paid for by cash or through private insurance), intervention code “MZ - Required Prior Therapy Documented” can be submitted to override the QM response code rejection. Pharmacists must properly document the required prior therapy.

• If an FGM claim is submitted and the dispensed quantities summed in the qualifying historical claims exceeds the limit of 33 sensors per 365-day period, the claim will be rejected with a response code “LO – Benefit Maximum Exceeded”.

• The HNS will send a message line “Remaining Qty: xxxx until MMM DD, YYYY” when a claim is approved or rejected due to the quantity restriction, for example:

  Remaining Qty: 0 until APR 01, 2021

• If an FGM claim is submitted and the dispensed quantities summed in the qualifying historical claims plus the quantity in the current claim exceeds the limit of 33 sensors per 365-day period, the claim will be rejected with a response code “OC – Quantity Reduction Required”.

• The HNS will send a message line “Remaining Qty: xxxx until MMM DD, YYYY” when a claim is approved or rejected due to the quantity restriction, for example:

  Remaining Qty: 2 until APR 01, 2021

When an OC response code is received, the dispensed quantity can be reduced to align with the remaining quantity as indicated in the message line, and the claim can be resubmitted for the lower quantity.

No interventions codes are permitted to override LO or OC response codes.

For billing purposes, pharmacy documentation must be maintained in a readily available format for the purpose of post-payment verification for a period of at least 10 years from the last recorded pharmacy service provided to the ODB recipient, or 10 years after the day on which the ODB recipient reached or would have reached the age of 18 years, whichever is longer. Overpayments due to inappropriate claim submissions are subject to recovery.
**Message Format**

For machine readability, the remaining quantity and date appear at fixed positions in the message line:

- the quantity appears right - justified at positions 16-19
- the date appears at positions 27-38

Example message lines for various quantities:

```
Remaining Qty: 1000 until DEC 01, 2016
Remaining Qty: 100 until DEC 01, 2016
Remaining Qty: 10 until DEC 01, 2016
Remaining Qty: 1 until DEC 01, 2016
```

**6.19 Temporary Benefit Listing**

**Temporary Benefits**

A Temporary Benefit on the ODB Formulary is a clinically-appropriate alternate drug that is publicly funded on a short-term basis to facilitate the management of a drug shortage. Certain drug submission requirements are waived to allow for the short-term funding. The Temporary Benefit will be designated as such on the Formulary.

**Claim Submission Process**

Billing procedures for Temporary Benefit listings are the same as the billing procedures for other listed drug products on the ODB Formulary.

Pharmacies are eligible to be reimbursed for the Drug Benefit Price (DBP) associated with the DIN or PIN assigned to the Temporary Benefit product, plus the applicable mark-up and the pharmacy’s usual ODB dispensing fee, minus any applicable co-payment amount. The usual conditions for payment of a dispensing fee under the ODB program must be followed.
Reimbursement Policy

Pharmacies should continue to dispense regular, non-temporary Formulary benefits (i.e., General Benefit or Limited Use) as long as there is supply in stock. The Temporary Benefit should only be dispensed in situations where a regular, non-temporary Formulary benefit is required but unavailable due to shortages in the supply chain.

Generally, Temporary Benefit drug products are not interchangeable with the drug product in shortage. A new prescription may be required.

The ministry will monitor the supply and shortage status of the original listed product. Once resolved and if the listing of the Temporary Benefit is no longer in the public interest, the removal of the Temporary Benefit from the Formulary will be communicated to pharmacies.

Please call the ODB Pharmacy Help Desk at 1-800-668-6641 for additional information on Temporary Benefits.

6.20 Biosimilar Policy

The Ontario government is expanding its biologic drug coverage policy to further promote the use of biosimilars funded through the Ontario Drug Benefit (ODB) program. As a key health system partner, the Ministry of Health ("the ministry") is seeking support from pharmacists in the implementation of this policy. These changes support the ministry’s objectives of creating a modern and sustainable drug system that continues to offer high-quality treatment, while allowing the government to fund more new drug therapies, bring innovation to the health care system and continue its work to deliver better, connected patient care.

In general, effective March 31, 2023, the ODB program will start transitioning coverage for Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Glatect® and Copaxone® are non-biologic complex drugs (NBCDs), however, the biosimilars policy will apply to their funding. As a result, in this document, references to an originator biologic include Copaxone® and references to a biosimilar include Glatect®.

3 Humalog® 200 units/mL KwikPen® 200U/mL Inj Sol-Pref Pen 5x3mL Pk (DIN 02439611) is excluded from the biosimilar policy. No biosimilar is available for this strength.
Remicade®, and Rituxan® to their biosimilar versions. As new biosimilars enter the Canadian market, these biosimilars and their corresponding originator biologic drugs may be included as part of this policy change.

Effective December 29, 2023, coverage for these originator biologic drugs through the ODB program will not be available for patients and the ODB program will only provide coverage for the biosimilar version of these drugs for all ODB program recipients, with limited exemptions (see below). In general, for ODB program recipients who are already on these biologic drugs, there is up to a 9-month transition period (see below for more information).

This biosimilars policy does not apply to coverage outside of the ODB program, including private drug plans and prescriptions paid out-of-pocket. However, the biosimilar policy will apply to patients transitioning from other coverage types to the ODB program; such patients who are on originator biologic drugs subject to the biosimilar policy will need to transition to a biosimilar version to receive coverage for these biologic drugs under the ODB program, with exemptions.

**Transition period**

ODB program recipients on any of the drugs listed above will be required to transition to a biosimilar version to continue receiving coverage for their medication under the ODB program, unless they meet a medically necessary exemption. A transition period of up to nine months, beginning March 31, 2023, will be granted for ODB program recipients (including existing Exceptional Access Program (EAP) recipients) to provide an opportunity for patients and their health care professionals to discuss biosimilar transition.

EAP approvals for Copaxone®, Enbrel®, Humira®, Remicade® or Rituxan® expiring between March 31, 2023, and June 29, 2023, will be extended to June 30, 2023. The purpose of this extension is to give prescribers adequate time to contact their patients and discuss the transition to the biosimilar version or to determine if the patient may require a medically necessary exemption.

Patients with EAP approvals for Copaxone®, Enbrel®, Humira®, Remicade® or Rituxan® expiring after June 29, 2023, will be required to transition to a biosimilar by the expiry date of their EAP approval OR December 28, 2023, whichever is earlier, in order to continue receiving ODB program coverage for these biologics.
Prescribers are being asked to contact their patients to discuss transitioning to a biosimilar version of their medication and will need to write a new prescription. Prescribers should access the biosimilar for their patients on the ODB Formulary by using an eligible Limited Use (LU) code as applicable.

**Medically Necessary Exemptions for Formulary Biologics**

Medically necessary exemptions to this policy may be granted on a case-by-case basis through the EAP. Note that patients are generally expected to trial at least two\(^4\) biosimilars of the originator biologic before a request to the EAP will be considered to resume funding of the originator product.

During the transition period of March 31, 2023 to December 28, 2023, prescribers with patients requiring medically necessary exemptions to this policy for Lantus®, NovoRapid®, and Humalog® may include the corresponding temporary LU codes on their prescriptions, but only if the patient is currently established on the originator. These temporary LU codes will be available for medically necessary exemptions until the effective date of the December 2024 Formulary update, and any medically necessary exemptions for Lantus®, NovoRapid®, and Humalog® will need to be submitted to the EAP for case-by-case consideration. Physicians are encouraged to submit EAP requests as soon as possible during the transition period to avoid a gap in coverage.

As of December 29, 2023, access to Enbrel® and Humira® for plaque psoriasis will be discontinued and that indication will be removed from the ODB Formulary. Requests for patients requiring medically necessary exemptions to this policy for Enbrel® or Humira® for plaque psoriasis will need to be submitted to the EAP.

**Compensation for Pharmacists**

Pharmacists may claim a Biosimilar Support Fee in the amount of $15 when filling the first prescription for a biosimilar included in the biosimilars policy for a transitioning ODB recipient. Along with filling the prescription, pharmacists are expected to provide patients with the information they need to assist with their

---

\(^4\) Where an originator biologic only has one biosimilar, a patient would only be required to trial one biosimilar before an EAP request for the originator biologic would be considered.
transition to a biosimilar, which could include educating the patient on the safety and efficacy of the product and answering any questions they have.

The fee can be claimed **once per patient per drug transitioned to a biosimilar product**. Claims for the support fee will only be paid during the transition period for eligible patients.

Note that the fee **can only be claimed for transitioning ODB recipients between March 31, 2023 and December 28, 2023**. It is **not** eligible to be claimed for:

- Recipients who are new to ODB on or after March 31, 2023;
- Prescriptions for biosimilars that were dispensed prior to March 31, 2023 or after December 28, 2023;
- Subsequent prescriptions for a biosimilar product, after the patient's initial transition to that drug product;
- Recipients who are not enrolled in the ODB program and pay out-of-pocket or are reimbursed by a third-party insurer; or
- Treatment-naïve recipients.

In order to be reimbursed for the Biosimilar Support Fee, pharmacies must follow the normal process for submitting claims to the Health Network System (HNS) (See Section 5 of the Ontario Drug Programs Reference Manual (“Manual”)), with the following additional information:

- Intervention code ‘PS’: (Professional Care Services)
- PIN: see Table below for list of PINs
- Valid Pharmacist ID

New PINs will be added if the policy is expanded to include new biosimilars. The claim for the Biosimilar Support Fee must be submitted on the same day as the initial claim submission for the biosimilar. All other HNS rules and Ministry Policies remain the same.

For purposes of post-payment verification, pharmacy records related to claims for the Biosimilar Support Fee must be maintained in a readily available format for the purpose of ministry inspection for the Retention Period.
Overpayments due to inappropriate claim submissions are subject to recovery.

Pharmacy records must include the following:

- A valid prescription;
- Signed and dated documentation, that includes but is not limited to the following:
  - Cross-referencing to the biosimilar claim to which the support fee relates; and
  - Confirmation of the originator biologic that the patient was taking; and
  - When the originator biologic was last dispensed, if available; and
  - Summary of the pharmacist-patient interaction.

<table>
<thead>
<tr>
<th>Drug Product</th>
<th>Biosimilar Patient Support Fee PINs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td>09858133</td>
</tr>
<tr>
<td>Etanercept</td>
<td>09858104</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
<td>09858107</td>
</tr>
<tr>
<td>Infliximab</td>
<td>09858105</td>
</tr>
<tr>
<td>Insulin aspart</td>
<td>09858238</td>
</tr>
<tr>
<td>Insulin glargine</td>
<td>09858108</td>
</tr>
<tr>
<td>Insulin lispro</td>
<td>09858132</td>
</tr>
<tr>
<td>Rituximab</td>
<td>09858106</td>
</tr>
</tbody>
</table>

Compliance with all ministry policies is required under section 3.2 of the Health Network System (HNS) Subscription Agreement for Pharmacy Operators.
Section 7: Professional Pharmacy Services

Overview

The Ontario government compensates pharmacists through the HNS for providing a number of professional pharmacy services.

This section outlines the different programs available and the billing requirements for submitting professional pharmacy services via the Ministry’s HNS including:

- MedsCheck Programs (see Section 7.1)
  - MedsCheck Annual Medication Review and Follow-Up
  - MedsCheck Diabetes
  - MedsCheck at Home
  - MedsCheck LTC (Note: Funding parameters for MedsCheck for Long Term Care residents have changed effective January 1, 2020. For more information, see Section 6.16)

- Pharmaceutical Opinion Program (see Section 7.2)

- Pharmacy Smoking Cessation Program (see Section 7.3)

- Ontario Naloxone Program for Pharmacies (see Section 7.4)

- Reimbursement and Claims Submission using the Health Network System relating to Drugs for Medical Assistance in Dying (see Section 7.5)

- Reimbursement and Claim Submissions for Mifepristone/Misoprostol (Mifegymiso) (see Section 7.6)

- Reimbursement and Claims Submissions for Minor Ailment Services (see Section 7.7)

Please refer to the Professional Pharmacy Services Guidebook for program details and mandatory requirements.
Pharmacists are required to use the fillable Ministry forms and templates, or an adapted version based on the Ministry template. The pharmacy system software must match the Ministry forms and templates exactly unless otherwise specified.

### 7.1 MedsCheck Program

The Ministry compensates pharmacists for providing professional pharmacy services in its MedsCheck. The program also includes MedsCheck Follow-up, MedsCheck for Diabetes and MedsCheck at Home.

The MedsCheck program is voluntary and requires the patient’s signed acknowledgment of the services each year. This process builds patient awareness and a better understanding of the MedsCheck services offered at community pharmacies.

Ontarians who meet the respective MedsCheck program criteria are eligible for one annual MedsCheck review each year.

MedsCheck medication reviews take place in the community pharmacy. Exceptions apply for the MedsCheck at Home.

Pharmacists are required to follow up on potential drug-related problems resulting from all MedsCheck reviews (see Section 7.2 for the Pharmaceutical Opinion Program [POP]).

Pharmacists may bill for one MedsCheck annual review per patient per year provided patients meet the respective program criteria.

**Note:** Billing a MedsCheck service without complete documentation or without patient consent or for purposes that are outside of the specified program criteria may be subject to recovery.

**Examples of improper billing include MedsCheck for patient monitoring programs, medication reviews conducted over the phone or by video-conferencing, and medication reviews incorporated in medical directives.**

The **Professional Pharmacy Services Guidebook** contains further details on the program including:

- eligibility Criteria
• location for service provision (where applicable)

• mandatory requirements, including the completion of the new MedsCheck forms

• documentation requirements for each of these services

**MedsCheck Programs**

Please see below for a brief description of the various MedsCheck programs. For more information please refer to the Professional Pharmacy Services Guidebook:

• MedsCheck Annual
• MedsCheck Follow-up
• MedsCheck for Diabetes
• MedsCheck At Home

Program details and requirements for the MedsCheck programs, including patient acknowledgement of services, the use of a worksheet for the pharmacist’s professional notes as well as sharing the MedsCheck personal medication record with the primary provider, are available in the Professional Pharmacy Services Guidebook.

**MedsCheck Annual**

The MedsCheck Annual medication review is a one-on-one, in-person medication review between the pharmacist and the patient that takes place in the community pharmacy for patients who are currently **taking a minimum of three prescription medications for a chronic condition**. The MedsCheck annual review will help patients understand their medications (drug names, strengths, adverse effects and usage instructions) and ensure that they are taking them as prescribed and if necessary, with any concerns to be referred to a prescriber. It will also provide patients with an accurate and up to date medication list.
MedsCheck Follow-Up

The MedsCheck follow-up medication review is an additional medication review for those patients who may benefit from a second MedsCheck within the annual time frame due to any of the following criteria:

- A hospital discharge (within two weeks of the discharge)
- A planned hospital admission
- A physician or nurse practitioner referral
- A pharmacist’s documented decision due to:
  - Significant changes made to an existing medication profile or the addition of new medications
  - Documented evidence of a patient’s non-compliance with a medication plan
  - Patient has changed both his/her place of residence and his/her pharmacy thus necessitating further review of his/her medications by the pharmacist.

The pharmacist must document in writing the reason for the MedsCheck follow-up for the purposes of claim validation.

MedsCheck for Diabetes

The MedsCheck Diabetes program is an annual medication review by a community pharmacist for Ontarians living with type 1 or type 2 diabetes. There is no minimum number of prescription medications that the patient must be taking. Patients may be on fewer than three prescription medications, not yet taking medication for their diabetes or managing their diabetes through diet alone. It provides an opportunity for the pharmacist to engage patients in a focused medication review including advice, training, blood glucose monitoring and education on diabetes. As many patients living with diabetes may have other medical conditions, pharmacists are expected to provide advice on overall therapy management as well as for diabetes.

Eligible patients may receive a MedsCheck for Diabetes medication review assessment service once per year based on the date that the recipient had his/her previous MedsCheck for Diabetes service. Should a patient require follow-up
education and/or communication, the pharmacist will include this plan as part of the annual assessment with the projected monitoring, training, education and communication as appropriate with the patient. Patients targeted for education are eligible for a Diabetes Education service within the same year. The Diabetes Education service does not include a medication review component and the visit must take place at the same pharmacy that provided the MedsCheck for Diabetes service. Once a patient is the recipient of the MedsCheck for diabetes, he/she is not eligible to receive a MedsCheck Annual.

**MedsCheck at Home**

The MedsCheck at Home medication review program conducted by a community pharmacist is for those patients who are not able to physically attend the community pharmacy in person for a MedsCheck due to their physical and/or mental health condition. Patients who may benefit from the program include those who are at risk of drug therapy problems because of their co-morbidities, age or social circumstances. During the home visit, pharmacists are required to conduct a medicine cabinet review and remove unused and expired drugs for proper disposal at the pharmacy.

**MedsCheck for Long-Term Care**

Effective January 1, 2020, funding for MedsCheck LTC has changed. All professional pharmacy services including dispensing fees and Professional Pharmacy Services (e.g., MedsCheck LTC, Pharmaceutical Opinion Program) provided to residents of long-term care homes are now reimbursed through a per-bed-fee capitation model.

To receive the fee-per-bed, pharmacists are expected to continue to provide medication management services, including medication reviews (e.g., MedsCheck LTC annual and quarterly medication reviews) and medication assessments (e.g., as with the Pharmaceutical Opinion Program) as appropriate to residents of LTC homes.

Pharmacies are no longer required to submit claims through the Health Network System (HNS) for MedsCheck LTC (both annual and quarterly medication reviews). The PINs have been discontinued.

For more information, please see Section 6.16 or the Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 on the ministry’s website at:
Confidentiality

Pharmacists are reminded to take all reasonable precautions to ensure personal health information is treated with the greatest sensitivity and to respect the patient’s privacy when discussing this information with the patient and/or other health care professionals. (Refer to Section 3.1, Privacy of Patient Information)

Acknowledgement of Services

Patient acknowledgement of professional pharmacy services is facilitated with the use of a mandatory form and, when completed by the patient, confirms the patient’s understanding of the MedsCheck service.

This Patient Acknowledgment of Professional Pharmacy Service Form: (Refer to the Professional Pharmacy Services Guidebook for information on Forms)

- Must be completed annually and provided to the patient; a completed copy is maintained at the pharmacy.
- Aims to build patient awareness and understanding of professional pharmacy services.
- Replaces the patient’s signature on the MedsCheck personal medication record.
- May be reproduced / generated by pharmacy software vendors to exactly match the Ministry form.

Pharmacists will ensure the patient has:

- Signed and dated the annual Patient Acknowledgment of Professional Pharmacy Service form to confirm their agreement and understanding of the MedsCheck services.
- Signed the form before the pharmacist conducts the MedsCheck service and before the pharmacist bills the Ministry for the MedsCheck service through the HNS.
Claim Requirements for MedsCheck Programs

A claim for payment is submitted on the day the MedsCheck takes place, unless the MedsCheck was conducted outside the pharmacy as in the case of the MedsCheck at Home, where pharmacists may submit the claim for service up to one business day later.

Pharmacists should make every effort to complete a MedsCheck review and submit claims to the Ministry on the same day the patient visits the pharmacy for their consultation. This includes resolving any drug therapy problems that can be immediately addressed and ensuring all required documentation is complete.

The completed signed/dated MedsCheck Personal Medication Record form must be shared with the patient and primary prescriber as soon as possible. Documentation of the MedsCheck should support the date of service submitted. Dates of service that cannot be supported with documentation may be subject to recovery.

Pharmacists must use their Pharmacist ID as the prescriber ID when submitting a claim for a MedsCheck service.

A paper-based system must cross-reference the ODB claims Transaction Number.

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting a claim for a MedsCheck, namely:

**Fields required for all MedsCheck claims (ODB/TDP recipients and non-ODB recipients):**

**Claims for MedsCheck Annual + MedsCheck Follow-up Reviews:**

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the appropriate Professional Care Service PIN:</td>
</tr>
</tbody>
</table>
### Claims for MedsCheck Diabetes Annual + Diabetes Follow-up Reviews:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the appropriate Professional Care Service PIN:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>938999988 = MedsCheck Diabetes Annual Assessment Summary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>938999989 = Diabetes Education Follow-up</td>
</tr>
<tr>
<td>Pharmacist’s ID code</td>
<td>Y</td>
<td>Pharmacist License #</td>
</tr>
<tr>
<td>Professional Fee</td>
<td>Y</td>
<td>MedsCheck Diabetes Assessment:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Annual Summary = $75 per year/patient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Education Follow-up = $25 (at same pharmacy as diabetes annual assessment)</td>
</tr>
</tbody>
</table>
### Claims for MedsCheck at Home:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the appropriate Professional Care Service PIN:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>93899987 = MedsCheck Home Assessment Summary</td>
</tr>
<tr>
<td>Pharmacist's ID code</td>
<td>Y</td>
<td>Pharmacist License #</td>
</tr>
<tr>
<td>Professional Fee</td>
<td>Y</td>
<td>MedsCheck Home Assessment Summary: $150 per year/patient</td>
</tr>
</tbody>
</table>

### Additional fields required for non-ODB/TDP recipients for all types of MedsCheck claims:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“ML” = Eligibility established - Standard coverage</td>
</tr>
<tr>
<td>Patient Gender</td>
<td>Y</td>
<td>“F” = female, “M” = male</td>
</tr>
<tr>
<td>Patient Date of Birth</td>
<td>Y</td>
<td>YYYYMMDD</td>
</tr>
<tr>
<td>Client ID # or Code</td>
<td>Y</td>
<td>Health number</td>
</tr>
<tr>
<td>Carrier ID</td>
<td>Y</td>
<td>“S” = Non ODB MedsCheck Service Plan Code</td>
</tr>
</tbody>
</table>
Claim Validation of MedsCheck Claims:

MedsCheck program documentation must be readily retrievable and includes “original records” that could be original paper documents, electronic scanned images of original paper documents or electronic records.

Required documentation that must be available at the pharmacy in a readily retrievable format includes:

- **MedsCheck Patient Acknowledgement of Professional Pharmacy Services** (standardized form). The completed form replaces the patient signature on the final MedsCheck Personal Medication Record.

- **Pharmacist’s worksheet/professional notes** — for every MedsCheck, pharmacists must have professional notes and/or a worksheet. Notes may be shared with the patient and/or primary prescriber on request.

- **MedsCheck Personal Medication Record** (standardized form). The record must be signed and dated by the pharmacist indicating the date of the consultation and all drug therapy problems must be followed up or have a plan for resolution prior to providing the form to the patient.

- **MedsCheck Patient Take-Home Summary.** This record, if used or if offered to the patient, must be signed and dated by both the pharmacist and the patient.

- **Mandatory Fax/Letter to the primary prescriber** (standardized form). Pharmacists must share the MedsCheck record with the primary prescriber using this form, thereby indicating the MedsCheck was shared with the patient’s prescriber.

- **Other documents, as necessary, as referenced in the Professional Pharmacy Services Guidebook.**

It is important to document all patient interactions to support payment. Documentation may be requested for inspection purposes. MedsCheck documents must be kept in a readily retrievable format (either electronically or as a hard copy) at the pharmacy for the Retention Period for claim validation purposes, and in accordance with O Reg 264/16 if applicable.
Note: Billing a MedsCheck service without complete documentation or without patient consent or for purposes that are outside of the specified program criteria may be subject to recovery.

Examples of improper billing include Meds Checks for patient monitoring programs, medication reviews conducted over the phone or by video-conferencing; medication reviews incorporated in medical directives.

Program details and mandatory requirements on the MedsCheck program are detailed in the Professional Pharmacy Services Guidebook.

The Ministry may recover funds for claims lacking documentation meeting mandatory requirements.

### 7.2 Pharmaceutical Opinion Program

The Pharmaceutical Opinion Program (POP) refers to the identification by the pharmacist of a potential drug therapy problem – a clinical intervention – during the course of dispensing a new or repeat prescription, or when conducting a MedsCheck medication review for a recipient of the ODB program (excluding a LTC home resident; for more information, see Section 6.16).

To be eligible for a professional intervention fee, the pharmacist must document and make a recommendation to the prescriber regarding the medication with the intent to achieve optimum patient health outcomes.

While the POP is only billable for ODB program recipients (with the exception of LTC Home residents), there is an expectation as per the Standards of Practice that pharmacists aim to resolve or prevent any drug therapy problems for all patients.

**Outcomes**

As a result of implementing a pharmaceutical opinion, the following outcomes are expected:

**Not filled as prescribed.** Prescription not filled resulting from a confirmed forged or falsified prescription or not filled due to a clinical concern based on prescriber consultation.
No change to prescription therapy; filled as prescribed. Recommendations by the pharmacist were discussed with the prescriber and no change was made to the prescription therapy. Prescription filled as prescribed; prescription therapy continued as prescribed in the case of a MedsCheck.

Change to prescription therapy. Recommendations by the pharmacist were discussed with the prescriber and led to a change in therapy as prescribed.

Types of Prescription Interventions in a Pharmaceutical Opinion

In situations not already captured by the Health Network System (HNS) such as a Drug Utilization Response (DUR) code, the pharmacist may implement a pharmaceutical opinion based on one of the following prescription intervention criteria or drug therapy problems:

i. Therapeutic Duplication; drug may not be necessary

ii. Requires drug; patient needs additional drug therapy

iii. Sub-optimal response to a drug; drug is not working as well as needed

iv. Dosage too low

v. Adverse drug reaction; possibly related to an allergy or a conflict with another medication or food, or a side effect

vi. Dangerously high dose; patient may, either accidentally or on purpose, be taking too much of the medication

vii. Non-compliance; patient is refusing to take the drug, or not taking it properly

viii. Prescription has been confirmed false or has been altered

Identification of the Drug Therapy Problem

In the course of filling a prescription or when conducting a MedsCheck medication review, a pharmacist may identify a problem or potential problem that they feel should be discussed with the patient’s prescriber. An intern or a registered pharmacy
student may conduct a POP service as long as the intern or student is under the supervision of a licensed pharmacist.

**Contacting the Prescriber**

- On identifying the potential drug therapy problem, the pharmacist must contact/consult with the prescriber to discuss the drug therapy problem or concern.

- The pharmacist provides the prescriber with a recommendation and documents the intervention on the prescription or worksheet (i.e., the drug therapy problem and recommendation). If a recommendation is not provided and documented, a claim for a POP cannot be billed.

- The pharmacist must document the outcome on the prescription or worksheet based on the interaction with the prescriber:
  - Not filled
  - No change to prescription therapy; filled as prescribed; therapy continued
  - Change to prescription therapy; filled as per change(s) (includes adding new drug therapy and discontinuing drug therapy)

- The main elements of discussion between the pharmacist and the prescriber must also be documented.

**Communication with the Patient**

- The pharmacist must inform the patient (or caregiver) why the prescription will not be dispensed as written/prescribed and what the potential drug therapy problem is.

- The pharmacist must also discuss any alternative therapeutic plan (if applicable) and convey such information to the patient and the prescriber.
• The pharmacist will provide the patient with an updated MedsCheck Personal Medication Record based on the outcome of the drug therapy problem if the intervention resulted from a MedsCheck.

What is NOT Eligible for Payment under the Pharmaceutical Opinion Program

1. Other than a confirmed prescription forgery or falsified prescription, a pharmaceutical opinion may not be claimed if the pharmacist has not made a recommendation to the prescriber.

2. Contacting the prescriber without a clinical intervention when a patient missed a methadone dose (or a dose of any other drug).

3. A one-way fax communication to the prescriber without a documented resolution to the problem as discussed with the prescriber.

4. Recommendations to the prescriber for medical device therapy (including but not limited to blood glucose test strips, blood glucose meters, flash glucose meters, valved holding chambers).

5. Recommendation for the Smoking Cessation program.

6. Recommendation for an influenza or COVID-19 vaccine (or other routine vaccines).

7. Contacting the prescriber for a clinical intervention related to a drug recall, shortage or backorder.

8. Contacting the prescriber for an early release of medication for interval restricted drugs (e.g., narcotic prescription) without a clinical recommendation.

9. Referral to go see their primary care provider, a specialist, other health care provider or to go to the hospital.

10. Pharmaceutical opinion conducted in conjunction with medical clinics or other health care facilities (e.g., cancer clinic pharmacies).

11. Drug therapy monitoring (e.g., INR monitoring).
12. Recommendation to prescriber for patient to take over-the-counter or Schedule II medications (including naloxone).

13. Recommending that a patient already enrolled in a methadone maintenance treatment (MMT) program requires drug therapy relating to the MMT.

14. Making a recommendation relating to Paxlovid™ prescribing and dispensing that is not eligible to be billed as a pharmaceutical opinion in the circumstances set out in the Executive Officer Notice on Prescribing and Dispensing of Paxlovid™ in Ontario Pharmacies on the ministry website.

15. Making a recommendation in relation to a pharmacist prescribing allowable medications for minor ailments as set out in Section 7.7 of this manual.

Invalid Pharmaceutical Opinion Scenarios

Scenario #1 – Therapeutic Duplication

The patient presents a prescription for a Flovent (fluticasone propionate) inhaler. On checking the profile, the pharmacist sees that the patient is already taking Breo Ellipta (fluticasone furoate & vilanterol). The pharmacist contacts the prescriber and mentions that the patient has two prescriptions for the same therapy; they ask the prescriber which inhaler should be used? The physician / prescriber responds back to indicate that the patient requires both.

- The above scenario is not an acceptable POP claim as the pharmacist failed to make a recommendation to the prescriber.
- While the documentation indicated therapeutic duplication, it did not outline a recommendation to the prescriber by the pharmacist.
- A valid claim would have seen documentation that the pharmacist recommended one of the inhalers be discontinued and the rationale.

Scenario #2 – Adverse Drug Reaction

A patient with a penicillin allergy was prescribed cefuroxime. The pharmacist contacts the prescriber to ask for an alternate drug to be prescribed. The prescriber changes the prescription to azithromycin.
• The above scenario is not an acceptable POP claim as the pharmacist failed to make a recommendation to the prescriber.
• While the documentation indicated the allergy and potential for an adverse reaction, it did not outline a recommendation to the prescriber.
• A valid claim would have seen documentation that the pharmacist recommended azithromycin or another drug that a patient with a penicillin allergy could take.

Scenario #3 – Adverse Drug Reaction

A pharmacist received a prescription for cimetidine for a patient taking methadone for maintenance treatment (MMT). The pharmacist contacted the prescriber to indicate that cimetidine may increase the levels of methadone and therefore the dose should be adjusted or alternatively another drug should be prescribed. The prescriber discontinued the prescription for cimetidine and prescribed pantoprazole instead.

• The above scenario is not an acceptable POP claim as the pharmacist failed to make a recommendation to the prescriber.
• While the documentation indicated that the cimetidine dose should be adjusted, the pharmacist did not provide a recommended dose. In addition, while the pharmacist indicated that an alternate drug be prescribed, they did not recommend an alternative to the prescriber.
• A valid claim would have seen documentation that the pharmacist recommended the adjusted dose for cimetidine or an alternate drug treatment such as pantoprazole be prescribed.

Definitions of Prescription Intervention Terms or Drug Therapy Problems

1. Therapeutic Duplication; drug may not be necessary

   The prescribed medication or a medication from the same therapeutic class is being taken by the patient. The addition of the prescribed medication may provide no clinical benefit beyond the medication already being taken or it may harm the patient.
2. **Requires drug;** patient needs additional drug therapy

   Additional prescription drug therapy is required to treat or to prevent a medical condition in the patient.

3. **Sub-optimal response to a drug;** drug is not working as well as needed

   The drug is not the most effective or is not effective for the medical problem. This may include situations in which:
   
   - the dosage form for the drug product is not appropriate
   - the medical condition is refractory to the drug product (not yielding to drug therapy)
   - the prescribed medication has been previously taken by the patient and the patient did not experience the intended benefit of the medication

   This would also include refill prescriptions or a second fill to the Trial Prescription Program in which it is determined by the pharmacist that the patient is not receiving the intended benefit of the medication.

4. **Dosage too low**

   The total daily dose is below the usual recommendation and it is of little clinical value for the patient to take the medication in the dose that is prescribed.

5. **Adverse drug reaction;** possibly related to allergy or conflict with another medication or food

   The prescribed medication may result in a potential drug interaction between it and the current medication therapy, the prescribed medication and a medical condition or the medication is contraindicated for use during pregnancy or breastfeeding or another condition.

   The drug interaction is such that it has the potential to cause significant harm to the patient.

   The prescribed medication has been previously taken and resulted in an adverse reaction, allergy or side effect that resulted in the medication being
discontinued. The adverse reaction was such that in the pharmacist’s judgement the medication should not be received again by the patient.

This would also include refill prescriptions where the patient is having side effects with a prescribed medication, and because of the actions of the pharmacist in identifying the problem the medication is discontinued.

6. **Dangerously high dose**: patient may, either accidentally or on purpose, be taking too much of the medication

The total daily dose prescribed is above the maximum recommended daily dose and would harm the patient.

7. **Non-compliance**: patient is refusing to take the drug, or not taking it properly

The patient does not understand the instructions.

The patient prefers not to take the medication or forgets to take the medication.

The patient cannot swallow or self-administer the drug product appropriately.

The frequency that the patient is taking the medication does not align with the frequency prescribed.

8. **Prescription has been confirmed false or has been altered**

The pharmacist or pharmacy technician must confirm the validity of the prescription with the prescriber or the appropriate references including the respective prescriber’s regulatory authority.

A copy of the forgery is maintained for the record and cross-referenced with the Pharmaceutical Opinion claim; documentation includes findings regarding the confirmed forgery.

In the majority of cases, recommendations to prescribers regarding forgeries do not apply due to the nature of this prescription intervention.

Pharmacists are expected to report the prescription forgery to the appropriate authority.

**Note**: Only ODB program recipients (excluding residents of LTC homes) are eligible for the POP (see Section 4.1 for ODB Patient Eligibility). All claims will be monitored.
by the Ministry. Claims submitted for non-ODB program recipients or residents of LTC homes will be subject to recovery. Also, see page 2 of the Executive Officer Notice for the POP as it relates to Prescribing & Dispensing Publicly Funded Paxlovid™ in Ontario Pharmacies. Separate POP PINs and criteria are used for the Paxlovid program.

Claim Requirements for Pharmaceutical Opinion Program

POP claims for payment may only be submitted for ODB program recipients (excluding residents of LTC homes). Claims submitted for pharmaceutical opinion for residents of long-term care homes will be subject to recovery as reimbursement parameters for LTC residents have changed effective January 1, 2020. For more information, please see Section 6.16 or the Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 on the ministry’s website at: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx

A claim for payment is made after:

- The pharmaceutical opinion has occurred
- The patient has been informed
- The prescriber has been contacted
- Documentation is completed and signed by the pharmacist.

All POP claims documentation must be cross-referenced to the prescription or the MedsCheck Personal Medication Record and include the reason for the pharmaceutical opinion.

It is imperative that pharmacists submit POP claims using the appropriate PIN indicating the outcome of the drug therapy intervention that was conducted in relation to the prescription presented or to the MedsCheck medication review.

Pharmacists must use their Pharmacist ID as the Prescriber ID in the HNS system when submitting a POP.

Aside from including the fields indicated in Section 5.1, there are additional fields required (or certain exceptions applicable to specific fields) when submitting a POP claim, namely:
<table>
<thead>
<tr>
<th>Fields</th>
<th>Required (Y/N)</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention Code</td>
<td>Y</td>
<td>“PS” = Professional Care Service</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>Y</td>
<td>Enter the appropriate Professional Care Service PIN:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>93899991 = Forgery confirmed / Not Filled</td>
</tr>
<tr>
<td></td>
<td></td>
<td>93899992 = No Change to Rx therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>93899993 = Change to Rx therapy</td>
</tr>
<tr>
<td>Pharmacist’s ID code</td>
<td>Y</td>
<td>Pharmacist License #</td>
</tr>
<tr>
<td>Professional Fee</td>
<td>Y</td>
<td>$15.00</td>
</tr>
</tbody>
</table>

The claim submission follows the same process for submitting a claim for other professional services with the use of a PIN that is associated with the pharmaceutical opinion outcome.

**Claim Validation for POP Claims:**

**Documentation must be on the patient’s electronic profile, pharmacist’s worksheet or on the prescription hardcopy record. All documentation must be in a readily retrievable format. The use of a pharmaceutical opinion form is also accepted as documentation provided the pharmaceutical opinion is cross-referenced with the original prescription and revised prescription if applicable. As a minimum to include:**

- **Details of the drug therapy problem (there are 8 reasons for not dispensing the prescription as written/prescribed).**
- **Medication(s) involved.**
- **Recommendation to the prescriber**
- **The date and the name of the prescriber who was contacted.**
• **Action plan / discussion with the patient (caregiver)**

• **The outcome:**  
  1) Not filled due to a confirmed forgery / clinical concern;  
  2) Prescription filled as prescribed/therapy continued as prescribed;  
  3) Prescription therapy changed.

• **The date of the transaction and the pharmacist’s signature.**

• **Other comments required to substantiate the decision**

• **In the case of MedsCheck, the POP is documented on the pharmacist’s worksheet and an updated MedsCheck Personal Medication Record is provided to the patient and the primary care provider as per MedsCheck standards.**

*Please note the documentation must be maintained for the Retention Period for purposes of claim validation, and in accordance with [O. Reg. 264/16](#) made under the DPRA if applicable. The Ministry may recover funds for claims lacking documentation meeting mandatory requirements.*

### 7.3 Pharmacy Smoking Cessation Program

Community pharmacists are funded by the Ontario Government for their expertise in providing a smoking cessation program to ODB program recipients.

The Pharmacy Smoking Cessation Program provides an opportunity for community pharmacists to provide a one-to-one support service and advice to people eligible to receive ODB benefits who want to give up smoking. The program includes a readiness assessment where a patient may enroll in the smoking cessation program with the pharmacy combined with a first consultation as well as a number of follow-up counselling sessions over a one-year period.

The pharmacist helps to facilitate access to, and where appropriate, supply suitable stop-smoking drugs and aids. For example, if a patient could benefit from prescription therapy to stop smoking, a pharmacist may independently prescribe as per their scope of practice.
Patient eligibility

The program is available to recipients of benefits under the ODB program (with the exception of LTC Home residents; for more information, see Section 6.16) who smoke and demonstrate a willingness or readiness to quit.

ODB recipients may enrol in the program once per year from the date of the patient’s first meeting with the pharmacist at which time they have agreed to work together on a stop-smoking strategy.

A patient who smokes may self-identify their interest in the smoking cessation program. As pharmacists are in dialogue with their patients and caregivers daily for MedsCheck appointments, for questions related to over-the-counter medications and in fulfilling their dispensing services, there are many opportune times to talk about smoking cessation.

While pharmacists already provide advice to their patients on the risks of smoking during these interactions, the opportunity may also arise when patients are indeed ready to quit smoking and decide to enrol in the smoking cessation program.

The Process

Using the 5 As algorithm (Ask, Advise, Assess, Assist, Arrange) the pharmacist will guide the patient through a smoking cessation program (refer to 5 A’s Algorithm below).

As with all professional pharmacy services, pharmacists will provide the smoking cessation service in an area of the pharmacy that provides a sufficient level of privacy and safety for the patient.

All meetings with the patient must be documented to ensure program continuity. Follow-up meetings may be in person, via telephone, electronic messaging or other agreed-upon methods of communication.

---

5 The 5 As algorithm of Ask, Advise, Assess, Assist and Arrange is a smoking cessation algorithm that is commonly used by health care providers. For more information refer to the Smoking Cessation resource tools on the Ontario Pharmacists Association website: [https://opatoday.com/product/smoking-cession/](https://opatoday.com/product/smoking-cession/)
Standardized template forms are provided as minimum standards of care to assist pharmacists with the mandatory documentation at each patient point of contact. (Refer to Appendix F). While pharmacists may develop their own forms, the standardized template forms from the ministry must be adapted to maintain consistency of the program protocol.

While one pharmacist may be the initial contact with the patient, any pharmacist at the same pharmacy who has the appropriate training may meet with the patient over the course of the program. It is important, however, that there is a trusting relationship between the patient and the pharmacist(s) for the duration of the program. A one-to-one relationship between the patient and the counselling pharmacist may support a more successful quit attempt.

**Duration of Program**

The program includes nine points of contact over 365 days, including the readiness assessment whereby the patient agrees to the requirements to enrol, the first consultation meeting and the follow-up counselling sessions.

**Readiness Assessment**

The outcome of the Readiness Assessment is that the patient agrees to enrol in the smoking cessation program and establish a quit date.

- The pharmacist provides information that fosters program awareness for the patient and asks of their willingness to quit smoking. Generally, this is an in-person interaction and may result from the MedsCheck appointment, a patient enquiry about over-the-counter nicotine replacement therapy or as a result of another interaction where the opportunity to discuss the patient’s desire to quit in the next month occurs.

- The Readiness Assessment includes a questionnaire to determine the level (rating) of the desire to quit smoking. A patient may not be ready to quit and may require more time to reflect before finally deciding to enrol.

- When the patient agrees to move forward and work with the pharmacist, the initial consultation will be arranged.
• A pharmacist and the patient may engage in a quit smoking discussion many times before a patient agrees to enrol and indicates a willingness to set a quit date.

• The readiness assessment process requires the pharmacist to document the patient’s name, contact information and date of the discussion in which the patient agrees to enroll in the program.

• Documentation should also outline the questions asked, the level of desire to quit smoking and the pharmacist’s name. Patients may request a copy of this record.

**Patient’s Signature**

Patients who enrol in the Smoking Cessation program are required to establish a quit date and provide consent to the service including the method of communication whether in person, by phone or other means, and the time(s) for the consultations.

Patients also provide consent for sharing the readiness assessment or first consultation summary or other documentation within the circle of care.6

**First Consultation Meeting**

The outcome of the first consultation is to engage the patient in a dialogue about their smoking history, and to ensure the patient understands the goals and objectives of the program including their responsibilities towards success. The first consultation occurs after the pharmacist has conducted the readiness assessment and obtained the patient’s consent to enroll in the program enrolment and share their health information within their circle of care.

The pharmacist meets with the patient in-person for the first consultation to discuss tobacco use and medication history, health risks, triggers/strategies; a quit date and consideration of pharmacotherapy.

---

6 Circle of Care is a commonly used term in the health care community that refers to the health care providers who share patient health information; for more information regarding patient consent refer to the OCP website ([www.ocpinfo.com](http://www.ocpinfo.com)) and the Information and Privacy Commissioner website at [www.ipc.on.ca](http://www.ipc.on.ca)
• Patient enrolment and consent forms should be signed prior to the first consultation meeting.

• An in-person appointment should be scheduled for the first consultation to ensure adequate time to discuss the patient’s history and pharmacotherapy options.

• Patients should be provided with supporting printed education material relating to the benefits of quitting smoking and/or information pertaining to internet resources, peer groups and contact information such as the Smokers Help Line, other health care professionals and programs to reinforce their quit smoking goals.

• The first consultation includes developing a plan or an agreement on the chosen treatment pathway, ensuring that the patient understands the ongoing support and monitoring arrangements. Patients will use a quit smoking plan, which the pharmacist is required to provide. It is a personal plan for preparing to quit smoking and what to expect regarding their process. Other quit smoking management tools including brochures, referral information to support groups and other tools and/or strategies to promote positive results should also be provided.

• The first consultation also includes the appropriate advice and documentation that it may be necessary for the pharmacist to discuss and share the patient’s health information with other health care professionals (physicians, nurse practitioners) in the process of assisting with the quit smoking program. While patients have signed consent forms, they should be informed if the pharmacist provides a copy of the readiness assessment and/or first consultation or follow-up session(s) information to the physician or other health care professionals.

• Follow-up counselling sessions for the purpose of patient progress, evaluation and monitoring smoking status, addressing any concerns or issues and providing support are outlined and tentatively scheduled at the time of the first consultation.

A billing code (noted below) through the ODB Health Network System is used by the pharmacist to claim payment after the first consultation. The claim for payment is processed once documentation of the first consultation meeting is complete and the patient has signed the appropriate agreements (Readiness Assessment).
Follow-up Counselling Sessions

All follow-up counselling sessions must be documented to ensure continuity of the program and evaluation of it and for the purpose of ministry inspection.

There are a total of seven follow-up counselling sessions that are billable by the pharmacist through the ministry’s Health Network System. Pharmacists may meet with their patient more often if required such as prior to the targeted quit date or other times that require support strategies and pharmacotherapy intervention; however, the program limits payment to defined parameters.

The first three or primary follow-up counselling sessions should take place within three weeks of the first consultation, and the latter four or secondary follow-up sessions are expected to take place at intervals as agreed by the pharmacist and the patient between one and two months; between three and four months; between six and seven months; and between eight and twelve months.

Suggested timelines for follow-up counselling sessions:

**Primary Follow-up sessions**

- Day 3–5 (10 minutes)
- Day 7–10 (10 minutes)
- Day 14–21 (10 minutes)

**Secondary Follow-up sessions**

- Day 30–60 (3–5 minutes)
- Day 90–120 (3–5 minutes)
- Day 180–210 (3–5 minutes)
- Day 240–365 (3–5 minutes)

**Primary Follow-up Counselling Sessions 1 – 3**

- The first three follow-up counselling sessions should take approximately ten minutes and should occur within the first three weeks of the program being initiated.
• The sessions include a dialogue with the patient on their success with the strategy chosen including identifying any potential drug therapy issues. It is a time to discuss what is working or not working and ways in which the patient can overcome triggers, cravings or withdrawal symptoms. Pharmacists will optimize on the program successes and encourage continuation of those favourable outcomes. In addition, a review of biological incidents including personal, psychological or social issues, if any, that prevented the patient from reaching their goal are part of the discussion.

Secondary Follow-up Counselling Sessions 4 – 7

• The four secondary follow-up counselling sessions are approximately five minutes in duration and occur at the suggested intervals following the first month.

• The sessions continue to build on the program success history and review incidents including drug therapy issues and biological incidents, if any, that prevented the patient from reaching their goal.

A billing code (noted below) for the ODB Health Network System is used by the pharmacist to claim payment for each of the primary and secondary follow-up counselling sessions. The claim for payment is processed once documentation of the session is complete.

Program Evaluation

Pharmacists are asked to document smoking cessation program results for the purpose of program evaluation.

The following results are claimed using the ODB HNS PINs for the purpose of establishing patient success in the Ontario government’s quit smoking program. The three PINs used for program evaluation provide no remuneration. Only one of the three program evaluation PINs is claimed per patient.

Once a program evaluation PIN is claimed, no further meetings are billable for that program period.
Successful Quit

- The successful quit is claimed when a patient indicates at any time during the program that they have successfully quit smoking. Once the PIN is claimed, no further meetings are scheduled or billable.

Unsuccessful Quit

- The unsuccessful quit is claimed when a patient indicates at any time during the program that they have not succeeded in quitting smoking. Once the PIN is claimed, no further meetings are scheduled.

- Pharmacist should inform patients who withdraw from the program of their eligibility to re-enrol at a later date (one year from the date of their first consultation with the pharmacist).

Unknown Status/Program Withdrawal

- The unknown status is claimed when a patient cannot be reached to continue with their program or when a patient withdraws from the program without indicating their success in quitting smoking.

Location of Meetings

In recognition of providing professional services by community pharmacists, the Smoking Cessation program meetings are ideally conducted in the community pharmacy, in person with the patient. The first consultation meeting should take place in the pharmacy, in person. Follow-up sessions are more flexible.

A sufficient level of privacy and safety for the patient must be ensured by the pharmacist.

The Ontario government recognizes that not all interactions between the pharmacist and the patient for the smoking cessation program can be conducted in person at the pharmacy. Should a meeting occur outside the community pharmacy or by another mechanism including telephone, email or other means as arranged and agreed upon by both parties, the location and method used must be documented.
Pharmacist Education Requirements

The Smoking Cessation program is considered to be within the scope of practice of a pharmacist licensed to practise direct patient care (Part A of the Register, Ontario College of Pharmacists). An intern or a registered pharmacy student may conduct a Pharmacy Smoking Cessation service as long as the intern or student is under the supervision of a licensed pharmacist.

In addition, pharmacists are required to take a smoking cessation training program to ensure they have a basic level of training including motivational interviewing strategies, a familiarity with more involved smoking cessation counselling and quit smoking planning.

The training program must support the Smoking Cessation Algorithm (5 As) of Ask, Advise, Assess, Assist, Arrange. Smoking cessation programs are obtainable in Ontario through the Ontario Pharmacists Association, the Canadian Pharmacists’ Association and the Centre for Addiction and Mental Health.

Additional Requirements

- The designated manager of a pharmacy that provides a smoking cessation program must be trained in smoking cessation within six months from the time the pharmacy provides the smoking cessation service.
- A pharmacist who is trained in smoking cessation must be available during hours of operation at the pharmacy that offers a smoking cessation program.
- Training for smoking cessation must be updated at a minimum of every five years.
- A copy of the completed smoking cessation training program should be readily retrievable at the pharmacy for purposes of audit.

Quit Smoking Information and Resources

- Information on the Ontario Government’s Support to Quit Smoking

---

7 Refer to Ontario Government’s [Support to quit smoking | ontario.ca](https://www.ontario.ca/page/support-to-quit-smoking)
Quit Smoking Helplines

- Smoke-Free Ontario Smokers Helpline — 1-877-513-5333
- Canadian Cancer Society Smokers' Helpline — 1-877-513-5333
- Ontario Lung Association — 1-888-344-LUNG (5864)
- Centre for Addiction and Mental Health (CAMH) Information Centre — 1-800-463-6273

Pharmacists may develop their own smoking cessation materials for patients. However, standardized template forms are provided by the Ontario Government as minimum mandatory standards of care to assist pharmacists document each patient point of contact. While pharmacists may develop their own forms, the standardized templates from the ministry need to be adapted to maintain a consistency of the program protocol.

Refer to the ministry templates for the Pharmacy Smoking Cessation Program (Appendix F).

---

8 Refer to Smoking and Tobacco references on the Canadian Cancer Society website: https://www.cancer.ca/en/support-and-services/support-services/quit-smoking/?region=on

9 Refer to Smoking and Tobacco references on the Canadian Cancer Society website: https://lunghealth.ca/tobacco/

10 Refer to Tobacco and Smoking references on the Centre for Addiction and Mental Health website: https://www.camh.ca/en/health-info/mental-illness-and-addiction-index
Templates for pharmacist’s materials are also available from the Ontario Pharmacists Association\(^\text{11}\)

**Documentation and Record Keeping**

Each point of contact or meeting between the pharmacist and the patient must be documented to ensure program continuity and for the purposes of counselling, support, data analysis, evaluation and claims adjudication.

Using the ministry template forms as a minimum standard, full documentation is required of all pharmacist/patient engagement including patient readiness, patient consent and agreement terms, first consultation meeting, follow-up counselling sessions and any incidence of program withdrawal.

Pharmacy records that are associated with the claims submission of professional services using the ODB HNS PIN mechanism are subject to inspection and must be maintained in the pharmacy.

All documents and records relating to the Smoking Cessation program may be stored electronically or as a hard copy when completed and be readily available for retrieval at a later date.

Refer to [Section 12](#) for requirements on supporting documentation.

**Results**

Patients are entitled to a copy of their readiness assessment, consent forms and any documentation from the first consultation and follow-up counselling sessions.

Please note that pharmacists are required to take a smoking cessation training program to ensure that they have a basic level of training, including training on motivational interviewing strategies, more involved smoking cessation counselling and quit smoking planning.

\(^{11}\) Refer to Smoking Cessation resource tools on the Ontario Pharmacists Association website: [https://www.opatoday.com/professional/resources/education/learn/addiction](https://www.opatoday.com/professional/resources/education/learn/addiction)
## The 5 As Algorithm

<table>
<thead>
<tr>
<th>Point of Contact</th>
<th>Description</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Readiness Assessment</strong></td>
<td>ASK client if they smoke</td>
<td>If client is NOT ready to make a quit attempt:</td>
</tr>
<tr>
<td></td>
<td>ADVISE smokers to quit</td>
<td>Provide client with an information sheet to encourage self-reflection. No signature will be required</td>
</tr>
<tr>
<td></td>
<td>ASSESS patient readiness to make a quit attempt now</td>
<td>If the client is ready to make a quit attempt and set a quit date: Client’s agreement to enrol, to receive counselling and that health information may be shared within the circle of care will be sought through a signature</td>
</tr>
<tr>
<td><strong>First Consultation</strong></td>
<td>ASSIST the client in making a quit attempt</td>
<td>Using the standardized template as a minimum guide, the pharmacist and patient will:</td>
</tr>
<tr>
<td>(~ 20 mins in duration)</td>
<td></td>
<td>• Set a quit date</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Create a quit plan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Provide practical counselling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Offer pharmacologic therapy, handouts and refer to community supports</td>
</tr>
<tr>
<td><strong>Follow-up Counselling</strong></td>
<td>ARRANGE for follow-up contact, either in person or via telephone</td>
<td>Using the standardized template as a minimum guide, the pharmacist and patient will:</td>
</tr>
<tr>
<td>Sessions 1–3 (~10 mins in duration)</td>
<td>Contact client according to agreed-upon intervals. For example:</td>
<td>• Determine quit status</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assess pharmacotheraphy use</td>
</tr>
<tr>
<td>Point of Contact</td>
<td>Description</td>
<td>Outcomes</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Between days 3–5</td>
<td>• Discuss triggers and strategies to overcome them</td>
</tr>
<tr>
<td></td>
<td>Between days 7–10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Between days 14–21</td>
<td></td>
</tr>
<tr>
<td>Follow-up Counselling Sessions 4–7 (~3–5 mins in duration)</td>
<td>ARRANGE for follow-up contact, either in person or via telephone Contact client according to agreed-upon intervals. For example: Between days 30–60 Between days 90–120 Between days 180–210 Between days 240–365</td>
<td>Using the standardized template as a minimum guide, the pharmacist and patient will: • Determine quit status • Assess pharmacotherapy use</td>
</tr>
<tr>
<td>• Successful Quit</td>
<td>To determine patient's success status with the program</td>
<td>Using the standardized template, the pharmacist will indicate one of the following outcomes: • Patient succeeded in quitting smoking • Patient did not succeed in quitting • Patient did not indicate whether they quit smoking</td>
</tr>
<tr>
<td>• Unsuccessful Quit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Unknown Quit Status</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Payments under the Long-Term Care Home Capitation Funding Model, 2020 on the ministry’s website at: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.asp

A claim for payment is made after documentation is complete and the respective smoking cessation meeting/session has occurred using the appropriate PIN; claim to be submitted on the date of service.

Pharmacists must use their Pharmacist ID as the prescriber ID when submitting a claim for the Pharmacy Smoking Cessation Program.

<table>
<thead>
<tr>
<th>Point of Contact</th>
<th>PIN</th>
<th>Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Readiness Assessment</td>
<td>93899941</td>
<td>$40</td>
</tr>
<tr>
<td>(May only be claimed once per year)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary Follow-up Sessions</td>
<td>93899942</td>
<td>$15</td>
</tr>
<tr>
<td>(May be claimed three times per year)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary Follow-up Session</td>
<td>93899943</td>
<td>$10</td>
</tr>
<tr>
<td>(May be claimed four times per year)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Program Evaluation Tracking**

A claim for evaluation is made using the appropriate PIN after documentation is complete and the pharmacist is made aware of the program quit status of the patient. The program evaluation PIN should be submitted on the date the pharmacist is made aware of the program quit status. Once a program evaluation PIN is claimed, no further meetings are billable for the program period.
Only one of the three program evaluation PINs is claimed per patient per year:

<table>
<thead>
<tr>
<th>Outcome</th>
<th>PIN</th>
<th>Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient succeeded in quitting smoking (may be claimed once per year if applicable)</td>
<td>93899944</td>
<td>$0</td>
</tr>
<tr>
<td>Patient did not succeed in quitting smoking (may be claimed once per year if applicable)</td>
<td>93899945</td>
<td>$0</td>
</tr>
<tr>
<td>Patient quit smoking status is unknown (may be claimed once per year if applicable)</td>
<td>93899946</td>
<td>$0</td>
</tr>
</tbody>
</table>

**Claim Validation**

*Each point of contact and/or meeting between the pharmacist and the patient must be documented to ensure program continuity and for the purposes of counselling, support, data analysis, evaluation and claims adjudication.*

*Using the Ministry template forms (refer to Appendix F) as a minimum standard, full documentation is required of all pharmacist/patient engagement including patient readiness, patient consent and agreement terms, first consultation meeting, follow-up counselling sessions and any incidence of program withdrawal.*

*Follow-up meetings may be in-person, by telephone, electronic messaging or other agreed upon method of communication. The method and location of these meetings must be included in the documentation.*

*Smoking cessation documents and associated patient records including any written referrals and patient consent documentation; drug therapy information and desired outcomes / action plans; and specifics on quit smoking plans and advice offered to the patient must be maintained by the pharmacist in a readily retrievable format for inspection purposes.*
Please note for claim validation purposes, in accordance with O. Reg. 264/16 made under the Drug and Pharmacies Regulation Act ("DPRA") if applicable, the documentation must be maintained for the Retention Period.

A copy of the completed smoking cessation training program by the pharmacist must also be readily retrievable at the pharmacy for purposes of an inspection.

Pharmacy records that are associated with the claims submission of professional services using the ODB HNS PIN mechanism are subject to inspection and must be maintained in the pharmacy.

The Ministry may recover funds for claims lacking documentation meeting mandatory requirements.

7.4 Ontario Naloxone Program for Pharmacies

On June 24, 2016, the National Association of Pharmacy Regulatory Authorities (NAPRA) finalized the scheduling change for naloxone hydrochloride injection (naloxone). Naloxone, when indicated for emergency use for opioid overdose outside hospital settings, is now classified as a Schedule II drug in the NAPRA’s National Drug Schedule (NDS).

As a result, effective June 24, 2016, naloxone no longer requires a prescription to be sold in Ontario pharmacies if indicated for emergency use for opioid overdose outside hospital settings. All pharmacies receive reimbursement for providing naloxone emergency kits by submitting claims through the HNS. Effective March 27, 2018, intra-nasal naloxone spray (INNS) (Narcan® Nasal Spray) is publicly funded allowing eligible recipients a choice between injectable naloxone and INNS kits.

If you have any questions, please contact the Ministry by email at PublicDrugPrgrms.moh@ontario.ca or the ODB Help Desk at 1-800-668-6641.

Pharmacy Compliance

A notice from the Executive Officer and the accompanying FAQs constitute a Ministry policy that pharmacy operators must comply with when submitting claims through the HNS for providing naloxone kits. Compliance with the Ministry policy is required under the HNS Subscription Agreement for Pharmacy Operators.
Eligibility

All pharmacies are eligible to provide naloxone injectable or INNS emergency kits, through the Ontario Naloxone Program for Pharmacies (ONPP), at no cost to eligible persons, if certain terms and conditions are met. Criteria for an ‘eligible person’ include:

- A person who is either currently using opioids or is a past opioid user who is at risk of returning to opioid use, or
- A family member, friend or other person in a position to assist a person at risk of overdose from opioids.

Eligible recipients have the choice between injectable naloxone and INNS kits.

Also, effective March 27, 2018, in limited circumstances, pharmacists may:

- Provide naloxone kits to Ontarians who do not have an Ontario Health number or to those who do not wish to provide identification; and
- Provide two naloxone kits to an eligible recipient at one time.

Procedures for Providing and Billing

The Ontario Pharmacists Association (OPA) has developed an online education module and a guidance document for the providing or selling of naloxone available on their website. There may be other resources available to pharmacists. The pharmacist who provides the publicly funded naloxone kit must be identified in the pharmacist field on the claim submitted for payment through the HNS using the appropriate PIN that was provided.

The Ministry does not provide pre-made kits. Pharmacies may procure pre-made naloxone kits or the required supplies to assemble the injectable and INNS kits through usual and/or other local suppliers. All kits shall be assembled by a pharmacist, or a person under the supervision of a pharmacist.

Each injectable naloxone kit must include:

- One hard case (preferred zippered hard black case with red ‘naloxone’ cross);
- Two 1 mL ampoules or vials of naloxone hydrochloride 0.4 mg/mL injection;
Two safety engineered syringes with 25 g one-inch needles attached;

Two safe ampoules opening devices (also known as ‘breakers’, ‘snappers’, or ‘openers’);

One rescue breathing barrier;

One pair of non-latex gloves;

One card that identifies the person trained to give the naloxone; and

One updated instructional insert (English and French).

Each intra-nasal naloxone spray (INNS) kit must include:

- One hard case (preferred zippered hard black case with red ‘naloxone’ cross);
- Two doses of 4mg/0.1mL naloxone hydrochloride intra nasal spray;
- One rescue breathing barrier;
- One pair of non-latex gloves;
- One card that identifies the person trained to give the naloxone; and
- One updated instructional insert (English and French).

The list of items for both kits can be found at:
www.opatoday.com/professional/naloxone_kit_tools

Pharmacies are encouraged to seek out local suppliers for obtaining components required for pharmacy-assembled naloxone kits. Local suppliers are the usual manufacturers, distributors or wholesalers that pharmacies go to procure medications for their pharmacy. For more information, please refer to the Ontario Pharmacists Association website at:
**Pharmacy Eligibility**

All pharmacies that comply with the requirements of this Ministry policy are able to provide emergency naloxone kits, and bill the cost of those kits to the Ministry through the HNS.

Prior to providing naloxone kits to eligible persons, pharmacies must ensure that their pharmacists are trained to provide the necessary training to eligible persons who are to receive the naloxone kits.

**Pharmacy Record Requirements**

Standard record keeping requirements under current standards of practice apply. Pharmacies must keep a record when the naloxone kit (see table below) is provided to the eligible recipient. Pharmacists must keep records consistent with their obligations under the Pharmacy Act, 1991, the Drug and Pharmacies Regulation Act and any guidance (i.e., Documentation Guidelines) provided by the Ontario College of Pharmacists or the Ministry.

For the purposes of claim validation, and in accordance with O. Reg. 264/16 made under the DPRA if applicable, all records must be maintained for the Retention Period.

**Pharmacy Billing Procedure**

Naloxone emergency kits are reimbursed by the Ontario government in accordance with Ministry policy. The PINs listed below are to be used whenever an emergency naloxone kit is supplied to an eligible person, regardless of the person’s eligibility under the ODB program.

**PINs to support reimbursement of Naloxone emergency kits:**

<table>
<thead>
<tr>
<th>PIN</th>
<th>Description</th>
<th>Dosage Form</th>
<th>Total Amount Reimbursed</th>
</tr>
</thead>
<tbody>
<tr>
<td>93877255</td>
<td>Intra-Nasal Naloxone Kit $110 – naloxone kit</td>
<td>Intra-Nasal</td>
<td>$120.00</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Type</td>
<td>Cost</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>93877251</td>
<td>Initial Injectable Naloxone Kit</td>
<td>Injectable</td>
<td>$70.00</td>
</tr>
<tr>
<td></td>
<td>$35 – naloxone kit</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$10 – professional fee</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$25 – training fee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>93877252</td>
<td>Replacement Injectable Naloxone Kit (or initial kit with no training)</td>
<td>Injectable</td>
<td>$45.00</td>
</tr>
<tr>
<td></td>
<td>$35 – naloxone kit</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$10 – professional fee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>93877256</td>
<td>Two Intra-Nasal Naloxone Kits (one professional fee only)</td>
<td>Intra-Nasal</td>
<td>$230.00</td>
</tr>
<tr>
<td></td>
<td>$220 – two naloxone kits</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$10 – professional fee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>93877257</td>
<td>Two Injectable Naloxone Kits (one initial and one replacement kit with one professional fee only)</td>
<td>Injectable</td>
<td>$105.00</td>
</tr>
<tr>
<td></td>
<td>$70 – two naloxone kits</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$10 – professional fee</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$25 – training fee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>93877258</td>
<td>Two Injectable Naloxone Kits (two replacement kits with one professional fee only)</td>
<td>Injectable</td>
<td>$80.00</td>
</tr>
<tr>
<td></td>
<td>$70 – two naloxone kits</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$10 – professional fee</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Claims must be submitted using the Ministry assigned PIN associated with the
naloxone emergency kit and service provided. Do not use the DIN of the naloxone that is contained in the naloxone kit.

**For Ontario Drug Benefit eligible recipients:**

The claim submission follows the normal process for submitting claims on the HNS with the following additional information:

- Intervention code “PS” = Professional Care Services
- PIN: see table above for list of PINs
- Valid Pharmacist ID
- Professional Fee: see table above for ‘Maximum Reimbursed Amount’ for each kit

**For non-Ontario Drug Benefit eligible recipients WITH an Ontario Health number:**

When submitting a claim for an eligible person who does not have ODB coverage, pharmacists must submit the following information:

- Person’s Gender: “F” = female; “M” = male
- Person’s Date of Birth: Valid YYYYMMDD
- Person’s Ontario Health number
- Intervention codes:
  - “PS” = Professional Care Services
  - “ML”: Established eligibility coverage (i.e., 1 day of the Plan ‘S’ coverage)
- Carrier ID: “S”
- PIN: see table above for list of PINs
- Valid Pharmacist ID
- Professional Fee: see table above for ‘Maximum Reimbursed Amount’ for each kit
For non-Ontario Drug Benefit eligible recipients WITHOUT an Ontario Health number:

When submitting a claim for an eligible person who does not have an Ontario Health number, pharmacists must submit the following information:

- First Name: HARM
- Last Name: REDUCTION
- Person’s Gender: “F” = female; “M” = male; (or) Blank
- Person’s Date of Birth: Valid YYYYMMDD (if known) or 20000101
- Proxy patient ID: 89999 999 91
- Intervention codes: PS (Professional Care Services)
- Product Identification Number (PIN)
- Valid Pharmacist ID
- Maximum Reimbursement Amount

Restrictions

In addition to the maximum of two naloxone kits, the recipient must be an eligible person. An eligible person includes:

- A person currently using opioids; and
- Past opioid user at risk of returning to opioid use; and
- Family member, friend or other person in a position to assist at-risk person.

For further information please refer to the following:  

For further information on naloxone and the ONPP, please refer to the EO Notice and FAQs on naloxone posted on the Ministry’s website in August 2016:  
Pharmacy Compliance

As of March 27, 2018, all pharmacies are eligible to provide naloxone kits with intranasal naloxone at no cost to eligible persons, if certain terms and conditions are met.

The Executive Officer’s notice and the accompanying updated FAQs constitute a Ministry policy that pharmacy operators must comply with when submitting claims through the HNS. Compliance with the Ministry policy is required under section 3.2 of the HNS Subscription Agreement for Pharmacy Operators.

Updated Quarterly Report Back Form (QRBF)

Effective December 12, 2022, the Quarterly Report Back Form (QRBF) is no longer required to be submitted by participating pharmacies to the ministry under the Ontario Naloxone Program for Pharmacies (ONPP).

Pharmacies participating in the ONPP can email the ministry at PublicDrugPrgrms.moh@ontario.ca if they have any comments or concerns about the program.

7.5 Reimbursement and Claims Submission using the Health Network System relating to Drugs for Medical Assistance in Dying

Overview

The Executive Officer has issued a notice that provides information to pharmacies regarding reimbursement and claim submissions for drugs used for Medical Assistance in Dying (MAID) using the HNS. This notice is available on the Ministry’s website.

In addition, the CPSO and the OCP have each established MAID policies for their members.

Pharmacists and dispensing physicians must be familiar with the policies provided by their respective professional colleges. The colleges’ policies can be found on their respective websites:
The term “dispensing physician” refers to a physician who has a valid Health Network System (HNS) Subscription Agreement with the ministry and is connected to the HNS.

You can also access the Ministry’s website for more information: www.ontario.ca/page/medical-assistance-dying-and-end-life-decisions or email at endolifedecisions@ontario.ca.

Compliance

The Executive Officer’s notice and the accompanying Frequently Asked Questions constitute a Ministry policy that pharmacy operators and dispensing physicians must comply with when submitting claims through the HNS for dispensing drugs used in MAID. Compliance with the Ministry policy is required under section 3.2 of the HNS Subscription Agreement for pharmacy operators and dispensing physicians (“HNS Agreement”).

Patient Eligibility

Federal legislation governs the provision of MAID. Providers are encouraged to contact their respective regulatory college for more information and guidance about who is eligible to receive MAID.

Individuals in Ontario who are insured persons under the Health Insurance Act and able to receive MAID under federal law are eligible to receive publicly funded drugs for MAID (“eligible persons”).

Procedures for Dispensing and Billing

Pharmacists and dispensing physicians must ensure that the eligible person’s correct date of birth, Ontario Health number (or ODB eligibility number) and name (as it appears on the Ontario Health card or ODB eligibility documentation) are entered accurately as part of the HNS claims submission, as applicable. Failure to do so,
especially for non-ODB eligible persons, may impact the ability to submit future claims for these individuals.

Pharmacies and dispensing physicians will purchase drug(s) and the required supplies to assemble the MAID kits in accordance with Table 1 below.

**Documentation Requirements for MAID drugs**

Standard documentation requirements for prescriptions apply. Pharmacists and dispensing physicians shall keep records consistent with their obligations under, as applicable, the Pharmacy Act, 1991, DPRA, NSAA, *the Medicine Act, 1991*, their HNS Agreement, and any instructions provided by the OCP, the CPSO or the Ministry.

For the purposes of claim validation and in accordance with [O. Reg. 264/16](https://www.e-Laws.ca) made under **DPRA if applicable**, records must be maintained for the Retention Period. Within the context of the definition of Retention Period, dispensing by a dispensing physician is considered a pharmacy service. The definition of Retention Period also applies with modification to non-ODB eligible persons who receive MAID drugs.

**Billing procedure for MAID drugs**

Drugs for MAID provided to eligible persons (based on the regimen prescribed) will be reimbursed by the Ministry. The product identification numbers (PINs) are used for both ODB-eligible and non-ODB eligible persons for the purposes of billing the value of the drugs in Ontario.

**Funded MAID Drug Protocols**

Pharmacists and dispensing physicians should work with prescribers and eligible persons to determine the appropriate MAID drug regimen for individual cases. Prescribers should refer to their regulatory college for guidance regarding the drug protocols for the provision of MAID.

- CPSO: [www cpso on ca](https://www.cpso.on.ca)
- OCP: [www ocpinfo com](https://www.ocpinfo.com)
Table 1: PINs to support reimbursement of MAID kits

<table>
<thead>
<tr>
<th>PIN</th>
<th>Description</th>
<th>Contents in MAID Kit*</th>
<th>Total Amount Reimbursed</th>
</tr>
</thead>
<tbody>
<tr>
<td>93877101</td>
<td>MAID intravenous (IV) Kit with Supplies</td>
<td>Midazolam 1mg/mL</td>
<td>$325.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lidocaine 2% (without epinephrine)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Magnesium sulfate 500mg/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Propofol 10mg/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Citraturia besylate 2mg/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rocuronium bromide 10mg/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sodium chloride (NaCl 0.9%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Syringes and tubes</td>
<td></td>
</tr>
<tr>
<td>93877102</td>
<td>MAID IV Kit (backup) with Supplies</td>
<td>Same as above</td>
<td>$325.00</td>
</tr>
<tr>
<td>93877103</td>
<td>MAID IV Kit with Phenobarbital and Supplies</td>
<td>Midazolam 1mg/mL</td>
<td>$999.00</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Contents</td>
<td>Price</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>93877104</td>
<td>MAID IV Kit (backup) with Phenobarbital and Supplies</td>
<td>Lidocaine 2% (without epinephrine), Magnesium sulfate 500mg/mL, Propofol 10mg/mL, Phenobarbital 120mg/mL, Citraturia besylate 2mg/mL, Rocuronium bromide 10mg/mL, Sodium chloride (NaCl 0.9%), Syringes and tubes</td>
<td>$999.00</td>
</tr>
<tr>
<td>93877105</td>
<td>MAID Self-Administration Kit (Hydromorphone/Morphine)</td>
<td>Metoclopramide 10 mg, Ondansetron 8 mg, Propranolol 40 mg, Morphine sulfate (liquid)</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
Morphine sulfate 30 mg
Hydromorphone 1 mg/mL liquid
Hydromorphone 8 mg

93877110 | MAID Self-Administration Kit (Secobarbital) | Secobarbital 15 g (mixture)
Metoclopramide 10 mg
Dexamethasone 8 mg
Ondansetron 8 mg | $665.00

*Dispensers need to ensure that they select the appropriate quantities, package sizes, and brand of the product from the applicable guidelines and protocols.*

Claims must be submitted using the Ministry-assigned PIN associated with the appropriate MAID kit dispensed. Do not use DINs of the products in each MAID kit.

**Note:** For MAID kits, it is best practice for a primary kit and a back-up kit to be dispensed at the same time for a patient.

- For MAID intravenous (IV) Kits, the back-up kit will have the same drugs as the primary kit. For example, primary is PIN 93877101 and the backup is PIN 93877102.
- For MAID Self-Administered kit, one of the MAID IV (backup) kits may be used (i.e., PIN 93877102, PIN 93877104).

Unused drugs are to be returned to the pharmacy for appropriate disposal.

**For ODB-eligible persons**

The claim submission follows the normal process for submitting claims on the HNS with the following additional information:
• Intervention code ‘PS’: (Professional Care Services)

• PIN: see Table 1 above for list of PINs

• Valid Pharmacist ID

• Professional Fee: Up to the Total Amount Reimbursed

  Note: The Total Amount Reimbursed listed in Table 1 refers to the maximum amount for that MAID kit. Where appropriate, a lower total amount must be claimed in situations where a prescription does not require one (or more) of the drugs or components in a kit. The lower amount claimed is the acquisition cost of the drugs within the kit that are dispensed.

For Non-ODB eligible persons

When submitting a claim for a person who does not have ODB coverage, pharmacists and dispensing physicians must submit the following information:

• Patient Gender: ‘F’ = female; ‘M’ = male

• Patient Date of Birth: Valid YYYYMMDD

• Patient’s Ontario Health number

• Intervention codes:
  
  o “PS”: Professional Care Services

  o “ML”: Established eligibility coverage (i.e., 1 day of the Plan ‘S’ coverage)

  Note: for MAID IV kits (i.e., PIN 93877103 and PIN 93877104) by manual claims:

  o “PS”: Professional Care Services

  o “ML”: Established eligibility coverage (i.e., 1 day of the Plan ‘S’ coverage)

  o “MO”: Valid Claim - value $500.00 to $999.99

• Carrier ID: “S”

• PIN: see Table 1 above for list of PINs
• Valid Pharmacist ID

• Professional Fee: Up to the Total Amount Reimbursed

   Note: The Total Amount Reimbursed listed in Table 1 refers to the maximum amount for that MAID kit. Where appropriate, a lower total amount must be claimed in situations where a prescription does not require one (or more) of the drugs or components in the kit. The lower amount claimed is the acquisition cost of the drugs within the kit that are dispensed.

Restrictions

Only the drugs provided in the MAID kits will be reimbursed, as well as other components such as the syringes and tubes for IV MAID kits (according to Table 1).

7.6 Reimbursement and Claim Submissions for Mifepristone / Misoprostol (Mifegymiso)

Ontario publicly funds the drug Mifegymiso (combination mifepristone/misoprostol) for eligible patients.

Overview

On January 10, 2017, Mifepristone/misoprostol (Mifegymiso) was approved for use in Canada to achieve a medical abortion in early pregnancy (i.e., with a gestational age up to 63 days or within 63 days of last menstrual period).

The medication induces a miscarriage-like process and no surgical intervention is required.

Mifepristone/misoprostol (Mifegymiso) is recognized as a positive step in supporting autonomy for reproductive health, provides an alternative to surgical abortions, and expands access to care.

Mifepristone/misoprostol (Mifegymiso) is manufactured by Linepharma International Limited, and is distributed in Canada by Celopharma Inc.

The OCP has established a guidance document for its members at
In addition, CPSO also has issued a guidance document for its members at www.cpso.on.ca/Physicians/Policies-Guidance/Statements-Positions/Mifegymiso


On May 18, 2017, Health Canada issued a Dear Healthcare Professional Letter to clarify the different requirements and steps to follow in order to prescribe, order, stock, and/or dispense Mifepristone/misoprostol (Mifegymiso). The letter is available at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63330a-eng.php

**Pharmacy Compliance**

The Executive Officer’s notice on Mifepristone/misoprostol (Mifegymiso), available on the Ministry’s website, and the accompanying FAQ constitute a Ministry policy that pharmacy operators must comply with when submitting claims through the HNS for dispensing Mifepristone/misoprostol (Mifegymiso). Compliance with the Ministry policy is required under the HNS Subscription Agreement for Pharmacy Operators.

**Regulatory Guidance**

Pharmacists should work with prescribers and patients to determine the appropriateness of prescribing Mifepristone/misoprostol (Mifegymiso) for individual patients.

Prescribers should refer to their respective regulatory college (i.e., CPSO, CNO) for any guidance and policies regarding the appropriate prescribing and patient monitoring related to Mifepristone/misoprostol (Mifegymiso).

**Patient Eligibility**

All Ontarians with a valid Ontario Health number and a valid prescription are eligible for Mifepristone/misoprostol (Mifegymiso).

This includes ODB recipients and non-ODB recipients.
Procedures for Dispensing and Billing

Pharmacists must ensure the eligible person’s correct date of birth, Health number and name (as it appears on the Ontario Health Card) are entered accurately as part of the HNS claims submission.

Pharmacy Documentation Requirements

Standard documentation requirements for prescriptions apply. Pharmacists shall keep records consistent with their obligations under the Pharmacy Act, 1991, the Drug and Pharmacies Regulation Act, and any further instructions provided by the OCP and the Ministry.

For the purposes of claim validation and in accordance with O. Reg. 264/16 made under the DPRA if applicable, records must be maintained for the Retention Period.

Pharmacy Billing Procedure

Mifepristone/misoprostol (Mifegymiso) supplied to patients with a valid Ontario Health number and a valid prescription will be reimbursed by the Ministry. The DIN is to be used for both ODB-eligible recipients and non-ODB eligible patients for billing purposes.

Pharmacies will be reimbursed for supplying Mifepristone/misoprostol (Mifegymiso) in accordance with the table below.

<table>
<thead>
<tr>
<th>DIN</th>
<th>Description</th>
<th>Total Amount Reimbursed (includes mark-up and dispensing fee)</th>
</tr>
</thead>
<tbody>
<tr>
<td>02444038</td>
<td>Mifepristone/misoprostol (Mifegymiso)</td>
<td>$337.25</td>
</tr>
</tbody>
</table>

Ontario Drug Benefit Eligible Recipients

The claim submission follows the normal process for submitting claims on the HNS with the following additional information:

- Intervention code ‘PS’: (Professional Care Services)
- DIN: 02444038
• Valid Pharmacist ID
• Professional Fee: $337.2500 (includes mark-up and dispensing fee)

**Non-Ontario Drug Benefit Eligible Recipients**

When submitting a claim for a person who does not have ODB coverage, pharmacists must submit the following information:

• Patient Gender: ‘F’ = female; “M” = male
• Patient Date of Birth: Valid YYYYMMDD
• Patient’s Ontario Health number
• Intervention codes:
  o PS: Professional Care Services
  o ML: Established eligibility coverage (i.e., 1 day of the Plan ‘S’ coverage)
• Carrier ID: ‘S’
• DIN: 02444038
• Valid Pharmacist ID
• Professional Fee: $337.2500 (includes mark-up and dispensing fee)

**Restrictions**

Only Mifepristone/misoprostol (Mifegymiso) supplied to an eligible patient with a valid prescription will be reimbursed.
7.7 Funding for Minor Ailment Services in Ontario Pharmacies

As of January 1, 2023, Ontario pharmacists\textsuperscript{12} are authorized to prescribe certain medications for the 13 minor ailments listed below (“minor ailments”), in accordance with the \textit{Pharmacy Act, 1991} and Ontario Regulation 202/94 under that Act.

\textbf{List of Minor Ailments}\textsuperscript{13}

- Allergic rhinitis
- Candidal stomatitis (oral thrush)
- Conjunctivitis (bacterial, allergic or viral)
- Dermatitis (atopic, eczema, allergic or contact)
- Dysmenorrhea
- Gastroesophageal reflux disease (GERD)
- Hemorrhoids
- Herpes labialis (cold sores)
- Impetigo
- Insect bites and urticaria (hives)
- Tick bites, post-exposure prophylaxis to prevent Lyme disease
- Musculoskeletal sprains and strains
- Urinary tract infections (uncomplicated)

\textsuperscript{12} For the purposes of this section, where the term “pharmacist” is used it is inclusive of pharmacy interns and registered pharmacy students, and subject to any terms, conditions, and limitations on their certificates of registration. Where this is not the case, it will be clearly identified.

\textsuperscript{13} The Ontario College of Pharmacists describe minor ailments as health conditions that can be managed with minimal treatment and/or self-care strategies that are usually a short-term condition, where lab results are not usually required, there is a low risk of treatment masking underlying conditions, no medication/medical history red flags that could suggest a more serious condition and only minimal or short-term follow-up required.
The medications that may be prescribed by a pharmacist for the above minor ailments are set out in Schedule 4 to Ontario Regulation 202/94 under the *Pharmacy Act, 1991* (“allowable medication”).

This section and the accompanying Questions and Answers document on the ministry’s website (the Qs & As) set out the terms and conditions for an eligible pharmacy’s submission of claims for payment (claims) for providing a therapeutic assessment regarding the appropriateness of an allowable medication to treat a minor ailment for an eligible person (the “minor ailment services”).

Eligible pharmacies that decide to participate in this publicly funded program must comply with all of the terms and conditions set out in this section and Qs & As.

**General Description**

- There is no cost to eligible persons (see definition in section below) who receive a minor ailment service from an eligible pharmacy (see definition in section below).

- The minor ailment service must be provided in-person at an eligible pharmacy or virtually (including by phone) from the location of the pharmacy. Note that claims for virtual care must follow the requirements provided by the Ontario College of Pharmacists [Virtual Care Policy](#).

- Prescriptions provided by the pharmacist must adhere to Ontario Regulation 202/94 under the *Pharmacy Act, 1991*, as well as the guidelines and requirements provided by the Ontario College of Pharmacists, including the guideline on [Initiating, Adapting and Renewing Prescriptions](#).

- For each valid claim submitted for minor ailment services using one of the Product Identification Numbers (PINs) in Table 1 below, a pharmacy will receive $19 as payment for services provided in-person or $15 for services provided virtually regardless of whether a prescription is issued. The minor ailment services include the following:
  - Obtaining informed consent from the eligible person or the eligible person’s substitute decision maker to provide the minor ailment services (consent may be given verbally or in writing).
o Collecting and reviewing all relevant information about the eligible person to evaluate them and the situation (e.g., history of presenting complaint, person’s health and medication history, etc.).

o Assessing the eligible person to verify the person’s self-diagnosis and identifying the best course of action.

o Determining through a shared decision-making process the appropriate care plan.

o Implementing the care plan which may include issuing a prescription (if applicable) or referring the eligible person to their primary care provider (if any), providing education for the eligible person, documentation, and notification of the eligible person’s primary care provider if an allowable medication is prescribed.

o If applicable, prescription requirements including:
  ▪ Date prescribed
  ▪ Eligible person’s name, address, and date of birth
  ▪ Drug name and strength, directions for use, quantity authorized
  ▪ Pharmacist’s signature / authorization (including registration #)

o Following-up with the eligible person (or their substitute decision-maker) to establish monitoring parameters, evaluate safety and efficacy of the care plan, and additional next steps as required.

• Table 1 lists the PINs to submit claims for providing minor ailment services to eligible persons, including a description of each PIN and any restrictions.

• If a prescription for an allowable medication is issued, the eligible person must be informed that they are permitted to take the prescription to any pharmacy of their choice for dispensing. Where the eligible person decides to have their prescription filled at another pharmacy, the pharmacy/pharmacist that provided the minor ailment services must follow-up with the eligible person as part of the care plan.
Eligible pharmacies

Pharmacies that meet the following criteria (“eligible pharmacies”) are eligible to submit claims for providing minor ailment services for eligible persons:

- Have a valid HNS Subscription Agreement with the ministry
- Ensure that only pharmacists (see definition on page 1) who have completed the Ontario College of Pharmacists’ Mandatory Orientation for Minor Ailments Module and who comply with applicable legislative and OCP requirements provide the minor ailment services.

Eligible pharmacies are strongly encouraged to enrol in one of the provincial clinical viewers (ConnectingOntario or ClinicalConnect) at no cost through Ontario Health. The viewers provide health information about eligible persons, including laboratory test results and dispensed medications that could enhance clinical decision-making and help improve health outcomes. It also provides a history of publicly funded professional services.

Eligible persons

A person who meets the following criteria (“eligible person”) is eligible to receive publicly funded minor ailment services from an eligible pharmacy:

- Has a valid Ontario health number14
- Presents with one of the minor ailments listed in Table 1 below; and
- Is not precluded from receiving minor ailment services based on the claim maximums listed in Table 1 (next page).

---

14 “Ontario health number” means Ontario Health Insurance Plan (OHIP) Card Number or Ontario Drug Benefit (ODB) eligibility number issued by the Ministry of Children, Community and Social Services or by a Home and Community Care Support Service organization for some ODB eligible recipients.
Table 1: PINs to Support Payment of Publicly Funded Minor Ailment Services

The Table below includes claim maximums. When a claim for a minor ailment service fee is submitted, the HNS will look back 365 days from the claim’s date of service to determine whether the maximum number of claims for that particular minor ailment has been exceeded. For example, if a patient receives a minor ailment service at one pharmacy and the pharmacy submits the PIN for “No Rx Issued (In Person)” and the next day, receives another minor ailment service (for the same minor ailment) at another pharmacy and that pharmacy submits the PIN for “Rx Issued (In Person)”, this will count as 2 claims against the maximum number of claims.

• If a claim is submitted to the HNS for a minor ailment service fee that exceeds the maximum number of claims allowed for a particular minor ailment, the claim will be rejected with the response code “LO – Benefit Maximum Exceeded”. No intervention code can be used to override the claim.

Pharmacists must also adhere to the OCP guidelines, appropriate clinical guidance and applicable algorithms for a particular condition when determining whether minor ailment services can be provided and billed to the ministry. This includes identifying situations (also known as “red flags”) where an individual may not have a minor ailment or has signs or symptoms that may not be solely attributed to a minor ailment. Where such “red flags” occur, the individual should be referred to another health care provider. See OCP’s Infographic for an overview for treating minor ailments, including identifying and responding to red flags.

The red flags are also reflected in the claim maximums established for each PIN. The claim maximums are intended to identify situations where an individual may not have a minor ailment or has signs or symptoms that may not be solely attributed to a minor ailment, based on the frequency in which the individual is self-reporting a

15 Primary pharmacy service providers of long-term care (LTC) homes are paid for providing minor ailment services for residents of LTC homes through the LTC home capitation model and will not be paid a minor ailment service fee. Except in emergency situations, secondary pharmacy service providers (i.e., those that do not have a contract with a LTC home) are also not eligible for a service fee for providing minor ailment services for LTC home residents. Pharmacies ineligible to receive a service fee must submit claims for minor ailment services with a zero dollar fee.
minor ailment and receiving minor ailment services from a pharmacy in a year. Where the claim maximum has been met, the pharmacy cannot submit a claim to the HNS for reimbursement for minor ailment services and the pharmacist must exercise their professional judgment in deciding whether to refer the individual to another health care provider, such as a physician or nurse practitioner.

<table>
<thead>
<tr>
<th>Minor Ailment</th>
<th>Maximum number of claims per year(^6)</th>
<th>Rx Issued (In-Person)* Total Amount Paid $19</th>
<th>No Rx Issued (In-Person)** Total Amount Paid $19</th>
<th>Rx Issued (Virtual)*** Total Amount Paid $15</th>
<th>No Rx Issued (Virtual)**** Total Amount Paid $15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic Rhinitis</td>
<td>4</td>
<td>9858181</td>
<td>9858182</td>
<td>9858183</td>
<td>9858184</td>
</tr>
<tr>
<td>Candidal Stomatitis</td>
<td>4</td>
<td>9858185</td>
<td>9858186</td>
<td>9858187</td>
<td>9858188</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>3</td>
<td>9858189</td>
<td>9858190</td>
<td>9858191</td>
<td>9858192</td>
</tr>
<tr>
<td>Dermatitis</td>
<td>4</td>
<td>9858193</td>
<td>9858194</td>
<td>9858195</td>
<td>9858196</td>
</tr>
<tr>
<td>Dysmenorrhea</td>
<td>2</td>
<td>9858197</td>
<td>9858198</td>
<td>9858199</td>
<td>9858200</td>
</tr>
<tr>
<td>GERD</td>
<td>3</td>
<td>9858201</td>
<td>9858202</td>
<td>9858203</td>
<td>9858204</td>
</tr>
<tr>
<td>Hemorrhoids</td>
<td>3</td>
<td>9858205</td>
<td>9858206</td>
<td>9858207</td>
<td>9858208</td>
</tr>
<tr>
<td>Herpes Labialis</td>
<td>8</td>
<td>9858209</td>
<td>9858210</td>
<td>9858211</td>
<td>9858212</td>
</tr>
<tr>
<td>Impetigo</td>
<td>2</td>
<td>9858213</td>
<td>9858214</td>
<td>9858215</td>
<td>9858216</td>
</tr>
<tr>
<td>Insect Bites/Urticaria (cannot be combined with PINs for tick bites on the same day)</td>
<td>8</td>
<td>9858217</td>
<td>9858218</td>
<td>9858219</td>
<td>9858220</td>
</tr>
<tr>
<td>Musculoskeletal Sprains &amp; Strains</td>
<td>4</td>
<td>9858221</td>
<td>9858222</td>
<td>9858223</td>
<td>9858224</td>
</tr>
</tbody>
</table>

\(^6\) The maximum number of claims per year will be based the individual's claim history in the last 365-day period.
Tick Bites (cannot be combined with PINs for insect bites on the same day)  2  9858225  9858226  9858227  9858228

Urinary Tract Infections (uncomplicated)  3  9858229  9858230  9858231  9858232

* Rx Issued (In-Person) refers to minor ailment services provided in-person at the pharmacy for an eligible person that result in a prescription for an allowable medication being issued for the eligible person.

** No Rx Issued (In-Person) refers to minor ailment services provided in-person at the pharmacy for an eligible person that do NOT result in a prescription being issued (e.g., individual needs to be seen by a physician or nurse; or there is a recommendation to provide alternative treatments like non-pharmacological therapies and/or over-the-counter medications).

*** Rx Issued (Virtual) refers to minor ailment services conducted virtually (including by telephone) from the location of the pharmacy for an eligible person that result in a prescription for an allowable medication being issued for the eligible person.

**** No Rx Issued (Virtual) refers to minor ailment services conducted virtually (including by telephone) from the location of the pharmacy for an eligible person that do NOT result in a prescription being issued (e.g., individual needs to be seen by a physician or nurse practitioner; or there is a recommendation to provide alternative treatments like non-pharmacological therapies and/or over-the-counter medications).

Refer to OCP’s Assessment and Prescribing Algorithm for Uncomplicated Urinary Tract Infection (Cystitis) for complicating factors (e.g., male sex, pregnancy, age < 12 years, etc.) that may require referral to a physician or nurse practitioner.
Billing Procedures – Summary

- Claims for providing minor ailment services can only be submitted electronically using the HNS (see “Billing Procedures - Detailed” below). No manual paper claims will be accepted unless 3 intervention codes are required in order to process the claim.

- The Part A pharmacist who provides the minor ailment services or who is supervising a registered pharmacy student or an intern who is providing the service must be identified in the prescriber field on the claim.
  - Prescriber ID Reference must be entered as ‘09’ (not ‘01’ or ‘99’). Any other Prescriber ID Reference code will be rejected with response code “60 – Prescriber License Code Error”.

- Each claim must include the PIN corresponding to the service provided to the eligible recipient (see Table 1 above).

- For clarity, a claim can be submitted for minor ailment services that do not result in the issuance of a prescription for an allowable medication. Please choose the appropriate PIN in Table 1 for this scenario.

- The person submitting the claim on behalf of the pharmacy operator must ensure that the eligible person’s date of birth, Ontario health number and name (as it appears on the health card / document) are included in the claim. Failure to do so – especially for non-Ontario Drug Benefit (ODB) Program recipients – may impact the ability to submit future claims for these persons.

Pharmacy Documentation Requirements

Eligible pharmacies must keep a record of their provision of minor ailment services that result in a claims submission.

Pharmacists shall keep records consistent with their obligations under the Pharmacy Act, 1991, the Drug and Pharmacies Regulation Act, and any instructions or guidelines provided by the OCP or the ministry.

For purposes of post-payment verification, pharmacy records related to claims for minor ailment services must be maintained in a readily available format for the purpose of ministry inspection for a minimum of 10 years from the last recorded
pharmacy service provided to the individual, or until 10 years after the day on which the individual reached or would have reached the age of 18 years, whichever is longer.

Overpayments due to inappropriate claim submissions are subject to recovery.

Pharmacy documentation must be maintained in a readily retrievable format and recordkeeping requirements include the following records:

- Record of name, address, date of birth and Ontario health number of eligible person.

- Record confirming the consent of the eligible person or their substitute decision maker to the minor ailment services (whether such consent was provided verbally or in writing)

- Record of:
  - The minor ailment service including whether a prescription for an allowable medication was issued:
    - If a prescription was issued – a copy of the prescription including but not limited to: date prescribed; eligible person's name, address and date of birth; name, strength (where applicable) and quantity of drug prescribed; directions for use including dose, frequency, route of administration; name, address, telephone number and OCP registration number of pharmacist issuing the prescription
    - If a prescription was not issued – rationale must be provided including whether referral to another health care provider is warranted, that other non-pharmacological therapies and/or over-the-counter medications were recommended
  - The care plan including date and method of notification to the primary care provider (if any) if a prescription is issued
  - The follow-up with the individual including any monitoring parameters or next steps
Billing Procedures – Detailed

Claims submission requirements for minor ailment services are as follows:

For ODB-eligible recipients

The claim submission follows the usual process (See Section 5 of the Ontario Drug Program Reference Manual) for submitting claims on the HNS with the following additional information:

- Intervention code ‘PS’: (Professional Care Services)
- Product Identification Number (PIN): for the applicable minor ailment services provided (see Table 1 above)
- Valid Pharmacist ID
- Professional Fee: see Table 1 above for ‘Total Amount Paid’

For Non-ODB recipients

When submitting a claim for an eligible person who does not have ODB coverage, pharmacists must submit the following information:

- Patient Gender: ‘F’ = female; ‘M’ = male; ‘U’ = unknown
- Patient Date of Birth: Valid YYYYMMDD
- Patient’s Ontario Health Card number*
- Intervention codes:
  - PS: Professional Care Services
  - ML: Established eligibility coverage (i.e., 1 day of the Plan ‘S’ coverage)
- Carrier ID: ‘S’
- Product Identification Number (PIN): for the applicable minor ailment services provided (see Table 1 above)
- Valid Pharmacist ID
- Professional Fee: see Table 1 above for ‘Total Amount Paid’
Exclusions and Restrictions

- Individuals who do not have a valid Ontario health number are not eligible to receive publicly funded minor ailment services.

- Pharmacists cannot conduct minor ailment services for themselves or a family member. See OCP’s policy on Treating Self and Family Members.

- Only one claim for minor ailment services can be submitted by a pharmacy per day per eligible person for a particular minor ailment (e.g., if a minor ailment service is provided and claimed for Urinary Tract Infections (UTIs) by one pharmacy that does not result in a prescription, another minor ailment service for UTI that results in a prescription by the same pharmacy cannot be conducted and claimed on the same day).
  
  o If a second claim is submitted for the same patient, on the same day, from the same pharmacy, for the same minor ailment (using any one of the 4 PINs for that minor ailment), the claim will be rejected with the response code “A3 – Identical Claim Processed”. No intervention code can be used to override the claim.

  o If a second claim is submitted for the same patient, on the same day, from a different pharmacy, for the same minor ailment (using any one of the 4 PINs for that minor ailment), the claim will be accepted with the warning response code “NU – Too Soon After Previous Therapy”. If the pharmacist chooses to provide another minor ailment service for the same condition, there must be proper documentation and rationale as to why it was provided so soon after the previous minor ailment service.

- Claims for the minor ailment service must be submitted electronically using the HNS on the day the service was provided.

- Pharmacies cannot claim a fee for a minor ailment service if the individual does not qualify and/or where they should automatically be referred to another health care provider (e.g., “red flags” like a UTI in pregnancy).

- Minor ailment services for an eligible person who is a resident of a LTC home are paid under the LTC capitation funding model and must be provided by the LTC home’s contracted primary pharmacy service provider. A LTC home
primary pharmacy service provider is not eligible for the fee described in this Notice for providing minor ailment services for a LTC home resident.

- In emergency situations, secondary pharmacy service providers (i.e., those that do not have a contract with a LTC home) are eligible for the professional fee described in this Notice for providing minor ailment services for LTC home residents.

- Pharmacies not eligible for a professional fee must submit claims for minor ailment services with a zero dollar fee. If a dollar amount is submitted as a professional fee on the claim, it will be rejected with the response code "68 – Professional Fee Error". Only secondary pharmacy service providers will be allowed to override the claim with intervention code "LT – LTCH Dispensing Fee Payment for Emergency Rx".

- A professional intervention fee for a Pharmaceutical Opinion Program (POP) service cannot be claimed in relation to a pharmacist prescribing allowable medications for minor ailments.

- A fee for a MedsCheck Follow-Up cannot be claimed in combination with minor ailment services that result in a prescription for an allowable medication.
Section 8: Paper Drug Benefit Claim Submissions and Drug Benefit Claim Reversals

Overview

The HNS is designed to process online transactions for prescriptions dispensed on any of the most recent seven calendar days, including the current date.

If more than seven calendar days have elapsed, the pharmacy must submit their claim for payment manually, provided that the claim for payment meets one of the conditions for submission set out in Section 24 of O. Reg. 201/96 made under ODBA.

For claim reversals, as of April 1, 2020, the submission window for electronic drug benefit claim reversals was extended from seven days to 90 days.

This section outlines specific instructions for submission of a manual claim for payment or claim reversal on paper (“manual claim” or “paper claim”):

- Conditions that require the use of paper Drug Benefit Claim Submission and Drug Benefit Claim Reversal forms (see Section 8.1)
- Features of the Drug Benefit Claim Submission and Drug Benefit Claim Reversal forms (see Section 8.2)
- How to complete the Drug Benefit Claim Submission and Drug Benefit Claim Reversal forms (see Section 8.3)
- Supporting documentation required (see Section 8.4)
8.1 When to Submit Manual Benefit Claim
Submission and Drug Benefit Claim Reversal Forms

Subsection 24(2) of the O. Reg. 201/96 under the ODBA sets out the circumstances under which claims for payment and claim reversals (i.e., claim cancellations) may be submitted to the Ministry via the Drug Benefit Claim Submission or Drug Benefit Claim Reversal forms.

The following claims may be submitted on paper:

- A claim for payment submitted to the Ministry more than seven days after the drug is supplied because proof that the drug is for an eligible person was not provided to the operator of the pharmacy or prescriber who supplied the drug until that time.

- A claim for payment that requires more than two intervention codes as set out in this Reference Manual.

- A claim for payment where the amount claimed is $10,000 or more (see Section 6.4).

- A claim for payment for an extemporaneous preparation where the claimed compounding time is 100 minutes or more.

- A claim reversal that is made more than 90 days after the day the original claim to which the claim reversal relates was submitted.

- A claim for payment that is determined by the Ministry to be eligible for submission following a review by the Ministry or an inspection.

- A claim for payment that is submitted in accordance with subsection 26(3) of O. Reg. 201/96.

Pharmacies are reminded that a manual claim submission due to accidental reversal is not within the allowable circumstances noted above.

If more than 90 days have passed since the original online or paper claim was submitted, a paper claim reversal (i.e., claim cancellation) must be submitted for the following reasons:

- Overpayment has occurred
- A prescription was not picked up
- A claim was submitted in error
- A cancellation is required for another reason

**Paper claim reversals must be submitted as soon as possible after the pharmacy becomes aware of one of these occurrences.**

**Note:** Most paper claims for payment must be submitted within six months of the day on which the service giving rise to the claim was provided as per subsection 24(3) of the O.Reg. 201/96 under the ODBA.

### 8.2 Paper Drug Benefit Claim Submission and Drug Benefit Claim Reversal Forms

To submit a paper claim for payment or claim reversal, the pharmacy must complete a Drug Benefit Claim Submission form or Drug Benefit Claim Reversal form and forward it via fax to:

**Ministry of Health**
**Claims Services Branch**
**Fax: 1-613-237-3246**

The [Drug Benefit Claim Submission and Drug Benefit Reversal forms](https://www.cfrwebsite.com) are available on the [Central Forms Repository](https://www.cfrwebsite.com) website.

**Drug Benefit Claim Submission Forms Fields**

The following tables provide detailed descriptions of Drug Benefit Claim Submission and Drug Benefit Claim Reversal forms fields:

The asterisk (*) indicates optional fields required in certain situations.

<table>
<thead>
<tr>
<th>Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resubmission Number*</td>
<td>Number assigned to rejected claims, as shown on the <a href="https://www.cfrwebsite.com">Reject Report for Paper Submissions</a> (see Section 11.2)</td>
</tr>
</tbody>
</table>
Must be provided (together with the Original Client ID/Code) when resubmitting a previously rejected claim.¹

Reason for Submission

Select one or more of the following:

- More than seven days have elapsed from the date of service, because proof that the drug is for an ODB-eligible person was not available before
- > 2 Intervention/Exception Codes
- >99 minutes compounding time
- Amount being claimed exceeds $9,999.99
- Ministry Authorized Submission

Provider Transaction Date

Date (YYYYMMDD) of service

Provider ID

Unique identification number assigned to the pharmacy also referred to as “Pharmacy I.D.” (see Section 2.1)

Client ID/Code (ODB Eligibility/ Health No.)

Recipient identification number. Note: If Eligibility Number is different, the Health number must be provided. (See Section 4 for more details.)

Version

Ontario Health number version

¹Note: Additional data requirements include Provider Transaction Date, Pharmacy ID, and only the information needed to correct the previously rejected claim.

Claim Submission Information

Client Information:

<table>
<thead>
<tr>
<th>Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Last Name*</td>
<td>Last name of patient</td>
</tr>
<tr>
<td>Field</td>
<td>Explanation</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Patient First Name*</td>
<td>First name of patient</td>
</tr>
<tr>
<td>Middle Initial</td>
<td>Initial of patient’s middle name</td>
</tr>
<tr>
<td>Patient Date of Birth’</td>
<td>Birthdate (YYYYMMDD) of patient</td>
</tr>
<tr>
<td></td>
<td>Must be provided when a photocopy of the Eligibility Card is attached or</td>
</tr>
<tr>
<td></td>
<td>when Carrier ID = H or E is specified (see Eligibility Establishment</td>
</tr>
<tr>
<td></td>
<td>Summary Chart in Section 4.2).</td>
</tr>
<tr>
<td>Sex*</td>
<td>Must be provided when a photocopy of the Eligibility Card is attached or</td>
</tr>
<tr>
<td></td>
<td>when a Carrier ID=H or E is specified (see Eligibility Establishment</td>
</tr>
<tr>
<td></td>
<td>Summary Chart).</td>
</tr>
<tr>
<td>Carrier ID (Plan Code)*</td>
<td>Identifies the appropriate plan code (see Eligibility Establishment</td>
</tr>
<tr>
<td></td>
<td>Summary Chart).</td>
</tr>
<tr>
<td>Group No./Code* (Long Term Care Agency I.D.)</td>
<td>LTC or HSC home number (see LTC and HSC list) must be provided when services</td>
</tr>
<tr>
<td></td>
<td>are rendered to recipients from LTC homes or HSC.</td>
</tr>
</tbody>
</table>

**Prescription Service Information:**

<table>
<thead>
<tr>
<th>Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIN/PIN*</td>
<td>Drug Identification Number or Product Identification Number</td>
</tr>
<tr>
<td>Current Prescription Number*</td>
<td>Unique prescription number</td>
</tr>
<tr>
<td>Quantity*</td>
<td>Quantity dispensed. Field allows one decimal place (e.g., 6 ½ tablets = 00006.5)</td>
</tr>
<tr>
<td>Day(s) Supply*</td>
<td>Number of days supplied by the prescription</td>
</tr>
<tr>
<td>Prescriber ID*</td>
<td>Prescriber license number</td>
</tr>
<tr>
<td><strong>Prescriber ID Ref.</strong></td>
<td>Reference number for prescriber. (see <a href="#">Prescriber ID Reference Chart</a> in <a href="#">Section 5.1</a>)</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Drug Cost/Product Value</strong></td>
<td>Total drug cost</td>
</tr>
<tr>
<td><strong>Cost upcharge</strong></td>
<td>Enter the mark-up amount, 8% when the total drug cost is less than $1,000.00 or 6% when the total drug cost is greater than or equal to $1,000.00. Can be equal to 0.</td>
</tr>
<tr>
<td><strong>Professional Fee</strong></td>
<td>Pharmacist’s fee for professional services (i.e., the lesser of the pharmacist’s usual/customary fee or the current ODB fee). Can be equal to 0.</td>
</tr>
<tr>
<td><strong>Special Service Code/SSC</strong></td>
<td>Enter “U” if submitting a claim for a child/youth 24 years of age and under who does not have a private plan (i.e., OHIP+ eligible). Otherwise, leave blank.</td>
</tr>
<tr>
<td><strong>Product Selection Code</strong></td>
<td>Only required if submitting medically necessary “no substitution” claims. Enter reason code “1” to indicate prescriber directed medically necessary “No Substitution”.</td>
</tr>
<tr>
<td><strong>Unlisted Compound Type</strong></td>
<td>If a DIN (not a Ministry-assigned extemporaneous PIN) is entered for a Formulary benefit product (or EAP approved product), enter the appropriate Compound Type. (see <a href="#">Extemporaneous Preparations Claim Requirements</a> in <a href="#">Section 6.1</a>)</td>
</tr>
<tr>
<td><strong>Compounding Time</strong></td>
<td>Actual time required to mix the ingredients. This does not include weighing, measuring and other dispensing activities.</td>
</tr>
<tr>
<td><strong>Compounding Charge</strong></td>
<td>Total amount billed for compounding the prescription (equal to Compounding Rate x Compounding Time).</td>
</tr>
</tbody>
</table>
| **Medical Reason Ref.** | Use “B” (i.e., ODB reason for use codes), when:  
| | a prescriber has completed and signed the Canada vigilance side effect reporting form for a medically necessary “No Substitution” claim, or  
| | a claim is for a LU prescription for a drug listed as a LU product in the ODBF/CDI.  
| **Medical Condition - Reason for Use** | Use “901” to indicate that a Canada Vigilance Adverse Reaction Reporting Form has been completed and signed by the prescriber.  
| | (Refer to Section 6.2, Medically Necessary “No Substitution” Claims)  
| | For Limited Use claims, use the prescriber’s designation for the applicable RFU code if a LU prescription (copy of prescription with LU documentation) is provided.  
| | (Refer to Section 6.3, Limited Use Products)  
| | (Refer to ODBF/CDI for RFU codes.)  
| **Previously Paid** | Not applicable.  
| **Special Authorization Number (SAN)/Code** | Select the appropriate SAN corresponding to the hospital. Refer to the Ministry’s website for a listing of SAN codes.  
| **Intervention/Exception Codes** | Select the applicable intervention/exception code(s) for the submitted claim from the list of available codes, if necessary.  
| | (Refer to Section 10.2, Intervention/ Exception Code Table)  
| **Pharmacist ID** | Pharmacist license number.  
| | Must be provided, when the Claims Submission Intervention/ Exception Code is supplied.
**Authorized Signature**

Original signature of an individual who has been included in the List of Parties with Signing Authority section on the Application for OPDP Application.

---

**Drug Benefit Claim Reversal Form Fields (pertains to the original paid claim)**

The following table provides detailed descriptions of Drug Benefit Claim Reversal forms fields:

The asterisk (*) indicates optional fields required in certain situations.

<table>
<thead>
<tr>
<th><strong>Fields</strong></th>
<th><strong>Explanation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider I.D. *</td>
<td>Unique identification number assigned to the pharmacy also referred to as “Pharmacy I.D.” (see Section 2.1)</td>
</tr>
<tr>
<td>Number of Pages Submitted (Including this form) *</td>
<td>Total number of Drug Benefit Reversal Form pages being submitted.</td>
</tr>
<tr>
<td>Transaction Date</td>
<td>Date (YYYYMMDD) of service</td>
</tr>
<tr>
<td>Client ID/Code (ODB Eligibility/ Health No.) *</td>
<td>Recipient identification number. Note: If Eligibility Number is different, the Health number must be provided. (See Section 4 for more details.)</td>
</tr>
<tr>
<td>Rx Number *</td>
<td>Prescription number of the claim to be reversed.</td>
</tr>
<tr>
<td>DIN/PIN</td>
<td>Drug Identification Number or Product Identification Number</td>
</tr>
<tr>
<td>Amount Billed to ODB *</td>
<td>Amount paid for the claim to be reversed.</td>
</tr>
<tr>
<td>Total $</td>
<td>Total amount of “Amount Billed to ODB” for all claims submitted for reversal.</td>
</tr>
</tbody>
</table>
Authorized Signature *  

Original signature of an individual who has been included in the List of Parties with Signing Authority section on the OPDP Application.

The Drug Benefit Claim Reversal Form allows users to submit more than one claim reversal at a time, if required. The user may enter up to ten reversal claims on this form or submit a report generated from their pharmacy system for processing multiple reversals along with this form. The pharmacy-generated report must, at a minimum, include the same columns of data as listed on the form.

**8.3 Instructions for Completion of Manual Drug Benefit Claim Submission and Drug Benefit Claim Reversal Forms**

When submitting the details for manual claims, complete the Drug Benefit Claim Submission or Drug Benefit Claim Reversal form based on the following instructions/guidelines:

- Fields marked with an asterisk (*)
  
  - Identify the required fields
  
  - Refer to Section 5 and Section 6 for detailed explanations of the required fields

**Resubmission Number & Original Client ID/Code (Ontario Drug Benefit Eligibility/Health Number)**

When resubmitting a previously rejected claim:

- Use the Resubmission Number from the Reject Report for Paper Submission

- Provide only the Provider Transaction Date, your Pharmacy ID, and the corrected information

When a reversed claim resulting from an inspection is eligible for resubmission:
• Use the Resubmission Number from the Summary Remittance Advice (see Section 11.2) to resubmit the previously reversed claim
• Provide all the required fields, including the corrected information

**Reason for Submission**

• The applicable Reason for Submission must be indicated
• This information is optional if the Resubmission Number is provided to correct a previously rejected or reversed claim

**Intervention/Exception Codes**

• The Drug Benefit Claim Submission Form may require intervention/exception codes when submitting a claim
• Check or select the box corresponding to the applicable intervention/exception code
• This information is required to request special consideration based on special coverage and payment rules (as described in this Reference Manual)

**Authorized Signature**

The form must be signed by an individual who has been included in the List of Parties with Signing Authority section on the original Application for OPDP Application submitted.

**Reconciliation of Manual Claim Submissions and Reversals**

It is the responsibility of the pharmacy to track the status of a manual claim submission. The Ministry is not responsible for providing status updates on manual claims awaiting processing. Refer to Section 11, Reconciliation/Payment for further details regarding reconciliation of ODB payments.

• A Summary Remittance Advice for manual claim submissions/reversals or adjustments processed by the Ministry will be provided to the pharmacy for a payment period, via their O365 email account
Rejected manual claims for payment and reversals will be recorded on a “Reject Report for Paper Submissions”, delivered to the pharmacy via O365 email on the day following the date the paper claim was adjudicated by the Ministry. Pharmacies can use this report to reconcile accounts and correct manual claim submissions and reversals.

If a pharmacy receives confirmation of claim payment through their O365 email account and it does not match the manual submission, the following steps should be undertaken:

- Re-submit the original manual claim noting a keying error by the Ministry
- No reversal form is necessary

**Note:** All manual claim submissions are processed on a “first-in, first-out” basis, to maintain the same service standard for all stakeholders.

The pharmacy is advised to retain a copy of the confirmation record indicating a successful fax submission. Only in cases where the pharmacy receives a failed fax transmission notice, are they advised to resubmit the claim.

Unless advised to do so by the Ministry, re-submitting manual claims that have already previously been submitted to the Claims Services Branch (CSB) may result in delays in processing.

### 8.4 Supporting Documentation for Manual Drug Benefit Claim and Drug Benefit Claim Reversal Forms

The supporting documentation required for a manual Drug Benefit Claim form or Drug Benefit Claim Reversal form is the same as that for a claim submitted through the HNS and includes:

- provide a photocopy of the Drug Benefit Eligibility Card; or
- provide the SAV Portal eligibility result information and SAV helpline confirmation number in the comment section of the form for patients who present their Ontario Health Card or Ontario Health number (see Section 4.2) to establish eligibility for ODSP and OW program recipients; or
• provide a photocopy of a faxed notification provided by an HSP/OHT for Home Care recipients; or

• provide a copy of the Ontario Health Card, or other proof of OHIP eligibility (e.g., a copy of the detachable portion of the Ontario Health Coverage Infant Registration Form) for eligible children and youth who do not have a private plan; or

• provide documentation that eligibility has been confirmed with the Ministry’s Financial Management Branch (FMB) for residents of Homes for Special Care/Community Homes for Opportunity.

• The Carrier ID (Plan Code) is a required field to establish eligibility.

• The Patient Date of Birth and Sex are required fields.

Note: Eligibility will be established for the date of service only.

Comments

Where possible, provide additional information or clarification.

**Standard Claims:**

All submitted paper claims to establish eligibility for payment for Home Care, ODSP or OW recipients must include a photocopy of the Drug Benefit Eligibility Card (see Section 4.2), the patient’s plan code and SAV helpline confirmation number or the faxed notification provided by a LHIN in the comment section of the form for patients who present their Health number.

**Non-Standard Claims:**

Refer to Section 12 for inspections’ documentation requirements.
Section 9: Prospective Drug Utilization Review

Overview

The prospective Drug Utilization Review (DUR) process is a part of the online claims adjudication system. Its primary objective is to monitor new medication/prescription orders for potential drug related problems. It is intended to enhance, not replace, the current principles of pharmacy practice by making supplementary information available to health care professionals.

Prospective DUR involves the analysis of previous prescription/claims data and current prescription data to identify potential drug related problems. Health care professionals may evaluate this information, in consultation with appropriate resources (prescriber, recipient, literature, etc.), to address and resolve the potential drug related problem.

The Ministry does not warrant the accuracy and completeness of the DUR information supplied by the HNS. The information is advisory only and is intended to supplement the current information available to health care professionals. It is not intended to replace professional judgement or individualized patient care and consultation in the delivery of health care services.

This section provides/describes:

- The prospective DUR system design, including its different modules (see Section 9.1)
- DUR response codes (see Section 9.2)
- Applicable intervention codes for DUR response codes (see Section 9.3)
- How prospective DUR operates for:
  - Claim submissions (see Section 9.4)
  - Claim resubmissions (see Section 9.5)
9.1 Overall System Description

When a claim transaction is transmitted to the HNS, the prospective DUR process is initiated upon the validation of recipient eligibility, DIN/PIN and Pharmacy ID.

Through analysis and retrieval of historical and current prescription claims data, the prospective DUR will warn of potential problems with the current prescription. All potential problems are identified by DUR response codes.

The DUR response codes are based on patient medication information submitted on a claim. It is essential that accurate information is provided so that a useful patient profile database can be developed. The patient history is limited to those prescriptions submitted for eligible recipients and drug products eligible under the ODB program.

Four prospective DUR modules are currently available, namely:

- Drug/Drug Interactions
- Double Doctoring
- Multiple Pharmacies (Poly-Pharmacy)
- Fill too soon/Fill too late

**Drug/Drug Interactions**

This module is designed to detect potential drug interactions between the prescription claim being adjudicated and other prescriptions that are considered “active” in the recipient’s historical claims. The module can identify potential interactions for single ingredients and combination products. An “active” drug is determined by the service date of the claim and the days’ supply end date.
System Description

When a claim is submitted for adjudication, the DIN/PIN is compared to the recipient’s historical claims to determine whether there are any interactions. If any interactions are noted, the pharmacy will be advised of the potential problem(s) by the display of DUR Response Codes on the HNS.

Like most drug interaction databases, the DUR system includes a classification system that rates drug/drug interactions based on clinical significance.

The Ministry information is supplied by First DataBank and has been adapted for Canadian content. This database uses three reference sources (Hansten’s Drug Interactions, Facts & Comparisons, and the United States Pharmacopeia - Drug Information (USP DI) and a panel of clinical experts to classify the clinical significance of an interaction. The drug/drug interaction information is kept current through monthly updates.

The clinical significance rating used by First DataBank comprises three levels of significance (or severity). These are shown in the Drug/Drug Interaction Potential table below.

<table>
<thead>
<tr>
<th>Level</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity</td>
<td>Contraindicated Drug Combination</td>
<td>Severe Interaction</td>
<td>Moderate Interaction</td>
</tr>
<tr>
<td>Action</td>
<td>This drug combination is clearly contraindicated in all cases and should not be dispensed or administered to the same patient.</td>
<td>Action to reduce risk of adverse interaction usually required. Assess risk to patient and take action as needed.</td>
<td>Assess risk to patient and take action as needed.</td>
</tr>
<tr>
<td>All interactions (for this level) detected for online claims</td>
<td></td>
<td></td>
<td>Information Message</td>
</tr>
</tbody>
</table>
The priority for transmitting and reporting drug/drug interactions is such that all Severity Level 1 interactions will be transmitted first followed by all Severity Level 2 interactions, and then all Severity Level 3 interactions.

**Multiple Prescribers (Double Doctoring)**

This module is designed to advise of the possibility of a patient obtaining specific drugs that have the potential for abuse (e.g., narcotic analgesics, psychotherapeutic agents, sedatives/hypnotics) through multiple prescribers.

**System Description**

When a claim is submitted for adjudication, the DIN/PIN is compared to each of the recipient’s historical prescriptions. The check is based on the identification of prescriptions for drugs which have the potential for abuse prescribed by a specific number of prescribers over a specific period.

**Multiple Pharmacies (Poly-Pharmacy)**

This module is designed to advise of the possibility of a patient obtaining specific drugs that have the potential for abuse (e.g., narcotic analgesics, psychotherapeutic agents, sedatives and hypnotics) through multiple pharmacies.

**System Description**

When a claim is submitted for adjudication, the DIN/PIN is compared to each of the recipient’s historical prescriptions. The check is based on the identification of prescriptions for drugs which have the potential for abuse dispensed by a specific number of pharmacies over a specific period.

**Fill Too Soon/Too Late**

This module is designed to detect non-compliance consisting of:
• Possible overuse by prescription renewal intervals that show the patient may be taking excessive doses [Fill Too Soon]; or

• Possible underuse by prescription renewal intervals that show the patient may be taking inadequate doses [Fill Too Late].

System Description

When a claim is submitted for adjudication, the DIN/PIN is compared to each of the recipient’s historical prescriptions to determine the elapsed days since the previously submitted claim for the same product and any instances of "Fill Too Soon/Fill Too Late". The check is based on the assumption that the predicted duration of therapy of the recipient’s historical prescriptions is accurate.

There are limitations on the accuracy of the number of days supplied. In addition, there may be other valid reasons for a change in the predicted duration of therapy (e.g., an adjustment in the dose by the prescriber, inconsistent standard dosage measurements that may arise with oral liquids or topical creams).

The HNS will detect instances wherein prescriptions are filled more than 10 days too soon or more than 10 days too late based on the days’ supply of the previously submitted claim for the same product.

9.2 Drug Utilization Review Response Codes

When a potential problem is identified by the HNS, the pharmacy is notified by a DUR response code.

For prospective DUR, a response code may cause the prescription claim to be:

• Rejected with the ability to override the warning with the appropriate intervention code; or

• Approved for payment with information messages.
### Response Code/Message, Potential DUR Problem, Response Status

<table>
<thead>
<tr>
<th>Response Code/Message</th>
<th>Potential DUR Problem</th>
<th>Response Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>ME</td>
<td>Drug/drug interaction potential</td>
<td>Severity Level 1 - Reject Message (with the ability to override)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severity Level 2 - Reject Message (with the ability to override)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severity Level 3 - Information Message</td>
</tr>
<tr>
<td>MH</td>
<td>May be double doctoring</td>
<td>Information Message</td>
</tr>
<tr>
<td>MI</td>
<td>Poly-pharmacy use indicated</td>
<td>Information Message</td>
</tr>
<tr>
<td>D7</td>
<td>Refill too soon</td>
<td>Information Message</td>
</tr>
<tr>
<td>DE</td>
<td>Fill/refill too late</td>
<td>Information Message</td>
</tr>
</tbody>
</table>

Supplementary information related to the drug/drug interactions may be displayed in three message data lines.

Response code "DD" indicates that there are more than 3 drug interactions and there is insufficient space to display the supplementary information for all drug interactions. Information about these drug interactions may be obtained by phoning the ODB Help Desk (see Section 16 Help Desk).

**Reject Message:**
*When a Reject Message appears, the claim has not been approved for payment because a potential DUR problem has been detected. This type of message can be overridden.*

*The pharmacist must investigate the problem and use the applicable intervention code (see Section 9.3) with the Pharmacist ID if resubmitting the claim.*

**Information Message:**
*When an Information Message appears, the claim has been approved for payment but there is a cautionary message that advises that the potential DUR problem should be investigated.*
The pharmacist must reverse the claim if the drug product is not dispensed to the recipient. (Refer to Section 5.2, To Reverse a Standard (or Non-Standard Claim).

**Drug/Drug Interaction**

If a drug/drug interaction is found, the pharmacy will receive the DUR response code "ME", meaning Drug/Drug Interaction potential.

In addition, a DUR response message will also be transmitted. This message will identify the severity level of the interaction, the DIN/PIN and the corresponding brand name for each interacting drug on the patient’s profile.

The priority for transmitting and reporting Drug/Drug Interactions is such that all Severity Level 1 interactions will be transmitted first followed by all Severity Level 2 interactions and then all Severity Level 3 interactions.

For Drug/Drug Interactions, a single message data line will be used for each potential interaction.

The message data line contains:

- Severity code for the potential interaction
- DIN/PIN of historical drug
- Brand name of historical drug (up to the maximum for one message data line).

**For example:** 1--00609013-SOMOPHYLLIN-12

This message text means that a Severity Level 1 (Contraindicated Drug Combination) potential interaction has been identified between the current prescription being claimed and a drug that is on the patient/recipient’s current profile. The interacting drug is identified through the DIN number "00609013" and the brand name of the drug Somophyllin - 12.

*The amount of space in a message data line is limited. Therefore, it may not always be possible to transmit the full name of the drug, based on the length of the drug name. In this case, the full name of the interacting drug may be verified by referring to the ODBF/CDI.*
After receiving the above information, the pharmacist should select an appropriate course of action. This may include, but not be limited to:

- Discussion with the patient to confirm that the patient is still receiving the historical interacting drug, because the drug may have been discontinued or the entry of number of days supplied did not match the actual days supplied. In addition, the pharmacy may verify the dosing regimen and the name of the prescriber. This information may not be available if the interacting drug was dispensed from another pharmacy;

- Reviewing the effect and proposed mechanism of the interaction, clinical documentation substantiating the interaction, and suggested management in a drug interaction reference book;

- Taking steps to intervene in drug therapy when, in the pharmacist’s professional opinion, the therapy prescribed is not in the patient’s best interest. These steps may include contacting the prescriber about the therapy, consulting other health care professionals and/or refusing to fill the prescription.

**Multiple Prescribers (Double Doctoring)**

A multiple prescribers encounter is communicated to the pharmacy with the DUR response code "MH", meaning the patient may be double doctoring.

Upon receipt of this DUR information, the pharmacist would then assess the specific information to select an appropriate course of action. This may include, but not be limited to:

- Entering into discussion with the patient to confirm the dosing regimen, directions for use, or other possible reasons for the “Double Doctoring” encounter;

- Establishing that the prescription is not being obtained through fraudulent means or for abuse purposes;

- Taking steps to intervene in drug therapy when, in the pharmacist’s professional opinion, the therapy prescribed is not in the patient’s or the public’s best interest. These steps may include contacting the prescribers regarding the therapy, consulting other health care professionals, and/or
refusing to fill the prescription. If the prescription is not filled, reverse the claim using the appropriate intervention code.

**Multiple Pharmacies (Poly-Pharmacy)**

A Multiple Pharmacy encounter is communicated to the pharmacy with the DUR response code "MI", meaning poly-pharmacy use indicated.

Upon receipt of this DUR information, the pharmacist would then assess the specific information to decide an appropriate course of action. This may include, but not be limited to:

- Discussion with the patient to confirm the dosing regimen, directions for use, or other possible reasons for the Multiple Pharmacy encounter;
- Establishing that the prescription is not being obtained through fraudulent means or for abuse purposes;
- Taking steps to intervene in drug therapy when, in the pharmacist’s professional opinion, the therapy prescribed is not in the patient’s or the public’s best interest. These steps may include contacting the prescriber regarding the therapy, consulting with other health care professionals and/or refusing to fill the prescription. If the prescription is not filled, reverse the claim using the appropriate intervention code.

**Fill Too Soon/Too Late**

A "Fill too soon" encounter is communicated to the pharmacy with the DUR response code "D7" and a "Fill too late" with the DUR response code "DE".

Upon receipt of this DUR information, the pharmacy would assess the specific information to decide upon an appropriate course of action. This may include, but not be limited to:

- Discussion with the patient to confirm the dosing regimen, directions for use, etc.
- Taking steps to intervene in drug therapy when, in the pharmacist’s professional opinion, the therapy prescribed is not in the patient’s best interest. These steps may include contacting the prescriber regarding the therapy, consulting other health care professionals, and/or refusing to fill the
If the prescription is not filled, reverse the claim using the appropriate intervention code.

9.3 Drug Utilization Review Intervention Codes

Specific intervention codes can be used in response to DUR response codes. An intervention code is required for:

- Reject Messages; or
- Information Messages requiring the reversal of a claim approved for payment.

The pharmacist (based on previous experience with the patient) may sometimes submit a claim with an acceptable intervention code and Pharmacist ID, prior to seeing the DUR response code.

Although this may eliminate the need to respond to a Reject Message, this practice is not encouraged as this could result in other response codes being overlooked or possible claim rejections.
The table on the following page lists the DUR response codes, response status and intervention codes for the DUR modules.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Response Status</th>
<th>Condition Generating Response Code</th>
<th>Intervention Code/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D7</td>
<td>Refill too soon</td>
<td>Information Message</td>
<td>Indicates a refill should not be required at this time. The claim has been approved for payment. The pharmacist may want to ensure that the medication has been taken appropriately and verify if there have been changes to the therapy (e.g., changed dose or directions). However, if the prescription is not filled, reverse the claim using the appropriate intervention code.</td>
<td>UD* = consulted prescriber and changed drug&lt;br&gt;UE* = consulted prescriber and changed quantity&lt;br&gt;UL* = prescription not filled - pharmacist decision&lt;br&gt;UH* = counselled patient. Prescription not filled</td>
</tr>
<tr>
<td>DE</td>
<td>Fill/refill too late</td>
<td>Information Message</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>---------------------</td>
<td>---------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Indicates that a refill is overdue at this time. **The claim has been approved for payment.**
The pharmacist may want to ensure that the recipient is compliant and taking adequate doses.
However, if the prescription is not filled, reverse the claim using the appropriate intervention code. |
| UD* = consulted prescriber and changed drug |
| UE* = consulted prescriber and changed quantity |
| UL* = prescription not filled - pharmacist decision |

<table>
<thead>
<tr>
<th>ME</th>
<th>Drug/drug interaction potential</th>
<th>Severity Level 3 Information Message</th>
</tr>
</thead>
</table>
| Indicates a potential drug/drug interaction between the prescription being filled and one which the recipient is already receiving. **The claim has been approved for payment.**
However, if the prescription is not filled, reverse the claim using the appropriate intervention code. |
<p>| UD* = consulted prescriber and changed drug |
| UL* = prescription not filled - pharmacist decision |</p>
<table>
<thead>
<tr>
<th>ME</th>
<th>Drug/drug interaction potential</th>
<th>Severity Level 1 or 2</th>
<th>Indicates a potential drug/drug interaction between the prescription being filled and one which the recipient is already receiving. The claim has been rejected. However, if the pharmacist should ascertain that the prescription is required, the claim may be processed using the appropriate intervention code.</th>
</tr>
</thead>
<tbody>
<tr>
<td>UA</td>
<td>consulted prescriber and filled prescription as written</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UB</td>
<td>consulted prescriber and changed dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UC</td>
<td>consulted prescriber and changed instructions for use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UF</td>
<td>patient gave adequate explanation. Prescription filled as written</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UG</td>
<td>cautioned patient. Prescription filled as written</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UI</td>
<td>consulted other source. Prescription filled as written</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MH</th>
<th>May be double doctoring</th>
<th>Information Message</th>
<th>Indicates that the recipient may be visiting multiple prescribers to obtain drugs which have the potential to be abused. The claim has been approved for payment. However, if the prescription is not filled, reverse the claim using the</th>
</tr>
</thead>
<tbody>
<tr>
<td>UD*</td>
<td>consulted prescriber and changed drug</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UE*</td>
<td>consulted prescriber and changed quantity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UL*</td>
<td>prescription not filled - pharmacist decision</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MI</td>
<td>Poly-pharmacy use indicated</td>
<td>Information Message</td>
<td>Indicates that the recipient may be visiting multiple pharmacies to obtain drugs which have the potential to be abused. <strong>The claim has been approved for payment.</strong> However, if the prescription is not filled, reverse the claim using the appropriate intervention code.</td>
</tr>
<tr>
<td>----</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
|    |                             |                     | **UD** = consulted prescriber and changed drug  
**UE** = consulted prescriber and changed quantity  
**UL** = prescription not filled - pharmacist decision  
**UH** = counselled patient. Prescription not filled |

The asterisk (*) indicates intervention code is applicable during claim reversal processing only.

It is important for pharmacists to familiarize themselves with these intervention codes. If an incorrect intervention code is used, the transaction will be rejected and must be resubmitted.

### 9.4 Claim Submissions

Once the initial adjudication checks are made, the HNS conducts prospective DUR on every claim.

Based on the previous experience with the patient, the claim may be submitted with an acceptable intervention code and Pharmacist ID before seeing the DUR response. The system will then verify if the intervention code is acceptable for the prospective DUR Override-able Warning.
This may eliminate the need to respond to an Override-able Reject Message, but this practice is not encouraged as this could result in other DUR response codes being overlooked or possible claim rejections.

9.5 Claim Resubmissions

For all claim transactions with a potential Override-able Warning, the HNS will check for the presence of an acceptable intervention code and Pharmacist ID. Claims with unacceptable intervention codes and/or missing Pharmacist ID will be rejected.

9.6 Claim Rejections

If a claim is rejected because of an unacceptable intervention code and/or a missing Pharmacist ID, the claim must be resubmitted.

9.7 Claim Reversals

Interventions that require a change in the prescription (e.g., discontinuation or change of drug) will require a claim reversal (refer to Section 5.2). The pharmacy may reverse the claim with an appropriate Claim Reversal intervention code following an Information Message.

9.8 Help Desk Assistance

Please refer to Section 16.2 for the ODB Help Desk hours of operation to help pharmacies with inquiries about DUR response codes or intervention codes.

ODB Help Desk operators are not pharmacists and are not permitted to enter into any clinical discussions or to recommend an appropriate course of action to be taken.
9.9 Confidentiality

Under the Freedom of Information and Protection of Privacy Act (FIPPA) and PHIPA, all patient information is considered personal.

Therefore, pharmacists are reminded to take all reasonable precautions to ensure this information is treated with the greatest sensitivity and to respect the patient’s privacy when discussing this information with the patient and/or other health care professionals. (Refer to Section 3.1, Privacy of Patient Information).
Section 10: Response and Intervention Codes

Overview

Claim transactions submitted will be validated and processed to determine eligibility. Claim transactions may be approved with information messages or rejected.

This section contains two "Quick Reference" Guides for:

- Interpretation of Response Codes (see Section 10.1)
- Interpretation of the Intervention/Exception Codes (see Section 10.2)

Refer to Section 9, Prospective DUR for more details on how DUR response codes are generated and the use of intervention codes.

10.1 Response Codes Table

Response Code

This column lists the code assigned by the system in response to a particular transaction that may warrant attention.

Message Description

This column provides a brief explanation of the response code.

Field Requirement or Explanation of Condition Generating Response Code

This column identifies the field requirements when the response code shows a field error (i.e., the response code is often an indication that the field requirements have not been met).
### Intervention Code/Description

This column displays all applicable intervention codes for response codes that can be overridden. ODB program payment rules provide the opportunity to override the system decision.

### Table of Response Codes

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
<th>Field Requirement or Explanation of Condition Generating Response Code</th>
<th>Intervention Code/ Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>BIN error</td>
<td>Bank ID Number # 610054 required</td>
<td>N/A</td>
</tr>
<tr>
<td>02</td>
<td>Version number error</td>
<td>Current CPhA Version required</td>
<td>N/A</td>
</tr>
<tr>
<td>03</td>
<td>Transaction code error</td>
<td>Transaction code (01, 11, 30, 31, 32, or 33) required</td>
<td>N/A</td>
</tr>
<tr>
<td>04</td>
<td>Provider software ID error</td>
<td>Pharmacy’s Provider Software ID required</td>
<td>N/A</td>
</tr>
<tr>
<td>05</td>
<td>Provider software version error</td>
<td>Pharmacy’s Provider Software Version required</td>
<td>N/A</td>
</tr>
<tr>
<td>21</td>
<td>Pharmacy ID code error</td>
<td>Pharmacy ID Code required</td>
<td>N/A</td>
</tr>
<tr>
<td>22</td>
<td>Provider transaction date error</td>
<td>Date (YYMMDD) of service required</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Trace number error</td>
<td>A numeric value greater than 0</td>
<td>N/A</td>
</tr>
<tr>
<td>---</td>
<td>-------------------</td>
<td>--------------------------------</td>
<td>-----</td>
</tr>
<tr>
<td>30</td>
<td>Carrier ID error</td>
<td>If Carrier ID is entered, must be a valid Plan Code. Only mandatory if intervention code “MK” or “ML” is applied.</td>
<td>N/A</td>
</tr>
<tr>
<td>31</td>
<td>Group number error</td>
<td>Group Number is mandatory for services provided to an LTC and to override the dispensing fees restriction when dispensed to a resident of an HSC. Refer to <a href="http://www.health.gov.on.ca/en/pro/programs/drugs/">http://www.health.gov.on.ca/en/pro/programs/drugs/</a></td>
<td>N/A</td>
</tr>
<tr>
<td>32</td>
<td>Client ID # error</td>
<td>Invalid format. For intervention code “MJ”, Client ID # will be blank.</td>
<td>&quot;MK&quot; - eligibility established - emergency coverage</td>
</tr>
<tr>
<td>34</td>
<td>Patient date of birth error</td>
<td>YYYYMMDD format. Only mandatory if intervention code “MK” or “ML” is applied.</td>
<td>N/A</td>
</tr>
<tr>
<td>37</td>
<td>Patient first name error</td>
<td>Must match the first initial of the patient on file.</td>
<td>&quot;PB&quot; - name entered is consistent with card</td>
</tr>
<tr>
<td>38</td>
<td>Patient last name error</td>
<td>Must match the last name of the patient on file.</td>
<td>&quot;PB&quot; - name entered is consistent with card</td>
</tr>
<tr>
<td>39</td>
<td>Provincial Health</td>
<td>Invalid Health number format</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>Number</strong></td>
<td><strong>Error</strong></td>
<td><strong>Description</strong></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Patient gender error</td>
<td>May be &quot;M&quot;, &quot;F&quot;, &quot;U&quot;, or blank. &quot;M&quot; or &quot;F&quot; is mandatory if intervention code &quot;ML&quot; or &quot;MK&quot; is applied.</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Medical reason reference error</td>
<td>The Medical Reason Reference field should be blank. If the drug dispensed is a LU product or a medically necessary &quot;No Substitution&quot; prescription claim, this field should contain &quot;B&quot; (i.e., ODB reason for use codes).</td>
<td></td>
</tr>
</tbody>
</table>
| 51 | Medical condition/reason code error | The Medical Condition/Reason for Use field should be blank unless the drug dispensed is a LU product or a medically necessary "No Substitution" prescription claim (No Sub).

When a claim is both LU and No Sub, the LU Reason for Use code supersedes the No Sub code of 901.

This Response Code will not be generated if the drug dispensed is an ODB recognized AIDS treatment drug or an EAP approved benefit. |
<p>| 55 | Current Rx # error | Must be numeric value greater than 0. |
| 56 | DIN/GP#/PIN error | Must be a valid DIN/PIN. |</p>
<table>
<thead>
<tr>
<th></th>
<th>SSC error</th>
<th>SSC code was submitted inappropriately. Must be blank or U.</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>57</td>
<td>Quantity error</td>
<td>Must be a numeric value greater than 0. May not exceed maximum allowed for DIN.</td>
<td>&quot;MQ&quot; = valid claim - quantity over limit</td>
</tr>
<tr>
<td>58</td>
<td>Days’ supply error</td>
<td>Must be a numeric value greater than 0</td>
<td>N/A</td>
</tr>
<tr>
<td>59</td>
<td>Invalid Prescriber ID Reference code</td>
<td>The Prescriber ID Reference field must be &quot;01&quot;, &quot;02&quot;, &quot;03&quot;, &quot;05&quot;, &quot;08&quot;, &quot;09&quot;, &quot;43&quot;, &quot;44&quot;, &quot;N0&quot; or &quot;99&quot; (See <a href="#">Prescriber ID Reference Chart in Section 5.1</a>)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| 60 | Prescriber ID error | This field cannot be blank. For transactions in which the Prescriber ID relates to a prescriber who is retired or deceased or whose licence is suspended, the HNS will also return the following Message Line:  
  • “Prescriber is not active”  
For transactions in which the Prescriber ID relates to a prescriber who has not been registered on the HNS, no Message Line is returned and | "MH" = override - prescriber ID. The use of the MH Intervention Code is based on the professional judgement of the pharmacist. Proper documentation to support the use of the MH Intervention Code must be maintained (e.g., documentation explaining why the prescription is still valid and being |
only response code 61 will appear. dispensed), and is subject to inspection and post-submission verification. Resources are available on the OCP website [here](#).

For prescribers (other than physicians licensed with the College of Physicians and Surgeons of Ontario [CPSO]) who are not registered on the HNS, no Message Line is returned. The claim can be resubmitted with an "MH" intervention code and the proper Prescriber ID and Prescriber ID Reference.

For physicians licensed with the College of Physicians and Surgeons of Ontario (CPSO) who are not registered on the HNS, no intervention code
can be used. Please contact the ODB Pharmacy Help Desk at 1-800-668-6641, and the physician will be added to the HNS, as soon as possible.

<table>
<thead>
<tr>
<th>Code</th>
<th>Error Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>62</td>
<td>Product selection code error</td>
<td>The claim has been rejected because the required information in the Medical Condition/Reason for Use field is missing or incorrect. If the Product Selection code is &quot;1&quot;, the Medical Condition/Reason for Use must be &quot;901&quot;. In the case of medically necessary &quot;No Substitution&quot; for a Limited Use Product, use the RFU code (as listed in the Formulary/CDI which is appropriate for the product) instead of “901&quot;.</td>
</tr>
<tr>
<td>63</td>
<td>Unlisted compound code error</td>
<td>May be blank, or value between 0 and 9 (Refer to Compound Type Codes in Appendix A)</td>
</tr>
<tr>
<td>64</td>
<td>Special authorization number/code error</td>
<td>Must be supplied on initial claims for Vfend.</td>
</tr>
</tbody>
</table>

N/A
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Value Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>65</td>
<td>Intervention / exception code error</td>
<td>Must be a valid and appropriately used intervention/exception code. (Refer to Section 10.2, Intervention/ Exception Code Table)</td>
<td>N/A</td>
</tr>
<tr>
<td>66</td>
<td>Drug cost/produ ct value error</td>
<td>Numeric value greater than or equal to 0</td>
<td>N/A</td>
</tr>
<tr>
<td>67</td>
<td>Cost mark-up error</td>
<td>Numeric value greater than or equal to 0</td>
<td>N/A</td>
</tr>
<tr>
<td>68</td>
<td>Professional fee error</td>
<td>Numeric value greater than or equal to 0</td>
<td>N/A</td>
</tr>
<tr>
<td>70</td>
<td>Compounding charge error</td>
<td>Numeric value greater than or equal to 0</td>
<td>N/A</td>
</tr>
<tr>
<td>71</td>
<td>Compounding time error</td>
<td>Numeric value greater than or equal to 0</td>
<td>N/A</td>
</tr>
<tr>
<td>75</td>
<td>Previously paid error</td>
<td>Numeric value greater than or equal to 0</td>
<td>N/A</td>
</tr>
<tr>
<td>76</td>
<td>Pharmacist ID code error/ missing</td>
<td>This field cannot be blank. A valid Pharmacist ID is required for all ODB and NMS submissions. Response Code 76 will also be received for transactions that include a Pharmacist ID of a pharmacist whose licence is suspended.</td>
<td>N/A</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Details</td>
<td>Resolution</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>87</td>
<td>Exceeds max. # of prof. fees for this drug</td>
<td>Payment of a dispensing fee is limited to a maximum five fees per 365 days for certain chronic-use medications for some ODB recipients. Please refer to “Conditions for Payment of a Dispensing Fee” on the Ministry website.</td>
<td>&quot;UN&quot; = Assessed patient. Therapy is appropriate</td>
</tr>
<tr>
<td>88</td>
<td>Zero dispensing fee 28-Day limit exceeded</td>
<td>Payment of a dispensing fee is limited to a maximum of two dispensing fees per 28-days for some medications for some ODB recipients. Please refer to “Conditions for Payment of a Dispensing Fee” on the Ministry website.</td>
<td>N/A</td>
</tr>
<tr>
<td>90</td>
<td>Adjudication date error</td>
<td>Must be a numeric value (YYMMDD format)</td>
<td>N/A</td>
</tr>
<tr>
<td>91</td>
<td>Beginning record error</td>
<td>Numeric value greater than or equal to 0</td>
<td>N/A</td>
</tr>
<tr>
<td>92</td>
<td>Ending record error</td>
<td>Must be numeric value greater than 0 and greater than beginning record number</td>
<td>N/A</td>
</tr>
<tr>
<td>A1</td>
<td>Claim too old</td>
<td>Transaction date must be less than seven calendar days from current date (e.g., if the current date is October 21, a claim with a transaction date of October 14 will be rejected (response code “A1”); a transaction date of October 15 will be accepted).</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>A2</strong></td>
<td><strong>Claim is post-dated</strong></td>
<td><strong>Transaction date future dated</strong></td>
<td><strong>N/A</strong></td>
</tr>
<tr>
<td><strong>A3</strong></td>
<td><strong>Identical claim processed</strong></td>
<td><strong>Prior claim exists for:</strong></td>
<td><strong>&quot;UA&quot; = consulted prescriber and filled Rx as written</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>&quot;UB&quot; = consulted prescriber, changed dose</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>&quot;UC&quot; = consulted prescriber, changed instructions for use</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>&quot;UE&quot; = consulted prescriber, changed quantity</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>UF = patient gave adequate explanation, Rx filled as written</strong></td>
</tr>
</tbody>
</table>

Transaction date must be less than seven calendar days from claim adjudication date for OLTP. Claims with transaction dates more than seven calendar days and less than six months from the current date may be submitted as a manual claim or claim reversal. (See Section 8.1, When to Submit a Manual Claim or Claim reversal)
<table>
<thead>
<tr>
<th>A7</th>
<th>Submit manual reversal</th>
<th>Reversal transaction submitted more than 90 days from adjudication date must be submitted manually</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>A8</td>
<td>No reversal made/ original claim missing</td>
<td>No claim on file that matches submitted information</td>
<td>N/A</td>
</tr>
<tr>
<td>A9</td>
<td>Reversal processed previously</td>
<td>Claim previously reversed</td>
<td>N/A</td>
</tr>
<tr>
<td>B1</td>
<td>Pharmacy not authorized to submit claims</td>
<td>Pharmacy ID is required. Pharmacy must be registered with MOH for claim submission on date of service.</td>
<td>N/A</td>
</tr>
</tbody>
</table>

"MM" = replacement claim, drug cost only

"MN" = replacement claim due to dosage change

"MR" = replacement claim, item lost or broken

"MV" = vacation supply
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Details</th>
<th>Response Codes</th>
</tr>
</thead>
</table>
| C2   | Service provided before effective date | The patient must have effective coverage in the program. This response code is set if the patient’s program effective date is later than the claim’s date of service. (Refer to Section 4, Eligibility) | "MK" = eligibility established emergency coverage  
"ML" = eligibility established standard coverage |
| C3   | Coverage expired before service | The patient must have effective coverage in the program. This response code is set if the patient’s program expiration date is before the claim’s date of service. (Refer to Section 4, Eligibility) | "MK" = eligibility established emergency coverage  
"ML" = eligibility established standard coverage |
<p>| C8   | No record of this beneficiary | This response code is set when the Client ID # is not found on the patient file. (Refer to Section 4, Eligibility) | &quot;ML&quot; = eligibility established standard coverage |
| CD   | Patient not entitled to drug claimed | Health care item claimed is not a benefit based on the information provided on the claim. | N/A |
| CF   | Quantity exceeds maximum days of treatment | Quantity dispensed exceeds the allowable number of days for the course of treatment. | N/A |
| CG   | Drug not eligible for LTC home | Patients in an LTC home are not normally eligible for benefits supplied by the Ontario Government Pharmaceutical and Medical Supply Service. | N/A |</p>
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>Program not eligible for established eligibility</td>
<td>An eligibility establishment intervention code has been submitted (e.g., “ML”, “MK”) but the patient’s plan is not eligible under eligibility establishment.</td>
</tr>
<tr>
<td>CJ</td>
<td>Patient not covered by this plan</td>
<td>A Plan Code has been provided in the Carrier ID for a program that has no current active record for this patient.</td>
</tr>
<tr>
<td>CK</td>
<td>Health Card version code error</td>
<td>Information Message only.</td>
</tr>
<tr>
<td>CL</td>
<td>Exceeds established eligibility limit</td>
<td>The number of claims eligible under eligibility establishment has been exceeded.</td>
</tr>
<tr>
<td>D2</td>
<td>DIN/GP#/PIN is discontinued</td>
<td>Health care item no longer available as a benefit.</td>
</tr>
<tr>
<td>D3</td>
<td>Prescriber is not authorized</td>
<td>Prescriber ID must be valid and active for date of service. Prescriber ID must not be suspended. (Note: Do not apply override if prescriber privileges have been suspended or restricted)</td>
</tr>
</tbody>
</table>

"MK" = eligibility established emergency coverage
"ML" = eligibility established standard coverage
"MW" = valid reason to exceed eligibility limit
"MH" = override prescriber ID
<table>
<thead>
<tr>
<th>Code</th>
<th>Message</th>
<th>Description</th>
</tr>
</thead>
</table>
| D6   | Maximum cost is exceeded | Claim exceeds $499.99  
"MO" = valid claim value $500 to $999.99  
"MP" = valid claim value $1,000 to $9,999.99 |
| D7   | Fill/Refill too soon | Information Message only.  
Indicates a refill should not be required at this time. The claim has been approved for payment. The pharmacist may want to ensure that the medication is being taken appropriately and verify if there have been any changes to the therapy (e.g., changed dose or directions). However, if the Rx is not filled, reverse the claim using the appropriate intervention code.  
(Refer to Section 9, Prospective DUR)  
"UD"* = consulted prescriber changed drug  
"UE"* = consulted prescriber changed quantity  
"UL"* = prescription not filled, pharmacist decision  
"UH"* = counselled patient. Rx not filled |
| D8   | Reduced to generic cost | Information Message only.  
Drug cost reduced (e.g., reduced to the cost for generic drug and/or ODB list price).  
N/A |
| DD   | Insufficient space for all DUR warnings | Information Message only.  
There is insufficient space for all DUR messages. Additional messages are available by  
N/A |
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Message</th>
<th>Intervention Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>Fill/refill too late non-compliant</td>
<td>Information Message only. Indicates that a refill is overdue at this time. The claim has been approved for payment. The pharmacist may want to ensure that the recipient is compliant and taking adequate doses. However, if the Rx is not filled, reverse the claim using the appropriate intervention code. (Refer to Section 9, Prospective DUR)</td>
<td>&quot;UD&quot;* = consulted prescriber and changed drug&lt;br&gt;&quot;UE&quot;* = consulted prescriber and changed quantity&lt;br&gt;&quot;UL&quot;* = prescription not filled, pharmacist decision</td>
</tr>
<tr>
<td>DF</td>
<td>Insufficient space for all warnings</td>
<td>Information Message only. There is insufficient space for all response codes. Additional response codes are available by calling the ODB Help Desk within days of the transaction.</td>
<td>N/A</td>
</tr>
<tr>
<td>DG</td>
<td>Duplicate prescription number</td>
<td>Prior claim exists for: same pharmacy same date of service same prescription number Prescription number must be unique for each dispensing.</td>
<td>N/A</td>
</tr>
<tr>
<td>DZ</td>
<td>Days’ supply limited due</td>
<td>The claim has been rejected because the days’ supply has been exceeded for a recipient of the Trillium Drug Program.</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Trillium recipients are entitled to the lesser of a 100-day supply or a quantity sufficient to extend up to 30 days after the end of the Trillium eligibility period (e.g., in July, a quantity sufficient to last until August 30 will be covered).

This response code is accompanied by a message indicating the maximum allowed days’ supply for the date of service indicated on the claim.

<table>
<thead>
<tr>
<th>Error Code</th>
<th>Description</th>
<th>Message</th>
</tr>
</thead>
<tbody>
<tr>
<td>E1</td>
<td>Host processing error</td>
<td>System Error. Contact the ODB Help Desk. (Refer to Section 16, Help Desk)</td>
</tr>
<tr>
<td>E8</td>
<td>Patient must remit cash receipt to Trillium</td>
<td>The claim has been rejected because the Trillium recipient has previously indicated to the Ministry that he/she has private insurance coverage in effect on the date of service indicated on the claim. The recipient must submit the receipt to their private insurer and then submit the insurance statement from the private insurer along with a copy of the receipt to the Trillium Drug Program. A receipt which indicates the amount previously paid by a private insurer through electronic claims submission is also acceptable.</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Reason for Rejection</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>EG</td>
<td>No Record of Trying 1st Line Therapy</td>
<td>The claim has been rejected because the required smoking cessation program first consultation assessment or primary follow up counselling is missing</td>
</tr>
<tr>
<td>EL</td>
<td>Prior to pro-rated start date</td>
<td>The claim has been rejected because the date of service is earlier than the enrolment start date indicated by the household on the Trillium Drug Program application form.</td>
</tr>
<tr>
<td>EM</td>
<td>ODB pricing - TDP deductible reached</td>
<td><strong>Information Message only.</strong> The claim caused a Trillium quarterly or annual deductible to be reached, therefore, the reimbursement amount has been reduced according to ODB payment rules.</td>
</tr>
<tr>
<td>FX</td>
<td>Possible Forgery-Check authenticity</td>
<td>Indicates that the ODB program has been made aware of alleged forgeries for specific drugs (mostly monitored drugs) and/or stolen prescription pads (Refer to <a href="#">Section 13</a>)</td>
</tr>
</tbody>
</table>
| KG   | Authorisation refills exceeded | This claim has been rejected because it exceeds claim count limits over period.  
Note: currently used for Xarelto and Eliquis to limit reimbursement to 1 claim in a 120-day period. | "VE" = treatment of acute condition  
Note: Only for use under RFU code 433 or 434 (e.g., for surgery of opposite knee/hip) |
<table>
<thead>
<tr>
<th>KT</th>
<th>Assess Recipient SDP eligibility</th>
<th>As per the “Special Drugs Program”, if the recipient does not have coverage established yet, this informs the dispensing pharmacy. Note: There are only a small set of pharmacies authorized to submit claims through the Special Drugs Program.</th>
<th>&quot;NC&quot; = patient SDP eligibility confirmed</th>
</tr>
</thead>
<tbody>
<tr>
<td>LN</td>
<td>Check potential benefit criteria</td>
<td>Initial claim for Vfend drug products must establish a Limited Use Authorization.</td>
<td>&quot;LU&quot; = start new LU authorization</td>
</tr>
<tr>
<td>LO</td>
<td>Benefits maximum exceeded</td>
<td>This claim has been rejected because benefits maximum exceeded. For example, when a second annual MedsCheck claim is received within 12 months.</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| ME | Drug/drug interaction potential | **Severity Level 1 or 2**  

**Overrideable Warning.**  
Indicates a potential drug/drug interaction between the prescription being filled and one which the recipient is already receiving. The claim has been rejected. However, if the pharmacist should ascertain that the prescription is required, the claim may be processed using | "UA" = consulted prescriber and filled Rx as written  
"UB" = consulted prescriber and changed dose  
"UC" = consulted prescriber and changed instructions for use  
"UF" = patient gave adequate |
<table>
<thead>
<tr>
<th>ME</th>
<th><strong>Drug/drug interaction potential</strong></th>
<th><strong>Severity Level 3</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Information Message only.</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Indicates a potential drug/drug interaction between the prescription being filled and one which the recipient is already receiving. The claim has been approved for payment. However, if the prescription is not filled, reverse the claim using the appropriate intervention code.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>U”D“”</strong> = consulted prescriber and changed drug</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>U”L“”</strong> = prescription not filled - pharmacist decision</td>
<td></td>
</tr>
<tr>
<td>MH</td>
<td><strong>May be double doctoring</strong></td>
<td><strong>Information Message only.</strong></td>
</tr>
<tr>
<td></td>
<td>Indicates that the recipient may be visiting multiple prescribers to obtain drugs which have a potential to be abused. The claim has been approved for payment.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>U”D“”</strong> = consulted prescriber and changed drug</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**U”E“” = consulted prescriber and changed quantity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**U”L“” = prescription not filled - pharmacist decision</td>
<td></td>
</tr>
<tr>
<td><strong>MI</strong></td>
<td>Poly-pharmacy use indicated</td>
<td>Information Message only. Indicates that the recipient may be visiting multiple pharmacies to obtain drugs which have a potential to be abused. <strong>The claim has been approved for payment.</strong> However, if the prescription is not filled, reverse the claim using the appropriate intervention code.</td>
</tr>
<tr>
<td><strong>MY</strong></td>
<td>Duplicate drug other pharmacy</td>
<td>Prior claim exists for: same patient same DIN/PIN or interchangeable product same date of service different pharmacy</td>
</tr>
</tbody>
</table>

“UH”* = counselled patient. Rx not filled

“UD”* = consulted prescriber and changed drug

“UE”* = consulted prescriber and changed quantity

“UL”* = prescription not filled - pharmacist decision

“UH”* = counselled patient. Rx not filled
<table>
<thead>
<tr>
<th>OC</th>
<th>Quantity Reduction Required</th>
<th>An initial prescription that previously was rejected with response code (OF = Initial Rx Days' Supply exceeded) was resubmitted with a reduced Days' supply, but the corresponding quantity was not reduced accordingly.</th>
</tr>
</thead>
<tbody>
<tr>
<td>OF</td>
<td>Initial Rx Days' Supply Exceeded</td>
<td>An initial prescription for a drug product must not exceed 30 days' supply.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>&quot;NF&quot;</strong> = Override - Quantity Appropriate</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>&quot;NH&quot;</strong> = Initial Rx Program Declined</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Reason</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>--------</td>
</tr>
<tr>
<td>OI</td>
<td>Claim precedes start of current period</td>
<td>The dispense date of the claim precedes the start of an already recorded treatment period.</td>
</tr>
<tr>
<td>PC</td>
<td>Not a benefit for this prescriber type</td>
<td>This claim has been rejected because the drug product is not an ODB benefit for this prescriber type.</td>
</tr>
<tr>
<td>PM</td>
<td>No Private Insurance Attestation Missing</td>
<td>The claim has been rejected for a child/youth 24 years of age and under as the Special Service Code (SSC) “U” is missing. Confirm that the recipient does not have a private plan and resubmit with SSC “U”. If the recipient has a private plan, do not submit claim to the HNS.</td>
</tr>
<tr>
<td>QM</td>
<td>No record of required prior therapy</td>
<td>N/A</td>
</tr>
<tr>
<td>QN</td>
<td>Agency restriction for this drug</td>
<td>Special Drugs can only be dispensed by an authorized pharmacy.</td>
</tr>
<tr>
<td>ZR</td>
<td>Submit receipt to TDP or Attest to No PI</td>
<td>The claim has been rejected for a child/youth 24 years of age and under because the recipient has TDP coverage. Verify private plan status. If the recipient does</td>
</tr>
</tbody>
</table>
not have a private plan, resubmit the claim with SSC "U". Or if the recipient has a private plan, submit the claim to the private plan and advise recipient to submit private plan information and receipts for out-of-pocket expenses to TDP.

The asterisk (*) indicates intervention code is applicable during claim reversal processing only.

10.2 Intervention/Exception Codes Table

Intervention/exception codes are required to be submitted on some claims to facilitate proper adjudication and payment. Generally, they indicate that some assessment or additional review has been performed, and a claim that would otherwise be rejected, should be paid. Rules applicable to the use of intervention/exception codes are described in other sections of the Manual, as follows:

Section 4.2, Policy for Establishing Eligibility for Payment

Section 6, Submit Non-Standard Online Claims

Section 9.3, DUR Intervention Codes

Note: The Pharmacist ID is mandatory (unless the dispenser is a physician) when intervention/exception codes are applied. An intervention/exception code error will be generated if the system determines that the code applied was not necessary.

Only two intervention/exception codes will be accepted against a single transaction. If more than two intervention/exception codes are necessary, then claims must be submitted manually. See Section 8, Manual Drug Benefit Claim Submission and Drug Benefit Claim Reversals.

The following table lists all of the intervention/exception codes. See Section 9.3 for full descriptions.
### Table of All Intervention/Exception Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>LT</td>
<td>Payment of dispensing fee for secondary pharmacy service provider for providing emergency/additional prescription to long-term care home recipient. Also used for submitting Pharmaceutical Opinion Program claim for long-term care home recipient by secondary pharmacy service provider.</td>
</tr>
<tr>
<td>LU</td>
<td>Start new LU authorization</td>
</tr>
<tr>
<td>MG</td>
<td>Override - Clinical Reasons - Clinical various reasons</td>
</tr>
<tr>
<td>MH</td>
<td>Override - Prescriber ID (Note: If practitioner prescribing privileges have been suspended or restricted, the override should not be applied.)</td>
</tr>
<tr>
<td>MI</td>
<td>No interchangeable available at less than or equal to Drug Benefit Price plus allowable mark-up (i.e., copies of supplier invoices which demonstrate that the lowest-priced interchangeable product had been ordered and unavailable during the appropriate time period must be kept on file for claim validation)</td>
</tr>
<tr>
<td>MJ</td>
<td>Government pharmacy authorized claim</td>
</tr>
<tr>
<td>MK</td>
<td>Eligibility established - Emergency coverage</td>
</tr>
<tr>
<td>ML</td>
<td>Eligibility established - Standard coverage</td>
</tr>
<tr>
<td>MM</td>
<td>Replacement claim, drug cost only</td>
</tr>
<tr>
<td>MN</td>
<td>Replacement claim due to dosage change</td>
</tr>
<tr>
<td>MO</td>
<td>Valid claim - value of $500.00 to $999.99</td>
</tr>
<tr>
<td>MP</td>
<td>Valid claim - value of $1,000.00 to $9,999.99</td>
</tr>
<tr>
<td>MQ</td>
<td>Valid claim - quantity over limit</td>
</tr>
<tr>
<td>MR</td>
<td>Replacement, item lost or broken</td>
</tr>
<tr>
<td>MV</td>
<td>Vacation supply</td>
</tr>
<tr>
<td>MW</td>
<td>Valid reason to exceed established eligibility limit</td>
</tr>
<tr>
<td>NC</td>
<td>Patient SDP eligibility confirmed</td>
</tr>
<tr>
<td>NF</td>
<td>Override - Quantity Appropriate</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>NH</td>
<td>Initial Rx Program Declined</td>
</tr>
<tr>
<td>PB</td>
<td>Name entered is consistent with card</td>
</tr>
<tr>
<td>PS</td>
<td>Professional Care Service</td>
</tr>
<tr>
<td>UA</td>
<td>Consulted prescriber and filled Rx as written</td>
</tr>
<tr>
<td>UB</td>
<td>Consulted prescriber and changed dose</td>
</tr>
<tr>
<td>UC</td>
<td>Consulted prescriber and changed instructions for use</td>
</tr>
<tr>
<td>UD*</td>
<td>Consulted prescriber and changed drug</td>
</tr>
<tr>
<td>UE*</td>
<td>Consulted prescriber and changed quantity</td>
</tr>
<tr>
<td>UF</td>
<td>Patient gave adequate explanation. Rx filled as written</td>
</tr>
<tr>
<td>UG</td>
<td>Cautioned patient. Rx filled as written</td>
</tr>
<tr>
<td>UH*</td>
<td>Counseled patient. Rx not filled</td>
</tr>
<tr>
<td>UI</td>
<td>Consulted other source. Rx filled as written</td>
</tr>
<tr>
<td>UL*</td>
<td>Prescription not filled - pharmacist decision</td>
</tr>
<tr>
<td>UN</td>
<td>Assessed patient, therapy is appropriate</td>
</tr>
<tr>
<td>VE</td>
<td>Treatment of acute condition</td>
</tr>
</tbody>
</table>

*Used during claim reversal processing only.*
Section 11: Reconciliation/Payment

Overview

This section explains:

- Payment procedures for online claims/reversals processed by pharmacies (see Section 11.1)
- Payment procedures for manual claims/reversals processed by the Ministry (see Section 11.2)
- Reconciliation of remittance statements by the Ministry (see Section 11.3)
- Payment scheduling (see Section 11.4)
- Registering for direct deposit (see Section 11.5)

11.1 Payment Information for Online Claims/Reversals

Pharmacies should extract payment information for online claims/reversals daily.

Procedures for requesting this payment information are described within Section 5, Submit Standard Online Claims.

The following payment information is available for any one of the most current seven days:

<table>
<thead>
<tr>
<th>Payment Information</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily Totals*</td>
<td>Accumulated payment amount for a specific day (see Section 5.4, To Request Daily Totals)</td>
</tr>
<tr>
<td>Claim Details</td>
<td>Details of claims processed for a specific day (see Section 5.5, To Request Claim Details)</td>
</tr>
</tbody>
</table>
Same Day Reversal Details, or Prior Day Reversal Details

Details of claims reversed for the specified day (see Section 5.6, To Request Same Day Reversal Details or Section 5.7, To Request Prior Day Reversal Details)

*Pharmacies must request and reconcile claim totals on a daily basis.

**Note:** After seven days, this payment information will not be available.

Keep records of this information to reconcile with ODB program payments (issued twice a month).

No Summary Remittance Advice is produced for online claims/reversals. Only when the Ministry processes manual claims/reversals or adjustments for a pharmacy or a pharmacy begins a payment period with a negative balance, a Summary Remittance Advice will be produced for the payment period and will be delivered to the pharmacy’s O365 email account.

### 11.2 Payment & Drug Utilization Review Information for Manual Drug Benefit Claim Submissions and Drug Benefit Claim Reversals

For manual claims for payment or claim reversals adjudicated by the Ministry, the following payment information will be sent directly via email to the pharmacy’s O365 email account:

<table>
<thead>
<tr>
<th>Payment Information</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary Remittance Advice</td>
<td>Approved manual claims and claim reversals, and adjustments for a payment period</td>
</tr>
<tr>
<td>Reject Report for Manual Submissions</td>
<td>Rejected manual claims and claim reversals</td>
</tr>
<tr>
<td>DUR Responses for Manual Submissions</td>
<td>Prospective DUR responses</td>
</tr>
</tbody>
</table>
Refer to Section 14, Electronic Mail, for specific instructions on how to retrieve email messages from the HNS.

When a pharmacy ceases to operate, the payment method will revert to cheque. The Summary Remittance Advice will be mailed with the final cheque payment(s). Any remaining Reject Reports for Manual Submissions will be mailed separately.

**Summary Remittance Advice**

**Note:** The Summary Remittance Advice will only be produced when one or more of the following occur during the payment period:

- Manual drug benefit claims and drug benefit claim reversals are processed by the Ministry;
- The Ministry posts an adjustment to the pharmacy’s account (e.g., due to an inspection);
- The pharmacy’s account is at a negative balance at the beginning or end of the payment period.

The Summary Remittance Advice is produced twice a month and delivered to pharmacies via their O365 email account. Pharmacies are reminded that under the terms of the HNS Subscription Agreement, they are required to log on to the O365 email at least once per week.

The Summary Remittance Advice may include the following information, if applicable:

- Totals for online transactions for the same payment cycle
- Details of approved manual drug benefit claim submissions and drug benefit claim reversals processed by the Ministry
- Adjustments against previously paid claims and recoveries, as well as the Adjustment/Reason Type Code (see table below)
- Transaction Codes (see Transaction Code table below)
- Response status of the claim transaction such as:
If the Summary Remittance Advice shows that the pharmacy has been in a negative balance for a period of more than 30 days, a notification letter will be sent to the pharmacy requesting payment for the balance owing.

The pharmacy will be required to send a cheque payable to the “Minister of Finance” for the outstanding amount to:

Ministry of Health
Financial Management Branch
49 Place d’Armes, 2nd Floor
Kingston, ON
K7L 5J3

Summary Remittance Advice Sample
# Adjustment/Reason Type Codes

<table>
<thead>
<tr>
<th>Reason/ Adjustment Type Code</th>
<th>Description</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>02</td>
<td>Supporting Documentation</td>
<td>The payment of certain claims, such as medically necessary “No Substitution”, Limited Use, Nutrition Products and establishing eligibility, is conditional upon the pharmacy producing the required supporting documentation at the Ministry’s request.</td>
</tr>
<tr>
<td>03</td>
<td>Inspection Recovery</td>
<td>Payments are recoverable by the Ministry when inspection results reveal a violation of a specific section of the ODBA, <a href="https://www.ontario.ca/document/106919">O. Reg. 201/96</a> or the pharmacy’s HNS Subscription Agreement. Claim has been adjusted or reversed.</td>
</tr>
<tr>
<td>04</td>
<td>Retroactive Drug Cost</td>
<td>The Ministry may from time to time modify drug costs which may require adjustment at the agency or claim levels.</td>
</tr>
<tr>
<td>05</td>
<td>Negative Balance Recovery</td>
<td>Credits will be applied to pharmacies in negative balance situations when they make a direct payment to the Ministry.</td>
</tr>
<tr>
<td>06</td>
<td>Retroactive Fee</td>
<td>The Ministry may from time to time modify dispensing fees which may require adjustment at the agency or claim levels.</td>
</tr>
<tr>
<td>07</td>
<td>Miscellaneous Adjustment</td>
<td>This code is used in exceptional circumstances where an adjustment is not directly attributable to one of the other existing Adjustment/Reason Type Codes.</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Details</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>08</td>
<td>Ministry Correction</td>
<td>This code indicates the reversal of an earlier incorrect Agency Adjustment transaction.</td>
</tr>
<tr>
<td>10</td>
<td>Subject to Ministry Review</td>
<td>The Ministry reserves the right to adjust claim amounts, pending further review.</td>
</tr>
<tr>
<td>11</td>
<td>Pharmacy Initiated Reversal</td>
<td>This code denotes a pharmacy-initiated On-Line Transaction Processing (OLTP) claim reversal or a manual claim reversal.</td>
</tr>
<tr>
<td>12</td>
<td>Ministry Correction</td>
<td>This code is used to correct a manual claim that was inadvertently reversed or adjudicated.</td>
</tr>
<tr>
<td>13</td>
<td>Methadone Capitation Payment</td>
<td>This code is used to identify methadone capitation payments to pharmacies that have entered into a Capitation Agreement with the Ministry for the supply of methadone to ODB-eligible recipients.</td>
</tr>
<tr>
<td>15</td>
<td>Eligible for Resubmission</td>
<td>A Drug Benefit Claim or Drug Benefit Claim Reversal form may be submitted, indicating the Resubmission Number, the original ODB number (in the Original Client ID/Code field), and the appropriate changes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Patient First Name, Patient Last Name, Client ID/Code and Version, Provider Transaction Date, Patient Date of Birth, Sex, and Pharmacy ID cannot be altered.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In order for the resubmission to be accepted, the amount payable must be less than the original claim.</td>
</tr>
</tbody>
</table>
16
Not Eligible for Resubmission
This claim is not eligible for resubmission.

17
Eligible for New Claim Submission
A Drug Benefit Claim or Drug Benefit Claim Reversal form may be submitted, indicating the Resubmission Number, the original ODB number (in the Original Client ID/Code field), and the appropriate changes.

Either the ODB number (in the Client ID/Code field) or date of service (in the Provider Transaction Date) must be altered.

22
Transition payment
Additional dispensing fee over and above standard dispensing fee.

Rejected Claims
Rejected manual claims for payment and claim reversals will be recorded on a ‘Reject Report for Manual Submissions’ and will be delivered to the pharmacy via email on the next business day.

Transaction Codes

<table>
<thead>
<tr>
<th>Transaction Code</th>
<th>Purpose of Transaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2</td>
<td>Ministry-initiated Batch Adjustment</td>
</tr>
<tr>
<td>A4</td>
<td>Ministry-initiated Agency Adjustment</td>
</tr>
<tr>
<td>D1</td>
<td>Claim level adjustment - Online claim</td>
</tr>
<tr>
<td>D2</td>
<td>Claim level adjustment - Manual claim</td>
</tr>
<tr>
<td>M1</td>
<td>Manual claim submission</td>
</tr>
<tr>
<td>M2</td>
<td>Manual claim reversal submission</td>
</tr>
</tbody>
</table>
Reject Report for Manual Submissions

The Reject Report for Manual Submissions will:

- List claim transactions that have been rejected
- State the reason for the rejection

**Note:** The Reject Report for Manual Submissions will be generated nightly by the Health Network System. It will be available to pharmacies via email on the day following the date the paper claim was adjudicated by the Ministry (refer to Section 14, Electronic Mail).

Pharmacies can use this report to reconcile accounts and correct manual claim submissions and claim reversals. The resubmission of rejected manual claims may be expedited by using the Resubmission Number shown on the Reject Report for Manual Submission (refer to Section 8.2, Manual Drug Benefit Claim Submission and Drug Benefit Claim Reversal Forms).

Sample Reject Report for Manual Submissions

Run Date: DEC 13, 2014   ODB - REJECT REPORT
Adj Date: DEC 12, 2014   FOR PAPER SUBMISSIONS

Dispense Dt: YYYY-MM-DD   Pharm ID: ON12345678   Resub No: 123456789
Client ID/Ver: XXXXXXXXXX XX
First Name: XXXXXXXXXXXX   Last Name: XXXXXXXXXXXXXXX
Birth: XXXX-XX-XX
Sex: X   Carrier ID:   Group No:
Health No: XXXXXXXXXXXXX DIN/GP #:   Curr RX: 1234567
Quantity:   Days Supp:
Presc ID: XXXXXXXXXX   Presc Ref: XX
Drug Cost:   Cost Upchg:   Prof Fee:
SSC:   Prod Sel:   Unl Comp:
Comp Tm:   Comp Chg:   Med Reas:
Drug Utilization Review Responses

Prospective DUR responses identified in the processing of manual claims will be reported on a DUR Responses for Manual Submissions report and will be delivered to the pharmacy via email on the next business day.

Drug Utilization Review Responses for Manual Submissions

The DUR Responses for Manual Submissions will list details for DUR responses identified while processing manual claims.

The DUR Responses for Manual Submissions will be generated nightly by the HNS. It will be available to pharmacies via email on the day following the date the manual claim was adjudicated by the Ministry.

Sample Drug Utilization Review Responses for Manual Submissions

Run Date: DEC 20, 2014   ODB - DUR RESPONSES
Adj Date: DEC 19, 2014   FOR PAPER SUBMISSIONS
CPhA Pharmacy ID: ODP1234567

Client ID: XXXXXXXXXXX XX First Name: XXXXXXXXXXXX Last Name: XXXXXXXXXXXXXXX
DIN / PIN: 09850724   Drug Name: Allergen extracts
Dispense Dt: YYYY-MM-DD   Current Rx: 123456
11.3 Reconciliation of Remittance Statements

There are two ways of reconciling drug benefit payments deposited to your bank account by the Ministry:

**Note:** Remittance advice reports will only be received if there were manual drug benefit claims or drug benefit claim reversals processed or a Ministry adjustment in any given payment period.

**Using the Summary Remittance Advice:**

- From the O365 email account, retrieve the Summary Remittance Advice for the same (payment) date as the “deposit date”
- Check for the payment amount (in the “Amount to be paid” column)
- Compare this payment amount to the amount deposited by the Ministry
If there is no Summary Remittance Advice:

- Gather all daily totals (previously requested online and kept on file) within that particular payment period that is covered by the “deposit date” (See Section 11.4, Payment Schedule)
- Based on the information collected, calculate the payment amount
- Compare this payment amount to the amount deposited by the Ministry

**Payment Discrepancies**

*If there is an unresolved payment discrepancy, contact the ODB Help Desk (see Section 16, Help Desk). Be prepared to provide your pharmacy name, Pharmacy ID and payment date.*

### 11.4 Payment Schedule

The Ministry issues two payments per month:

- At the middle of each month
- At the end of each month.

Approved online claims/reversals will be processed by the Ministry for payment according to the following Online Payment Periods schedule:

**Online Payment Periods**

<table>
<thead>
<tr>
<th>Cut-off Date</th>
<th>Covers this period</th>
<th>For payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>By 9th of each month (up to 3:30 a.m. Eastern Time)</td>
<td>23rd of previous month (after 3:30 a.m. Eastern Time) to 9th of current month (up to 3:30 a.m. Eastern Time)</td>
<td>End of month payments</td>
</tr>
<tr>
<td>Cut-off Date</td>
<td>Covers this period</td>
<td>For payment</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>By 23rd of each month (up to 3:30 a.m. Eastern Time)</td>
<td>9th of current month (after 3:30 a.m. Eastern Time) to 23rd of current month (up to 3:30 a.m. Eastern Time)</td>
<td>Middle of following month payments</td>
</tr>
</tbody>
</table>

### 11.5 Direct Deposit

To register for direct deposit or change direct deposit information, complete the Notification of Change form (see Section 2.2) and send it by fax to (613) 548-6614 or by email to HNS-Registration.MOH@ontario.ca or by mail to:

**Ministry of Health**  
**Claims Services Branch**  
ODB Registry  
P.O. Box 68 Kingston ON  
K7L 5K1

**Note:** A blank cheque marked “VOID” will be required with the direct deposit application.

When changing direct deposit information, existing bank accounts should be kept open for at least one month.
Section 12: Inspection

Overview

Under the authority of Section 14 of the ODBA, the minister appoints inspectors to conduct inspections of pharmacies.

This section explains policies and procedures that pharmacies must observe and explains how compliance with the policies and procedures will be assessed during an inspection.

Use of Intervention/Exception Codes

The pharmacy must adhere to the rules applicable to the use of intervention/exception codes as described in this manual. It is essential that the appropriate intervention/exception codes are used.

Inspectors in the Ministry’s Pharmaceutical Strategy Unit will closely monitor the use of these codes.

Policy for Establishing Eligibility

The pharmacy must ensure that proof of eligibility is kept on file. Failure to do so will result in recovery of payments.

Acceptable Supporting Documentation

Many claims require supporting documentation, as indicated in the chart below.

For claim validation purposes under the ODB program, documentation must be kept in a readily retrievable format according to the appropriate retention schedule as outlined in the chart below and throughout the manual. In the case of the operator of a pharmacy, the documentation must be kept in or be readily available to the pharmacy or the dispensary of the pharmacy and, in the case of a dispensing physician, the documentation must be kept in or be readily available to the dispensary of the physician.
All documentation must be complete and accurate, and may be in the form of original paper documents, unaltered electronic scanned images of original documents, or electronic records.

<table>
<thead>
<tr>
<th>Type of submission</th>
<th>Supporting Documentation Required</th>
<th>Retention Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>All claims</td>
<td>Prescriptions and all supplier invoices (wholesalers and manufacturers) as directed in Section 5 of Regulation 936 under DIDFA. This includes any invoices and documentation related to transfers of drugs to/from other pharmacies from additional sources.</td>
<td>Supplier Invoices – 2 years from day the invoice was received. Prescriptions – the Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Claims for Home Care recipients</td>
<td>Drug Benefit Eligibility Card (or written/fax notification from an HSP/OHT valid for the date of service. See Section 4.2, Policy For Establishing Eligibility for Payment.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Claims for OW and ODSP</td>
<td>For claims validated using a paper drug card, the paper drug card must be maintained on file. For claims validated successfully in the HNS using the patient’s valid Ontario Health number, where no intervention codes are required, no further documentation is required. For claims validated through the SAV Portal or SAV Helpline when the patient’s eligibility cannot be established on the HNS network: 1. A print out of the SAV Portal search results or documentation of the following:</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Claims for Home for Special Care / Community Home for Special Opportunity</td>
<td>Patient eligibility (i.e., residents of Homes for Special Care/Community Homes for Opportunity) can be confirmed by contacting the MOH’s Financial Management Branch (FMB) at: 416-326-9842. Documentation that eligibility has been confirmed is needed.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Claims for children and youth when the pharmacist has</td>
<td>A copy of the Ontario Health Card, or other proof of OHIP eligibility (e.g., a copy of the</td>
<td>The Retention Period (see</td>
</tr>
</tbody>
</table>

See Section 4.2, Policy For Establishing Eligibility for Payment.

2. The SAV Helpline upon completion of the call will provide the pharmacy information for eligible results based on the following:

- The confirmation number
- Date and time of call
- Eligibility Coverage period
- Type of Coverage (Plan Code C or D)
- Results of the search (e.g., eligible or ineligible)
<table>
<thead>
<tr>
<th>Claim Type</th>
<th>Description</th>
<th>Retention Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extemporaneous preparations claim</td>
<td>The formula of the preparation, set out in a manner that clearly indicates all the ingredients and the quantities of those ingredients, the cost of each ingredient (i.e., copy of the manufacturer’s or wholesaler’s invoice(s) which demonstrate the Acquisition Cost of the ingredients) and the compounding time.</td>
<td>Documents other than purchase records - the Retention Period (see Glossary of Terms). Invoices – 2 years from the day the invoice was received</td>
</tr>
<tr>
<td>Medically necessary “No Substitution” claim</td>
<td>Health Canada Side Effect Reporting form(s) completed and signed by the prescriber where a patient has experienced significant adverse reactions with two lower cost interchangeable drug products (where available), the prescription on which the prescriber has prescribed the higher cost interchangeable product, and the prescriber has directed that there be “No Substitution” or “No Sub”.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>LU product claim</td>
<td>Prescription with LU documentation, including an RFU code. RFU codes may be communicated in writing, electronically or verbally. RFU code must be documented on the prescription.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Emergency Authorization claim</td>
<td>Copy of the authorization to dispense items usually provided to LTC homes by the Ontario Government Pharmaceutical and Medical Supply Service.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Allergen claim</td>
<td>Valid SAA form (completed and signed by the prescriber). Manufacturer or wholesaler</td>
<td>Invoices - 2 years from the day the invoice was received</td>
</tr>
<tr>
<td>Claim Type</td>
<td>Documentation Requirements</td>
<td>Retention Period</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Cost-to-Operator claim</td>
<td>Copy of the manufacturer’s or wholesaler’s invoice(s) which demonstrate the Acquisition Cost claimed, invoices which show that the lowest priced interchangeable product was ordered and not available at the time of the cost-to-operator claim, and a detailed calculation in accordance with section 14 of O. Reg. 201/96 of the cost of purchasing the drug product.</td>
<td>2 years from the day the invoice was received.</td>
</tr>
<tr>
<td>Vacation Supply claim</td>
<td>Copy of a letter signed and dated by the recipient indicating dates of travel, or a copy of the recipient’s travel insurance, confirming that the recipient is leaving the province for between 100 and 200 days.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>EAP claim</td>
<td>When Acquisition Cost is being claimed, a copy of the supplier’s invoice and a detailed calculation of the cost of purchasing the drug product. Reminder: Reimbursement is subject to lowest cost OFI products.</td>
<td>2 years from the day the invoice was received.</td>
</tr>
<tr>
<td>Nutritional Product claim</td>
<td>Valid nutrition product form(s) (completed and signed by the prescriber and the dispenser).</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Diabetic Testing Agent claim</td>
<td>If intervention codes are entered to override the test strip limit, reasons for the override must be documented on the prescription.</td>
<td>The Retention Period (see</td>
</tr>
<tr>
<td>30-Day Prescription Program claim</td>
<td>If intervention codes are used to override the 30-day limitation, reasons for the override must be documented on the prescription hard copy.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>SDP claim</td>
<td>Supplier invoices (wholesalers and manufacturers) may be required to validate claims.</td>
<td>2 years from day the invoice was received.</td>
</tr>
<tr>
<td>MedsCheck claim</td>
<td>MedsCheck documentation records including assessment summaries must be maintained by the pharmacist in a readily retrievable format. Please refer to the Professional Pharmacy Services Guidebook for program details.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Claims dispensed that are less than the maximum quantity in accordance with s. 18(8)(c) of O. Reg. 201/96</td>
<td>A written record of the reasons for the dispenser’s opinion. A copy of the notification to the prescriber about the determination. The agreement of the eligible recipient or the person presenting the prescription. Please refer to s. 18(9) of O. Reg. 201/96 and Section 5 of this Reference Manual.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Claims dispensed that are less than the maximum quantity in accordance with s. 18(8)(a) of O. Reg. 201/96</td>
<td>A written record of the reasons for the dispenser’s opinion. A copy of the notification to the prescriber about the determination. Please refer to s. 18(8.1) of O Reg 201/96 and Section 5 of this Reference Manual.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Claims dispensed more</td>
<td>A written record of the reasons for the dispenser’s opinion. A copy of the notification to the prescriber about the determination. Please refer to Section 5 of this Reference Manual.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Description</td>
<td>Details</td>
<td>Reference</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>frequently than twice per 28-day period in the circumstances described in s. 18(8)(a) of O. Reg. 201/96</td>
<td>notification to the prescriber about the determination. Please refer to s. 18(8.1) of O Reg 201/96 and Section 5 of this Reference Manual.</td>
<td>Glossary of Terms.</td>
</tr>
<tr>
<td>Claims dispensed more frequently than five times per 365-day period in the circumstances described in s. 18(8)(c) of O. Reg. 201/96</td>
<td>A written record of the reasons for the dispenser’s opinion. A copy of the notification to the prescriber about the determination. The agreement of the eligible recipient or the person presenting the prescription. Please refer to s. 18(9) and 18(11.1) of O Reg 201/96 and Section 5 of this Reference Manual.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Claims dispensed more frequently than five times per 365-day period in the circumstances described in s. 18(11.1)(c)</td>
<td>A written record of the reasons for the dispenser’s opinion. A copy of the notification to the prescriber about the determination. The agreement of the eligible recipient or the person presenting the prescription. Please refer to Section 5 of this Reference Manual.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>POP (Pharmaceutical Opinion Program) claims</td>
<td>Original prescription or a copy, whether verbal or written, along with the documentation criteria set out in the Professional Pharmacy Services Guidebook must be maintained by the pharmacist in a readily retrievable format.</td>
<td>The Retention Period (see Glossary of Terms).</td>
</tr>
<tr>
<td>Smoking Cessation</td>
<td>Smoking cessation documents and associated patient records including any written referrals and patient consent</td>
<td>The Retention Period (see</td>
</tr>
</tbody>
</table>
documentation; drug therapy information and desired outcomes / action plans; and specifics on quit smoking plans and advice offered to the patient must be maintained by the pharmacist in a readily retrievable format.

| Flu vaccine claims | See [Section 6.15](#) of Manual for documentation requirements. | The Retention Period (see Glossary of Terms) |
| Claims for epinephrine auto-injector administration for emergency use following flu vaccine | See [Section 6.15](#) of Manual for documentation requirements. | The Retention Period (see Glossary of Terms) |
| Manual claims for payment or manual claim reversals | A copy of each manual claim for payment or claim reversal submitted to the Ministry, together with a record of the date on which the claim was submitted | The Retention Period (see Glossary of Terms) |
| Claims relating to COVID-19 programs (testing, vaccine administration, Paxlovid, Evusheld) | See applicable Executive Officer notice on Ministry’s website | The Retention Period (see Glossary of Terms) |
| Claims relating to Professional Pharmacy Services not described in the rows above (e.g., | See applicable subsection in Section 7 of Manual for documentation requirements. | The Retention Period (see Glossary of Terms) |
During an on-site inspection, the above records must be readily available. If filing is such that the documents are not readily retrievable, it is the responsibility of the pharmacy owner/manager to provide the required documents. Failure to do so will result in recovery of amounts paid for claims for which the required documents are not supplied.

The Ministry may periodically select a sample of claims for which a pharmacy must supply supporting documentation.

Failure to provide supporting documentation for a select sample of claims will prompt one or more of the following actions:

- Request for expanded sample of documentation;
- Recovery of funds for claims not supported by documentation;
- An inspection.

**Other Rules Regarding Retention of Records**

In addition to the records to support the various submissions outlined in the table above, the following records must be maintained by the pharmacy:

- A copy of a statement of daily transaction totals prepared each day (must be maintained for a period of two years from the day on which the daily statement is prepared)

- A copy of each summary remittance statement or reject statement received from the Executive Officer (must be maintained for a period of two years from the day on which the statement is received)

In accordance with O. Reg. 264/16 under the DPRA, all pharmacies are required to keep documents relating to the care of a patient for a period of at least 10 years from the last recorded pharmacy service provided to the patient or until 10 years after the day on which the patient reaches or would have reached the age of 18 years, whichever is longer.
Examples of records and documents included but are not limited to:

- MedsCheck documentation
- Pharmacist refill authorization information
- Pharmaceutical opinion
- Medication management
- Identified drug related problems
- Consent forms
- Dialogue with patients
- Any other information essential for continuity of care
- Any future record keeping requirements under the new expanded scope of practice

Please refer to OCP’s Guideline on Record Retention, Disclosure and Disposal for more information.

**Control of Network Access**

The pharmacist owner/manager is responsible for authorizing and delegating network access to the HNS. They are also responsible for maintaining security on their systems and keeping confidential any information received from the Ministry. Refer to Section 3, Confidentiality and Security.

**Recoveries**

The Ministry may recover amounts paid for claims which are submitted contrary to the provisions of the ODBA, O. Reg 201/96 or the HNS Subscription Agreement or which relate to dispensing activities that are contrary to accepted standards of professional practice. This includes, but is not limited to, amounts paid for:

- Claims for prescriptions improperly cancelled or not dispensed
- Claims paid in error
• Claims for quantities in excess of the maximum number of days’ supply
• Claims resulting from failure to monitor dosages
• Claims associated with improper use of intervention codes
• Claims for which required supporting documentation is expired or not supplied upon request
• Claims that do not satisfy Program or documentation criteria
• Claims submitted for amounts in excess of what is allowed by the ODBA, O. Reg 201/96, and the HNS Subscription Agreement
• Claims associated with improper number of days’ supply
• Claims for MedsCheck services for which MedsCheck documentation records, including assessment summaries signed and dated by the patient and the pharmacist, are not available for review
• Claims for Expanded Services for which the original prescription, whether verbal or written, along with the documentation criteria are not available in a readily retrievable format. When verbal prescription is in question, the rules set out by the college apply.
• Claims for dispensing fees submitted in violation of the “Conditions for Payment of Dispensing Fees” (see Section 5).

Recovery Letters (outlining the amount of overpayment identified from an inspection) will be sent to the pharmacy.

Penalties

Penalties for violation of certain provisions of the ODBA are set out in Section 15 of the Act. Inappropriate use of the HNS can result in revocation of network access (as specified in the terms and conditions of the HNS Subscription Agreement).

Pursuant to Sections 11.1 and 11.2 of the ODBA, breach of a condition prescribed by the regulations or agreed to by the pharmacy operator or physician can result in suspension from entitlement to receive payment from the Ministry.
Section 13: Prescription Forgery

Effective November 23, 2020, the ministry implemented system changes to notify dispensers in real-time about reports of alleged forgeries and/or stolen prescription pads utilizing the ministry’s online claim adjudication system - the Health Network System (HNS), which includes the Narcotics Monitoring System (NMS). Prescription Forgery Alert Notices being sent out to pharmacies via electronic mail have been discontinued effective November 23, 2020.

- Pharmacies will receive a Forgery Notification Alert (in ‘real-time’, as part of the adjudication response) that this prescription order contains attributes that relate them with a recorded Forgery Notification Alert issued under the prescriber’s name.

- The system will display a warning response code “FX” and a message that is cautionary/informational in nature.
  - For ODB Claims Adjudication: ‘Possible Forgery-Check authenticity’
  - For NMS Adjudication: ‘NMS: Possible Forgery-Check authenticity’

- The dispenser should follow their established process to confirm the authenticity of the prescription and use their professional judgment to determine the appropriate course of action, including verifying authenticity by consulting with the prescriber. If the prescription is confirmed to be a forgery, the pharmacist should not proceed with dispensing the prescription drug and must submit a claim reversal if the drug is not dispensed.

The pharmacist and the associated prescriber should contact the Ontario Drug Benefit program at drugprogramsdelivery@ontario.ca to report the occurrence of a forgery. The following information is required when reporting a prescription forgery:

- The prescriber details on the forged prescription including prescriber name, address, phone/fax number;

- The name(s) of the drug(s) mentioned on the forgeries (if known); and

- Attach a copy of the prescription and any additional forged prescription pages you may have.
Section 14: Electronic Mail

Overview

As of January 15, 2022, the ministry will be replacing the ONE® Mail email service with Microsoft Office 365 (O365) email account for dispensers.

O365 is a secure email service developed and operated by Microsoft that is accessible via the internet (e.g., a web browser). It meets the high security requirements to exchange information between the ministry and stakeholders.

O365 email is used to advise pharmacies of drug benefit changes, program changes, and payment information. A single O365 email account is provided to each pharmacy upon approval of a new HNS account for accessing ministry messages. Any changes to the accreditation number of a pharmacy will require a new HNS account number and new corresponding O365 email account.

The ministry will address the communication directly to registered email account users. O365 email messages will include important Executive Officer Communication, Summary Remittance Advice statements, Formulary Updates, Monitored Drugs Updates, and CPSO Notices.

Pursuant to their HNS Subscription Agreements, pharmacies must check their O365 email accounts at least once per week.

In addition, pharmacies should delete old messages that are no longer required from the O365 email account on a regular basis.

This section outlines the process involved with:

- [O365 Email Account Registration](#)
- [O365 Email Account Activation](#)
- [O365 Email Account Forms](#)
- [Troubleshooting](#)
**O365 Email Account Registration**

The O365 email account registration form is provided as part of the HNS registration process. The pharmacy owner/pharmacist with signing authority for the operator will be the owner of the O365 email account. The pharmacy must submit the completed O365 email account registration form to the ODB registration desk.

**O365 Email Account Activation**

Upon registration, the ministry will notify the pharmacy that the O365 email account registration is complete. This automated confirmation email will be sent to the pharmacy’s personal or corporate email address (provided by the pharmacy on the O365 email account registration form).

The confirmation email will contain the new username (e.g., ON#@opddp.ca), a unique temporary password for the initial log-in, and a direct link for logging in.

You will be required to change the temporary password the first time you login.

To launch the email service, please log in to https://outlook.office.com to change the temporary password, then proceed to follow the on-screen setup process.

When changing the password, please follow the password complexity rules. It is recommended that a unique password be used that is not used with any other applications.

- Password must be 12 or more characters long.
- Password must contain characters from all the following four categories:
  - Uppercase characters A-Z (Latin alphabet).
  - Lowercase characters a-z (Latin alphabet).
  - Digits 0-9.
  - Special characters (@, $, #, %, etc.).

Type in the current (temporary) password and your new password based on the password complexity above. Follow the steps in your browser.
O365 Email Account Forms

1. Email Account Registration and Enrolment Request Form (for O365 email account)

   The Email Account Registration and Enrolment Request Form can be obtained by contacting the ODB Help Desk or email to HNS-Registration.MOH@ontario.ca

2. Email Account Information Change Request Form

   Complete this form for O365 email account changes including change of O365 email account ownership.

3. O365 Email Account Revocation Form

   The O365 email Account Revoke Form is provided as part of the HNS account closing process. The pharmacy must submit the completed O365 email account revoke form to the ODB registration desk. The O365 email account will be cancelled as part of the HNS account closing process. Your E-mail account will remain active for three months after the closure date.

   Pharmacies must forward the signed and completed form by email, fax, or mail to:

   Email: HNS-Registration.MOH@ontario.ca
   Fax: (613) 548-6614
   Ministry of Health
   Claims Services Branch
   Provider Registry
   P.O. Box 68
   Kingston ON  K7L 5K1

Troubleshooting

For O365 email account login issues, including password resetting, call the ODB Help Desk at 1-800-668-6641.

For O365 email account registration, call the ODB Help Desk at 1-800-668-6641.
Section 15: Narcotic Monitoring System

Overview


The Narcotics Monitoring System (NMS) collects dispensing data from dispensaries in respect of all dispensed narcotics, controlled substances and other monitored drugs, irrespective of whether the prescription is paid for under a publicly funded drug program, through private insurance, or by cash. The collected data will be reviewed and analyzed by the Ministry of Health (the “ministry”) for a variety of purposes including, but not limited to: educational and public health purposes, reporting possible professional misconduct to regulatory authorities, and reporting possible criminal conduct to law enforcement agencies.

The Narcotics Safety and Awareness Act, 2010, S.O. 2010, c.22 (the “Act” or “NSAA”) and Ontario Regulation 381/11 (General) made under the NSAA (the “Regulation”) govern the NMS. The NSAA and the Regulation require a dispenser to keep certain records for a period not less than 2 years. This retention period applies to all records described in this section.

The NSAA defines a “monitored drug” as: (i) a controlled substance as defined in the Controlled Drugs and Substances Act (Canada) (CDSA), unless the controlled substance has been excluded by the regulations under the NSAA; and (ii) any other drug designated by the regulations. Any drug product that is an opioid that is not listed under the CDSA has been designated under the Regulation as a monitored drug. No controlled substance under the CDSA has been excluded by the Regulation.

Section 8 of the NSAA confers authority on the Executive Officer of Ontario Public Drug Programs (the “Executive Officer”) or the Minister to direct prescribers, dispensers and pharmacy operators to disclose certain information to the ministry about the monitored drugs they prescribe or dispense. By notice from the Executive Officer, dispensers and pharmacy operators have been directed to submit the required information about monitored drugs to the ministry electronically using the Narcotics Monitoring System (NMS).
Effective May 14, 2012, all dispensers in Ontario are required to submit the following information to the NMS when dispensing a monitored drug to a patient:

- Prescriber’s registration number issued to the prescriber by the College of which he or she is a member
- Prescriber ID reference (identifying the professional college to which the prescriber belongs – e.g., CPSO, RCDSO)
- Identifying number of the patient and the identifying number type
- Name of the patient for whom the monitored drug is prescribed
- Date of birth and gender of the patient
- Date on which the monitored drug is dispensed
- Drug identification number
- Quantity of the monitored drug dispensed
- Length of therapy, in number of days, of the monitored drug
- Prescription number
- Pharmacist ID (registration number from the Ontario College of Pharmacists)
- Pharmacy ID

Pursuant to subsection 8(2) of the NSAA, prescribers, dispensers and pharmacy operators are required to disclose the information specified under the Act at the time and in the form and manner that the Minister of Executive Officer directs. The Executive Officer directs that the required dispensing information be submitted by dispensers and pharmacy operators to the NMS in accordance with this section of the Reference Manual.

Prescribers, dispensers and pharmacy operators may be inspected for the purpose of determining their compliance with the requirements of the NSAA (see section 13 of the Act).

This section of the Reference Manual outlines requirements for submission of NMS claims and also describes the various system responses:
15.1 NMS Requirements

General

To ensure that information in the NMS database is current and accurate, dispensers must submit the required dispensing information to the NMS at the time that a monitored drug is dispensed. Reversals must be submitted to the NMS as soon as the need for a reversal transaction is identified.

Dispensers and pharmacy operators are responsible for ensuring that the dispensing information submitted to the NMS is true, accurate and complete. Pursuant to section 14(1) of the NSAA, a dispenser or pharmacy operator may be found guilty of an offence if the person fails to maintain the records required under section 11 of the NSAA, fails to submit the required dispensing information to the NMS, or submits information to the NMS that the person knows to be false or misleading.

A dispenser or pharmacy operator may use the NMS only for the purpose of carrying out the dispenser’s or pharmacy operator’s duties and functions under the NSAA.

Prescriber Identification

The NSAA requires prescribers of all monitored drugs to record the registration number or certificate number issued to the prescriber by the college (i.e., the prescriber license number) on prescriptions for monitored drugs.
A valid prescriber ID and the appropriate corresponding prescriber ID reference are mandatory for submitting NMS transactions. Please refer to the prescriber ID reference chart (Section xx.4) for the prescriber ID references of those prescribers who can prescribe monitored drugs.

Transactions submitted to the NMS using the unknown prescriber ID reference “99” and the unknown prescriber ID “99999” are not valid. Failure to properly identify the prescriber in the NMS constitutes a breach of the dispenser’s disclosure obligations under the NSAA.

**Dispenser Identification**

The registration number of the dispensing pharmacist is mandatory for transactions submitted to the NMS.

**Non-application to Veterinary Prescriptions**

Submission to the NMS is not required when dispensing prescriptions for monitored drugs written by veterinarians in the course of their practice. The NSAA does not apply to such prescriptions.

**Exceptions**

Submission to the NMS is not required when dispensing prescriptions for monitored drugs dispensed to prisoners or inmates. This includes prescriptions written for people confined to a correctional institution, penitentiary, prison or youth custody facility. The NSAA does not currently apply to these populations as they have been exempted by the Regulation.

Submission to the NMS is not required when dispensing prescriptions for monitored drugs to an in-patient of a public hospital as part of his or her treatment in a public hospital. The NSAA does not currently apply to in-patients of public hospitals as they have been exempted by the Regulation. The NSAA does apply, however, to out-patients of public hospitals and to in-patients of private hospitals or any other institution that is not a public hospital.
Prescriptions for Residents of Long-Term Care Homes

The NSAA applies to prescribing and dispensing prescriptions for monitored drugs to residents of long-term care homes.

NMS Transactions

Pharmacists can submit dispensing information to the NMS before or after the submission of a claim to the ministry’s Health Network System (HNS) or to any other third-party claim adjudicator.

Prior to dispensing, pharmacists have an option to send an NMS inquiry transaction with an intervention code “DU”. The NMS will perform all data integrity checks and Drug Utilization Review (DUR) checks, but will not store the drug information as a dispense transaction. If the pharmacist subsequently dispenses the drug, the ministry will require the submission of a dispense transaction to record the correct dispensing information. NMS inquiry transactions do not require a reversal transaction to be submitted.

While the NMS will accept electronic submission of monitored drug dispensing information and reversal transactions up to 365 days from the date of service, dispensers are required to submit NMS transactions at the time of dispensing.

The special service code “6” is mandatory for all NMS dispense transactions, NMS inquiry transactions and NMS reversal transactions.

Prescription (Rx) number is a mandatory field for NMS dispense transactions. The same Rx number submitted to the HNS for claim adjudication or to any other third-party claim adjudicator must also be sent to the NMS for recording dispense transactions.

15.2 Monitored Drugs List

The monitored drugs list (MDL) provides a list of products that the ministry has selected for monitoring. This list will be used as a reference to determine if a submission to the NMS is required for the product being dispensed. Pharmacy software vendors and pharmacies are required to update their software with the latest information when new versions are published.
The MDL will be reviewed on a regular basis and notification will be provided to pharmacies and pharmacy software vendors whenever an updated list is made available.

The MDL can be downloaded in Excel or XML format from the following location:


**Monitored drugs that are not on the MDL**

If a pharmacist submits an NMS dispense or inquiry transaction for a monitored drug, which is not on the ministry’s MDL, the NMS will reject the transaction with a response code “56” = DIN/GP#/PIN error. This may occur when a new monitored drug becomes available on the Canadian market and an update to the MDL has not yet been published.

If this situation is encountered, pharmacists are directed to notify the ministry by calling the ODB business helpdesk at 1-800-668-6641. Once notified, the ministry will verify the information and publish an updated MDL. Each DIN in the MDL will include an effective date indicating when it was added to the list and when the requirement for submission to the NMS became effective.

Although the NMS will allow electronic submission of dispensing information (and reversals) up to 365 days from the date of service, dispensers are required to make submissions to the NMS at the time of dispensing.

**15.3 Identifying Numbers**

Prescribers are required to legibly record an identifying number on all prescriptions for monitored drugs. Ministry-approved forms of identification are listed below.

- Ontario Health Card or other health card issued by a Province or Territory in Canada
- Valid Driver’s License or Temporary Driver’s License (issued by Ontario or other jurisdiction)
- Ontario Photo Card
- Birth Certificate from a Canadian province or territory
- Government-issued Employee Identification Card
- Ontario Outdoors Card
- BYID (age of majority card)
- Certificate of Indian Status
- Valid Passport – Canadian or other country
- Certificate of Canadian Citizenship
- Canadian Immigration Identification Card
- Permanent Resident Card
- Old Age Security (OAS) Identification Card
- Canadian Armed Forces Identification Card
- Royal Canadian Mounted Police/Provincial/Municipal Police Identification
- Firearms Possession and Acquisition License (PAL)

Please note that the above list of approved forms of identification is subject to change based on direction received from the Minister. Pharmacists will be advised of changes to the approved list through the O365 email and an up-to-date list will be posted on the ministry’s website.

**Identifying Numbers Reference Chart**

<table>
<thead>
<tr>
<th>Province/Other</th>
<th>Client ID Number/Code Format/Value</th>
<th>Cardholder Identity Code</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alberta</td>
<td>9 digits</td>
<td>AB</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>British Columbia</td>
<td>10 digits</td>
<td>BC</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Manitoba</td>
<td>9 digits</td>
<td>MB</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>New Brunswick</td>
<td>9 digits</td>
<td>NB</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Province/Region</td>
<td>Format Type</td>
<td>Prefix</td>
<td>Validation</td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
<td>-----------------</td>
<td>--------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Newfoundland and Labrador</td>
<td>12 digits</td>
<td>NL</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>10 digits</td>
<td>NS</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Nunavut</td>
<td>9 digits</td>
<td>NU</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Northwest Territories</td>
<td>1 letter+ 7 digits</td>
<td>NT</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Ontario</td>
<td>10 digits</td>
<td>ON</td>
<td>Must be valid Ontario Health number</td>
</tr>
<tr>
<td>PEI</td>
<td>8 digits or 9 digits</td>
<td>PE</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Québec</td>
<td>4 letters + 8 digits</td>
<td>QC</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>9 digits</td>
<td>SK</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Yukon</td>
<td>9 digits</td>
<td>YT</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Canadian Forces</td>
<td>1 letter + 8 digits</td>
<td>CF</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>Royal Canadian Mounted Police</td>
<td>5 or 6 digits</td>
<td>RCMP</td>
<td>Format will be validated</td>
</tr>
<tr>
<td>First Nations, Inuit, and Aboriginal Health</td>
<td>Between 8 and 10 digits in length</td>
<td>FNIAH</td>
<td>DIAND or other FNIA identification</td>
</tr>
<tr>
<td>Out of Country Residents with Approved Identification</td>
<td>0011984275</td>
<td>ONG</td>
<td>For out of country residents. DUR checks are not performed on these transactions</td>
</tr>
<tr>
<td>Residents of Canada with Other Approved Identification</td>
<td>0011984276</td>
<td>ONO</td>
<td>For residents of Canada for whom the prescriber has recorded another approved ID as the identifying number.</td>
</tr>
<tr>
<td>Residents of Canada with No Approved Identification</td>
<td>0011984277</td>
<td>ONX</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>------------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>DUR checks are not performed on these transactions</td>
<td>For a person who meets the regulatory exemption requirements whereby the person is unable to produce any of the approved identification and for whom the <strong>prescriber</strong> has recorded on the prescription the reason why the person needs to receive the monitored drug before he or she can obtain the appropriate identification. DUR checks are not performed on these transactions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Office Use Prescriptions</th>
<th>0011984283</th>
<th>ONOU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Used for dispensing prescriptions for monitored drugs to prescribers for office use. DUR checks are not performed on these transactions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** The cardholder identity code “ONO” and “ONG” must be used only when a patient provides one of the following ministry-approved forms of identification to the prescriber:

- Valid Driver’s License or Temporary Driver’s License (issued by Ontario or other jurisdiction)
- Ontario Photo Card
• Birth Certificate from a Canadian province or territory
• Government-issued Employee Identification Card
• Ontario Outdoors Card
• BYID (age of majority card)
• Valid Passport – Canadian or other country
• Certificate of Canadian Citizenship
• Canadian Immigration Identification Card
• Permanent Resident Card
• Old Age Security (OAS) Identification Card
• Provincial/Municipal Police Identification
• Firearms Possession and Acquisition License (PAL)

**Provincial Health Card**

Dispensing information submitted to the NMS for which the identifying number is a provincial health card is to be entered as follows:

• Cardholder Identity: Provincial Identifier (please see table below)
• Client ID Number or Code: Patient health card number
• Quantity: Total drug quantity
• Days Supply: Total number of days supply
• DOB: Patient birth date
• Gender: M or F or U
• Last name: Patient last name
• First Name: Patient first name
Canadian Forces (CF)

Dispensing information submitted to the NMS for which the identifying number is a Canadian Forces ID is to be entered as follows:

- Cardholder Identity: CF
- Client ID Number or Code: ID number as issued by CF
- Quantity: Total drug quantity
- Days Supply: Total number of days supply
- DOB: Patient birth date
- Gender: M or F or U
- Last name: Patient last name
- First Name: Patient first name

Royal Canadian Mounted Police (RCMP)

Dispensing information submitted to the NMS for which the identifying number is a Royal Canadian Mounted Police ID is to be entered as follows:

- Cardholder Identity: RCMP
- Client ID Number or Code: ID number as issued by RCMP
- Quantity: Total drug quantity
- Days Supply: Total number of days supply
- DOB: Patient birth date
- Gender: M or F or U
- Last name: Patient last name
- First Name: Patient first name
First Nations, Inuit, and Aboriginal Health (FNIAH)

Dispensing information submitted to the NMS for which the identifying number is a First Nations, Inuit and Aboriginal Health ID is to be entered as follows:

- Cardholder Identity: FNIAH
- Client ID Number or Code: ID number as issued by FNIAH
- Quantity: Total drug quantity
- Days Supply: Total number of days supply
- DOB: Patient birth date
- Gender: M or F or U
- Last name: Patient last name
- First Name: Patient first name

Out-of-country Residents with Approved Identification (ONG)

Dispensing information submitted to the NMS for out-of-country residents are to be entered as follows:

- Cardholder Identity: ONG
- Client ID Number or Code: 0011984275
- Quantity: Total drug quantity
- Days Supply: Total number of days supply
- DOB: Patient birth date
- Gender: M or F or U
- Last name: Patient last name
- First Name: Patient first name
Residents of Canada with Other Approved Identification (ONO)

Dispensing information submitted to the NMS for residents of Canada for whom the prescriber has recorded another approved ID as the identifying number are to be entered as follows:

- Cardholder Identity:  ONO
- Client ID Number or Code:  0011984276
- Quantity:  Total drug quantity
- Days Supply:  Total number of days supply
- DOB:  Patient birth date
- Gender:  M or F or U
- Last name:  Patient last name
- First Name:  Patient first name

Residents of Canada with No Approved Identification (ONX)

Section 6 of the Regulation sets out the conditions under which a dispenser will be exempt from the NSAA requirement to maintain a record of a patient’s identifying number:

1. The patient is unable to present an identifying number to the prescriber of the prescription.
2. The prescriber records on the prescription the reason why the patient needs to receive the monitored drug before he or she can present an identifying number.
3. The dispenser keeps a record of the reason why the patient needs to receive the monitored drug before he or she can present an identifying number.
4. The dispenser provides the monitored drug directly to the patient, either at the dispenser’s place of business or through the dispenser’s delivery service, without any agent being used to receive the drug on the patient’s behalf and
without a third-party mail or courier service being used to deliver the monitored drug.

In cases where all of the foregoing conditions have been met, the submission to the NMS must be entered as follows:

- Cardholder Identity: ONX
- Client ID Number or Code: 0011984277
- Quantity: Total drug quantity
- Days Supply: Total number of days supply
- DOB: Patient birth date
- Gender: M or F or U
- Last name: Patient last name
- First Name: Patient first name

**Prescriber’s Office Use Prescriptions (ONOU)**

Dispensing information submitted to the NMS for prescriptions that are being filled for use in a prescriber’s office are to be entered as follows:

- Cardholder Identity: ONOU
- Client ID Number or Code: 0011984283
- Quantity: Total drug quantity
- Days Supply: 999
- DOB: 20010101
- Gender: M or F or U
- Last name: Prescriber’s last name
- First Name: Prescriber’s first name
### Prescriber ID Reference Chart

<table>
<thead>
<tr>
<th>Prescriber ID Reference</th>
<th>Prescriber ID Reference #</th>
</tr>
</thead>
<tbody>
<tr>
<td>The College of Physicians &amp; Surgeons of Ontario</td>
<td>01</td>
</tr>
<tr>
<td>Royal College of Dental Surgeons of Ontario</td>
<td>02</td>
</tr>
<tr>
<td>College of Chiropodists of Ontario</td>
<td>03</td>
</tr>
<tr>
<td>Out of Province</td>
<td>05</td>
</tr>
<tr>
<td>College of Midwives of Ontario</td>
<td>08</td>
</tr>
<tr>
<td>Ontario College of Pharmacists</td>
<td>09</td>
</tr>
<tr>
<td>College of Optometrists of Ontario</td>
<td>43</td>
</tr>
<tr>
<td>College of Nurses of Ontario</td>
<td>44</td>
</tr>
</tbody>
</table>

### Prescriber ID for Out-of-province Prescribers

When the prescriber is known to be registered in a Canadian province or territory outside of Ontario, the Prescriber ID Reference 05 should be used, along with a Prescriber ID from the following table:

<table>
<thead>
<tr>
<th>Prescriber ID</th>
<th>Province of Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>10001</td>
<td>British Columbia</td>
</tr>
<tr>
<td>10002</td>
<td>Alberta</td>
</tr>
<tr>
<td>10003</td>
<td>Saskatchewan</td>
</tr>
<tr>
<td>10004</td>
<td>Manitoba</td>
</tr>
<tr>
<td>10005</td>
<td>Quebec</td>
</tr>
<tr>
<td>10006</td>
<td>Newfoundland and Labrador</td>
</tr>
<tr>
<td>10007</td>
<td>New Brunswick</td>
</tr>
</tbody>
</table>
Note: The above values must be used for the Prescriber ID or the submission will be rejected with Response Code “61”.

15.4 NMS On-line Dispense Transaction

A standard NMS on-line dispense transaction must conform to the Canadian Pharmacists’ Association (CPhA) Pharmacy Claim Standard Version 03.

- While the NMS will accept electronic submission up to 365 days from date of service, on-line dispense transactions must be submitted to the NMS at the time of dispensing

- The NMS will validate the information submitted

- For online dispense transactions, the NMS will verify if there is an existing ‘forgery notification alert’ set-up under the prescriber

- If a pharmacy’s computer system is unable to make a submission to the NMS at the time that a monitored drug is dispensed, pharmacists are required to submit the required dispensing information to the NMS as soon as possible after their system becomes available

- The NMS will not perform DUR checks for dispense transactions submitted for Cardholder Identity codes ONG, ONO, ONX, and ONOU

The table below shows the required fields for submitting a standard NMS on-line dispense transaction:

(Please refer to your Pharmacy Software Vendor’s (PSV) manual for specific instructions on how to use your pharmacy software for this type of transaction.)
<table>
<thead>
<tr>
<th>Required Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank ID Number (BIN)</td>
<td>610054</td>
</tr>
<tr>
<td>Version Number</td>
<td>CPhA Pharmacy Claim Standard Version currently used (i.e., Version 03)</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>01</td>
</tr>
<tr>
<td>Provider Software ID</td>
<td>CPhA-assigned code, identifying pharmacy software currently used</td>
</tr>
<tr>
<td>Provider Software Version</td>
<td>PSV-assigned code, identifying the version of the pharmacy software currently used</td>
</tr>
<tr>
<td>Pharmacy ID Code</td>
<td>CPhA number or Ministry-assigned number of the dispensary</td>
</tr>
<tr>
<td>Provider Transaction Date</td>
<td>Date (YYMMDD) of service</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number, assigned to the transaction</td>
</tr>
<tr>
<td>Client ID Number or Code</td>
<td>Recipient identification number (See Section xx.3 “Identifying Numbers” for more details)</td>
</tr>
<tr>
<td>Patient Date of Birth</td>
<td>Must be in the format YYYYMMDD</td>
</tr>
<tr>
<td>Cardholder Identity</td>
<td>(See Section xx.3 “Identifying Numbers” for more details)</td>
</tr>
<tr>
<td>Patient First Name</td>
<td>First name of patient</td>
</tr>
<tr>
<td>Patient Last Name</td>
<td>Last name of patient</td>
</tr>
<tr>
<td>Patient Gender</td>
<td>Must be M-Male or F-Female or U-Unknown</td>
</tr>
<tr>
<td>Current Prescription Number</td>
<td>Unique prescription number (from the prescription label or record of service). Not mandatory for “NMS Inquiry Transaction”</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>DIN/PIN of product (See Monitored Drugs list for DIN/PINs)</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>Special Service Code (SSC)</td>
<td>Must be value of ‘6’ for NMS</td>
</tr>
<tr>
<td>Quantity</td>
<td>Quantity dispensed (one assumed decimal place)</td>
</tr>
<tr>
<td>Days Supply</td>
<td>Estimated number of days of treatment (as accurate as possible) supplied by the prescription</td>
</tr>
<tr>
<td>Prescriber ID Reference</td>
<td>Reference number for prescriber (See Prescriber ID Reference Chart)</td>
</tr>
<tr>
<td>Prescriber ID</td>
<td>Prescriber license number must be entered</td>
</tr>
<tr>
<td>Unlisted Compound</td>
<td>Indicates the transaction is for an extemporaneous compound that has not been assigned a PIN that is included in the MDL. Code identifies the type of compound and is mandatory for all compounds not identified by a PIN</td>
</tr>
<tr>
<td>Pharmacist ID</td>
<td>Pharmacist Registration Number</td>
</tr>
</tbody>
</table>

**System Response for NMS Dispense Transaction**

The Narcotics Monitoring System will provide the following details:

<table>
<thead>
<tr>
<th>Response Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication Date*</td>
<td>Date (YYMMDD) assigned to the transaction by the Narcotics Monitoring System</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>51</td>
</tr>
<tr>
<td>Reference Number</td>
<td>Internal reference number assigned by the Narcotics Monitoring System</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>Response Status</td>
<td>A=accepted as transmitted, no warnings</td>
</tr>
<tr>
<td></td>
<td>B=accepted with warnings</td>
</tr>
<tr>
<td></td>
<td>R= rejected, data integrity issues</td>
</tr>
<tr>
<td>Response Code</td>
<td>(See Section xx.7 for NMS data validation response codes and messages.)</td>
</tr>
<tr>
<td>Message Data Line Number 1</td>
<td>Detailed Forgery Notification Alert or DUR response information, Message will contain “NMS” even if no warnings.</td>
</tr>
<tr>
<td>Message Data Line Number 2</td>
<td>Detailed DUR response information</td>
</tr>
<tr>
<td>Message Data Line Number 3</td>
<td>Detailed DUR response information</td>
</tr>
</tbody>
</table>

**Note:** During early morning hours, the adjudication date will not be the same as the provider transaction date. Adjudication date begins at 3:30 a.m. (Eastern Time) and concludes 24 hours later.

### 15.5 NMS On-line Inquiry Transaction

Prior to dispensing, pharmacists have the option to send an NMS on-line inquiry transaction for DUR purposes. The NMS inquiry transaction will perform all data integrity checks and DUR checks but will not store the drug information as a dispense transaction. If the pharmacist subsequently dispenses the drug, the ministry will require the separate submission of a dispense transaction to record the required dispensing information in the NMS.

Dispense transactions and inquiry transactions that generate DUR responses do not refer to historical inquiry records when generating a response.

NMS inquiry transactions do not have to be reversed.
A standard NMS on-line inquiry transaction must conform to the Canadian Pharmacists’ Association (CPhA) Pharmacy Claim Standard Version 03.

- The data fields required for submitting a standard NMS inquiry transaction are the same as an NMS dispense transaction, except an intervention code “DU” is required for each inquiry transaction.
- Prescription (Rx) number is optional for inquiry transactions.
- The NMS will not perform DUR checks for inquiry transactions submitted for Cardholder Identity codes ONG, ONO, ONX, and ONOU.
- The system response for NMS inquiry transactions is identical to NMS dispense transaction system response (See Section xx.4 above).

### 15.6 NMS On-line Reversal Transaction

In certain circumstances, pharmacists may be required to reverse a dispense transaction that has been submitted to the NMS.

- On-line reversal transactions are delivered in real-time to the NMS which will validate the information submitted.
- NMS on-line reversal transactions must be processed as soon as the need for a reversal is identified. If it is not possible in the circumstances for a pharmacy to submit a reversal transaction immediately, then the transaction must be reversed as soon as possible to keep the NMS database accurate and up-to-date.

The table below shows the required fields for submitting a standard NMS on-line reversal transaction.

<table>
<thead>
<tr>
<th>Required Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank ID Number (BIN)</td>
<td>Must be 610054</td>
</tr>
<tr>
<td>Version Number</td>
<td>CPhA Pharmacy Claim Standard Version currently used (i.e., Version 03)</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>11</td>
</tr>
<tr>
<td>Provider Software ID</td>
<td>CPhA-assigned code, identifying pharmacy software currently used</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pharmacy ID Code</td>
<td>CPhA number or ministry-assigned number of the dispensary</td>
</tr>
<tr>
<td>Provider Transaction Date</td>
<td>Date (YYMMDD) of service of claim to be reversed</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number, assigned to the transaction</td>
</tr>
<tr>
<td>Client ID Number or Code</td>
<td>Must match the original dispense transaction</td>
</tr>
<tr>
<td>Cardholder Identity</td>
<td>Must match the original dispense transaction</td>
</tr>
<tr>
<td>Current Prescription Number</td>
<td>Must match the original dispense transaction</td>
</tr>
<tr>
<td>DIN/GP#/PIN</td>
<td>Must match the original dispense transaction</td>
</tr>
<tr>
<td>Special Service Code (SSC)</td>
<td>Must be '6'</td>
</tr>
<tr>
<td>Adjudication Date</td>
<td>Date (YYMMDD) on which dispense transaction to be reversed was originally adjudicated</td>
</tr>
</tbody>
</table>

**System Response for NMS Reversal Transaction**

The system response will provide the following details:

<table>
<thead>
<tr>
<th>Response Fields</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication Date</td>
<td>Date (YYMMDD) assigned to the transaction by the Narcotics Monitoring System</td>
</tr>
<tr>
<td>Trace Number</td>
<td>Pharmacy system-generated number assigned to the transaction</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>61</td>
</tr>
</tbody>
</table>
Reference Number | Internal reference number assigned by the Narcotics Monitoring System
---|---
Response Status | R= rejected reversal  
V= reversal accepted
Response Code | (See Section xx.7 for NMS data validation response codes and messages.)

**Note:** The system response for NMS reversal transactions is identical to the system response for HNS claim reversals.

### 15.7 NMS Data Validation Response Codes and Messages

The table below shows the various response codes associated with the validation of data submitted on NMS transactions. The table shows ‘Reject Response Codes’ and ‘Warning Response codes’ separately.

Please note that all definitions indicated are based on the CPhA response code descriptions. In some cases, individual software vendor response code descriptions may be different from the CPhA definitions.

#### Reject Response Codes and Messages:

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
<th>Field Requirement or Explanation of Condition Generating Response Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>BIN error</td>
<td>Bank ID Number # 610054 required</td>
</tr>
<tr>
<td>02</td>
<td>Version number error</td>
<td>Current CPhA Version required</td>
</tr>
<tr>
<td>03</td>
<td>Transaction code error</td>
<td>Transaction code (01, 11) required</td>
</tr>
<tr>
<td></td>
<td>Error Description</td>
<td>Detailed Description</td>
</tr>
<tr>
<td>----</td>
<td>--------------------------------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>04</td>
<td>Provider software ID error</td>
<td>Dispensary’s Provider Software ID required</td>
</tr>
<tr>
<td>05</td>
<td>Provider software version error</td>
<td>Dispensary’s Provider Software Version required</td>
</tr>
<tr>
<td>21</td>
<td>Pharmacy ID code error</td>
<td>Dispensary’s Pharmacy ID Code required</td>
</tr>
<tr>
<td>22</td>
<td>Provider transaction date error</td>
<td>Date (YYMMDD) of service required</td>
</tr>
<tr>
<td>23</td>
<td>Trace number error</td>
<td>A numeric value greater than 0</td>
</tr>
<tr>
<td>32</td>
<td>Client ID # error</td>
<td>Client ID error may occur due to any one of following:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Client ID number missing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Invalid health card number for Ontario</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Invalid format for other provinces</td>
</tr>
<tr>
<td>34</td>
<td>Patient date of birth error</td>
<td>Birth date of patient must be entered.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Must be valid date value and must be in format of YYYYMMDD and not future dated</td>
</tr>
<tr>
<td>35</td>
<td>Cardholder Identity error</td>
<td>Cardholder identity must be one of following values:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Province of health coverage: ON, AB, BC, MB, NB, NL, NS, NU, NT, PE, QC, SK, YT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Canadian Forces: CF</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Royal Canadian Mounted Police: RCMP</td>
</tr>
<tr>
<td></td>
<td>Errors</td>
<td>Details</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>37</td>
<td>Patient first name error</td>
<td>Patient first name is mandatory</td>
</tr>
<tr>
<td>38</td>
<td>Patient last name error</td>
<td>Patient last name is mandatory</td>
</tr>
<tr>
<td>40</td>
<td>Patient gender error</td>
<td>Patient gender must be one of following values: &quot;M&quot;, &quot;F&quot;, or &quot;U&quot; if unknown</td>
</tr>
<tr>
<td>55</td>
<td>Current Rx # error</td>
<td>Must be numeric value greater than 0</td>
</tr>
<tr>
<td>56</td>
<td>DIN/GP#/PIN error</td>
<td>Must be a valid DIN/PIN as of Date of Service.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Must be found in Monitored Drugs list as of Date of Service</td>
</tr>
<tr>
<td>57</td>
<td>SSC error</td>
<td>Must be &quot;6&quot;</td>
</tr>
<tr>
<td>58</td>
<td>Quantity error</td>
<td>Quantity of medication dispensed must be entered on transaction as numeric value. Cannot be value of zero</td>
</tr>
<tr>
<td>59</td>
<td>Days supply error</td>
<td>Days supply must be entered on transaction as numeric value. Cannot be value of zero</td>
</tr>
<tr>
<td>60</td>
<td>Prescriber licensing authority code error</td>
<td>The Prescriber ID Reference field must be &quot;01&quot;, &quot;02&quot;, &quot;03&quot;, &quot;05&quot;, &quot;08&quot;, &quot;44&quot;</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Information</td>
</tr>
<tr>
<td>------</td>
<td>----------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>61</td>
<td>Prescriber ID error</td>
<td>This field cannot be blank and a valid prescriber registration number is required. For transactions in which the Prescriber ID relates to a prescriber who has not been registered on the HNS, no Message Line is returned and only response code 61 will appear. MH” = override -prescriber ID. The use of the MH Intervention Code is based on the professional judgement of the pharmacist. Proper documentation to support the use of the MH Intervention Code must be maintained (e.g., documentation explaining why the prescription is still valid and being dispensed), and is subject to inspection and post-submission verification. Resources are available on the OCP website here. For prescribers (other than physicians licensed with the College of Physicians and Surgeons of Ontario [CPSO]) who are not registered on the HNS, no Message Line is returned. The claim can be resubmitted with an “MH” intervention code and the proper Prescriber ID and Prescriber ID Reference. For physicians licensed with the College of Physicians and Surgeons of Ontario (CPSO) who are not registered on the HNS, no intervention code can be used. Please contact the ODB Pharmacy Help Desk at 1-800-</td>
</tr>
<tr>
<td>Code</td>
<td>Error Type</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>65</td>
<td>Intervention code error</td>
<td>Must be a valid intervention code. Intervention code “DU” is accepted for NMS inquiry transactions. Intervention code “MH” is accepted for overriding prescriber ID error</td>
</tr>
<tr>
<td>76</td>
<td>Pharmacist ID code error/missing</td>
<td>This field cannot be blank. A valid Pharmacist ID is required for all ODB and NMS submissions. Response Code 76 will also be received for transactions that include a Pharmacist ID of a pharmacist, whose licence is suspended.</td>
</tr>
<tr>
<td>90</td>
<td>Adjudication date error</td>
<td>Must be a numeric value (YYMMDD format). This field must be completed for reversal submissions</td>
</tr>
<tr>
<td>A1</td>
<td>Claim too old</td>
<td>Transaction date must be less than 365 days from current date</td>
</tr>
<tr>
<td>A2</td>
<td>Claim is post-dated</td>
<td>Date must not greater than the current date</td>
</tr>
<tr>
<td>A8</td>
<td>Original transaction missing or not found</td>
<td>No transaction on file that matches reversal transaction information submitted</td>
</tr>
<tr>
<td>A9</td>
<td>Reversal processed previously</td>
<td>Transaction previously reversed</td>
</tr>
<tr>
<td>B1</td>
<td>Pharmacy not authorized to submit claims</td>
<td>Pharmacy ID is required. Dispensary must be registered with MOHLTC for NMS transaction submission on date of service</td>
</tr>
</tbody>
</table>
**Warning Response Codes and Messages:**

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
<th>Field Requirement or Explanation of Condition Generating Response Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Patient date of birth error</td>
<td>Birth date of patient must match date on file</td>
</tr>
<tr>
<td>37</td>
<td>Patient first name error</td>
<td>Must match the first initial of the patient on file</td>
</tr>
<tr>
<td>38</td>
<td>Patient last name error</td>
<td>Must match the last name of the patient on file</td>
</tr>
<tr>
<td>40</td>
<td>Patient gender error</td>
<td>Patient gender must match gender value on file</td>
</tr>
<tr>
<td>A3</td>
<td>Identical claim processed</td>
<td>Prior dispense transaction exists for:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• same patient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• same DIN/PIN or interchangeable product</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• same date of service</td>
</tr>
</tbody>
</table>
Ontario Drug Programs Reference Manual

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DF</td>
<td>Insufficient space for all warnings</td>
<td>There is insufficient space for all response codes. Additional response codes are available by calling the ODB business helpdesk.</td>
</tr>
<tr>
<td>FX</td>
<td>PossibleForgery-Check authenticity</td>
<td>Indicates that the ODB program has been made aware of alleged forgeries for specific drugs (mostly monitored drugs) and/or stolen prescription pads. Refer to Section 13 for information on Prescription Forgery reporting process.</td>
</tr>
</tbody>
</table>

Note: For patient identification warning response code, pharmacists must submit a reversal transaction, correct the data error, and resubmit the NMS dispense transaction. If patient identification information has been confirmed and a warning response is received, please contact the ODB business helpdesk at 1-800-668-6641.

15.8 Drug Utilization Review (DUR) Warning Response Codes

When a pharmacist receives a DUR warning message, the message may indicate a potential overuse/misuse situation. The DUR message is based on a review of the current dispense or inquiry transaction and previously submitted dispense transactions that are recorded in the NMS database. Pharmacists must evaluate the response codes received and, in conjunction with other appropriate resources including the prescriber and the patient, determine the appropriate course of action.

The following DUR response codes may be received from the NMS:

- MH - May be Double Doctoring
- MI - Poly Pharmacy Use Indicated
- DE - Refill Too Late
- D7 - Refill Too Soon
• MY - Duplicate Drug Other Pharmacy

### DUR Response Codes and Messages

<table>
<thead>
<tr>
<th>Response Code</th>
<th>Message Description</th>
<th>Field Requirement or Explanation of Condition Generating Response Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>D7</td>
<td>Refill too soon</td>
<td>Based on days supply of previous dispense transaction, indicates that <strong>a refill should not be required at this time</strong>. The pharmacist may want to ensure that the medication is taken appropriately and verify if there have been any changes to the therapy (e.g., changed dose or directions).</td>
</tr>
<tr>
<td>DE</td>
<td>Fill/refill too late</td>
<td>Based on days supply of previous dispense transaction, indicates that <strong>a refill is overdue</strong> at this time. The pharmacist may want to ensure that the recipient is compliant and taking adequate doses.</td>
</tr>
<tr>
<td>MH</td>
<td>May be double doctoring</td>
<td>Indicates that, including the current submission, the recipient has obtained monitored drugs prescribed by 3 or more different prescribers in the previous 28 days.</td>
</tr>
<tr>
<td>MI</td>
<td>Poly-pharmacy use indicated</td>
<td>Indicates that, including the current submission, the recipient has obtained monitored drugs from 3 or more different dispensaries in the previous 28 days.</td>
</tr>
</tbody>
</table>
MY | Duplicate drug other pharmacy | Prior dispense transaction exists for:

- same patient
- same DIN/PIN or interchangeable product
- same date of service
- different dispensary

**Note:** The Ministry does not warrant the reliability of information supplied by third parties including, but not limited to, prospective DUR information and prescriber data. Such information is advisory only and is not intended to replace sound clinical judgment in the delivery of health care services. Pharmacists are required to use their discretion and professional judgment when determining what appropriate action is required when warning response codes are received from the NMS.

- For Drug Utilization Review (DUR) warning responses, pharmacists may decide to not dispense the monitored drug. If an inquiry transaction has been submitted, no further action is required. If a dispense transaction has been submitted, a reversal transaction is required.

- For DUR warning responses, pharmacists may decide to proceed with dispensing. If an inquiry transaction has been submitted, a dispense transaction is required. If a dispense transaction has been submitted, no further action is required.

- Reversal transactions are not required for any NMS inquiry transactions.

**DUR Message Line**

When the NMS returns any of the above DUR response codes, the System Response will also include a message line. Each System Response may include up to three DUR response codes and message lines.

The DUR message line will include the following information:

- The transaction date of the conflicting transaction
- The pharmacy phone number that filled the conflicting transaction
• The quantity dispensed for the conflicting transaction
• The drug identification number (DIN) of the conflicting transaction

The following is an example of a DUR message line:

<table>
<thead>
<tr>
<th>DUR response code</th>
<th>Date of conflicting prescription fill</th>
<th>Pharmacy telephone number</th>
<th>Drug quantity</th>
<th>DIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Message 1</td>
<td>NMS:MH111018 2507165773 00100.0 99119911</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Message 2</td>
<td>NMS:MI111004 1407653467 00150.0 99119911</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Message 3</td>
<td>NMS:MY110928 4164564356 00120.0 99119911</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please note that messaging may appear differently based on pharmacy software.

Note: In some instances, the pharmacy telephone number may not be available, and will appear as blanks. If this occurs, please contact the ODB business helpdesk at 1-800-668-6641 to obtain information about the previous dispensing pharmacy.

If you have questions regarding NMS transactions, NMS response messages or the Monitored Drugs List, please contact the ODB business helpdesk at 1-800-668-6641.
Section 16: Help Desk

Overview

The ODB Help Desk was established by the Ministry to provide both technical and business support to users of the HNS. The ODB Help Desk provides a central point of contact for prompt response to pharmacies' inquiries. The toll-free number provided to pharmacies is for pharmacy use only.

ODB recipients should call ServiceOntario INFOline at 1-866-532-3161 for inquiries or assistance.

This section explains:

- Procedures to deal with issues or problems that may be resolved prior to contacting the ODB Help Desk (see Section 16.1)
- The two types of issues/inquiries with which the ODB Help Desk is prepared to provide assistance (see Section 16.2)
- How the phone call will be handled by the ODB Help Desk (see Section 16.3)

16.1 Troubleshooting

Before you call the ODB Help Desk:

- Check all computer connections
- Contact your Pharmacy Software Vendor to ensure that all software packages are error free
- Refer to the applicable section of this Manual (for problems that you may be able to resolve) as shown on the following table:

<table>
<thead>
<tr>
<th>Type of Problem</th>
<th>What to do before you call…</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjudication of a Claim</td>
<td>Consult this Reference Manual</td>
</tr>
</tbody>
</table>
### 16.2 Types of Inquiries & Hours of Service

Pharmacy inquiries can be classified into two categories:

- **Business**
- **Technical**

Business inquiries are questions or problems relating to ODB program eligibility, claims processing, policy and procedures.

**Hours of service: 8 a.m. to 5 p.m. Mon to Fri (except Statutory Holidays) (Regular Ministry business hours)**

Technical inquiries/service calls are for questions or problems relating to the HNS and its operation.

**Hours of service: 24/7 (i.e., 24 hours a day, 7 days a week, 365 days a year)**

**Note:** Technical Help Desk agents are available to receive emergency technical inquiries outside of regular business inquiry hours (i.e., 5 p.m. to 8 a.m.); resolution of business inquiries will not be addressed until the next business day.
16.3 How Your Call is Handled

Be prepared to provide your [Pharmacy ID Code](#) (see [Section 2.1](#)) and patient ODB Eligibility Number when calling the ODB Help Desk.

Once a call is established:

- ODB Help Desk agent identifies the nature of the inquiry/problem
- ODB Help Desk agent logs inquiry/problem and assigns the inquiry/problem to a particular owner responsible for its resolution
- ODB Help Desk agent determines severity level
- A Problem Ticket Number is assigned
- If the inquiry/problem is resolved, the Problem Ticket is closed
- If the inquiry/problem cannot be resolved immediately, the affected pharmacy will be advised immediately, while steps are taken to address/resolve the inquiry/problem (within defined escalation standards)

*When calling back to the ODB Help Desk regarding an existing inquiry/problem, please provide the Problem Ticket Number.*
## Glossary of Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACSD</td>
<td>Assistance for Children with Severe Disabilities</td>
</tr>
<tr>
<td>Acquirer Host</td>
<td>Independent (third-party) system which accepts real-time transactions from pharmacies and routes them to the Health Network System</td>
</tr>
<tr>
<td>Acquisition Cost</td>
<td>Same as CTO. (Refer to <a href="#">Acquisition Cost Calculations in Section 6.7</a>)</td>
</tr>
<tr>
<td>Adjudication</td>
<td>Processing of a claim by the HNS that includes the following:</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired Immune Deficiency Syndrome</td>
</tr>
<tr>
<td>ANPD</td>
<td>Approved Non-Prescription Drug</td>
</tr>
<tr>
<td>BGTS</td>
<td>Blood Glucose Test Strips</td>
</tr>
<tr>
<td>BIN</td>
<td>Bank Identification No. (identifying Ministry of Health)</td>
</tr>
<tr>
<td>CBCRP</td>
<td>Case-by-Case Review Program</td>
</tr>
<tr>
<td>CCO</td>
<td>Cancer Care Ontario</td>
</tr>
<tr>
<td>CDI</td>
<td>Comparative Drug Index</td>
</tr>
<tr>
<td>CMQ</td>
<td>Collège des Médecins du Québec</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>CNO</td>
<td>College of Nurses of Ontario</td>
</tr>
<tr>
<td>Co-payment</td>
<td>Recipient share of the professional service fee for an ODB-eligible prescription, as set out in O. Reg 201/96 under the ODBA.</td>
</tr>
<tr>
<td>CPhA</td>
<td>Canadian Pharmacists Association</td>
</tr>
<tr>
<td>CPhA Standard</td>
<td>Pharmacy Claim Standard, published by the Canadian Pharmacists' Association</td>
</tr>
<tr>
<td>CPhA Version</td>
<td>Number assigned to a version of the CPhA Standard</td>
</tr>
<tr>
<td>CPR</td>
<td>Cardiopulmonary Resuscitation</td>
</tr>
<tr>
<td>CPSM</td>
<td>College of Physicians and Surgeons of Manitoba</td>
</tr>
<tr>
<td>CPSO</td>
<td>College of Physicians and Surgeons of Ontario</td>
</tr>
<tr>
<td>CRA</td>
<td>Canada Revenue Agency</td>
</tr>
<tr>
<td>CTO</td>
<td>Cost to Operator</td>
</tr>
<tr>
<td>DBP</td>
<td>Drug Benefit Price</td>
</tr>
<tr>
<td>Deductible</td>
<td>Amount an individual or household must spend on prescription drugs before becoming eligible for coverage</td>
</tr>
<tr>
<td>DHDR</td>
<td>Digital Health Drug Repository</td>
</tr>
<tr>
<td>DIDFA</td>
<td>Drug Interchangeability and Dispensing Fee Act</td>
</tr>
<tr>
<td>DIN</td>
<td>Drug Identification Number</td>
</tr>
<tr>
<td>DPP</td>
<td>Designated Pharmaceutical Product</td>
</tr>
<tr>
<td>DPRA</td>
<td>Drug and Pharmacies Regulation Act</td>
</tr>
<tr>
<td>DPV</td>
<td>Drug Profile Viewer</td>
</tr>
<tr>
<td>DUR</td>
<td>Drug Utilization Review</td>
</tr>
<tr>
<td>EAP</td>
<td>Exceptional Access Program</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
</tr>
<tr>
<td>EFT</td>
<td>Electronic Funds Transfer</td>
</tr>
<tr>
<td>Electronic Mail</td>
<td>Electronic messaging system</td>
</tr>
<tr>
<td>EO</td>
<td>Executive Officer</td>
</tr>
<tr>
<td>Establish eligibility</td>
<td>Policy which permits dispensing of prescriptions for recipients not yet registered as eligible on the HNS</td>
</tr>
<tr>
<td>Exception Code</td>
<td>Code used with online transactions to identify special situations (same meaning as Intervention Code)</td>
</tr>
<tr>
<td>FAQ</td>
<td>Frequently Asked Question</td>
</tr>
<tr>
<td>FIPPA</td>
<td>Freedom of Information and Protection of Privacy Act</td>
</tr>
<tr>
<td>FMB</td>
<td>Financial Management Branch</td>
</tr>
<tr>
<td>GP#</td>
<td>General Product Number</td>
</tr>
<tr>
<td>HIA</td>
<td>Health Insurance Act</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HNS</td>
<td>Health Network System</td>
</tr>
<tr>
<td>HSC</td>
<td>Homes for Special Care</td>
</tr>
<tr>
<td>HSCA</td>
<td>Homes for Special Care Act</td>
</tr>
<tr>
<td>HSP</td>
<td>Health service provider, which includes Local Health Integration Networks (may also be known as LHINs or Home and Community Care Support Services organizations)</td>
</tr>
<tr>
<td>ID</td>
<td>Identification</td>
</tr>
<tr>
<td>Intervention Code</td>
<td>Code used with online transactions to override specific situations (same meaning as Exception Code)</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>LHIN</td>
<td>Local Health Integration Network</td>
</tr>
<tr>
<td>LTC</td>
<td>Long-Term Care</td>
</tr>
</tbody>
</table>
LTC home is a place that is licensed as a long-term care home under the LTCHA, and includes a municipal home, joint home or First Nations home approved under Part VIII of the LTCHA.

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTCHA</td>
<td>Long-Term Care Homes Act, 2007</td>
</tr>
<tr>
<td>LU</td>
<td>Limited Use</td>
</tr>
<tr>
<td>MAID</td>
<td>Medical Assistance In Dying</td>
</tr>
<tr>
<td>Mandatory Field</td>
<td>Required data on claim submission</td>
</tr>
<tr>
<td>MAR</td>
<td>Maximum Allowable Reimbursement</td>
</tr>
<tr>
<td>MCCSS</td>
<td>Ministry of Children, Community and Social Services</td>
</tr>
<tr>
<td>MDL</td>
<td>Monitored Drugs List</td>
</tr>
<tr>
<td>MMT</td>
<td>Methadone Maintenance Treatment</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>NAPRA</td>
<td>National Association of Pharmacy Regulatory Authorities</td>
</tr>
<tr>
<td>NDS</td>
<td>National Drug Schedule</td>
</tr>
<tr>
<td>NMS</td>
<td>Narcotics Monitoring System</td>
</tr>
<tr>
<td>NOC</td>
<td>Notice of Compliance</td>
</tr>
<tr>
<td>NSAA</td>
<td>Narcotics Safety and Awareness Act, 2010</td>
</tr>
<tr>
<td>Non-Standard Claims</td>
<td>Claims which require special claim instructions, including input to data fields other than those listed under <a href="#">Section 5.1</a></td>
</tr>
<tr>
<td>OCP</td>
<td>Ontario College of Pharmacists</td>
</tr>
<tr>
<td>ODB</td>
<td>Ontario Drug Benefit</td>
</tr>
<tr>
<td>ODBA</td>
<td>Ontario Drug Benefit Act, R.S.O. 1990, c.O.10</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>ODBF</td>
<td>Ontario Drug Benefit Formulary</td>
</tr>
<tr>
<td>ODP</td>
<td>Ontario Drug Programs</td>
</tr>
<tr>
<td>ODSP</td>
<td>Ontario Disability Support Program</td>
</tr>
<tr>
<td>OFI</td>
<td>Off-Formulary Interchangeability</td>
</tr>
<tr>
<td>OGPMSS</td>
<td>Ontario Government Pharmaceutical and Medical Supply Service</td>
</tr>
<tr>
<td>OHIP</td>
<td>Ontario Health Insurance Program</td>
</tr>
<tr>
<td>OHIP+</td>
<td>ODB eligibility category for children and youth aged 24 and under, who do not have a private plan</td>
</tr>
<tr>
<td>OHT</td>
<td>Ontario Health Team</td>
</tr>
<tr>
<td>OLTP</td>
<td>On-Line Transaction Processing</td>
</tr>
<tr>
<td>Online</td>
<td>Submitted electronically via the network</td>
</tr>
<tr>
<td>Ontario Health number</td>
<td>10-digit number that identifies a recipient of health care benefits provided by the Ministry of Health</td>
</tr>
<tr>
<td></td>
<td>Note: In some cases, a one or two-character Version Code forms part of the Health number</td>
</tr>
<tr>
<td>OPDP</td>
<td>Ontario Public Drug Programs</td>
</tr>
<tr>
<td>OW</td>
<td>Ontario Works</td>
</tr>
<tr>
<td>Override</td>
<td>Intervention and Exception Code</td>
</tr>
<tr>
<td>Password</td>
<td>User-assigned code which must be entered before access can be gained</td>
</tr>
<tr>
<td>Pharmacist ID</td>
<td>Pharmacist's registration number with OCP</td>
</tr>
<tr>
<td>Pharmacy</td>
<td>The term ‘pharmacy’ is used in this manual for consistency and ease of reading, however, all pharmacy requirements refer equally to Dispensing Physician accounts as well</td>
</tr>
<tr>
<td>Pharmacy ID</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>PHIPA</td>
<td>Personal Health Information Protection Act, 2004</td>
</tr>
<tr>
<td>PIN</td>
<td>Product Identification Number</td>
</tr>
<tr>
<td></td>
<td>In certain situations, a listed drug product on the Formulary (or a drug approved through the EAP) may be assigned a product PIN instead of a DIN (e.g., if there are two different package sizes, a PIN may be assigned to one of the pack sizes). PINs are also used for listed substances - nutritional products and diabetic test strips. Other service PINs are used to bill claims for MedsCheck, Pharmaceutical Opinion Program, other expanded scope of practice activities, etc.</td>
</tr>
<tr>
<td>POP</td>
<td>Pharmaceutical Opinion Program</td>
</tr>
<tr>
<td>Professional service fee</td>
<td>The dispensing fee payable by the Ministry to pharmacies for supplying an ODB-eligible prescription, in accordance with the [O.\ Reg 201/96] under the ODBA.</td>
</tr>
<tr>
<td>PSV</td>
<td>Pharmacy Software Vendor</td>
</tr>
<tr>
<td></td>
<td>Person or organization which develops and maintains the pharmacy management software</td>
</tr>
<tr>
<td>Prospective DUR</td>
<td>Drug Utilization Review conducted at time of dispensing</td>
</tr>
<tr>
<td>Recipient</td>
<td>Person eligible for benefits provided by the ODB program</td>
</tr>
<tr>
<td>Response Code</td>
<td>Code assigned to error or information messages some of which may cause a claim to be rejected</td>
</tr>
<tr>
<td>Retention Period</td>
<td>A period of at least 10 years from the last recorded pharmacy service provided to the ODB recipient, or 10 years after the day on which the ODB recipient reached or would have reached the age of 18 years, whichever is longer.</td>
</tr>
<tr>
<td>Reversal</td>
<td>Transaction that reverses a previous claim submission</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>RFU</td>
<td>Reason for Use</td>
</tr>
<tr>
<td>RHPA</td>
<td>Regulated Health Professions Act, 1991</td>
</tr>
<tr>
<td>SAA</td>
<td>Special Authorization Allergen</td>
</tr>
<tr>
<td>SAN</td>
<td>Special Authorization Number</td>
</tr>
<tr>
<td>SAP</td>
<td>Special Access Program</td>
</tr>
<tr>
<td>SAV</td>
<td>Social Assistance Verification</td>
</tr>
<tr>
<td>SCP</td>
<td>Seniors Co-payment Program</td>
</tr>
<tr>
<td>SDP</td>
<td>Special Drugs Program</td>
</tr>
<tr>
<td>SSC</td>
<td>Special Service Code</td>
</tr>
<tr>
<td>Standard Claims</td>
<td>Claims which do not require special claim instructions</td>
</tr>
<tr>
<td>TCA</td>
<td>Temporary Care Assistance</td>
</tr>
<tr>
<td>Third-Party Host</td>
<td>See Acquirer Host</td>
</tr>
<tr>
<td>TDP</td>
<td>Trillium Drug Program</td>
</tr>
<tr>
<td>Transaction</td>
<td>Submission of a claim, claim reversal or request for information</td>
</tr>
<tr>
<td>Transaction Code</td>
<td>Unique code assigned to each type of transaction or system response</td>
</tr>
<tr>
<td>TRS</td>
<td>Telephone Request Service</td>
</tr>
<tr>
<td>UIIP</td>
<td>Universal Influenza Immunization Program</td>
</tr>
<tr>
<td>USPDI</td>
<td>United States Pharmacopeia - Drug Information</td>
</tr>
<tr>
<td>User ID</td>
<td>Unique code used to identify an authorized person or organization accessing the network</td>
</tr>
<tr>
<td>Version Code</td>
<td>One- or two-character code assigned to a replacement Health Card</td>
</tr>
</tbody>
</table>
## Appendix A: Extemporaneous Preparations Table

<table>
<thead>
<tr>
<th>Category</th>
<th>Compound Type Code&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Compounding PIN&lt;sup&gt;2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Methadone preparation (using methadone powder).</td>
<td>N/A</td>
<td>09857499</td>
</tr>
<tr>
<td>Exceptional Access Program approval is required for methadone compounding from powder.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Preparation is for oral consumption and contains a solid oral dosage form of a listed drug product compounded into a liquid or capsule and no other medicinally active substance.</td>
<td>3 or 5</td>
<td>N/A</td>
</tr>
<tr>
<td>Note: Enter the DIN/PIN of the listed drug product with the highest cost in all cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Preparation is for administration via infusion and contains an ODB benefit that is approved by Health Canada for injectable administration and meets the requirements of the Extemporaneous Preparation Reimbursement Policy for injectable preparations outlined in section 6.1 of this manual.</td>
<td>6 (when using the DIN/PIN of a listed drug product)</td>
<td>09850627</td>
</tr>
</tbody>
</table>

**Claim each prepared unit (i.e., bag) as a quantity of 1. For example:**

- claimed quantity for three 50mL bags is 3
- claimed quantity for one 250mL bag is 1
<table>
<thead>
<tr>
<th>Note: Use of this PIN is limited to infusions and should be used for the preparation of ALL IV bags for infusion</th>
</tr>
</thead>
</table>

4. Preparation is for dermatological/topical use and contains a single ODB listed drug product used for dermatological/topical purposes and no other medicinally active substances other than one or more of the following: camphor, compound benzoin tincture, hydrocortisone powder, liquor carbonis detergens, menthol, salicylic acid, sulfur or tar distillate.  

<table>
<thead>
<tr>
<th>0, 1 or 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Note: Enter the DIN/PIN of the listed drug product with the highest cost in all cases</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>09850635</td>
</tr>
</tbody>
</table>

6. A dermatological/topical preparation consisting of liquor carbonis detergens, salicylic acid, sulfur or tar distillate, but no other active substance, compounded in petrolatum jelly or lanolin.  

<table>
<thead>
<tr>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>09850643</td>
</tr>
</tbody>
</table>

7. An ophthalmic solution containing amikacin, cefazolin or vancomycin.  

| 7 |
| (when using the DIN/PIN of a listed drug product) |
| 09850651 |

8. An ophthalmic solution containing gentamycin or tobramycin in a concentration greater than three milligrams per millilitre.  

| 7 |
| (when using the DIN/PIN of a listed drug product) |
| 09850678 |
9. An Extemporaneous Total Parenteral Nutrition (TPN) Preparation.  N/A  09850686

10. IV Cassette preparation 50mL size.  N/A  09850694
   **Claim each prepared unit as a quantity of 1.**

11. IV Cassette preparation 100mL size.  N/A  09850708
   **Claim each prepared unit as a quantity of 1.**

12. Other IV Infusion Device* up to 100mL.  N/A  09857134
   **Claim each prepared unit as a quantity of 1.**

13. Other IV Infusion Device* 101mL to 250mL.  N/A  09857135
   **Claim each prepared unit as a quantity of 1.**

14. Other IV Infusion Device* greater than 250mL.  N/A  09857136
   **Claim each prepared unit as a quantity of 1.**

*Note: All regular IV infusion bags, regardless of volume (e.g., NS 250mL) should be claimed under Compounding PIN 09850627 or Compound Code Type 6 (if using the DIN/PIN of a listed drug product).

1 Compound Type Code

This code identifies the type of compound. It is entered in the Unlisted Compound field and indicates that the claim is for an extemporaneous preparation (compound) for a formulary benefit product (or an EAP approved drug) with a DIN/PIN. Please note that the Compounding PIN should not be used in these cases.

<table>
<thead>
<tr>
<th>Code</th>
<th>Type of Compound</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>compounded topical cream</td>
</tr>
<tr>
<td>1</td>
<td>compounded topical ointment</td>
</tr>
<tr>
<td>2</td>
<td>compounded external lotion</td>
</tr>
<tr>
<td></td>
<td>Description</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>3</td>
<td>compounded internal use liquid</td>
</tr>
<tr>
<td>5</td>
<td>compounded internal powder</td>
</tr>
<tr>
<td>6</td>
<td>compounded injection or infusion</td>
</tr>
<tr>
<td>7</td>
<td>compounded ear/eye drop</td>
</tr>
</tbody>
</table>

Compounding PIN

Compounding PINs should only be used for preparing a compound with an unlisted drug product (as its highest cost) that meets the Extemporaneous Preparations guidelines (see Section 6.1). In addition, certain compounding PINs are assigned to allow billing of approved extemporaneous preparations that are compound specific.

Infusion sets, tubings, empty bags, syringes, adaptacaps, etc. are not eligible for reimbursement under the Extemporaneous program and therefore should not be added to the drug cost.
## Appendix B: Approved Non-Prescription Drug Products

The [Pharmacy](#) and [LTC Home](#) Requisition forms for ODB ANPDs can be accessed from the [Central Forms Repository](#) website.

<table>
<thead>
<tr>
<th>PIN</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>9857143</td>
<td>Acetaminophen 325mg Tab</td>
</tr>
<tr>
<td>9857144</td>
<td>Acetaminophen 500mg Tab</td>
</tr>
<tr>
<td>9857145</td>
<td>Acetylsalicylic Acid 325mg Ent Tab</td>
</tr>
<tr>
<td>9857147</td>
<td>Acetylsalicylic Acid 650mg Ent Tab</td>
</tr>
<tr>
<td>9857238</td>
<td>Ascorbic acid 500mg Tab</td>
</tr>
<tr>
<td>9857149</td>
<td>Bisacodyl 5mg Ent Tab</td>
</tr>
<tr>
<td>9850783</td>
<td>Chlorpheniramine Maleate 4mg Tab</td>
</tr>
<tr>
<td>9850775</td>
<td>Cyproheptadine HCl 4mg Tab</td>
</tr>
<tr>
<td>9850848</td>
<td>Dimenhydrinate 50mg Tab</td>
</tr>
<tr>
<td>9850791</td>
<td>Diphenhydramine 25mg Tab or Caplet</td>
</tr>
<tr>
<td>9850805</td>
<td>Diphenhydramine 50mg Tab or Caplet</td>
</tr>
<tr>
<td>9857153</td>
<td>Docusate Sodium 100mg Cap</td>
</tr>
<tr>
<td>9857154</td>
<td>Ferrous Gluconate 300mg Tab</td>
</tr>
<tr>
<td>9851267</td>
<td>Ferrous Sulfate 300mg Tab</td>
</tr>
<tr>
<td>9851178</td>
<td>Multivitamin Tab</td>
</tr>
<tr>
<td>9854347</td>
<td>Potassium Chloride 8mEq LA Cap</td>
</tr>
<tr>
<td>9857239</td>
<td>Potassium Chloride 8mEq LA Tab</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>9857164</td>
<td>Sennosides A &amp; B 8.6mg Tab</td>
</tr>
<tr>
<td>985194</td>
<td>Vitamin B Compound &amp; C Cap or Tab</td>
</tr>
</tbody>
</table>
Appendix C: Approved Non-Prescription Drug Products - Emergency Authorization

If the Ontario Government Pharmaceutical and Medical Supply Service (OGPMSS) is unable to supply ANPD directly to the LTC Home and Emergency Authorization has been granted, the pharmacy may submit claims with the following PINs.

The Pharmacy and LTC Home Requisition forms for ODB ANPDs can be accessed from the Central Forms Repository website.

<table>
<thead>
<tr>
<th>PIN</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>9857143</td>
<td>Acetaminophen 325mg Tab</td>
</tr>
<tr>
<td>9857144</td>
<td>Acetaminophen 500mg Tab</td>
</tr>
<tr>
<td>9857145</td>
<td>Acetylsalicylic Acid 325mg Ent Tab</td>
</tr>
<tr>
<td>9857147</td>
<td>Acetylsalicylic Acid 650mg Ent Tab</td>
</tr>
<tr>
<td>9850759</td>
<td>Aluminum Hydroxide &amp; Magnesium Hydroxide &amp; Dimethylpolysiloxane 40mg &amp; 40mg &amp; 5mg O/L</td>
</tr>
<tr>
<td>9854320</td>
<td>Aluminum Hydroxide &amp; Magnesium Hydroxide 40mg &amp; 40mg/mL O/L</td>
</tr>
<tr>
<td>9854312</td>
<td>Aluminum Hydroxide 64mg/mL O/L</td>
</tr>
<tr>
<td>9850732</td>
<td>Analgesic Rub</td>
</tr>
<tr>
<td>9857238</td>
<td>Ascorbic acid 500mg Tab</td>
</tr>
<tr>
<td>9857148</td>
<td>Bisacodyl 10mg Sup</td>
</tr>
<tr>
<td>9857149</td>
<td>Bisacodyl 5mg Ent Tab</td>
</tr>
<tr>
<td>9850953</td>
<td>Body Lotion</td>
</tr>
<tr>
<td>9850961</td>
<td>Calamine Lotion</td>
</tr>
<tr>
<td>9850929</td>
<td>Cascara Sagrada O/L</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>9850813</td>
<td>Chlorhexidine Gluconate 0.05% w/v Sterile Aqueous Antiseptic Sol</td>
</tr>
<tr>
<td>9850783</td>
<td>Chlorpheniramine Maleate 4mg Tab</td>
</tr>
<tr>
<td>9857151</td>
<td>Cyanocobalamin 1mg/mL Inj Sol</td>
</tr>
<tr>
<td>9850775</td>
<td>Cyproheptadine HCl 4mg Tab</td>
</tr>
<tr>
<td>9857152</td>
<td>Dextromethorphan HBR 3mg/mL O/L</td>
</tr>
<tr>
<td>9850856</td>
<td>Dimenhydrinate 100mg Sup</td>
</tr>
<tr>
<td>9850872</td>
<td>Dimenhydrinate 3mg/mL O/L</td>
</tr>
<tr>
<td>9850864</td>
<td>Dimenhydrinate 50mg Sup</td>
</tr>
<tr>
<td>9850848</td>
<td>Dimenhydrinate 50mg Tab</td>
</tr>
<tr>
<td>9850996</td>
<td>Dimethylpolysiloxane 20% Cr</td>
</tr>
<tr>
<td>9850791</td>
<td>Diphenhydramine 25mg Tab or Caplet</td>
</tr>
<tr>
<td>9850805</td>
<td>Diphenhydramine 50mg Tab or Caplet</td>
</tr>
<tr>
<td>9857153</td>
<td>Docusate Sodium 100mg Cap</td>
</tr>
<tr>
<td>9857154</td>
<td>Ferrous Gluconate 300mg Tab</td>
</tr>
<tr>
<td>9851267</td>
<td>Ferrous Sulfate 300mg Tab</td>
</tr>
<tr>
<td>9854339</td>
<td>Glycerin 2.7g Adult Sup</td>
</tr>
<tr>
<td>9850945</td>
<td>Guaifenesin 20mg/mL O/L</td>
</tr>
<tr>
<td>9850821</td>
<td>Hydrogen Peroxide 3% Sol</td>
</tr>
<tr>
<td>9851011</td>
<td>Isopropyl Rubbing Alcohol</td>
</tr>
<tr>
<td>9857156</td>
<td>Magnesium Hydroxide 80mg/mL O/L</td>
</tr>
<tr>
<td>9857157</td>
<td>Methylcellulose 0.5% Oph Sol</td>
</tr>
<tr>
<td>9857158</td>
<td>Methylcellulose 1% Oph Sol</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>9851178</td>
<td>Multivitamin Tab</td>
</tr>
<tr>
<td>9857160</td>
<td>Nitroglycerin 0.6mg SL Tab</td>
</tr>
<tr>
<td>9857161</td>
<td>Potassium Chloride 1.33mEq/mL O/L</td>
</tr>
<tr>
<td>9854347</td>
<td>Potassium Chloride 8mEq LA Cap</td>
</tr>
<tr>
<td>9857239</td>
<td>Potassium Chloride 8mEq LA Tab</td>
</tr>
<tr>
<td>9854355</td>
<td>Povidone-Iodine 10% Top Sol</td>
</tr>
<tr>
<td>9857163</td>
<td>Psyllium Mucilloid Oral Pwd</td>
</tr>
<tr>
<td>9857164</td>
<td>Sennosides A &amp; B 8.6mg Tab</td>
</tr>
<tr>
<td>9857165</td>
<td>Sodium Biphosphate &amp; Sodium Phosphate 160mg &amp; 60mg/mL Enema</td>
</tr>
<tr>
<td>9851259</td>
<td>Sodium Chloride 0.9% Sol for Irrigation</td>
</tr>
<tr>
<td>9851119</td>
<td>Sterile Water for Irrigation</td>
</tr>
<tr>
<td>9851208</td>
<td>Vitamin A &amp; D &amp; C &amp; B Complex Ped O/L</td>
</tr>
<tr>
<td>9851194</td>
<td>Vitamin B Compound &amp; C Cap or Tab</td>
</tr>
<tr>
<td>9851135</td>
<td>Water for Injection</td>
</tr>
<tr>
<td>9851046</td>
<td>White Petroleum Oint</td>
</tr>
<tr>
<td>9854394</td>
<td>Zinc Oxide 15% Oint</td>
</tr>
<tr>
<td>9857167</td>
<td>Zinc Sulfate 0.5% Oint</td>
</tr>
</tbody>
</table>
# Appendix D: Allergen Products

<table>
<thead>
<tr>
<th>DIN/PIN</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>09850724</td>
<td>Allergen Extracts</td>
</tr>
<tr>
<td>00509558</td>
<td>Epipen 1/1000</td>
</tr>
<tr>
<td>00578657</td>
<td>Epipen Jr. 0.5mg/mL</td>
</tr>
<tr>
<td>00464988</td>
<td>Pollinex R</td>
</tr>
<tr>
<td>02382059</td>
<td>Allerject 0.15mg/0.15mL</td>
</tr>
<tr>
<td>02382067</td>
<td>Allerject 0.3mg/0.3mL</td>
</tr>
<tr>
<td>02458446</td>
<td>Emerade™ 0.3 mg/0.3 mL</td>
</tr>
<tr>
<td>02458454</td>
<td>Emerade™ 0.5 mg/0.5 mL</td>
</tr>
</tbody>
</table>
Appendix E: Attestation / Notice of Change in LTC Home Primary Pharmacy Service Provider Form

Ministry of Health
Health Programs and Delivery Division
Office of the Executive Officer and Assistant Deputy Minister

Ministère de la Santé
Division des programmes de santé et de la prestation des services
Bureau de l’administratrice en chef et sous-ministre adjointe

438 University Avenue, 10th floor
Toronto ON M5G 2K8

Attestation Notice of Change in LTC Home Primary Pharmacy Service Provider Form

This form is to be completed and sent to the Health Programs and Delivery Division if there are any changes to your Attestation to Receive Capitation Payments as a Primary Pharmacy Service Provider Form at any time during the calendar year (“Attestation”) OR if you are a new primary pharmacy service provider for a long-term care (LTC) home and previously did not receive an Attestation.

For example, you must complete this form if:

- Your pharmacy is entering or has entered into a new contract with a long-term care (LTC) home that was not originally identified in the Attestation (“New LTC Home Client(s)”); or
- Your pharmacy is ending, or has ended, its contract with a LTC home that was originally identified in the Attestation (“Former LTC Home Client(s)”).

This form must be submitted to the ministry by the 15th of the previous month before the effective date of the change, in accordance with the Ministry’s Policy and
your Health Network System Subscription Agreement. Failure to notify the ministry may result in a delay of payment and/or an incorrect payment.

Without completing this form, capitation payments for providing professional and dispensing pharmacy services under the capitation model may be delayed.

**Primary Pharmacy Service Provider Information:**

<table>
<thead>
<tr>
<th>Pharmacy ID #</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacy Name</td>
<td></td>
</tr>
<tr>
<td>Pharmacy Address</td>
<td></td>
</tr>
<tr>
<td>Pharmacy Fax</td>
<td></td>
</tr>
<tr>
<td>Pharmacy O365 email Address</td>
<td></td>
</tr>
</tbody>
</table>

**To Add New LTC Home Client(s):**

| Long-Term Care Home Agency ID# |          |
| Long-Term Care Home Name |          |
| Long-Term Care Home Address |          |
| Effective Start Date of the Contract |          |

**To Remove Former LTC Home Client(s):**

<p>| Long-Term Care Home Agency ID# |          |
| Long-Term Care Home Name |          |</p>
<table>
<thead>
<tr>
<th>Long-Term Care Home Address</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Effective End Date of the Contract</td>
<td></td>
</tr>
</tbody>
</table>

To attest that the information above is accurate, the pharmacy owner, or designated pharmacy manager, must complete the box below, including signature and date.

<table>
<thead>
<tr>
<th>Pharmacy Designated Manager or Owner (please print)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature</td>
<td>Date</td>
</tr>
</tbody>
</table>

Please send completed forms (all pages) to the Health Programs and Delivery Division by email at ODBLTCcap@ontario.ca.

Note: knowingly furnishing false or incomplete information to the Ministry in connection with the administration of the Ontario Drug Benefit Program is an offence under the Ontario Drug Benefit Act.
Appendix F: Templates for the Pharmacy Smoking Cessation Program

Readiness Assessment

<table>
<thead>
<tr>
<th>Name:</th>
<th>Date:</th>
</tr>
</thead>
</table>

Please answer the questions below:

<table>
<thead>
<tr>
<th>ASK</th>
<th>Question</th>
<th>Yes or No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Are you a smoker who is interested in quitting in the next month?</td>
<td>Yes or No</td>
</tr>
<tr>
<td>2.</td>
<td>Are you willing to set a QUIT date?</td>
<td>Yes or No</td>
</tr>
<tr>
<td>3.</td>
<td>If you answered YES to these questions would you like to enrol in the Ontario Government’s FREE Quit Smoking Program?</td>
<td>Yes or No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADVISE</th>
<th>Quitting smoking is the most important thing you can do to protect your health now and in the future.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Evidence suggests smoking cessation programs can reduce the risk of chronic disease, other health complications, and subsequent use of the health care system. If you are willing to quit in the next 30 days your community pharmacist can help to establish the best option for you including pharmacological therapy and other support mechanisms. If you are interested in learning more about the FREE Quit Smoking Program, please ask your pharmacist.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ASSESS</th>
<th>How Ready Are You?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>How important is it for you to QUIT SMOKING for good?</td>
</tr>
<tr>
<td></td>
<td>1 (not at all) 2 3 4 5 6 7 8 9 10 (completely)</td>
</tr>
<tr>
<td></td>
<td>How practical is it for you to quit NOW?</td>
</tr>
<tr>
<td></td>
<td>1 (not at all) 2 3 4 5 6 7 8 9 10 (completely)</td>
</tr>
<tr>
<td></td>
<td>How confident are you to do what it takes to quit smoking FOR GOOD?</td>
</tr>
<tr>
<td></td>
<td>1 (not at all) 2 3 4 5 6 7 8 9 10 (completely)</td>
</tr>
</tbody>
</table>

You may be ready to enrol!

After reviewing this form, please return it to your pharmacist.

<table>
<thead>
<tr>
<th>Pharmacist:</th>
<th>Date:</th>
</tr>
</thead>
</table>

To be filed for documentation and auditing purposes
If the patient has decided to enrol and is willing to set a quit date, the pharmacist may proceed with the consultation and agreement / consent forms
Pharmacy Smoking Cessation Program
Patient Agreement to Enrol & Patient Consent Form

Patient Name: 
Address: 
Phone: 
Email: 
Patient’s Signature: 

Patient Enrolment

By signing the enrolment form, the patient agrees to work together with the pharmacist to stop smoking on the date indicated.

Pharmacist’s Name: 
Pharmacist’s Signature: 
Date of Enrolment: 
Expected QUIT Date: 

Patient Consent

It may be necessary for the pharmacist to discuss and share your health information with other health care professionals (e.g., physicians, nurses, etc.) in the process of assisting you with this quit smoking program.

By signing below, you authorize the pharmacist to disclose and collect your personal health information to and from other health care professionals who are or have provided medical services to you for the purpose of assisting you during this quit smoking program.

Please sign below to indicate your consent to this exchange of information.

Patient’s Signature: 
Date: 
Comments (if any): 

To be completed prior to the first consultation meeting
Please note: It is important to set a QUIT date for program enrolment To be filed for documentation and auditing purposes Please provide a copy to the patient
# FIRST QUIT CONSULTATION MEETING

<table>
<thead>
<tr>
<th>Name:</th>
<th>Date:</th>
</tr>
</thead>
</table>

**Appointment location:**

Where possible, the First Quit Consultation should be an in person meeting at the pharmacy. If in-person meeting is not possible, please indicate method of appointment

- [ ] In person
- [ ] Telephone
- [ ] Video-conferencing
- [ ] Email
- [ ] Other

**Tobacco Use History:**

- [ ] Daily smoker
- [ ] Occasional smoker

Current use: Number of cigarettes per day _______ for _______ years

# of Pack-years: Years smoked _____ x Packs per day: _____ = _____ Pack-years

How soon after waking is first cigarette? _______ minutes

Where do you smoke most often? ________________________________

What time of day is smoking predominantly done? ________________________________

Days of week predominantly smoking: ________________________________

With whom do you smoke (alone or socially)? ________________________________

Number of other household smokers: _______ Workplace smoking: (Yes/No) _______

Are you a source of 2nd hand smoke for family & friends? (Yes/No) ________________

Number of previous attempts to quit (24 hrs or more of intentional stop): ________________

Duration of Past Quit Attempts: ________________________________________________

Previous methods used and reason for relapse, if applicable:

- a. Patch: ___________________________________________________________________
- b. Gum: ___________________________________________________________________
- c. Losenge: __________________________________________________________________
- d. Inhaler: __________________________________________________________________
- e. Medication: __________________________________________________________________
- f. “Cold Turkey”: __________________________________________________________________
- g. Hypnosis: __________________________________________________________________
- h. Other: __________________________________________________________________

---

Ontario Drug Programs Reference Manual
From the methods indicated above, which was associated with the best results to date (from your perspective, e.g. not based on what you’ve heard)? ________________________________

What led you to relapse? ____________________________________________________________

Withdrawal symptoms: (Yes/No) _______ Negative mood: (Yes/No) _______

Habit: (Yes/No) _______ Being with other smokers: (Yes/No) _______ Stress: (Yes/No) _______

Other: _____________________________________________________________________________

Do you drink (alcohol) when you smoke? (Yes/No) _______ Number of drinks per day: ______

Do you drink coffee when you smoke? (Yes/No) _______ Number of cups per day: _______

Are you under the care of your primary care provider for smoking cessation? (Yes/No) ______

### Medication Related History: May attach print out or MedsCheck if available

**Allergies/Intolerance to medications:** ________________________________

Concurrent medications: Benzodiazepines: (Yes/No) _______ Antipsychotic: (Yes/No) _______

Antidepressants: (Yes/No) _______ Other: ________________________________

**Chronic conditions and consequences of smoking:**

Cardiac History: High Blood Pressure: (Yes/No) _______ Blood Pressure: ____________

Arrhythmia: (Yes/No) _______ Heart Rate: ____________ Heart Failure: (Yes/No) _______

Hypercholesterolemia: (Yes/No) _______ Other heart related: __________________________

Diabetes: (Yes/No) _______ Type 1 _______ Type 2 _______

Respiratory History: Asthma: (Yes/No) _______ COPD: (Yes/No) _______

Lung related problems: (Yes/No) _______

Past Seizure history: (Yes/No) _______

Cancer: (Yes/No) _______

Hormone Replacement Therapy: (Yes/No) _______ Oral contraceptives: (Yes/No) _______

Alcohol Use: ________________________________

Depression: (Yes/No) _______ Anxiety: (Yes/No) _______ Eating disorder: (Yes/No) _______

Bipolar disease: (Yes/No) _______ Schizophrenia: (Yes/No) _______

Smoking-related health symptoms:

- [ ] Cough
- [ ] Wheeze
- [ ] Shortness of breath
- [ ] Distorted Smell/Taste
- [ ] Other _______
<table>
<thead>
<tr>
<th>Triggers:</th>
<th>Strategies to consider:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>□ Set a quit date</td>
</tr>
<tr>
<td>2.</td>
<td>□ Start an exercise program</td>
</tr>
<tr>
<td>3.</td>
<td>□ Change diet/start healthy snacking</td>
</tr>
<tr>
<td>4.</td>
<td>□ Take up a new hobby/activity</td>
</tr>
<tr>
<td>5.</td>
<td>□ Get plenty of rest;</td>
</tr>
<tr>
<td></td>
<td>□ Learn to relax/meditate</td>
</tr>
<tr>
<td></td>
<td>□ Join a smoking cessation group forum</td>
</tr>
<tr>
<td></td>
<td>□ Use quit smoking help-lines</td>
</tr>
<tr>
<td></td>
<td>□ Get counselling</td>
</tr>
<tr>
<td></td>
<td>□ Seek help/support from family/friends</td>
</tr>
<tr>
<td></td>
<td>□ Spend more time with non-smokers</td>
</tr>
<tr>
<td></td>
<td>□ Drink lots of water/cut down on alcohol</td>
</tr>
<tr>
<td></td>
<td>□ Other (specify)</td>
</tr>
</tbody>
</table>

**QUIT DATE:**

**CONSIDERING PHARMACOTHERAPY?**

- □ Nicotine Patch
- □ Nicotine Gum
- □ Nicotine Lozenge
- □ Nicotine Inhaler
- □ Bupropion
- □ Varenicline
- □ None
- □ Other ________________________

Start date: ______________________ Dose: ______________________

Advice regarding drug therapy for this patient:

If experiencing adverse events, patient to contact:

**OTHER NOTES:**

Name of Pharmacist:

Refer to Section 7.3 for claims submissions (limit to one claim per year)
To be filed for documentation and auditing purposes
A copy may be provided to the patient
# My Quit Plan

## Plan for Preparation to Quit Smoking

<table>
<thead>
<tr>
<th>Name</th>
<th>Phone Number</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Quit Date:**

**Medication:** (check all that apply)

- □ Nicotine Patch
  - Start Date: [ ]
- □ Nicotine Gum
  - Start Date: [ ]
- □ Nicotine Inhaler
  - Start Date: [ ]
- □ Nicotine Lozenge
  - Start Date: [ ]
- □ Bupropion
  - Start Date: [ ]
- □ Varenicline
  - Start Date: [ ]
- □ Other
  - Start Date: [ ]
- □ No medication [ ]

**Preparing environment:**

Remove tobacco and smoking from:

- □ Home [ ]
- □ Work area [ ]
- □ Automobile [ ]
- □ Other __________ [ ]

**Possible challenges to anticipate:**

- □ Stress [ ]
- □ Other smokers [ ]
- □ Drinking alcohol [ ]
- □ Nicotine urges [ ]
- □ Smoking cues [ ]
- □ Availability of cigarettes [ ]
- □ Weight gain [ ]
- □ Other [ ]
- □ Other [ ]

**Strategies to overcome these challenges:**

- □ Delay tactic [ ]
- □ Distraction strategies (e.g., walking) [ ]
- □ Places to avoid [ ]
- □ Places to go (where smoking prohibited) [ ]
- □ Use quit smoking help-lines [ ]
- □ Join a smoking cessation group forum [ ]
- □ Exercise program [ ]
- □ Change diet/start healthy snacking [ ]
- □ Take up a new hobby/activity [ ]
- □ Other [ ]

**Next appointment date:**

**Pharmacist’s Name:**

**Pharmacist’s contact information:**

Pharmacists to provide a copy for patient use; and a copy to attach to the patient’s pharmacy file.
Primary Follow-up Counselling Sessions # 1 - 3

<table>
<thead>
<tr>
<th>Name: ____________________________</th>
<th>Date: ____________________________</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appointment location: ____________</td>
<td>____________________________</td>
</tr>
<tr>
<td>Method of appointment:</td>
<td>□ In person □ Telephone □ Email □ Video-conferencing □ Other</td>
</tr>
</tbody>
</table>

**Primary Follow-up Counselling Sessions 1 - 3:**

Primary Follow-up counselling sessions 1-3 that are billable occur within the first 21 days of the program. Circle which appointment you are billing for. You may bill for 3 visits only.

Recommended meeting time-lines from date of first meeting:

#1: Day 3 – 5 (approximately 10 minutes)
#2: Day 7 – 10 (approximately 10 minutes)
#3: Day 14 – 21 (approximately 10 minutes)

**Quit Status:**
- Have you had any cigarettes since your quit date? (Yes/No) ______
  - If No, congratulate the patient
  - If Yes, encourage the patient to keep trying

**Medication status (if applicable):**
- Are you finding that the medication (_________________) you are taking is helping? (Yes/No) _____
- Any side effects that are bothersome?

**Triggers:**
- Have you been able to overcome your triggers? (Yes/No) ______
- What has worked? __________________________________________
- What has not worked? ________________________________________
- Are you having problems dealing with cravings or withdrawal symptoms? (Yes/No) ______
- What helps? What doesn’t help? __________________________________

**Program Withdrawal:** At any time after the first consultation, a patient may decide to withdraw from the program whether successful or not. The pharmacist may inform patients who withdraw and are not successful in quitting of their eligibility to re-enrol at a later date (one year from the date of the first consultation). Should this occur, pharmacists are asked to evaluate the patient’s quit status. Refer to Program Evaluation form.

**Additional Information:**

**Name of Pharmacist:** ____________________________

Refer to **Section 7.3** for claims submissions (limit to 3 claims per year)

If patient withdraws from the program please refer to Program Evaluation Form

To be filed for documentation and auditing purposes; A copy may be provided to the patient
# Secondary Follow-up Counselling Sessions # 4 - 7

**Name:**  
**Date:**

<table>
<thead>
<tr>
<th>Appointment location:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Method of appointment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ In person</td>
</tr>
<tr>
<td>□ Telephone</td>
</tr>
<tr>
<td>□ Email</td>
</tr>
<tr>
<td>□ Video-conferencing</td>
</tr>
<tr>
<td>□ Other ____________</td>
</tr>
</tbody>
</table>

**Secondary Follow-up Counselling Sessions 4 - 7:**  
The four Secondary Follow-up sessions occur after day 30 as described. Circle which appointment you are billing for. You may bill for 4 visits only.  
#4: Day 30 – 60 (approximately 3 - 5 minutes)  
#5: Day 90 – 120 (approximately 3 - 5 minutes)  
#6: Day 180 – 210 (approximately 3 - 5 minutes)  
#7: Day 240 – 365 (approximately 3 - 5 minutes)

**Quit Status:**  
- Have you had any cigarettes since your quit date? (Yes/No)  
  - If No, congratulate the patient  
  - If Yes, encourage the patient to keep trying

**Medication status (if applicable):**  
- Are you finding that the medication (___________________) you are taking is helping? (Yes/No) _______  
- Any side effects that are bothersome? ______________________________

**Review triggers and strategies**

**Program Withdrawal:** At any time after the first consultation, a patient may decide to withdraw from the program whether successful or not. The pharmacist may inform patients who withdraw and are not successful in quitting of their eligibility to re-enrol at a later date (one year from the date of the first consultation). Should this occur, pharmacists are asked to evaluate the patient’s quit status. Refer to Program Evaluation form.

**Additional Information:**

**Name of Pharmacist:**

---

*If continuing with the program and on completion of documentation, refer to Section 7.3 for claims submissions (limit to 4 claims per year)*

*If patient withdraws from the program, please refer to Program Evaluation Form*

*To be filed for documentation and auditing purposes; A copy may be provided to the patient*
Program Evaluation

This form is used for the purpose of program evaluation of the patients quit smoking status.

**Successful Quit**: PIN 93899944
- The successful quit PIN is claimed when a patient indicates at any time during the program that he or she has successfully quit smoking. Once the PIN is claimed, no further meetings are scheduled or billable.

**Unsuccessful Quit**: PIN 93899945
- The unsuccessful quit PIN is claimed when a patient indicates at any time during the program that he or she has not succeeded in quitting smoking. Once the PIN is claimed, no further meetings are scheduled.
- The pharmacist should inform patients who withdraw from the program of their eligibility to re-enroll at a later date (one year from the date of their first consultation with the pharmacist).

**Unknown Status / Program Withdrawal**: PIN 93899946
- The unknown status PIN is claimed when a patient cannot be reached to continue with his/her program or when a patient withdraws from the program without indicating their success in quitting smoking.

**Additional Information:**

**Name of Pharmacist:**

---

*On completion of documentation,*

*Refer to Section 7.3 for claims submissions*

successful quit
un-successful quit
unknown quit status

*(limit to ONE of the above claims per year as applicable to quit smoking status)*

To be filed for documentation and evaluation purposes

A copy may be provided to the patient